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Summary
The regulation of energy and nutrient homeostasis is a complex procedure involving 
interactions between numerous neuropeptides, neurotransmitters and hormones 
implicated in the control of this fundamental behaviour. The PP-fold peptide family 
member Neuropeptide Y (NPY) is a well documented stimulator of food intake and is 
believed to play a role in the physiological regulation of ingestive behaviour.
At the start of the work presented in this thesis the NPY receptor subtype responsible 
for mediating the characteristic augmentation in feeding was thought to be a novel, 
previously unidentified receptor subtype, as the pharmacology of the cloned NPY 
receptor subtypes failed to mimic the pharmacology known to stimulate NPY-elicited 
eating. The therapeutic implications for the development of an anti-obesity drug based 
on an antagonist to the "feeding" receptor for NPY made the cloning of this receptor 
subtype a rapidly evolving and highly competitive field. Initial efforts were therefore 
directed at cloning the feeding receptor for NPY using various novel receptor cloning 
strategies.
The structural diversity exhibited by the members of the NPY receptor gene family 
made cloning using a homology screening strategy difficult, as demonstrated by the 
difficulties encountered in designing degenerate primers pairs for PCR or 
Genetrapper™ technology. As a result, functional expression cloning strategies were 
employed as an alternative strategy to clone novel NPY receptor gene family members, 
in particular the feeding receptor for NPY. Two different COS cell expression cloning 
strategies were used to identify NPY receptor gene family members following ligand 
binding and screening for cells expressing the desired cDNA by different detection 
methods.
During the course of this work the structure of the NPY Y5 receptor was reported using 
an expression cloning strategy identical to one described in this thesis, and this initial 
report proposed that this receptor was the feeding receptor for NPY. However, 
subsequent reports describing a role for the NPY Y1 receptor in the regulation of NPY- 
induced feeding have generated considerable controversy regai'ding the identity of the 
NPY receptor subtype involved in feeding behaviour regulation. The cloning of the 
NPY Y5 receptor enabled further studies to be directed toward examining the regulation 
of the Y5 gene, with a view to elucidating further the role of both the Y1 and Y5 
receptors in the control of feeding behaviour. Hybridisation screening of a rat genomic 
library permitted the identification of a partial rat Y 5 genomic clone, and enabled 
further efforts to characterise the promoter region to be carried out. Additional studies 
were carried out to investigate the regulation of Y1 and Y5 receptors by examining 
changes in the levels of receptor mRNA expression.
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Chapter 1 
Introduction
Appetite, energy balance and body weight gain are modulated by diverse neurochemical and 
neuroendocrine signals originating from different organs in the body and diverse regions in the 
brain. Specific brain regions perform important integrative functions in this process, acting 
through a variety of systems to co-ordinate interactions between nutrients, amines, 
neuropeptides and hormones. These systems underlie normal nutrient intake and metabolism, 
and are thought to be responsible for regulating circadian cycle feeding behaviour and also 
gender and age related patterns of feeding behaviour in several species. Alterations in these 
normal neurochemical -neuroendocrine control systems may be associated with abnormal 
eating patterns and conditions such as obesity. Therefore, an understanding of the systems 
that control eating behaviour may provide a foundation for the treatment and possible 
prevention of such disorders.
1.1 Homeostatic control of feeding behaviour
Most species exhibit a strong circadian pattern of feeding behaviour, principally controlled by 
extensive central and peripheral entities involved in the control of food intake. Definitive brain 
structures and neurotransmitters have been allocated primary roles in the regulation of ingestive 
behaviour, and allied with behavioural and physiological regulation, these form the complex 
system responsible for the homeostatic control of food intake.
Maintenance of body weight is achieved by an intricate balance between energy intake (food 
consumption) and energy expenditure (basal metabolic rate and activity). This energy 
homeostasis is ultimately governed by the brain, where a variety of afferent signals reflect the 
nutritional state of the animal and its external environment, paiticulaiiy food availability. These 
signals are integrated in order to moderate efferent pathways which control feeding behaviour 
and energy expenditure. Several hypotheses ascribing pivotal roles for macronutrients in the 
maintenance of body weight have been described since the initial concept of body weight 
homeostasis was first introduced.
A role for glucose in the control of such energy homeostasis was outlined in the 1950's by 
means of the glucostatic hypothesis, which highlighted the role of blood glucose as fuel, and 
stated that animals would be hungry when blood glucose was low and satiated when blood 
glucose was high (Mayer, 1955). A similar function was attributed to fat regulation by 
Kennedy, as described in the lipostatic hypothesis. Kennedy suggested that an increase in
1
body fat is sensed by a central "adipostat" resulting in compensatory responses such as a 
reduction in food intake being enforced in order to return the body to its previous adipose 
steady state. Conversely, declining fat stores would prompt feeding when food was available 
(Kennedy, 1952). The identification of such a "lipostat" factor in the form of leptin, an 
adipocyte-derived hormone, lends further support to the role of lipostatic mechanisms 
governing energy balance ( Coleman, 1973 and Zhang, 1994).
1.2 Set Point Theory of food intake and body weight regulation.
The tendency of an individual to return to a certain body weight suggests that there is a 
biological set point for body weight much like the set points which form the basis of any 
negative feedback biological control system (Harris, 1990). Therefore when an individual's 
body weight is stable, and fat is neither being gained nor lost, energy acquisition must equal 
energy expenditure. Regardless of baseline body weight, energy conserving mechanisms are 
called upon when an intervention such as caloric restriction (resulting in low energy stores), 
results in a decrease in fat mass to below the steady state value and a concomitant decrease in 
daily energy expenditure. The resulting augmentation in food intake is stimulated via biological 
signals such as glucostatic and lipostatic signals, until energy stores are replenished, and the set 
point value is once again established (Figure 1.1). Conversely, if an individual is caused to 
gain fat mass in excess of the steady state value, energy expenditure increases until the set point 
value is re-established. Like any biological control system, if the set point were to be 
increased, body weight would increase accordingly to meet this new value (Leibel, 1995).
It is widely accepted that the regulation of human feeding is extremely complex, and that 
physiological variables play a crucial role alongside the numerous other aspects involved in the 
regulation of ingestive behaviour. A cognitive set point model, outlined by Booth in 1980, 
delineates the role which the environment (culture, socio-economic class etc.) has on body 
weight. Figure 1.2 illustrates that relative to a personally selected "ideal" body weight set point, 
as individuals we are constantly receiving a variety of cognitive signals about how we look, 
body weight, clothing size and health concerns (Booth, 1980). Adaptive changes of the larger 
human brain, whereby improved procurement of food is achieved by a complex of interacting 
food-related systems argues further the complexity of feeding behaviour as dependant on 
physiological and learned and cognitive aspects. Another important consideration in
Figure 1.1 Set-point model of body weight control whereby feeding behaviour is 
regulated via glucostatic and lipostatic signals relayed to control centres in the brain.
input 
+ or -
m.
output 
+ or -
+ or -
Figure 1.2 Cognitive set-point model of body weight control whereby feeding 
behaviour is regulated by valions cognitive signals.
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humans in favour of the complexity of feeding behaviour is that the type, amount and 
frequency of food intake is often dictated by a particular culture (Rowland, 1996)
1.3 Homeostasis and obesity
The central nervous system monitors body composition and ensures that energy acquisition and 
energy expenditure are co-ordinated and precisely regulated so that fat mass remains constant 
over long periods of time, despite variable food intake and activity. Failure to maintain a 
balance between these two processes results in the complex disorder of obesity, a disorder 
which remains a dilemma in Western society, with an increasing prevalence and affiliation 
with numerous associated health risks including cardiovascular disease, hypertension and non­
insulin dependant diabetes. Obesity is believed to be of both genetic and environmental origin, 
implicating accountable factors such as excess caloric intake, decreased physical activity, social 
and economic forces, and metabolic and endocrine abnormalities (Weiser, 1997).
Although evidence exists in support of these potential causative factors, a definitive mechanism 
for obesity remains to be defined. Contributing environmental factors include increased food 
intake in the form of high fat foods which are highly palatable, and more efficiently converted 
to body fat than carbohydrate or protein. Coupled with poor regulation of dietary fat, and a 
sedentaiy lifestyle, these factors promote the likelihood of development of obesity.
Evidence for genes which control body weight and composition in humans has come from 
sources such as adoption, twin and family studies. A convincing argument in favour of a 
genetic contribution predisposing obesity has come from results of these studies. Significant 
correlations were observed between the bodyweights of adoptees and their biological parents, 
upon comparing bodyweights of adoptees and both biological and adoptive parents. The lack 
of correlation observed between the adoptees and adoptive parents, who share a domestic 
environment, emphasises the role genetic factors may play in obesity (Naggert, 1997).
Early observations have led to the proposals that genes involved in body weight homeostasis 
act by sensing food intake, available energy stores in adipose tissue, and activity levels. These 
sensory inputs are then relayed to central regulatory sites, where the information is integrated 
and a response initiated relevant to the animal's nutritional status. Genetic variations in the 
signalling molecules involved in this regulatory system may therefore account for the heritable 
component of body fat content.
Several genes involved in the complex regulatory network responsible for maintaining a 
balance between food intake and energy expenditure, have recently been cloned and 
characterised (For a review see Weigle, 1996, Naggert, 1997). The precise role of such genes
in the regulation of feeding behaviour and their role in obesity remains to be completely 
elucidated. However, by examining the result of various mutations in these "obesity" genes, 
the role of individual genetic factors may be illuminated.
It is unlikely that either single genes or single brain structures exert stronger or predominant 
control over a process such as feeding, and in reality multiple and probably redundant genes, 
neural pathways, hormones and transmitters ai'e involved. Therefore, an appreciation of the 
forces which act ordinarily to regulate body composition is necessary in order to fully 
understand the mechanisms by which disruption of specific genes may contribute to obesity.
1.3.1 Identification of obesity genes
An "obesity gene" could be any gene encoding a protein involved in body weight regulation. 
The polygenic nature of human obesity, coupled with the impact of environmental vai’iables on 
body composition, make it difficult to directly identify novel obesity genes in humans.
Rapid progress has been facilitated by familiarity with rodent models of obesity and a detailed 
knowledge of the analogies between mouse and human genomic maps. Remarkable advances 
have been achieved by the isolation, identification and characterisation of the genes mutated in 
five monogenic mouse models of obesity. These mutations, which essentially predispose 
obesity in mice, have been positionally cloned by conventional methods, and are widely used 
as models for human obesity. The mutated genes for all five models provide definitive genetic 
evidence for specific pathways directly regulating body weight and adiposity. Figure 1.3 
summarises the genetic defects responsible for the five main mouse models of obesity. As the 
table outlines, each of these genes function at some level in one of the feedback pathways 
which ultimately link energy intake and energy expenditure to total adipose mass. Future 
research should establish which genes are involved in prevalent neurobiological pathways 
regulating ingestive behaviour, and in which tissue the altered gene product must be expressed 
to produce the obese phenotype. Deeper understanding of the complex control of feeding may 
ultimately provide potential new therapeutic options for human obesity. For a comprehensive 
review of human obesity and the genetic and environmental implications see Science 1998 Vol 
280, pp 1364-1390.
Figure 1.3 Summary of the genes involved in the five mouse models of genetic 
obesity.
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Name Normal
protein
function
Mutation E f f e c t  of  
mutation
Phenotype Date
cloned
Obese (ob) Leptin-circulating 
satiety signal
Nonsense at Arg 105 D efec tiv e  leptin  
production
•hyperphagia 
severe obesity 
•diabetes 
•reproductive 
deficiency 
•stunted growth
1994
Diabetes
(db)
Leptin receptor Splicing error Loss o f receptor 
function
Similar to (ob) 1996
Agouti (AY) H i g h  a f f i n i t y  
a n t a g o n i s t  o f  
M S H  at i ts  
receptor
Ubiquitous promoter Unregulated 
e x p r e s s i o n  o f  
agouti proteins
•all yellow coat 
•hyerinsulinema 
•insulin resistance 
•develop m ent o f  
tumours
1992
Tubby (tub) P u t a t i v e  P D E  
expressed in retina 
and brain
Unspliced intron Carboxy terminal 
deletion of protein
•Late-onset obesity 
•insulin resistance 
•retinal 
degeneration 
•deafness
1996
Fat (fat) Carboxypeptidase 
E enzyme involved 
in  p r o c e s s i n g  
neuropeptides 
involved in feeding
Missense mutation Lack o f  CPE  
activity resulting in 
defective
p r o c e s s i n g  o f  
hypothalamic 
peptides involved  
in feeding
•Progressive adult 
o n s e t  o b e s i t y  
•hyperinsulinema 
•infertilty
1995
1.4 Neurobiology of feeding
Neurochemical and neuroendocrine systems control macronutrient intake and metabolism. 
Diverse signals from the periphery and brain are co-ordinated to ensure effective modulation of 
energy balance, appetite and bodyweight gain.
1.4.1 Integration of diverse signals that determine energy and nutrient 
balance.
As the regulation and maintenance of bodyweight is undoubtedly complex, integrative, 
interdisciplinary approaches have been used to obtain information about multiple neurochemical 
and neuroendocrine determinants of energy balance, nutrient stores and bodyweight. Diverse 
signals involved include:
1)Simple nutrients in the blood e.g. glucose, fatty acids, amino acids.
2)Classical neurotransmitter molecules for rapid short-teixn communication.
3)Lai'ger neuropeptides for slower, more long-term action.
4)Hormones for both neuromodulatory and metabolic processes.
These signals derive from different peripheral organs and different areas of the central nervous 
system and contribute in co-ordinating physiological and behavioural regulation of eating 
behaviour. The main components of these diverse control systems are discussed below.
1.4.2 Peripheral neurochemlcal-neuroendocrlne systems
In the periphery a variety of substances have been identified and attributed major roles in the 
regulation of energy and nutrient homeostasis. These include g astro-intestinal signals in the 
form of various peptides, which upon release into the gastro-intestinal tract after a meal, are 
involved in co-ordinating several aspects of digestion, absorption and metabolism. 
Information from these peripherally released peptides can also be transmitted, via the vagus 
nerve to the brain, where behavioural processes related to feeding termination and satiety are 
instigated.
1.4.3 Neurochemical-neuroendocrine systems in the hypothalamus
The integration of metabolic information from the periphery with signals within the central 
nervous system requires the involvement and specialised functions of multiple brain areas. 
Several distinct brain regions serve to regulate specific aspects of feeding behaviour, in a
pathway of events encompassing the various afferent signals. These include the lower 
brainstem which relays and integrates neural information between peripheral autonomic 
endocrine organs and forebrain structures, the midbrain and thalamic areas which interpret this 
information in relation to signals generated by the sensory properties of foods, and forebrain 
structures such as the nucleus accumbens, amygdala and frontal cortex, which perform the task 
of integrating this incoming information with various cognitive factors related to the rewarding 
or aversive aspects of food (Leibowitz, 1992). Figure 1.4 illustrates the regulation of energy 
balance by the central nervous system, in particulai" the hypothalamus.
1.4.4 The hypothalamus and the neurobiology of feeding
A major function in this sequence of events is performed by the hypothalamus, which plays a 
central role in the integrated control of feeding and energy homeostasis. This structure exhibits 
extensive vasculai’ity and neural projections from the lower brainstem, and thus remains closely 
linked to both circulating nutrients and hormones and neural signals from the periphery 
(Leibowitz; 1986).
The belief that the hypothalamus plays a crucial part in the regulation of energy homeostasis 
was originally based upon results of brain lesions. Evidence from disruption of specific 
hypothalamic regions gave rise to the consensus that the hypothalamus acted as a centre for 
both satiety and feeding regulation. Lesions of the ventromedial hypothalamus resulted in the 
formation of hyperphagic obesity, whereas lesions of the lateral hypothalamus elicited severe 
hypophagia and weight loss. From these findings, the existence of a ventromedial 
hypothalamic satiety centre and a contrasting lateral hypothalamic feeding centre were 
postulated (see Figure 1.5) (Luiten, 1987).
The identification of a number of neurotransmitter and neuromodulator systems within the 
hypothalamus involved in the control of appetite and body weight homeostasis, allowed further 
examination of the neurochemical-neuroendocrine system underlying the complex regulation of 
these systems. By examining responses to hypothalamic injection of various neurochemicals 
implicated in feeding behaviour, the effects of neurotransmitters such as 5-hydroxytryptamine, 
noradrenaline, dopamine and various neuropeptides including neuropeptide Y, galanin and 
corticotrophin releasing hormone were elucidated.
Figure 1.4 Regulation of energy balance by the central nervous system, in paiticular 
the hypothalamus which integrates signals indicating the nutritional state, together with 
hedonic and cognitive signals to control food intake and metabolism (Adapted from 
Wilding, 1997).
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Figure 1.5 Anatomy of the hypothalamus. This figure shows a schematic section 
through the rat hypothalamus. The LH (lateral hypothalamus) and VMH (ventromedial 
hypothalamus) have been traditionally regarded as the feeding and satiety centre 
respectively. This simplistic view is now outdated and the PVN (paraventricular 
nucleus) and ARC (arcuate nucleus) are now thought to be equally important.
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1.4.5 Endogenous starvation and satiety signals
From these studies, it was clear that two distinct categories of neurotransmitter or neuropeptide 
existed; namely those whose actions augmented the feeding response, and those whose actions 
resulted in a marked attenuation of ingestive behaviour. The presence of such neurochemical 
systems within the hypothalamus, and their demonstrated dramatic effects on appetite 
regulation, would suggest these neurotransmitters and neuropeptides are present 
endogenously, where they serve to control feeding and maintain a balanced nutritional status. 
A more precise function for these neurochemicals is more resolutely defined by closer 
examination of the levels present in various nutritional states, such as fasted or fed models. 
Significant elevation of neurochemicals known to stimulate feeding behaviour have been 
observed in starved state models, therefore depicting a role for these neurochemicals in 
response to negative energy balance whereby an increase in food intake is physiologically 
desirable and tantamount to the survival of the animal. These neurotransmitters, neuropeptides 
or hormones may therefore be examples of endogenous starvation signals, present inherently to 
ensure survival. Examples of such endogenous starvation signals include: the neuropeptides 
neuropeptide Y, galanin, orexin and opioid peptides, the neurotransmitters noradrenaline and 
gamma-amino butyric acid (GAB A), and the hormones growth hormone releasing hormone 
and melanin concentrating hormone (Clark, 1984; Kyrkouli, 1990; Sakurai, 1998; Stanley 
1988; Grossman, 1960; Feizfel, 1994 and Qu, 1996). Conversely, markedly elevated levels of 
other specific neurochemicals have been found in fed state models, where they act to signal 
satiety and consequently a cessation of feeding. These include the peptides glucagon-like 
peptide-1, urocortin and CART (cocaine and amphetamine regulated transcript), the 
neurotransmitter 5-hydroxytryptamine, the hormones leptin, cholecystokinin, corticotrophin 
releasing factor and oxytocin (Turton, 1996; Spina, 1996; Kiistensen, 1998; Pollock, 1981; 
Zhang, 1994; Gibbs, 1973; Arase, 1988 and Verbalis, 1986). The opposing effects of these 
endogenous systems are functionally significant, as the hypothalamus behaves as both a 
starvation and satiety centre, and these neurotransmitters and neuropeptides play a part in the 
overall hypothalamic modulation of ingestive behaviour (For a review see Leibowitz, 1992 and 
Wilding, 1997).
Another interesting observation is the striking circadian rhythms displayed by these 
hypothalamic neurochemicals. These neurochemicals and their receptors are not uniformly 
active across the circadian cycle, with activities of stimulatory signals peaking sharply at the 
beginning of the natural feeding period, when the body's glycogen stores and blood glucose 
aie low (Tempel; 1989b, Leibowitz, 1990).
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Macronutrient selectivity is another phenomenon observed, whereby specific sets of 
neurochemicals have a role in stimulating the ingestion of a par ticular' food group.
1.4.6 Carbohydrate balance
One such system involved in potentiating carbohydrate intake in response to a decrease in 
carbohydrate utilisation, functions through the amino acid gamma amino butyric acid, the 
amine noradrenaline, and the peptide neuropeptide Y, in association with corticosterone and 
circulating blood glucose. A primary site of action lies in the medial region of the 
hypothalamus, in particular the paraventricular nucleus (PVN), where the neurochemicals and 
receptors are co-localised. The nature of macronutrient specificity was revealed by studies 
employing a diet selection paradigm, which allowed selection of pure macronutrient sources 
following PVN administration of the aforementioned agents. Carbohydrate ingestion was 
specifically potentiated compared to protein or fat ingestion, in addition to an increase in the 
size and duration of carbohydrate rich meals.
These neurochemicals are not uniformly active across the circadian cycle, with activities 
peaking at the beginning of the natural feeding period, consistent with a strong preference in 
both rats and humans, for this macronutrient during the early hours of the feeding cycle 
(Tempel, 1989b.).
1.4.7 Fat balance
Fat balance is also regulated by a similar system, whereby a different set of substances in the 
PVN of the hypothalamus specifically regulate the ingestion of fat. These neurochemicals 
include the neuropeptide galanin, the opioid peptides and the mineralocorticoid aldosterone. 
Like neurochemicals involved in the potentiation of carbohydrate intake, the substances which 
stimulate fat consumption are not consistently active throughout the circadian cycle, with 
highest potency during the late hours of the circadian cycle. In humans and rats, appetite for 
fat progressively rises over the course of the natural feeding cycle, and this appetite shift may 
be attributed to the increased action of these neurochemicals.
1.4.8 Protein balance
In rats and humans, appetite for protein increases gradually over the course of the active 
circadian cycle. Opioid peptides have been shown to potentiate protein intake, and also the 
peptide growth hormone releasing factor which stimulates protein intake upon hypothalamic 
injection.
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From these observations, it is clear that these endogenous satiety and starvation signals play a 
major part in maintaining a balanced nutritional status. The specific hypothalamic pathways 
traversed by these neurochemicals, and the belief that specific receptor subtypes within the 
hypothalamus mediate these dramatic effects, allows further exploitation of each 
neurotransmitter or neuropeptide system in an attempt to underpin the exact role of any one 
neurochemical in the regulation of feeding behaviour.
1.5 Neuropeptide Y
Neurons produce a variety of peptides, secreted from axons and dendrites and collectively 
known as neuropeptides. These peptides arise from larger precursors that are processed 
enzymatically, yielding the mature neuropeptides. These neuropeptides are believed to serve as 
both neurotransmitters and neuromodulators by their interactions at cell membrane receptors. 
Neuropeptide Y is a neuron ally derived peptide which belongs to a peptide family often 
referred to as the pancreatic polypeptide (PP) family, which also includes the endocrine 
peptides, peptide Y Y (PYY), pancreatic polypeptide (PP) and the non-mammalian (fish) 
pancreatic peptide Y(PY) (Tatemoto, 1982a; Kimmel, 1975 and Andrews, 1985).
1.5.1 Discovery of Neuropeptide Y
Neuropeptide Y (NPY) was isolated from porcine brain in 1982 by Tatemoto et al using a 
chemical method employed to identify polypeptides exhibiting an amide structure at their 
carboxy terminal (Tatemoto, 1982b). Sequence analysis revealed that NPY comprised 36 
amino acids, and had a tyrosine residue at its amino-terminus and a tyrosine amide at its 
carboxy-terminus (Figure 1.6) (Tatemoto, 1982c). The nomenclature of this family of peptides 
arose as the abbreviation for tyrosine using the single letter amino acid code is Y, and when 
discovered these peptides had no attributable functions, and were named according to their 
organ of origin, hence pancreatic polypeptide and neuropeptide Y. Evolution of the PP-fold 
peptides has been studied in detail, and it is believed that a common ancestral NPY/PYY 
sequence diverged early in evolution to give rise to the respective peptides (Larhammar, 
1996a). NPY is considered to be one of the most conserved peptide sequences known, 
exhibiting very few differences in sequence across a wide variety of species, and retaining a 
high percentage identity between species separated in evolution by millions of years 
(Larhammar, 1996a, Blomqvist, 1992). This species conservation is evident from the 
predicted human and rat mature NPY amino acid sequence which are identical, and differ from 
the porcine sequence only by a single amino acid substitution at position 17, where a leucine 
residue is replaced by a methionine residue (Laihammar, 1993, 1996a).
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Figure 1.6 Primary structure of neuropeptide Y (porcine).
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1 5 10Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-
15 20Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-AIa-Leu-
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NH2
All three peptides are 36 amino acids in length, and a striking conservation of amino acid 
sequence is maintained between this family of peptides, paitieularly those amino acids involved 
in the formation of the distinct tertiai’y structure shared by these peptides.
1.5.2 NPY structure
The structure of the PP family was deduced initially by x-ray crystallography analysis of the 
avian pancreatic polypeptide (Blundell, 1981; Glover, 1985). From these studies, it was 
revealed that NPY and the other PP family members all feature a compact tertiary structure 
comprising an N-terminal polyproline helix, encompassed by residues 1-8 and an amphiphilic 
a-heiix encompassed by residues 15-30. The helices lie anti-parallel, and are connected with a 
6-turn, creating a hair-pin loop often referred to as the PP-fold (Blundell, 1981). This fold is 
followed by a carboxy-terminal tail of six amino acids which project away from the a-helix 
(figure 1.7). Computer aided molecular modelling has lent support to this configuration, 
whereby the tertiary structure is preserved by extensive hydrophobic interactions between the 
helices (Allen et a l , 1987). These intramolecular' contacts confer spatial proximity between the 
N and C termini, which is believed to be essential for biological activity, as the epitope that 
binds to the NPY Y1 receptor is composed of residues present in the combined C- and N- 
termini of the molecule (Wahlestedt, 1986). Therefore, the tertiary structure of NPY appeal's to 
be essential for both the biological activity of the peptide and for receptor selectivity.
1.5.3 Neuropeptide Y distribution
1.5.3.1 NPY in the central nervous system
Since the initial discovery of NPY by Tatemoto, it has been shown that the concentration of 
NPY in certain brain regions is greater than other putative neurotransmitters. 
Immunocytochemistry and radioimmunoassay studies with antibodies to NPY revealed a 
massive neuronal system for NPY, where NPY was shown to be the most abundant 
neuropeptide found in rat brain (Allen et al, 1983). Neurones containing NPY-like 
immunoreactivity have been shown to be abundant in the central nervous system, and are 
notably most prevalent in the limbic system, hypothalamus, basal ganglia and cortex, with 
virtually no immunoreactivity found in the cerebellum (Allen et a l , 1983).
Broadly, two basic types of neurons have been shown to be immunoreactive for NPY; namely 
interneurons whieh give rise to short axons and local connections, and long-projecting neurons 
whose axons can traverse a long distance from the cell body, innervating structures in other 
brain regions. Within the central nervous system, NPY is co-localised with a wide variety of
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Figure 1.7 Computer constructed three-dimensional tertiary structure of NPY.
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other nenrotransmitters, in a distinct pattern dependent on anatomical location of the NPY- 
containing neurones.
1.5.3.2 NPY in the peripheral nervous system
Peripherally NPY is present in many post-ganglionic sympathetic nerves, especially around 
blood vessels supplying numerous tissues including heart, kidney, lungs, intestinal tract, 
pancreas, uterus and urinary bladder. NPY has also been detected in enteric, cardiac and 
noradrenergic perivascular nerves, and in a subset of parasympathetic nerves (Grundemar & 
Hakansen, 1994).
The widespread distribution displayed by NPY in numerous nerve terminals and cell bodies, 
lends support to the role of NPY in a number of diverse functions ranging from somatic, 
sensory and cognitive brain functions to endocrine and cardiovascular regulation. A 
modulatory role for NPY is also suggested by the observation that NPY is co-localised and co­
released with other neurotransmitters such as noradrenaline, gamma-amino butyric acid 
(GAB A) and somatostatin (Grundemar & Hakanson, 1994).
1.5.4 Biological Effects of the NPY family of peptides
NPY exerts potent biological effects on many targets both in the central and peripheral nervous 
systems, either involving NPY per se, or as a result of modulatory interactions with other 
agents. The aforementioned evolutionary conservation of NPY implies a role for NPY as an 
important neurotransmitter.
1.5.4.1 NPY actions in the central nervous system
The widespread distribution attributed to central NPY suggests that NPY may serve as a multi­
functional neuropeptide involved in numerous processes and involved in a variety of regulatoiy 
functions. The role of NPY in the central nervous system has been explored by direct injection 
of the peptide and peptide analogues and subsequent evaluation of the behavioural, endocrine 
and autonomic consequences. Central NPY has been associated with modulation of autonomic 
functions including cardiovascular and respiratory activity (Fuxe, 1983), regulation of 
behavioural aspects such as circadian rhythm (Albers & Ferris, 1985) and ingestive behaviour 
(Stanley, 1984), and has been implicated in the pathophysiology of the affective disorders 
depression and anxiety (Heilig, 1993). NPY also serves to help govern memory processing 
(Flood, 1989), neuronal excitability (Erickson, 1996), neuroendocrine function via the release 
of hypothalamic and pituitary hormones (Kerkerian, 1985) and sexual behaviour via an effect 
on luetenising hormone releasing hormone (McDonald, 1990).
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1.5.4.2 NPY actions in the peripheral nervous system
The role of neuropeptide Y in the peripheral nervous system has been determined by 
administering NPY to tissue preparations or by intravenous application of NPY. From these 
studies, NPY gained recognition as a well characterised vasoconstrictor, where the 
characteristic response to peripheral administration of NPY was potent and prolonged 
vasoconstriction. Intravenous application of NPY was shown to elicit a sustained elevation in 
blood pressure in numerous different species including man, an effect pai’ticularly prominent in 
the renal and coronary vasculature.
The most established role of NPY in the periphery is associated with the actions exerted by 
NPY at the sympathetic neuro-effector junction, where it is co-localised and co-released with 
the sympathetic nerve neuro transmitter noradrenaline (NA), and where it acts in a co-operative 
manner (Wahlestedt, 1990a). Indeed, a major portion of the NPY-immunoreactive nerves in 
peripheral organs represents classical sympathetic fibres where NPY co-exists with NA. The 
thiee main effects of NPY at the sympathetic neuro-effector junction are:
1) A direct post-junctional response i.e vasoconstriction manifested in certain vascular beds.
2) A post-junctional potentiating effect on NA evoked vasoconstriction, suggesting a 
modulatory role for NPY (Ekblad, 1984).
3)A pre-junctional suppression of stimulated NA release (Wahelstedt, 1990b).
Two main receptor subtypes were defined at the sympathetic neuro-effector junction, namely, 
Y1 and Y2 (Wahlestedt, 1986). At this junction, the Y1 receptor mediated the postsynaptic 
vasoconstrictor activity of NPY, whereas the Y2 receptor mediated the presynaptic effects of 
NPY on noradrenaline release. In this way the Y1 and Y2 receptors can be considered as 
analogous to the a l and a2 adrenoceptors where different receptor subtypes mediate different 
responses to the ligand. However, as for the a adrenoceptors, the site of expression of the Y1 
and Y2 receptors at the synapse is not rigid and it is now known that there are Y1 receptors at 
some presynaptic sites and Y2 receptors can occur postsynaptically. Subsequent studies with 
Y1 receptor antagonists have confirmed the role the Y1 receptor plays in mediating the 
vasoconstrictor action of NPY (Malmstrom, 1995 and Serradeil-Le Gal, 1997).
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1.6 Receptors mediating the actions of NPY
1.6.1 Historical aspects of receptor activation
The initial proposal of NPY receptor heterogeneity arose as a result of observations that the 
entire NPY molecule was necessary to evoke vasoconstriction, whereas C-terminal fragments 
of NPY were effective in suppressing sympathetic nerve activity (Wahlestedt, 1986). The 
subsequent principal subdivision of NPY receptors into the NPY Y 1 and Y2 subtypes has 
survived the test of time and is further supported by additional data such as the development of 
selective subtype analogues, synthesis of receptor antagonists, and cDNA and gene cloning 
technology (Michel, 1997).
1.6.2 Signal Transduction of NPY receptors
All known NPY receptors belong to the large superfamily of G-protein coupled heptahelical 
receptors. They appear to use similar signal transduction pathways, as illustrated by findings 
that in almost every cell type studied, NPY receptors demonstrate a preferential coupling to 
pertussis toxin sensitive G-proteins, namely members of the Gi and Go family (Limbrid, 
1988).
The signalling responses of NPY receptors are typically under the control of these G-proteins, 
in that inhibition of adenylyl cyclase is found in almost every tissue, and cell type investigated. 
However, adenylyl cyclase inhibition probably fails to explain many of the functional 
responses obtained following stimulation of NPY receptors, and additional signalling 
responses are observed in restricted cell types. These include inhibition of calcium channels, 
and either activation or inhibition of potassium channels.
1.6.3 Present definition of NPY receptors
To date five distinct NPY receptors have been cloned. A surprising phenomenon arising from 
sequence analysis of these cloned receptors, is the apparent lack of sequence homology 
exhibited between the different subtypes. However, even with the low sequence homology 
displayed amongst members, there appears to be a distinct clustering of amino acid sequence 
similarity between certain subtypes, with sequence alignments depicting a Y l, Y4 and Y6 
grouping, within which, these receptors appear to be more closely related to one another than 
the Y2 and Y5 receptors which clearly define another family (Larhammar, 1996b). Varying 
degrees of conservation are observed across species, with the Yl receptor displaying tight 
conservation across a variety of species, in contrast with the Y4 receptor which appears to be
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one of the most rapidly evolving receptors, possessing low sequence identity even between rat 
and, human sequences (Larhammar, 1996b).
1.6.4 Characteristics of receptor subtypes
1.6.4.1 Yl receptor
The NPY Y 1 receptor is the best characterised receptor for NPY . The cloning in 1990 of a rat 
cDNA encoding a G-protein coupled orphan receptor (Eva, 1990), which was subsequently 
shown to encode a Yl type receptor, marked the advent of NPY receptor subtype 
identification. Subsequently, species homologues from mice (Eva, 1992), man (Larhammar, 
1992) and Xenopus laevis (Blomqvist, 1995) were identified for this receptor which mediates 
many of the well established functions of NPY in the periphery. The genomic organisation of 
the gene encoding this Y 1 subtype has also been determined in humans and mice, with the 
human Yl gene being located on chromosome 4q (Eva, 1992; Herzog, 1993).
The human Y 1 receptor protein is 384 amino acids in length, contains the seven transmembrane 
motif characteristic of G-protein coupled receptors, and exhibits a striking degree of sequence 
conservation, with the rat and human gene being highly orthologous, displaying 94% amino 
acid identity (Larhammar, 1996b). This receptor can effectively couple to both 
phosphatidylinositol (PI) hydrolysis, and the inhibition of adenylyl cyclase activity, an effect 
dependent upon the cell type expressing the receptor (Herzog, 1992). The importance of this 
dual coupling ability in normal cell function is unknown, although it has been demonstrated 
that the Y1 receptor can couple to either second messenger system in tissue preparations or cell 
lines naturally expressing the receptor (Aakerlund, 1990 and Hinson, 1988). Three splice 
variants of the first exon have been identified in the 5' region of the human Yl receptor which 
are expressed in tissue specific patterns (Ball, 1995). The murine Yl receptor possesses two 
splice variants, both binding NPY, but differing in their efficiency of coupling to subsequent 
signal transduction procedures (Nakamura, 1995).
The pharmacology displayed by this receptor is characterised by the following order of 
potency, where:
NPY = PYY > Pro^'^-substituted analogue »  C-terminal NPY fragments.
As the order of potency for this receptor suggests, the whole NPY molecule is required for 
activation of the Yl receptor, as removal of either the N- or C-termini results in a loss of 
affinity for the Y1 receptor. Originally this receptor was described as possessing micromolar 
affinity for C-terminal fragments of NPY such as NPY 13-36, but interacted with the full 
length NPY and PYY molecules with nanomolar affinity (Wahlestedt, 1986). A selective Yl 
agonist was reported in 1990, in the form of the substituted NPY analogue Leu^lPro^^ NPY, 
which demonstrated Yl receptor selectivity (Fuhlendorf, 1990). Subsequent studies revealed
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that the substituted analogue Pro34 NPY was sufficient to display selectivity for the Y1 receptor 
(Potter, 1991).
The selectivity of this substituted NPY analogue for the Y1 receptor has been exploited and 
used as a means of elucidating the distribution of the receptor (Gehlert, 1992). With the aid of 
radio-labelled Pro^^ Npy, the Y1 receptor has been shown to be predominant in brain regions 
such as cerebral cortex, thalamus and certain nuclei of the amygdala, and consistent with a 
postsynaptic localisation, the mRNA for the Y1 receptor displays a similar distribution (Eva, 
1990). Messenger RNA for the Y1 receptor has also been detected in a variety of peripheral 
tissues, including heart, kidney and gastro-intestinal tract (Wharton, 1993). Screening of 
neuroblastoma cell lines using mono-iodinated NPY identified SK-N-MC cells as a human cell 
line containing an apparently homogenous population of Y1 receptors (Sheikh, 1989).
The effects associated with activation of Y1 receptors are shown in figure 1.8.
Relative progress has been made in the design of Y 1 antagonists. Peptide based compounds 
such as 1229U91 (GW11229), which is a symmetrical dimeric peptide joined in an anti-parallel 
fashion, is a compound with an extremely high affinity for the Y1 receptor, and is capable of 
blocking NPY-induced second messenger responses via this receptor (Daniels, 1995). 
However this compound also has a high affinity for Y4 receptors, where it can behave as either 
an agonist or antagonist (Gehlert, 1996b). A second molecule, BIBP3226, whose design was 
based on the C-terminal region of the NPY molecule and modified into a non-peptide stmcture, 
exhibits low nanomolar affinity for the Y 1 receptor, and appears to share overlapping binding 
sites with NPY (Doods, 1996 and Sautel, 1996). However, this compound has been shown to 
exhibit nanomolar affinity at other reported subtypes (Gerald, 1996), and unfortunately, limited 
aqueous solubility coupled with poor oral absorption and central nervous system penetration, 
limit the use of this compound for testing further the role of the Y1 receptor. A third Y1 
antagonist (SR120819) has been described which has nanomolar affinity and is capable of Y1 
inhibition in second messenger studies and tissue preparations (Serradeil-Le Gal, 1995). More 
recently, a series of novel benzimidazoles have been evaluated as Y1 selective antagonists 
(Zarrinmay eh, 1998).
1.6.4.2 Y2 receptor
Like the Y 1 receptor, this NPY receptor subtype was delineated using vascular preparations 
(Wahlestedt, 1986). Pharmacological evidence had detailed the existence of this subtype, 
which was initially cloned in 1995 from human SMS-KAN cells using an expression cloning 
technique (Rose, 1995). Subsequent independent groups also cloned this receptor from a 
variety of sources, namely: human brain cDNA libraries (Gehlert, 1996a and Gerald, 1996) 
and the human neuroblastoma cell line KAN-TX (Rimland, 1996).
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The human Y2 receptor protein is 381 amino acids, exhibits low homology with other known 
receptors for the PP-fold peptides, and displays a high degree of species conservation; the rat 
and human gene share 98% amino acid identity (Larhammer, 1996b). Like the Y1 receptor, 
this receptor is coupled to the inhibition of adenylyl cyclase, although some studies have 
demonstrated a lack of pertussis toxin sensitivity (Foucart, 1989; Colmers, 1989) in certain 
systems. Therefore, like the Y1 receptor, the Y2 receptor may display differential coupling to 
second messengers.
The pharmacology displayed by this receptor is characterised by the following order of 
potency:
NPY = PYY > C -terminal fragment NPY 13-36 > pro^d NPY > PP.
As the order of potency suggests, the Y2 receptor is capable of recognising carboxy- terminal 
fragments of NPY, and appears not to require the whole NPY molecule for activation, thereby 
creating a basis for pharmacological distinction between the Y1 and Y2 receptors. The C~ 
terminal region of the peptide is of crucial importance for recognition by Y2 receptors, as 
demonstrated by the inactivity of the substituted analogue Pro^^NPY at Y2 receptors 
(Fuhlendorf, 1990) and the selective Y2 agonist activity of the C-terminal fragment, NPY 13- 
36 (Wahlestedt, 1986).
The Y2 receptor is located in a variety of brain tissues, with particular abundance displayed in 
the hippocampus, substantia nigra, thalamus, hypothalamus and brainstem (Dumont, 1993 and 
Gehlert, 1992). In the periphery, Y2 mRNA is less abundant, with Y2 receptors distributed in 
the peripheral nervous system, particularly in sympathetic, parasympathetic and sensory 
neurones (Gehlert, 1998). SMS-KAN cells are a human cell line containing a homogenous 
population of Y2 receptors (Wieland, 1995)
The effects associated with activation of Y2 receptors aie illustrated in figurel.8.
Several agonists for this receptor have been described since the initial identification of this 
subtype using the C-terminal fragment NPY1^“36 (Wahlestedt, 1986). A modified, cyclic 
dodecapeptide analogue of NPY has been shown to be the smallest full agonist at the human 
Y2 receptor, and has aided modelling of the bio active conformation of NPY at the Y2 receptor 
(Rist, 1996). A competitive peptide antagonist based on the design of a cyclic molecule 
containing four attached COOH terminal fragments of NPY, and termed T4-[NPY(33-36)]4, 
has been described as a selective Y2 antagonist, and represents the first selective Y2 receptor 
antagonist (Grouzmann, 1997).
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1.6.4.3 Y3 receptor
The Y3 receptor is distinguished from other members of the NPY receptor family in that it 
displays a high affinity for NPY, while demonstrating a relatively low affinity for PYY. This 
receptor is best characterised in rat brainstem, in the region of the nucleus tractus solitarius, 
where application of NPY elicits a dose dependent attenuation of blood pressure and heart rate 
(Grundemar, 1991a, 1991b). A brainstem Y3 receptor has also been identified by 
electrophysiology technology (Glaum, 1997). However, the expression of Yl, Y2 and other 
PP family receptors in this area make pharmacological evaluation difficult, as a variety of 
receptor subtypes may play a role in cardiovascular regulation via the brainstem. Several other 
model systems such as rat colon (Dumont, 1994), rat lung (Hirabayashi, 1996) and rat and 
bovine adrenals (Bernet, 1994; Norenberg, 1995) also display the ligand binding profile which 
is characteristic of the Y3 receptor. In bovine adrenal chromaffin cells, the Y3 receptor is 
coupled to an influx of calcium and does not appear to affect adenylyl cyclase activity 
(Wahlestedt, 1992).
The pharmacology displayed by this receptor is characterised by the following order of 
potency:
NPY »Pi-o34nPY > N P Y  13-36 » p y Y, PP.
The effects associated with activation of the Y3 receptor are illustrated in figure 1.8.
As this receptor has not been cloned, and no specific agonists or antagonists have been 
described, the current consensus holds that the evidence is insufficient to grant the Y3 site 
receptor status. Recommendations outlined by the International Union of Pharmacology have 
designated nomenclature for such binding sites and responses where NPY is considerably 
more potent than PYY as "putative" NPY receptors (Michel, 1997).
1.6.4.4 Y4 receptor
A homology cloning strategy was responsible for the cloning of the Y4 receptor in 1995 
(Lundell, 1995). The gene was initially cloned from a human genomic library and originally 
designated PPl, while another group identified the clone and named it Y4 (Bard, 1995).
Rat (Lundell, 1996, Yan, 1996) and murine (Gregor, 1996a) homologues have subsequently 
been cloned, and there appears to be considerable sequence divergence exhibited when human 
and rat Y4 sequences are compared, in contrast to the apparent species conservation displayed 
by the Y 1 and Y2 receptors. Only 75% amino acid identity is observed, making this one of the 
most poorly conserved G-protein coupled receptors known (Lundell, 1996). Like other 
receptors in this family, agonist stimulation of Y4 results in an inhibition of adenylyl cyclase 
activity as well as stimulation of PI hydrolysis and mobilisation of intracellular calcium 
(Gehlert, 1998).
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A unique feature of the Y4 receptor is evident in the unusual pharmacology displayed, the 
predominant characteristic being the extremely high affinity for PP of the same species.
The pharmacology displayed by this receptor is characterised by the following order of potency 
(Gehlert, 1996b):
PP »L eu31 Pro34NPY > PYY > NPY > NPY13-36
This pharmacological order of potency suggests that like the Yl receptor, both the C- and N- 
termini are required for full potency, implying that the binding domain is similar in these two 
subtypes, as both the Yl and Y4 receptors fail to recognise C-terminal fragments of NPY. It is 
noteworthy that structure-activity analysis has revealed differing binding profiles between rat 
and human Y4 receptors. The rat Y4 receptor appears to possess a more selective receptor 
interaction with rat PP vs NPY or PYY, whereas the human Y4 receptor exhibits a less 
selective interaction with rat PP vs NPY or PYY, and a greater dependence on N-terminal PP 
residues, relative to rat (Walker, 1997).
The distribution of Y4 mRNA differs between species, with human Y4 mRNA levels being 
prevalent in colon, small intestine and pancreas, while other peripheral tissues appear to lack 
message, and various CNS regions display low expression levels (Lundell, 1995). In 
contrast, rat Y4 mRNA levels are abundant only in the testis and lung (Lundell, 1995). 
Additional heterogeneity has been suggested as a result of findings that in rat brain, high levels 
of 125% bPP binding are found principally in two structures, namely the area postrema and the 
interpeduncular nucleus. As the high level of binding in the interpeduncular nucleus is not 
observed using a radioligand with high affinity for Yl and Y4 receptors, such as 123% Leu^l 
Pro34_pYY, another subtype of PP receptor may be involved (Gehlert, 1997a).
The functions attributed to the Y4 receptor are likely to mediate some of the actions elicited by 
PP in the digestive tract such as, inhibition or stimulation of gastric secretion, inhibition of 
pancreatic secretion, decrease in gall bladder activity and a reduction in intestinal motility, as 
outlined in figure 1.8 (For a review see Hazelwood, 1993). Centrally administered PP 
produces a modest increase in feeding (Clark, 1984), which may be mediated by centrally 
located subtypes, but which remains unclear to date (Gehlert, 1997a).
Among the NPY antagonists, the Yl antagonist BIBP3226 has a very low affinity for the 
human Y4 receptor, whereas the other Yl antagonist 1229U91 behaves as a high affinity 
agonist at the Y4 receptor (Schober, 1998). PP is a useful tool for identifying and defining 
Y4 sites, as it exhibits low affinity for both Yl and Y2 receptors. There are currently no 
selective Y4 antagonists described.
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1.6.4.5 Y5 receptor
In 1996 the cloning of a fifth member of the NPY receptor family was described. The NPY Y5 
receptor was cloned using an expression cloning technique with libraries derived from rat 
hypothalamus (Gerald, 1996), and was shown to encode a 456 amino acid protein which 
displays relatively low identity (<35%) with other members of the PP-fold receptor family. 
Another group reported the cloning of a shorter 445 amino acid version, which may be the 
result of alternative splicing (Hu 1996). The human orthologue was subsequently cloned, and 
shown to exhibit 87% overall amino acid identity and 99% identity in the transmembrane 
domains. The human Y5 receptor displays an interesting genomic arrangement in that it 
appears to reside on human chromosome 4q i.e. the same location as the human Yl receptor 
gene but in the opposite orientation (Gerald, 1996 and Hu, 1996). A mouse homologue was 
isolated from a mouse brain cDNA library, and analysis of the predicted amino acid sequence 
indicates that the polypeptide encoded by this cDNA is 89% and 97% identical to the human 
and rat Y5 receptors respectively (Nakamura, 1997). When expressed in mammalian cells, this 
receptor, like the other NPY receptor family members, also couples to the inhibition of 
adenylyl cyclase (Gerald, 1996).
The pharmacology of this receptor is chai'acterised by the following order of potency:
NPY > PYY= Pro34NPY = NPY2-36 = pYy3-36 »NPYl3-36_
The rat clone for this receptor exhibits an unusual pharmacology in that the receptor displays 
highest affinity for NPY and PYY, with substantially lower affinity for rat PP. However, 
human PP has a very high affinity for the rat Y5 receptor (Gerald, 1996) and provides a 
potential tool for determining the physiological function of this receptor in the rat. Substituted 
analogues such as Pi’o34n p y  exhibit a high affinity for this subtype, as do longer C-terminal 
fragments of NPY and PYY such as NPY2-36, which has a similar potency when compared to 
the native peptide. The most selective peptide for this receptor is [d-Trp32]NPY, which 
displays low nanomolar affinity for the Y5 receptor, while exhibiting micromolar affinity for 
the other NPY receptor subtypes (Gerald, 1996).
The distribution of the Y5 receptor has been elucidated from Northern blot analysis and in situ 
hybridisation studies, with mRNA for tliis subtype being most prevalent in several brain areas, 
in particular within various hypothalamic structures, as well as a peripheral location in the testis 
(Gerald, 1996 and Hu, 1996). Y5 mRNA distribution is similar in humans, differing only in 
the amount of Y5 mRNA present, where levels are more abundant in rat brain (Jacques, 1997). 
Phenomenal interest has mounted surrounding this NPY receptor subtype, as the 
pharmacology of this receptor demonstrates great similarity to the pharmacology observed to 
mimic NPY-stimulated enhancement of food intake (Gerald, 1996). This receptor may 
therefore be responsible for mediating the characteristic effects that NPY exerts on feeding
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behaviour, and may represent the previously referred to "Yl-like" or "feeding receptor". 
Further evidence in support of the role of this receptor in food intake regulation is derived from 
the distribution of this subtype which is predominant in areas of the brain believed to be 
important in co-ordinating the regulation of food intake and energy balance (Gerald, 1996). 
The Y5 receptor may also be involved in mediating the NPY-stimulated enhancement of renal 
sodium excretion (Bischoff, 1997), as the order of potency for this receptor also mimics this 
response. Figure 1.8 summarises the effects of activation at theY5 receptor.
No selective Y5 antagonists have been described in the literature to date. However, the ability 
of proposed Yl selective antagonists to block NPY stimulation of feeding behaviour in several 
studies, has shed controversy upon the role of the Y5 receptor in NPY induced feeding 
(Kanatani, 1996). Further research will reveal which receptor subtype(s) are involved in 
mediating this effect of hypothalamic NPY.
1.6.4.6 y6 Receptor
In 1996 an additional receptor subtype was cloned from mouse genomic DNA, which exhibited 
Yl-like pharmacology, encoded a 371 amino acid protein and was initially designated Y5 
(Weinberg, 1996). Subsequent reports described the same clone as a high affinity PP receptor 
(PP2) (Gregor, 1996b) and a C-terminal peptide preferring Y2-like receptor (Y2b) 
(Matsumoto, 1996). Homologues have also been cloned from mice, rabbits, primates and 
humans. In primates and humans, the gene is a pseudogene, and therefore the recommended 
designated nomenclature for this receptor is denoted in lowercase as y6. Gene distribution 
studies have shown that the y6 gene is present in human, monkey, mouse, dog, cow, rabbit, 
and chicken, but completely absent in rat (Burkhoff, 1998). The y6 receptor exhibits very 
limited sequence homology to the other NPY receptor family members, and appears to be most 
closely related to the Y1 receptor.
The human and primate sequences differ from those in mice and rabbits, as they contain a 
deletion of a single nucleotide, resulting in a frame shift mutation located in the putative third 
intracellular loop of the receptor. As a result, the human and primate y6 receptor sequences 
contain a termination codon in a position that results in a 290 amino acid truncated protein, and 
lacks the characteristic 7 transmembrane domain. The resulting receptor fails to bind PP-fold 
peptides as the protein encoding the receptor is not expressed. In vitro mutagenesis of the 
pseudogene to restore the frame results in a protein with the predicted 7 transmembrane domain 
topology, but still fails to bind members of the PP family of peptides. In comparison the 
murine or rabbit clones readily express functional receptor proteins, suggesting that the y6 gene 
in primates may have become a non-functional pseudogene during evolution (Rose, 1997).
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This receptor has proved difficult to categorise in terms of pharmacology as various groups 
have observed differing results, with the receptor appearing to exhibit diverse pharmacology. 
The pharmacology of this NPY receptor therefore remains controversial (Weinberg, 1996; 
Gregor, 1996b and Matsumoto, 1996).
The mRNA for this receptor is unusually long at 9.8Kb in the mouse, and identification and 
subsequent distribution analysis has been accomplished by in situ hybridisation as opposed to 
Northern blot analysis which failed to detect y6 mRNA in murine and rabbit brain. Expression 
of the y6 receptor in murine brain was initially identified in the hypothalamus (Weinberg, 
1996), and was identified using RT-PCR in rabbit brain areas including hippocampus and 
hypothalamus, and in small intestine and adrenals (Matsumoto, 1996). The human y6 gene has 
been localised to human chi'omosome 5 (Gregor, 1996), and in contrast, mRNA for the human 
receptor has been readily detected using Northern blot analysis, and shown to be widespread in 
heart and skeletal muscle (Gregor, 1996b and Matsumoto, 1996).
This receptor remains in an experimental context, as it is unlikely that it plays any role in 
human physiology, and its unusual pharmacology needs to be characterised before an 
understanding of the role it may play, with regard to actions of the PP-fold peptides, can be 
delineated in other species expressing the full length receptor.
1.6.4.7 Additional sites
Additional receptor subtypes for the PP-fold family have been suggested from reports outlining 
a preferential PYY response in several systems. The PYY-preferring receptor has been 
identified in several systems, is distinguished by exhibiting a modest preference for PYY over 
NPY and was first described in the rat small intestine as having a 5-to 10-fold higher affinity 
for PYY over NPY (Laburthe, 1986). Subsequent reports have described this receptor in 
adipocytes (Castan, 1993) and in a kidney proximal tubule cell line (Voisin, 1993). This 
receptor behaves like the other PP-fold receptor family members in that it appears to be coupled 
to the inhibition of adenylyl cyclase via a pertussis toxin sensitive G-protein (Voisin, 1993). 
The receptor(s) responsible for this pharmacology have not been successfully cloned to date, 
and it has been suggested that the pharmacology may be the result of Yl receptor expression in 
a different tissue (Holliday, 1997). Critical to the further identification of this receptor will be 
the identification of specific clones for the receptor, resulting in a greater understanding of its 
physiological role.
A receptor belonging to the NPY receptor family has also been cloned from Drosophila 
melanogaster (Li, 1992), and more recently multiple NPY receptor subtypes have been cloned 
from the Zebrafish {Danio rerio), which appeal’ to be distinct from all known mammalian
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Figure 1.8 Summary of the physiological effects observed upon activation of the 
NPY receptor subtypes.
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Receptor
subtype
Effect Target
Yl Vasoconstriction and potentiation 
of vasoconstriction 
Anxiolysis and sedation 
Stimulation of feeding behaviour
Blood vessels
Amygdala
Hypothalamus
Y2 V asoconstriction
Suppression of transmitter release
Enhanced memory retention 
Suppression of glutamate release 
Suppression of noradrenaline 
release
Certain blood vessels 
S y m p a t h e t i c  and 
parasympathetic nerve 
fibres
Hippocampus 
Hippocampal neurons 
Locus coruleus
Y3 Centrally mediated increase and 
decrease in arterial blood pressure 
and bradycardia
I nh i b i t ion  of  g l u t ama te  
responsiveness and baroceptor 
reflex
Inhibition of catecholamine release
Nucleus tractus solitarius 
Nucleus tractus solitarius 
Adrenal medulla
Y4 Inhibition of pancreatic secretion 
Inhibition or stimulation of gastric 
secretion
Reduction in gall bladder activity 
Stimulation of feeding behaviour
Pancreas
Gastro-intestinal tract
Gall bladder 
Hypothalamus
Y5 Stimulation of feeding behaviour 
Stimulation of renal sodium 
excretion
Hypothalamus
Kidney
subtypes (Lundell, 1997 and Ringvall, 1997). It remains to be determined whether mammalian 
homologues exist, and more detailed studies are required in order to determine the role these 
subtypes play in the lai’ge family of NPY/PP receptors
1.7 The role of Neuropeptide Y in feeding behaviour
As detailed above in section 1.4, since the 1950's, the hypothalamus has been implicated in the 
control of feeding behaviour and energy homeostasis, with the pursuit of hypothalamic signals 
specifically encoding the sensation and experience of hunger, being highly competitive and of 
widespread interest. The past decade has witnessed numerous revelations implicating 
hypothalamic NPY as the long sought after transducer of appetite.
1.7.1 Historical aspects of the role of NPY in feeding behaviour
The wealth of interest surrounding NPY, with respect to obtaining new insight into the 
complex neural network underlying consummatory behaviour, can be attributed to the 
discovery of the orexigenic (from the Greek word orexus meaning appetite) properties of NPY 
in the rat. In 1984 the first studies were published describing stimulation of ingestive 
behaviour upon intracerebroventricular (icv) injection of NPY (Clark, 1984). Clark et al 
demonstrated that injection of a 2jxg dose of NPY resulted in significant stimulation of food 
intake in treated rats when compared with control treated rats. From these initial studies, NPY 
appeared to Induce satiated animals to eat a normal sized meal at low doses, while at higher 
doses, NPY was capable of inducing eating behaviour of unparalleled proportions. These 
dramatic effects suggested that NPY and other structurally related members of the PP-fold 
family, may play a role in regulating naturally occurring feeding behaviour (Clark, 1984). As a 
result of these findings, Clark concluded that NPY or an NPY-like peptide abundant in the rat 
brain may be the neurotransmitter or neuromodulator responsible for the physiological 
regulation of feeding behaviour.
Subsequent experiments demonstrated in a number of species including pigs (Parrot, 1986), 
mice (Morley, 1987a), and sheep (Miner, 1989), that central administration of NPY stimulates 
feeding and enhances the on-going pattern of feeding in a dose related manner. In the same 
year, Levine et al also described the ability of NPY to stimulate feeding, and proposed 
additionally that NPY could alter the receptor conformation of other compounds which act to 
augment ingestive behaviour for example dopamine and opioids, resulting in an enhanced 
effect due to cooperativity between these entities and NPY (Levine, 1984). NPY was shown 
to increase total ingestion time (Kalra, 1987), and repeated NPY injection effectively postponed 
the satiety which normally follows a single injection (Morley, 1987b), suggesting that NPY 
stimulates ingestive behaviour by a mechanism involving reduced satiety signals. Detailed
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analysis of ingestive patterns (Lynch, 1994), confirmed attenuation of satiety as a contributing 
mechanism by which NPY elicits its chaiacteristic effects on feeding behaviour.
Evidence also suggested that NPY, as well as attenuating satiety, could stimulate ingestive 
behaviour by increasing the motivation to eat. Using a selection of behavioural paradigms 
designed to assess motivation. Flood et al implicated increased motivation to eat as a 
mechanism by which NPY augments food intake (Flood, 1991). The potent stimulatory effect 
of NPY on feeding is evident from findings that NPY enhances feeding and drinking during 
nocturnal feeding, following a 24 hour food deprivation period, and during the first half of the 
light cycle, a period when rats normally refrain from eating (Kalra, 1996).
It is noteworthy that the pattern of feeding elicited by neuropeptide Y is of a discontinuous 
nature, resembling the normal nocturnal feeding pattern in the rat (Kalra, 1988), with NPY 
release in relevant brain sites activated at the onset of the dark phase, where it serves to initiate 
and sustain nocturnal feeding (Clark, 1984, 1985).
1.7.2 Anatomical Pattern of Neuropeptide Y induced feeding
As previously discussed in section 1.4.4 the hypothalamus is a brain region with paramount 
importance in the co-ordination of food intake and energy balance, and which also haitours the 
highest NPY concentration of any brain region (Allen et a l , 1983). With this in mind, 
experiments were performed in order to delineate the role of the hypothalamus in NPY-elicited 
eating.
The paraventricular nucleus (PVN) of the hypothalamus is richly innervated with this peptide, 
containing one of the densest supplies of NPY-containing presynaptic terminals in the brain, 
and also housing a close functional relationship between NA and NPY. As a result of existing 
evidence detailing a stimulation of feeding behaviour by PVN injection of exogenous NA, as 
well as by release of endogenous NA, it was suggested that NPY in the PVN may act similarly 
in its effects on feeding behaviour. In 1984, Stanley and Leibowitz demonstrated that 
injection of NPY into the PVN of satiated, brain cannulated rats, elicited a strong, dose- 
dependent increase in food intake, at picomolar doses (Stanley, 1984). This robust feeding 
response suggested an important role for hypothalamic NPY in the control of feeding 
behaviour.
The following year witnessed the advent of NPY as a powerful stimulant of ingestive 
behaviour in its own right, when previous hypotheses outlining a possible interaction between 
NPY and NA in the hypothalamic control of feeding were dispelled, and NPY was shown to 
elicit a robust increase in food intake without functional interaction with NA (Stanley, 1985a). 
Subsequent studies demonstrated the ability of NPY to elicit sustained hyperphagia and obesity
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in rats, upon PVN injection, and postulated that disturbances in NPY function may play a role 
in disorders of eating behaviour and bodyweight regulation (Stanley, 1986).
Immunocytochemistry studies documented the presence of NPY in the PVN, and revealed a 
pattern of NPY distribution in exclusive axon terminals, where NPY forms a variety of 
conventional synaptic contacts (Sawchenko, 1988). Studies detailing immediate early gene 
expression in various brain sites in response to intracerebroventricular injection of NPY, also 
confirmed the presence of NPY target cells in the PVN and surrounding sites implicated in 
feeding (Li, 1994).
More recent studies proposed that an additional hypothalamic site is involved in NPY elicited 
eating. A cannula mapping study of the hypothalamus revealed that NPY is most effective in 
stimulating feeding when injected into the perifornical hypothalamus (PFH), an area lateral to 
the PVN (Stanley, 1993). The multiple sites of action regarding feeding and NPY in the 
hypothalamus, suggests that NPY may have distinct functions in the PVN and PFH. NPY in 
the PFH has been implicated in mediating eating behaviour, while the PVN has additional roles 
in regulating metabolic and endocrine effects associated with NPY elicited eating behaviour 
(see sections 1.7.6.1 and 1.7.6.2) (Stanley, 1993).
1.7.3 Hypothalamic NPY and feeding-The pathway involved
Various studies have illustrated that two populations of NPY producing-neurones, the 
intrahypothalamic group clustered in the arcuate nucleus (ARC), and the extrahypothalamic 
group in the brainstem, project to various hypothalamic sites implicated in the control of 
ingestive behaviour; namely the PVN, PFH, dorsomedial nucleus, ventromedial nucleus and 
arcuate nucleus (Sahu, 1988b and Kalra, 1996). Projections of NPY-containing cells in the 
arcuate nucleus are postulated to be the primary source of NPY involved in the regulation of 
feeding, as almost complete elimination of NPY from the brainstem failed to alter the normal 
ingestive behaviour pattern in rats (Sahu, 1988b). Therefore, a specific pathway 
encompassing cell bodies in the ARC, projecting principally to terminals in the PVN, was 
proposed to mediate the augmentation of feeding behaviour elicited by hypothalamic NPY 
(Mjhanwar-Uniyal, 1993). Experimentally induced reduction in the NPY supply to the PVN, 
either by interruption of NPY production in the ARC by anti-sense oligodeoxynucleotides 
(Akabayashi, 1994), or by immunologic impairment of ARC NPY, resulted in a significant 
suppression of food intake (Burlet, 1995), highlighting further the importance of this pathway 
in the NPY mediated stimulation of feeding.
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1.7.4 Evidence for the role of NPY as an endogenous mediator of food 
intake
Evidence in favour of NPY as a physiological neurochemical signal involved in the regulation 
of food intake has come from observations that a single dose of NPY administered during the 
dark phase, when rats normally eat, rapidly and reliably enhances the ongoing rate of food 
intake for four hours (Clark, 1985), and that continuous intravenous NPY infusion produces 
sustained hyperphagia and obesity resembling that elicited by either hypothalamic lesions or 
genetic alterations (Stanley, 1986). Further support for the hypothesis that NPY may 
function as a physiological promoter of food intake, came from studies aimed at 
investigating NPY neuronal function in response to food intake and food deprivation. 
Fasting and feeding were shown to induce reciprocal changes in the concentration of NPY in 
the PVN of the rat, with food deprivation producing a dramatic accumulation of NPY in this 
hypothalamic region (Kalra, 1988). The reciprocal responses evoked by sequential food 
deprivation and satiety, indicate that under normal circumstances NPY in the PVN may act 
primarily to stimulate food intake. Perturbations in daily patterns of food intake, e.g. after a 
period of food deprivation, have been shown to promote a steady increase in NPY levels in 
the ARC, representing an enhanced rate of NPY synthesis, and further implicating NPY in 
the control of food intake (Kalra, 1988 and Sahu, 1988a). Subsequent studies demonstrated 
changes in PVN neuropeptide Y levels in an experimental paradigm which reliably reflects 
appetite in the rat, where sequential changes in appetite reflected alterations in NPY release in 
the PVN. NPY release in the PVN was shown to be a potent orexigenic signal for periodic 
eating behaviour, as NPY concentrations were shown to be elevated before the introduction 
of food, and thereafter, levels decreased significantly during the course of eating (Kalra, 
1991). Intense exercise has also been shown to elicit increased hypothalamic NPY levels, 
suggesting that negative energy balance, whether caused by decreased energy intake, or 
increased energy expenditure, results in stimulated hypothalamic NPYergic activity (Lewis, 
1993). Physiological situations such as lactation, which demand increased food 
consumption, also induce upregulation of the ARC-PVN NPYergic system (Malabu, 1994).
Further evidence supporting the role of NPY as an endogenous hypothalamic modulator of 
food intake, has come from studies where hypothalamic NPY expression has been shown to 
be elevated following food deprivation, with a specific increase in preproNPY (the NPY 
precursor) mRNA localised to the ARC of the hypothalamus. This supports the existence of 
a specific ARC-PVN NPY pathway regulating food intake, with increased levels of 
preproNPY mRNA in the ARC resulting in a concomitant increase in NPY synthesis, 
reflected by augmented levels of the peptide in terminals in the PVN (White, 1990). More 
recent findings have reported that low levels of hypothalamic NPY may also result in
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hyperphagia and obesity, and have attributed this to an increased receptor sensitivity to NPY 
(Kalra, 1997). The NPY receptor involved in the modulation of feeding behaviour will be 
discussed in detail in section 1.8.
Increased secretion of NPY in the PVN has been observed in animal models of hyperphagia 
and obesity, and also in diabetic animals, where hyperphagia coincides with increased release 
of NPY in the PVN (Sahu, 1992), with a concomitant activation of NPY synthesis in the 
ARC in response to the elevated demand imposed by NPY hypersecretion (White, 1990). 
NPY has also been implicated in the pathogenesis of eating disorders such as bulimia and 
anorexia. Cerebrospinal fluid NPY concentrations are significantly elevated in underweight 
anorexic patients, and in many anorexic patients studied at intervals after weight restoration, 
but are normalised following restoration of body weight in long term weight restored 
anorexics (Kaye, 1990). Similarly the related peptide family member PYY is implicated in 
the pathogenesis of bulimia, as PYY is significantly elevated in the cerebrospinal fluid of 
bulimic patients (Kaye, 1990).
The use of anti-sense technology as a means of evaluating the effects of NPY on feeding 
behaviour remains controversial, with different groups reporting conflicting data. Initial 
studies using anti-NPY oligonucleotides to determine the effects of this treatment on food 
intake, feeding behaviour and bodyweight, described a significant decrease in cumulative 
food intake, meal size and duration, and bodyweight after anti-sense treatment (Hulsey,
1995). More recently, findings have been presented which describe a lack of specificity, 
coupled with non-selective effects on food intake and bodyweight, in rats treated with an 
oligonucleotide against NPY (Dryden, 1998). Therefore, the validity of this approach in 
determining the physiological part NPY may play in the regulation of appetite, remains 
questionable.
Another strategy employed to assess the function of NPY with regard to ingestive behaviour, 
is the use of genetically deficient NPY mice. The use of NPY-knockout mice theoretically 
permits the study of the role performed by NPY in the long-term regulation of feeding and 
adiposity. Erickson et al in 1996 described the effects of NPY removal on bodyweight, and 
surprisingly, despite the absence of NPY, the knockout mice maintained normal bodyweight, 
appearing normal in every aspect, with the exception of a propensity for seizure development 
(Erickson, 1996). NPY deficient mice displayed a normal hyperphagic response, and rapidly 
gained weight following a fast. Consistent with these findings, the neuroendocrine response 
to fasting did not appear to be impaired in NPY deficient mice (Erickson, 1997). Potential 
explanations for the lack of detectable effects of NPY deficiency on feeding behaviour, is that 
unique adaptations to congenital NPY deficiency aie capable of functionally compensating for 
the absence of the peptide, or that redundant mechanisms exist. As food intake is a
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fundamental physiological process, essential to survival, it is exceedingly likely that such 
mechanisms are called into play when an endogenous mediator of food intake is removed 
during development of the organism.
1.7.5 Natural dietary preferences and NPY
NPY appears to have a role in controlling the ingestion of specific macronutrients, as 
revealed by studies employing self-selection paradigms, where rats had access to diets 
containing pure macronutrient (Stanley, 1985b). Hypothalamic NPY acts to preferentially 
augment carbohydrate ingestion, while having little or no effect on fat or protein consumption 
(Stanley, 1985b). It has been postulated that the highly favoured carbohydrate ingestion 
elicited by NPY (and PYY), could be related to the fact that this diet provides a rapid source 
of usable energy (Steffens, 1969).
The pathway thought to mediate the actions of NPY on food intake has also been associated 
with specific ingestion of carbohydrate. This was demonstrated when NPY projections from 
the arcuate nucleus to the parvocellular division of the PVN were shown to be uniquely 
involved in the selective consumption of carbohydrate elicited by NPY (Jhanwar-Uniyal,
1993).
1.7.6 Metabolic and endocrine effects of NPY in the regulation of feeding 
behaviour
The role of NPY in the regulation of nutrient and energy balance is not confined solely to an 
effect on feeding behaviour, as in addition, endocrine systems and metabolism are also 
crucially important factors which may be influenced by NPY.
1.7.6.1 Endocrine systems
NPY modulates the release of certain hormones which have the ability to influence energy 
metabolism and food intake. These include corticosterone (CORT), adrenocorticotrophin 
hormone (ACTH), insulin and anti-diuretic hormone (ADH). The neuroendocrine actions of 
NPY involve the PVN, which has a primary function in controlling the release of these 
hormones. The neuroendocrine effects of NPY are stimulatory in nature, with PVN injection 
eliciting enhanced release of CORT (Wahlestedt, 1987 and Stanley, 1989), insulin 
(Akabayashi, 1994) and ADH (Luiten, 1987). The effects of NPY on these endocrine 
systems is functionally significant, as these hormones influence nutrient metabolism. CORT 
promotes increased ingestion and metabolism of carbohydrate and synthesis and deposition 
of fat, insulin favours net energy gain to be stored as triglycerides, and ADH also elicits 
prominent effects on carbohydrate metabolism. The stimulatory effect of NPY on the release
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of CORT, ACTH, insulin and ADH is consistent with the proposed role of NPY in the 
control of cai'bohydrate intake and metabolism (Leibowitz, 1994).
1.7.6.2 Metabolic processes
Regulation of metabolism by paraventricular NPY was first described as a result of 
observations that NPY specifically enhanced carbohydrate intake (Stanley, 1984) and 
preferentially increased fat deposition (Stanley, 1986). In the PVN, NPY elicits a dose- 
dependent increase in respiratory quotient (RQ), with a resulting diversion of metabolism 
toward carbohydrate utilisation and fat synthesis (Menendez, 1990). The selective 
augmentation in carbohydrate consumption elicited by NPY may therefore occur as a result of 
this metabolic diversion. Intracerebroventricular injection of NPY has two effects on 
metabolism in addition to increased carbohydrate consumption; namely a reduction in brown 
fat thermogenesis, and an augmentation in white fat lipoprotein lipase (LPL) enzymatic 
activity, resulting in a decrease in energy expenditure in brown fat, and an increase in energy 
storage in white fat. The stiiuulation of LPL activity is consistent with the effects of NPY on 
respiratory quotient, as an increase in RQ promotes carbohydrate oxidation which in turn 
favours fat storage by promoting lipogenesis (Billington, 1994). NPY decreases brown fat 
thermogenesis by reducing gene expression for uncoupling protein (UCP) which is present 
in brown adipose tissue and serves to uncouple oxidative phosphorylation, thereby regulating 
energy balance (Billington, 1994). NPY also inhibits the sympathetic outflow from the 
hypothalamus, which drives thermogenesis in brown adipose tissue (BAT), and in doing so 
reduces energy expenditure (Egawa, 1990 and Bing, 1998).
The aforementioned information accumulated in recent years provides compelling evidence 
for regarding NPY as a potent orexigenic signal, and depicts a physiological role for NPY as 
an endogenous appetite-transducing signal. Via its effects on ingestive behaviour, endocrine 
systems and metabolism, NPY acts as a starvation signal, ensuring energy homeostasis is 
maintained. The dramatic effects elicited by NPY on feeding behaviour and body weight, 
have given rise to tremendous interest regarding how this peptide executes its characteristic 
effect. As a result, a rapidly evolving and highly competitive field of research has emerged, 
with a view to elucidating further the NPY receptor subtype involved in transducing these 
effects, and to understanding more comprehensibly a constituent of the complex network 
which regulates feeding behaviour and energy homeostasis.
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1.8 Evidence for a distinct receptor subtype m ediating NPY 
induced feeding
The NPY receptor responsible for mediating NPY induced eating attracted universal interest, 
as the cloning of this receptor subtype would permit further progress in the development of 
an anti-obesity agent. The pharmacology of the feeding response characterised by NPY was 
determined by studies using NPY fragments to reveal which aspects of the NPY molecule 
were important for stimulation of feeding, and selective NPY receptor agonists to determine 
the receptor subtype involved.
These studies revealed that both N- and C-terminal regions of the NPY molecule, as well as 
the a-helix, contribute to NPY elicited eating, as alterations of either terminal region 
significantly modified NPYs' potency (Kalra, 1991; McLaughlin, 1991 and Stanley, 1992). 
A structure-function analysis strategy was subsequently employed in order to determine the 
pharmacological profile of the feeding response, with respect to the role of the then cloned 
receptors, Yl and Y2 . With the aid of selective receptor agonists and fragments of the NPY 
molecule, the pharmacology of the feeding response elicited by NPY was delineated.
In 1990 Kalra and co-workers demonstrated an augmentation in ingestive behaviour after icv 
or PVN injection of NPY, the Yl selective agonist Leu^ Ipro^^MPY, and NPY2~36 ^n N- 
terminal tyrosine deleted fragment, which proved to be consistently more effective than the 
whole NPY molecule in the stimulation of feeding at each dose tested. The Y2 selective 
agonist NPY^3-36 appeared to be completely ineffective in eliciting a response. The ability 
of the Y 1 selective agonist to evoke a response implicated the Y 1 receptor in the NPY 
induced feeding response (Kalra, 1991). Additional studies confirmed the pharmacological 
profile shown to mediate NPY elicited eating, demonstrating the markedly greater 
effectiveness of the Yl selective agonist when compared with the Y2 selective agonist, and 
earmarking the Yl receptor as the NPY receptor involved in transducing the effects on 
appetite (Stanley, 1992). However, the indisputable potency of NPY2-36 which is 
unchaiacteristic of Y1-mediated effects, suggested that the receptor involved may be a variant 
of this subtype (Stanley, 1992). Another difficulty in establishing the Yl receptor as the 
entity that mediates the feeding response, is the apparent absence of substantial Y1 binding 
and Yl mRNA (Eva, 1990) in paraventricular and perifornical areas of the hypothalamus 
(Dumont, 1993).
As the pharmacology of the feeding response failed to resemble that required to activate Y1 or 
Y2 receptors (Kalra, 1991 and Stanley, 1994), and NPY2"36 was able to fully stimulate 
feeding, but not reduce body temperature like the whole NPY molecule (Jolicoeur, 1991),
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this led to the consensus that the NPY receptor responsible for eliciting NPY induced eating 
was a novel NPY receptor subtype with "Yl -like" properties. This theory was further 
supported by other studies describing evidence for a heterogeneous population of 
pharmacologically different NPY receptors mediating the central actions of NPY (Bouali,
1994).
The location of this postulated "feeding receptor" was believed to be the hypothalamus, as 
existing evidence had illustrated the role of the hypothalamus in co-ordinating energy 
homeostasis and food intake. The dramatic effects on feeding behaviour observed upon 
hypothalamic injection of NPY also supported a hypothalamic distribution (For more detail 
refer to section 1.4 and 1.7).
The ability of an NPY antagonist PYX-2 to block spontaneous carbohydrate intake at the 
onset of the dark cycle in freely feeding rats, and to inhibit the stimulatory action of 
exogenously administered PVN NPY, provided evidence for the existence of endogenous 
hypothalamic NPY receptors responsible for mediating the action of NPY in the PVN 
(Leibowitz, 1992).
1.8.1 Cloning of the Y5 receptor
The search for the "feeding receptor" finally yielded in 1996, when the cloning of an NPY 
receptor subtype involved in NPY -induced food intake was reported in Nature. An 
expression cloning strategy had been employed to clone the Y5 receptor from rat 
hypothalamus (Gerald, 1996). The mRNA for this receptor was distributed primarily in the 
central nervous system, including the PVN of the hypothalamus, the proposed location of the 
feeding receptor ( Gerald, 1996). The distribution of Y5 mRNA in midline thalamic nuclei, 
which project heavily to the amygdala, suggested another potential role for the Y5 receptor in 
the regulation of the emotional aspect of appetitive behaviours (Gerald, 1996). The mRNA 
for this receptor is rare, as illustrated by the extremely low level of abundance of the Y5 
receptor in the hypothalamic library used to clone the receptor, which contained only one Y5 
receptor clone (Gerald, 1996). Use of the peptide analogue demonstrated that the 
pharmacological profile of the cloned Y5 receptor appeared to be consistent with that for the 
in vivo pharmacology of feeding in rodents (Clark, 1984; Kalra, 1991 and Stanley, 1992), 
with C-terminal fragments of NPY and PYY; namely NPY2“36 ^nd PYY3“36 eliciting a 
robust stimulation of food intake (Gerald, 1996).
The Yl receptor was dismissed as the feeding receptor in this study; the evidence in favour of 
the Y5 receptor reinforced by findings that the Yl selective antagonist BIBP3226 failed to 
reduce food intake induced by NPY (Gerald, 1996). The distribution of Y5 mRNA in critical 
areas of the hypothalamus known to regulate food intake, together with an in vitro
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pharmacology profile consistent with the in vivo feeding data, strongly suggested that the Y5 
receptor was the primary mediator of NPY induced feeding. In the same year, another group 
reported the cloning of the Y5 receptor from rat hypothalamus, which shared a similar pattern 
of mRNA distribution, exhibited an identical pharmacological profile, and differed only in 
amino acid sequence, containing 11 fewer N-terminal residues than the previously reported 
Y5 receptor (Hu, 1996).
Anti-sense oligonucleotides targeted to the Y5 receptor were used to assess the functional 
importance of this receptor in vivo. Intracerebroventricular injections of Y5 anti-sense 
prevented fasting-induced food intake in rats, significantly decreased basal food intake, and 
inhibited the increase in food intake after icv NPY injection (Schaffhauser, 1997). The 
development of a non-peptide, high affinity Y5 selective antagonist also fuelled the argument 
in favour of the Y5 receptor as the feeding receptor, as in vivo studies using this antagonist 
(CGP71683A) revealed a dose dependent inhibition of NPY induced feeding in satiated rats, 
a reduction in meal size and number, and a concomitant decrease in bodyweight after 28 days 
administration (Hofbauer, 1997; Criscione, 1997). However, the apparently clear-cut role 
postulated for the Y5 receptor in mediating NPY-elicited eating was tainted, when a study 
describing the inability of a Y5 selective antagonist to inhibit NPY induced feeding was 
reported (Kanatani, 1997).
1.8.2 Feeding receptor controversy
The inability of the selective Y5 antagonist to inhibit NPY induced feeding (Kanatani, 1997) 
sparked considerable controversy regarding the identity of the feeding receptor, and coupled 
with recent findings strongly implicating the NPY Y1 receptor as the appetite transducing 
agent, the literature at present remains controversial and contentious. Various groups have 
reported contradicting findings, implicating either the Y5 receptor, the Yl receptor, a novel 
NPY receptor, or a functionally co-operative relationship between Yl and Y5 receptors, as 
the means by which NPY elicits eating.
The evidence incriminating the Y 1 receptor in the control of feeding, has arisen primarily 
from studies demonstrating the ability of Yl selective antagonists to inhibit food intake. The 
peptide antagonist 1229U91, which has previously been described as a potent and selective 
Yl receptor antagonist (Daniels, 1995), was shown to block both NPY induced and natural 
feeding in rats (Kanatani, 1996). In the same study, radiolabelled 125% 1229U91 detected 
high affinity binding sites in rat hypothalamic membranes, signifying the presence of Yl 
receptors in the hypothalamus, and further supporting the proposed role for Yl receptors in 
mediating ingestive behaviour (Kanatani, 1996, 1998).
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Subsequent studies with Y 1 selective antagonists have reinforced the argument in favour of 
the Y1 receptors' role in feeding. The di-peptide Y 1 selective antagonist GI 264879A also 
rendered a long lasting dose dependent decrease in food intake and bodyweight in rats, 
stimulated by an increase in either endogenous or exogenous NPY (Matthews, 1997). More 
recently, a novel NPY Yl receptor selective antagonist BIB3304 has also been shown to 
inhibit feeding in rodents (Wieland, 1998). Spontaneous food intake in Zucker fatty rats 
(who lack an enzyme required for effective processing of hypothalamic peptides) was also 
shown to be suppressed by the Yl selective antagonist 1229U91, suggesting NPY is 
involved in feeding behaviour in these animals, via the Yl receptor subtype (Ishihara, 1998).
Immunohistochemistry and in situ hybridisation studies revealed a decline in the number of 
Yl receptors and Yl mRNA levels in the ARC of fasted rats, thereby endorsing the 
postulated role outlined for Yl receptors in the feeding response to NPY (Cheng, 1998). An 
antisense strategy against the Yl receptor also implicated hypothalamic Yl receptor 
involvement in the feeding elicited by NPY (Lopezvalpuesta, 1996). However, other studies 
employing anti-sense technology have ruled out a role for Yl receptors in mediating this 
response, as food intake was shown to be paradoxically increased after Yl anti-sense 
treatment, in studies carried out in rats (Heilig, 1996).
1.8.2.1 Yl and Y5 receptor involvement in the feeding response to NPY
New evidence has emerged recently from studies with Yl and Y5 knockout mice, which 
suggests that both of these NPY receptors are involved in feeding behaviour. Like NPY 
knockout mice (Erickson, 1996), Yl and Y5 deficient mice do not display overt major 
disturbances in bodyweight and daily food intake. This isn’t entirely surprising considering 
the central control of feeding behaviour is highly redundant, ensuring this fundamental 
function is unaffected.
However, fasting induced feeding is severely affected in Y1 -deficient mice, in contrast with 
NPY induced feeding which appeared relatively unaltered when compared with wild-type 
controls. This data indicates that the Yl receptor participates in the stimulation of food 
intake, but that other types of NPY receptors are also involved (Pedrazzini, 1998).
In Y5 deficient animals, food intake induced by icv injection of high doses of NPY and 
PYY3-36  ^was significantly decreased compared with wild-type controls. Feeding induced 
by lower doses of NPY and related peptides was similar in both Y5 deficient and wild-type 
animals, suggesting that the Y5 receptor is partially responsible for the ability of NPY and 
PYY3-36 to stimulate food intake in mice, and implicates the involvement of another NPY 
receptor subtype (Marsh, 1998). The concurrent administration of the Yl selective
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antagonist 1229U91 completely abolished the orexigenic effects of NPY in Y5 deficient 
mice, suggesting that Yl or Yl-like receptors, together with Y5 receptors mediate the 
response to centrally administered NPY (Marsh, 1998).
A role for both Yl and Y5 receptors in the regulation of NPY-induced feeding is 
substantiated by findings that the Y5 selective antagonist L I52804 is ineffective at inhibiting 
NPY elicited eating, but can effectively attenuate bPP induced feeding. This implicates the 
Y5 receptor in the regulation of bPP but not NPY induced feeding. Conversely, the Yl 
selective antagonist 1229U91 was shown to inhibit NPY induced feeding, but was 
ineffective at inhibiting bPP evoked feeding, indicating that the Y1 receptor is involved in 
NPY induced feeding (Kanatani, 1997). These findings are corroborated by the 
aforementioned knockout studies, where hPP stimulated food intake was completely 
abolished in Y5 deficient mice, compared with wild-type controls, inferring that hPP may 
exert its actions via the Y5 receptor (Marsh, 1998).
As the Yl and Y5 receptor genes aie under the transcriptional control of a common promoter 
region on chromosome four, it remains to be ascertained whether this is of relevance to the 
function of the Yl and Y5 receptors in the feeding response (Herzog, 1997). Expression and 
characterisation of the Y5 receptor in rat brain has further perpetuated the ai'gument in favour 
of multiple NPY receptor subtypes mediating feeding (Dumont, 1998). The low densities of 
Y5 binding detected in rat hypothalamus, implies that Y5 receptor protein is expressed and 
translated by a small percentage of hypothalamic neurones, and that the effect of NPY on 
ingestive behaviour is likely to be mediated by more than one class of NPY receptor 
(Dumont, 1998).
1.8.2.2 A Novel NPY receptor involved in feeding behaviour
An additional theory adding to the existing controversy, has arisen from reports that a 
receptor distinct from any of those currently cloned, mediates NPY induced feeding. In a 
study by O'Shea and co-workers, dose-response relationships of the five cloned NPY 
receptors with various NPY analogues and C-terminal fragments revealed that NPY elicited 
eating in the rat appeared to be mediated by a functionally distinct receptor (O'Shea, 1997). 
Studies performed with Yl selective antagonists 1229U91 and BIBP3226, have suggested 
that the Yl receptor does not participate in the NPY feeding response, as 1229U91 failed to 
block NPY stimulated feeding in CD-I mice, and the inhibition of ingestive behaviour 
exhibited by BIBP3226 was shown to be non specific regarding the Y 1 receptor, as the 
stereoisomer of this compound BIBP3435, which has negligible affinity for the Y1 receptor, 
evoked a similar blockade of NPY induced feeding (Li, 1997). As a result of these findings, 
it was proposed that an undefined subtype of the Yl receptor, or indeed a unique NPY
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receptor may transduce the effects of NPY elicited eating (Li, 1997). These claims were 
further substantiated by reports that novel, high affinity Yl selective antagonists LY353485 
and LY357879, were capable of attenuating NPY induced food intake in vivo after icv 
administration of these compounds in CD-I mice. As the actions of these antagonists 
differed from those exhibited by the Yl antagonists 1229U91 and BIBP3226, this data 
suggests that a subtype of the Y1 receptor, or a novel NPY receptor may mediate ingestive 
behaviour (Ivengar, 1997).
To date, the identity of the receptor involved in mediating the NPY induced feeding response 
remains controversial with conflicting findings described in the literature. The advent of 
delineating the precise mechanics attributed to NPY elicited feeding remains to be fully 
embraced, and until such a date, the understanding of this peptide's role in regulating the 
physiology of feeding remains incomplete.
1,9 Functional relationships between NPY and other starvation  
and satiety signals
As the regulation of appetite and energy homeostasis, is accomplished by a complex network 
of neurotransmitters, neuropeptides and hormones, the interactions between the NPY 
pathway, and other components of the circuitry involved in the maintenance of energy 
homeostasis aie of paramount importance.
1.9. 1 NPY -Leptin interaction.
The adipocyte derived hormone leptin has been implicated in the control of energy 
homeostasis, where it is proposed to act as a negative feedback signal to the hypothalamus, 
limiting obesity in times of nutritional abundance (Zhang, 1994; Campfield, 1995). Dramatic 
regulation of the leptin transcript and protein have also been observed in response to short 
term alteration in food intake, with fasting eliciting a prominent down-regulation, and 
excessive caloric intake resulting in up-regulation (Frederick, 1995; Maffei, 1995). Leptin is 
secreted by fat cells in response to nutritional status where it acts on the brain to inhibit 
feeding, increase thermogenesis, and decrease bodyweight (effects which act in opposition to 
those observed with hypothalamic NPY). The actions of leptin in suppressing food intake 
and stimulating thermogenesis are proposed to be mediated in part by inhibiting NPY 
neurones in the hypothalamus (Stephens, 1995). Leptin appears to reduce levels of NPY in 
the ARC and PVN, implying concomitant inhibition of synthesis and transport (Stephens, 
1995; Wang, 1997). An additional role for leptin influence on NPY signalling has come 
from studies detailing inhibiton of NPY in the PVN after leptin administration, while UCP 
gene expression increases, stimulating thermogenesis (Kotz, 1998). As repletion of NPY in
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the PVN effectively reversed the feeding inhibitory and thermogenic effects of leptin 
administration, these results provide functional evidence for leptin modulation of the ARC- 
PVN NPYergic pathway (Kotz, 1998). Leptin may also have postsynaptic effects, reducing 
the activity of released NPY in that the hyperphagia induced by injections of NPY into the 
hypothalamus is attenuated by leptin administration.
1.9.2 NPY -5-HT interaction
The monoamine neurotransmitter 5-hydroxytryptamine (5-HT), is a well established 
suppressant of food intake. The inhibitory actions on food intake have been localised to the 
hypothalamus specifically the PVN, where injection of 5-HT attenuates feeding in free 
feeding and food deprived rats (Shor-Posner, 1986). Pharmacological analysis of the 5-HT 
elicited reduction in food intake has demonstrated that the effect is mediated by post-synaptic 
5 - H T i b  receptors (Grignashi, 1995). In rats, selective 5-HT reuptake blocking drugs such 
as fluoxetine are effective in blocking food intake, as are drugs which block both 5-HT 
reuptake and stimulate 5-HT release, such as fenfluramine (Gibson, 1993). Recent evidence 
has suggested that the hypophagic actions of 5-HT may be mediated, in part , through the 
NPY pathway. The 5-HT antagonist methysergide, which stimulates feeding, increases 
NPY concentrations in the ARC and PVN of the hypothalamus (Dryden, 1993). Opposing 
these effects, selective 5-HTi agonists which reduce food intake, significantly reduce NPY 
concentrations in the PVN (Dryden, 1996) , and in addition, fenfluramine injections, which 
reduce food intake by raising synaptic concentrations of 5-HT, reduce levels of NPY in the 
hypothalamus (Rogers, 1991). The current consensus suggests that NPY and 5-HT have 
opposing effects in the hypothalamus and that 5-HT may produce its hypophagic activity by 
directly inhibiting the firing of NPYergic neurones in the ARC leading to reduced NPY 
release from the PVN (Wilding, 1997).
1.9.3 NPY-Glucagon-like peptide-1 (GLP-1 ) interaction
The gut peptide Glucagon-like peptide-1 (GLP-1), an incretin hormone, is synthesised within 
the rat brain and is effective at reducing food intake when injected into the 3rd ventricle in the 
rat, following both food deprivation and icv injection of NPY (Turton, 1996). GLP-1 
receptors are present in appetite regulating areas of the brain, such as the PVN of the 
hypothalamus and the central nucleus of the amygdala. Injection of exendin 9-39, a selective 
GLP-1 antagonist, increases food intake in the rat and potentiates the appetite stimulating 
effect of NPY. Assessment of hypothalamic NPY mRNA levels after administration of 
GLP-1 , revealed no change in NPY mRNA levels , and suggested that GLP-1 does not act 
by altering hypothalamic NPY synthesis (Turton, 1996). The precise interaction between
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GLP-1 and NPY requires further investigation in order to fully appreciate the function of 
these centrally acting regulators.
1.9.4 NPY-Corticotrophin releasing factor (CRF) interactions
CRF is expressed in the PVN and is an important regulator of adrenocorticotrophin hormone 
(ACTH) secretion. CRF injected into the PVN elicits weight loss, by reducing appetite and 
stimulating thermogenesis. It has been proposed that CRF and NPY act as opposing 
influences in the regulation of energy balance, with CRF mRNA levels altered in the opposite 
direction to NPY in conditions of energy deficit, such as starvation. There is evidence of 
synaptic connections between NPY and CRF neurones in the PVN (Mercer, 1996), and CRF 
may normally inhibit NPY mediated feeding systems, as putative damage to the CRF- 
containing cells by prior injection of an imiuunotargeted toxin for CRF into the PVN of rats, 
has been shown to increase food intake elicited by NPY (Menzaghi, 1993).
1.9.5 NPY-Cocaine and amphetamine regulated transcript (CART) interactions
The centrally-located peptide CART is a satiety factor whose actions are closely related to 
hypothalamic levels of NPY and leptin. Food deprived animals display a pronounced 
decrease in expression of CART mRNA in the ARC, and in animal models of obesity with 
disrupted leptin signalling, CART mRNA is almost absent from the ARC. ICV injection of 
CART inhibits normal and stai vation induced feeding, and injection of an antibody to CART 
peptide stimulates feeding, suggesting that endogenous CART may exert an inhibitory tone 
on feeding (Lambert, 1998). Central injection of CART completely blocks the feeding 
response induced by NPY in a dose dependent manner, and immunostaining for CART 
revealed a distribution pattern in terminals of the PVN, in particular CART positive cell 
bodies have been observed around NPY positive varicosities, suggesting a functional 
interaction between CART and NPY (Lambert, 1998). It is proposed that CART may play a 
role in regulating the suppression of food intake mediated by leptin, as a balanced reduction 
and induction of NPY and CART respectively, may be the mechanism of action utilised by 
leptin (Kristensen, 1998).
1.9.6 NPY-Cholecystokinin (CCK) interactions
CCK is a well studied satiety signal, first described over 20 years ago and now widely 
regarded as a physiological mediator of satiety (Gibbs, 1973). CCK is synthesised within 
the gut wall and released into the circulation in response to the presence of nutrients, in 
particular fatty acids. In rats, injection of CCK peripherally or into the CNS reduces food 
intake, decreasing meal size by hastening the normal behaviour sequence associated with
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satiation, an effect which is blocked by vagotomy. CCK is known to act via 2 different 
receptors, the CCK-A receptor and the CCK-B receptor, which are found in the 
gastrointestinal tract and in the CNS (Wank, 1995). The development of specific antagonists 
at these receptor subtypes has permitted the role of these receptors to be clarified regaiding 
the role they may play in the regulation of food intake. Blockade of CCK-A receptors 
increases food intake by delaying the onset of satiety in rats, an effect thought to be 
predominantly mediated by peripheral CCK-A receptors. Administration of CCK-B receptor 
antagonists blocks the effect of peripheral and centrally administered CCK, and also 
increases food intake (Dourish, 1989). CCK stimulates receptors on the vagus nerve, which 
passes signals to the brainstem and thus to other appetite regulating areas, such as the 
hypothalamic PVN, where CCK appears to act as a neurotransmitter. CCK has been shown 
to elicit a marked satiety effect in NPY-treated rats, suggesting that NPY induced feeding 
may be modulated by the satiating action of prandially released CCK (Rowland, 1988).
1.9.7 NPY-Opioid interactions
Intracerebroventriculai' injection of P-endorphin has been shown to stimulate feeding, albeit to 
a lesser extent than NPY (Gosnell, 1986; Levine, 1989). Chronic administration of opioid 
antagonists have been shown to decrease food intake and bodyweight in rats (Mann, 1988), 
and blockade of endogenous dynorphin with antibodies or pharmacological antagonists 
reduces food intake in rats after food deprivation, suggesting a physiological role for opioid 
peptides in feeding behaviour (Lambert, 1993). A close anatomical relationship exists 
between opioid and NPY networks in the hypothalamus (Horvarth, 1992), and an interaction 
between NPY and opioid peptides has been suggested by findings that opiate receptor 
antagonists effectively attenuated NPY induced feeding and increased NPY concentrations in 
the hypothalamus (Levine, 1989 and Lambert, 1994). NPY has also been shown to 
stimulate p-endorphin release in the hypothalamus (Kalra, 1995), and it has been postulated 
that the potent orexigenic effects of NPY may include an augmentation of p-endorphin release 
evoked by NPY.
1.9.8 NPY -Galanin interactions
Galanin, a 29 amino acid neuropeptide which is widely distributed in both the central and 
peripheral nervous systems, is another potent orexigenic peptide densely concentrated in the 
hypothalamus, where it serves to increase preferentially fat ingestion and enhance fat 
deposition via a reduction in energy expenditure (Krykouli, 1990; Tempel, 1990 and 
Menendez, 1992). Galanin operates through neurones in the PVN and medial preoptic area, 
and galanin gene expression and synthesis are strongly activated under conditions associated 
with increased fat intake and fat deposition, such as the mid to late hours of the active feeding
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cycle in the rat. The actions of galanin are mediated through distinct G protein coupled 
receptors, of which the GalR2 receptor is the hypothalamic receptor believed to mediate the 
ingestive functions of galanin (Howard, 1997). Galanin, like NPY is believed to be a 
physiological mediator of nutrient and energy balance, via its effects on food ingestion, 
circulating hormones, and metabolism, and is thought to constitute a distinct hypothalamic 
circuit in the complex network of systems involved in regulation of feeding behaviour. 
Synaptic links between NPY and galanin have been observed in a number of hypothalamic 
sites including the ARC and PVN, suggesting a possible interaction between these 
neuropeptides.
1.9.9 NPY-Melanin concentrating hormone interactions
Melanin concentrating hormone (MCH), is a cyclic 19 amino acid neuropeptide which is 
located primarily in the lateral hypothalamus, with mRNA for MCH being confined to this 
area of the brain. The observation that MCH mRNA is overexpressed in the hypothalamus 
of ob/ob mice led to further investigation into the role of this peptide in relation to regulation 
of bodyweight. Administration of MCH into the hypothalamus of rats was shown to 
stimulate food intake, highlighting a role for this peptide as a potent orexigenic signal (Qu,
1996). A potential relationship exists between MCH and melanin-stimulating hormone 
(MSH). MSH is a satiety signal whose actions are antagonised in the agouti mouse, 
resulting in obesity. The MSH receptors MCI and MC4 are blocked by the overexpressed 
agouti protein, and it has been suggested that the obesity which develops could be due to a 
mimicking of the action of MCH by the agouti protein (Qu, 1996). The MC4 receptor is 
restricted to the brain, and it is believed that antagonism at this receptor elicits the 
characteristic obesity development. Recent findings have reported that the orexigenic effects 
of an MC4 antagonist are mediated by NPY, as administration of the Y1 selective antagonist 
1229U91 significantly attenuated the orexigenic effects of HS014 an MC4 antagonist (Kask, 
1998).
1.9.10 NPY-Orexin interactions
The orexin peptides are two recently discovered neuropeptides, which are derived from the 
same precursor by proteolytic processing. These peptides, termed orexin A-and B- have been 
localised to neurones in and around the lateral and posterior hypothalamus of rat brain. 
Central administration of these peptides elicits a stimulation in food consumption, and 
coupled with findings that prepro-orexin mRNA levels are up-regulated upon fasting, a role 
for these peptides in the regulation of feeding behaviour has been postulated (Sakurai, 1998).
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Possible interactions between these peptides, NPY, and other constituents of the complex 
circuitry which regulates ingestive behaviour remain to be elucidated.
Recent findings have presented evidence detailing interactions between leptin, and potential 
targets of leptin signalling in the hypothalamus. Central administration of leptin was 
associated with a decrease in hypothalamic galanin, melanin concentrating hormone, 
proopiomelanocortin and NPY gene expression, as well as decreased food intake and body 
weight gain (Sahu, 1998). This study has provided a more detailed insight into signalling in 
the hypothalamus, and suggest that leptin's action on food intake and bodyweight gain is 
most likely mediated by inhibiting excitatory signals in the feeding circuitry. These findings 
support the complex circuitry regulation of feeding behaviour, and suggest that other 
unidentified neural signals may also have a role to play in modulating this intricate 
physiological function.
Figure 1.9 illustrates the effects of NPY on feeding behaviour, endocrine systems and 
metabolism and highlights the putative interactions between NPY and the aforementioned 
mediators of feeding.
1.10 Scope of this thesis
The potential role of NPY in the regulation of feeding behaviour generated considerable 
interest in characterising the receptor (s) responsible for mediating this response. The 
therapeutic implications regarding the potential development of an anti-obesity agent make 
this field of reseai’ch highly evolving and extremely competitive.
The main aim of this thesis was to characterise the nature of the feeding NPY receptor(s) 
involved in the hypothalamic regulation of feeding behaviour. At the start of the work 
presented in this thesis, the available phaimacological data suggested that the NPY receptor 
responsible for the regulation of feeding behaviour was distinct. Initial efforts were therefore 
directed at using different strategies to clone this receptor. During the course of this work, 
the structure of the NPY Y5 receptor was reported, and this initial report proposed that this 
receptor was the feeding receptor for NPY.
However, two years after the cloning of this receptor, the identity of the receptor subtype 
involved in mediating NPY induced feeding is highly controversial, and a role for the NPY 
Y1 receptor subtype in the regulation of NPY elicited eating has been suggested.
Additional work was performed to explore the differential regulation of both the Y1 and Y5 
receptor genes with a view to elucidating further the role of these receptors in the control of 
feeding behaviour.
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Figure 1.9 The ai-cuato-paraventricuiar projection of NPY neuronal activity, showing 
the principal effects of NPY injected into the PVN, and outlining the role of other neural 
mediators on NPY activity.
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NPY receptor gene family analysis: Attempts at homology screening as a
cloning strategy.
Chapter 2
2.1 Introduction
Neuropeptide Y has numerous actions within the central nervous system including the well 
characterised effect on feeding behaviour. Centrally administered NPY has been shown to 
significantly augment ingestive behaviour (Clark, 1984), an effect attributed to the 
hypothalamus, where injection of NPY elicits the most potent stimulation of feeding described 
to date (Stanley, 1985). Hypothalamic NPY levels ai'e markedly elevated following a period of 
food deprivation, where NPY serves to promote feeding and reduce energy expenditure via 
effects on ingestive behaviour, endocrine systems and metabolism (Stanley, 1985., 
Wahlestedt, 1987., Stanley, 1989., Menendez, 1990). There is mounting evidence in favour 
of NPY as an endogenous mediator of food intake, as fasting and feeding have been 
demonstrated to elicit reciprocal changes in NPY concentration, with food deprivation 
producing a dramatic accumulation of NPY in the hypothalamus, with levels decreasing 
significantly during the course of eating (Kalra, 1988).
The paraventricular nucleus (PVN) of the hypothalamus harbours a dense supply of NPY- 
containing presynaptic terminals, and studies have implicated this hypothalamic region in 
mediating NPY elicited eating behaviour (Stanley, 1984., 1985). NPY is believed to mediate 
its physiological effects via an interaction with distinct receptor subtypes. Pharmacological 
studies with fragments of the NPY molecule and various analogues of NPY demonstrated the 
existence of multiple receptor subtypes (Wahlestedt, 1986). To date, five distinct NPY 
receptor subtypes have been cloned (Yl, Y2, Y4, Y5 and y6), all of which belong to the laige 
superfamily of G-protein coupled receptors, where they appeal’ to use similar signal 
tiansduction pathways, demonstrating a preferential coupling to pertussis toxin sensitive G- 
proteins, namely members of the Gi/Go family. The subsequent signalling response observed 
upon activation of receptor and G-protein is typical of receptors under the control of these G- 
proteins, in that inhibition of adenylyl cyclase activity is found in most cell types and tissues 
investigated. As outlined in Chapter 1 section 1.6, each NPY receptor subtype exhibits a 
chaiacteristic pharmacology, differing from the other NPY receptor family members and 
allowing distribution and physiological effects of receptor stimulation to be determined (see 
figure 1.8).
The feeding response to NPY failed to correlate with the known pharmacology described for 
the cloned family members. Studies revealed that Yl selective agonists such as 
Leu^ Ipro^^NPY were capable of stimulating ingestive behaviour as effectively as the whole 
NPY molecule, as were Y2 selective agonists such as C-terminal fragments of NPY; namely 
NPy2-36 2uid NPY^"^^ but not NPY^^'^b The markedly greater effectiveness of the Yl
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selective agonist to stimulate feeding when compared with the Y2 selective agonist, initially 
implicated the Yl receptor in the NPY induced feeding response. However, the ability of 
NPY2"36 to consistently stimulate feeding more effectively than the whole NPY molecule, 
suggested that a distinct NPY receptor subtype may be responsible for mediating the profound 
effects on feeding behaviour elicited by NPY, as this compound is not an effective agonist at 
Yl receptors.
As a result of these findings the receptor involved in mediating the feeding response to NPY 
was believed to be phaimacologically distinct from any of the NPY receptor subtypes 
previously described. A hypothalamic pattern of distribution was proposed for this "feeding 
receptor", as the hypothalamus is a critical brain region involved in maintaining energy and 
nutrient balance, housing a significant concenti*ation of NPY and responsible for the dramatic 
effects of NPY on food intake.
As obesity is highly prevalent paiticulaiiy in Western society, and associated with numerous 
related health risks including hypertension and diabetes mellitus, the cloning of a receptor 
involved in the physiological regulation of eating behaviour, would undoubtedly prove 
invaluable, as development of a selective antagonist at this receptor would theoretically 
represent a potential treatment for disorders such as obesity.
When the project of this thesis started, the primary structure of the human Yl, Y2 and Y4 
receptors had been defined, as these receptors had been cloned by orphan receptor homology 
cloning (Eva, 1990), expression cloning (Gerald, 1995) and homology cloning (Lundell ,
1995) respectively. These sequences were aligned in order to identify regions of homology to 
design degenerate oligonucleotide primers, for use in a PCR cloning strategy aimed at cloning 
the receptor involved in NPY elicited eating. The cloning of the Y5 receptor in 1996 permitted 
a more specific PCR cloning strategy to be employed, as oligonucleotide primers homologous 
to the Y5 receptor cDNA were able to be designed.
2.2 Experimental strategy
2.2.1 Degenerate PCR strategy
A degenerate PCR approach was employed in this study, as the sequences of three NPY 
receptor family members had been elucidated, and a homology screening approach to cloning 
this receptor was permitted by aligning these sequences and designing oligonucleotide primers 
from conserved regions of these receptors. The rationale behind this strategy was that the NPY 
receptor involved in mediating the feeding response would likely shai'e regions of homology 
with the other members of the NPY receptor gene family, thereby enabling use of a degenerate
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PCR approach to identify this receptor. Figure 2.1 represents a schematic approach to the 
degenerate PCR strategy employed.
2.2.2 Human and Rat Y5 PCR strategy
The cloning in 1996 of the Y5 receptor (Gerald, 1996) prompted further sequence alignments 
and permitted a more specific PCR strategy to be employed, as it enabled oligonucleotide 
primers homologous to the cDNA of this receptor to be designed and subsequently used in a 
PCR reaction with cDNA from various brain regions, including the hypothalamus. The 
rationale behind this experimental strategy was that the generation of a full length or paitial 
clone would provide DNA which could be used in future experiments such as Northern and 
Southern blot analyses. Figure 2.2 illustrates the cloning strategy employed for human and rat 
Y5 receptor cloning.
2.2.3 Tissue distribution of the human Y5 receptor
Disti’ibution of the human Y5 receptor was investigated by Northern blot analysis. A human 
RNA master blot containing poly A+ RNA from numerous tissues, was probed with a DNA 
fragment (obtained by PCR) encompassing a region of the human Y5 open reading frame in 
order to determine the distribution pattern exhibited by this receptor.
2.3 Chapter specific methods
2.3.1. Oligonucleotide design and synthesis
Degenerate oligonucleotide primers were designed from conserved regions of the Y l, Y2 and 
Y4 receptors (Figure 2.3). The sequences of the primers were derived from conserved regions 
of the first extracellulai’ loop and seventh transmembrane domain (see Appendix II for primer 
sequences).
The oligonucleotides used in these experiments were synthesised commercially by Dr V. Math 
(Division of Biochemistry and Moleculai' Biology, Institute of Life Sciences, University of 
Glasgow), on an Applied Biosystems Model 280A DNA synthesiser using phosphoramide 
technology. Oligonucleotides were supplied in 35% NH4OH, purified by ethanol precipitation
and dissolved in distilled water. The concentration of the purified oligonucleotide was then 
determined by measuring the absorbance at 260nm (see section 2.3.1.6 )
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Figure 2.1 Cloning strategy used for degenerate PCR:
PCR fragments obtained by degenerate PCR were cloned into a plasmid vector by the 
method depicted in the flowchart.
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Figure 2.2 Cloning strategy used for human and rat Y5 PCR.
PCR fragments obtained using oligonucleotide primers homologous to the Y5 receptor 
were cloned into a plasmid vector by the method depicted in the flowchart.
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Figure 2.3 Degenerate oligonucleotide primers schematic.
Schematic of cDNA sequences and the degenerate oligonucleotide primers designed for 
PCR purposes. Hatched regions on the cDNA correspond to translated sequnces, with 
wide bai's representing the oligonucleotide primers used in the PCR reaction.
EC 1 = extracellular domain 1 
TM7 = transmembrane domain 7 
PCR fragment = 800bp
54
EC 1
4 3 5 - 4 6 4
9 3 0 - 9 5 6
TM7
3 '
1 6 0 5
3 *
-1 6 7 3
3 *12 00
8 0 0  b a se  
pair
PCR product
2.3.1.1 Human foetal brain PCR
Ipg human foetal brain cDNA libraiy constmcted in the expression vector CDM was used in a 
PCR reaction with 0.1 pM of forward and reverse degenerate oligonucleotide primers. 
Reaction buffer 10 X (Promega Corp), 25mM MgCl2 (Promega Corp), ISOpMdNTP mix 
(containing equal concentrations of dATP, dCTP, dGTP and dTTP) and 2.5 units Taq 
polymerase (Promega Coip) were added and the reaction volume was increased to lOOpl. The 
reaction was carried out in a thin walled 0.5ml microcentiifuge tube, and after gentle mixing, 
40pl of mineral oil were layered on top of the reaction mix to prevent evaporation during 
amplification. After an initial dénaturation step at 94°C for 3 minutes, the reaction was 
allowed to cycle 30 times through a sequence of temperatures: 1) dénaturation of template: 
94°C for 45 seconds, 2) primer annealing at 35°C for 3 minutes, 3) DNA polymerisation at 
72°C for 2 minutes. A final elongation step at 72“C for 10 minutes was also performed. The 
annealing temperature used in the reaction was relatively low, in order to maximise the 
generation of products obtained with these degenerate oligonucleotide primers. Taq DNA 
polymerase was used to amplify cDNA fragments homologous to the NPY receptors, with the 
aim of isolating novel members of the NPY receptor family. This enzyme was used in 
preference to other DNA polymerases, as the ability of this polymerase to generate 3 ' 
deoxyadenosine overhangs (Clark, 1988., Myers, 1991) permits the use of vectors containing 
complementary 5' deoxy thymidine overhangs and enables convenient subcloning of PCR 
products obtained. Reaction mixtures containing no template DNA were used as PCR negative 
control reactions.
2.3.1.2 Recombinant plasmid generation
The PCR products generated using the thermostable Taq DNA polymerase were cloned into the 
p-TAG cloning vector using the LigATor kit (R&D Systems) following manufacturer 
instructions.
2.3.1.3 Ligation
T4 DNA ligase (R&D Systems) was used to catalyse the formation of a phosphodiester bond 
between adjacent 3'-hydroxyl groups and 5'-phosphate termini in DNA (Weiss, 1986). A p- 
TAG vector (R&D systems) containing 5' deoxythymidine overhangs was used as the recipient 
vector for the PCR fragment generated in the above reaction. A lOgl reaction volume contained 
IOitlM ATP, lOOmM DTT, 200ng PCR product, lOX ligase buffer, 50ng p-TAG vector and 
10 units of enzyme. The reaction was allowed to proceed overnight at 16°C.
55
2.3.1.4 Transformation of bacteria with DNA
A 20|il aliquot of competent cells (supplied) was thawed on ice for each sample of DNA to be 
transformed. Ipl of DNA containing between 10 to lOOng DNA was added to the suspension 
of competent bacteria, and after gentle mixing, was incubated on ice for 30 minutes. The 
bacteria/DNA mixture was then subjected to "heat shock" by incubation at 42°C for 40 seconds 
followed by incubation on ice for a further 2 minutes. Eighty microlitres of SOC media was 
then added and the mixture incubated at 37°C for 1 hour. A 50gl aliquot of this mixture was 
plated onto LB-ampicillin agai' plates containing IPTG/X-Gal. Control transformation 
reactions using circulai" non-recombinant plasmid vector were performed alongside 
experimental samples to assess transformation frequency. Reactions eliminating plasmid DNA 
served as negative controls. Recombinant transformants, which have an intermpted 
(3- Galactosidase gene, grew as white colonies while non-recombinant colonies were stained 
blue due to reaction of p- Galactosidase with X-Gal.
2.3.1.5 Isolation of plasmid DNA
Individual bacterial colonies were picked from agai" plates using sterile plastic disposable 
pipette tips, placed (one colony/tube) into 30ml sterile glass test-tubes containing 5ml of 
LB/ampicillin (lOOpg/ml) and grown overnight with constant agitation to saturation at 37“C. 
Bacteria in 1.5ml aliquots of these cultures were pelleted by centiifugation at 5000 X g for 2 
minutes. Supernatant was removed and the bacterial pellet was resuspended in lOOpl of an 
ice-cold solution containing 50mM glucose, 25mM Tris-Cl (pH 8.0) and lOmM EDTA (pH 
8.0). Bacteria were lysed by addition of 200gl of 0.2M NaOH, 1% SDS; protein was 
precipitated by addition of 150pl 3M potassium acetate, 5M acetic acid. Following gentle 
mixing by inversion and subsequent flicking with fingertips, tubes were centrifuged for 5 
minutes at 14000 X g at 4°C, and the supernatant poured into fresh microcentrifuge tubes. 
DNA was extracted by the addition of an equal volume of phenol:chloroform to eliminate 
protein, vortexing thoroughly, and centrifuging at 14000 X g for 2 minutes at room 
temperature. The upper aqueous layer was removed, placed in a fresh microcentrifuge tube 
and DNA was precipitated by addition of one volume of isopropanol and centi'ifugation for 10 
minutes at 4°C. The resulting pellet was rinsed with 70% ethanol, air dried and resuspended in 
50-100|il TE containing lOgg/ml RNase A which had been preboiled to inactivate DNase.
2.3.1.6 Quantification of DNA
DNA was quantitated by spectrophotometry (DU-640B or DU-62, Beckman) at 260nm. DNA 
quantity was calculated as one optical density unit at 260nm represented 50pg/ml of double 
stranded DNA (Maniatis, 1982).
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2.3.1.7 Restriction Enzyme digests
Restriction digest analysis was cairied out on the isolated DNA in order to confirm the 
generation of recombinant plasmid DNA. DNA was digested with restiiction endonuclease 
enzymes using conditions and buffers suggested and supplied by the manufacturer (Promega 
Corp or Boerhinger Mannheim). Typically 500ng-l|ig of DNA was digested in a volume of 
10-20pl using the appropriate buffer supplied by the manufacturer. Typically an excess of 
enzyme was used (5-10 units per digest) and digests were incubated at 37“C for up to 3 hours.
2.3.1.8 DNA agarose gel electrophoresis
One to two percent agarose (SeaKem LE, Seaplaque or MetaPhor high resolution agarose, 
EMC Bioproducts) was prepared in 1 x TAE and dissolved by heating in a microwave oven. 
Ethidium bromide 0.5pg/ml was added to the gel to allow visualisation of the DNA under 
ultraviolet light at 254nm. Gels were electrophoresed at 70-100V in 1 xTAE buffer and 
moleculai* weight markers {HindlHEcoRl digested DNA or 1Kb DNA ladder, Life 
Technologies) were run alongside the samples. Gels were then photographed under ultraviolet 
illumination at 254nm using Polaioid 667 Land film.
2.3.1.9 Sequence analysis
An ABI automated sequencer was used for double stranded sequencing of recombinant plasmid 
containing insert DNA of the correct moleculai* weight, using the dideoxy method of Sanger 
1977 (Sanger, 1977). Sequencing data was obtained courtesy of Pfizer Central Research, 
Sandwich, Kent.
2.3.2 Human and rat Y5 PCR
2.3.2.1 Oligonucleotide design
Oligonucleotide primers were designed from regions of the human and rat Y5 receptor open 
reading frame, as illustrated in figure 2.4. Typically each primer encompassed 20-25 bases 
and was between 50-60% GC rich. These oligonucleotides were synthesised commercially by 
Oswel DNA Service (University of Southampton) and were dissolved in sterile water. (See 
Appendix II for sequences of Y5 specific designated primers). All oligonucleotides were 
checked for complementai*y hybridisation with the DNA data bank using the blast or fasta 
programme (Wisconsin Package Version 9.1, Genetics Computer Group (GCG) software, 
Madison, Wise).
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2.3.2.2 Human and Rat Y5 receptor PCR
2 nanograms of Marathon-Ready cDNA (Clontech) or Igg human genomic DNA (Promega 
Corp) were used in a PCR reaction with IgM oligonucleotide primers. 10 X reaction buffer 
containing 25mM MgCh (Boerhinger Mannheim), 200gM dNTP mix (Boerhinger Mannheim), 
50% glycerol and 2.5 units Taq polymerase (Boerhinger Mannheim) were added and the 
reaction volume was increased to lOOgl with nuclease free water (Promega Corp). The 
reaction was carried out in a thin walled 0.5ml microcentrifuge tube, and after gentle mixing the 
tube was then subjected to cycled temperature conditions. After an initial dénaturation step at 
94“C for 3 minutes, the reaction was allowed to cycle 30 times through a sequence of 
temperatures: 1) dénaturation of template: 94°C for 1 1/2 minutes, 2) primer annealing at 58°C 
for 11/2 minutes, 3) DNA polymerisation at 72°C for 2 minutes. A final elongation step at 
72°C for 15 minutes was also performed to ensure generation of full length products. Taq 
DNA polymerase was used to amplify cDNA fragments homologous to the NPY Y5 receptor. 
Unless otherwise stated the annealing temperature used was as stated above. Reaction 
mixtures containing no DNA were used as negative controls for the PCR reaction, and positive 
control reactions were cai'ried out using primers homologous to a region of the glyceraldehye 
3-phosphate dehydrogenase (G3PDH) gene, at a reaction concentration of 0.2pM (Clontech).
2.3.2.3 Recombinant plasmid generation
The PCR products generated using the thermostable Taq DNA polymerase were cloned into the 
pCR2.1 cloning vector using the TA cloning kit (Invitrogen) following manufacturer 
instructions.
2.3.2.4 Ligation
T4 DNA ligase (R&D Systems) was used to catalyse the formation of a phosphodiester bond 
between adjacent 3'-hydroxyl groups and 5'-phosphate termini in DNA (Weiss, 1986). The 
cloning vector pCR2.1 (Invitrogen) was used as a recipient vector for the PCR fragments 
generated in the above reactions. A lOpl reaction volume typically
contained lOX ligase buffer, 50ng pCR2.1 vector, 50-100ng PCR product, 5 units T4 DNA 
ligase. The ligation reaction was allowed to proceed overnight at 14°C.
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Figure 2.4. Oligonucleotide primers schematic.
Schematic of cDNA sequences and the relevant oligonucleotide primers designed for 
PCR purposes. Hatched regions on the cDNA correspond to translated sequence, with 
wide bars representing oligonucleotide primers used in the PCR reaction.
FP = Forward primer 
IP = Internal primer 
RP = Reverse primer
A: Rat Y5 receptor : PCR fragments; FP & RP = 1285bp
IP & PR = 789bp
B: Human Y5 receptor: PCR fragments; FP & RP = 1154bp
IP & RP = 783bp
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23.2.5 Transformation of bacteria with DNA
A 50|il aliquot of One Shot (Invitrogen) competent cells was thawed on ice for each sample of 
DNA to be transformed. 2\il 0.5M (3-mercaptoethanol were added to the thawed cells and 
gently mixed with a sterile pipette tip. 2|il of DNA from the ligation reaction described above 
containing between lO-lOOng DNA was added to the suspension of competent bacteria, and 
after gentle mixing, each sample was incubated on ice for 30 minutes. The bacteria/DNA 
mixture was then subjected to "heat shock" by incubation at 42°C for 30 seconds, followed by 
incubation on ice for 2 minutes. Two hundred and fifty microlitres of SOC media was then 
added and the mixture incubated at 37“C for 1 hour. Aliquots of 50pl and 200pl were then 
spread onto LB agar plates containing lOOgg/ml ampicillin, IPTG and X-Gal. Control 
transformations were carried out as described in section 2.3. 1.3.
2.3.2.6 Isolation of plasmid DNA
Plasmid minipreps were prepaied using a Qiaprep Spin plasmid kit (Qiagen). Individual 
bacterial colonies were picked from agai* plates using sterile plastic disposable pipette tips, 
placed (one colony/tube) into 30ml sterile glass test-tubes containing 5ml of LB/ampicillin 
(lOOpg/ml) and grown overnight with constant agitation to saturation at 37 °C. Bacteria in 
1.5ml aliquots of these cultures were pelleted by centrifugation at 5000 X g for 10 minutes. 
The pellet was completely resuspended in 250gl of cell resuspension solution buffer PI 
(supplied) by pipetting up and down. Cell lysis solution buffer P2 (supplied), 250pl, was 
added to the suspension and the contents gently mixed by inversion; lysis was complete in 5 
minutes when the solution became cleai* and viscous. Neutralisation solution buffer N3 
(supplied), 350|il, was added and the preparation immediately mixed by gentle inversion of the 
microcentrifuge tube several times. Insoluble protein was removed by centrifugation at 14000 
X g for 10 minutes at room temperature. The DNA-containing supernatant was applied to a 
Qiaprep column (supplied) and centrifuged at 14000 X g for 1 minute at room temperature, to 
bind DNA on the column resin . Flow through containing no DNA was discai*ded and the 
spin columns washed in 500gl wash buffer PB (supplied) before centrifuging again at 14000 
X g for 1 minute and discaiding any flow through. The spin columns were then washed in 
750pl buffer PE (supplied) containing ethanol, and centrifuged at 14000 X g for 1 minute. To 
remove all traces of liquid, the column was then centrifuged again for 1 minute at 14000 X g. 
The columns were then placed in fresh 1.5ml microcentiifuge tubes and plasmid DNA eluted 
from the column by applying 50|il nuclease free water (Promega) to the centre of each column 
and centrifuging for 1 minute at 14000 X g after allowing the column to stand for 1 minute. 
The columns were discarded and DNA stored at -20“C.
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Restriction digest analysis was performed as described in section 2.3.1.6 in order to establish 
the success of recombinant plasmid generation. Typically the restriction endonuclease EcoRl 
was used, as the vector pCR2.1 contains 2 EcoRl sites on either side of the multiple cloning 
site, and digestion with this enzyme allows insert to be excised effectively, the results of which 
can be easily observed by DNA gel electrophoresis (section 2.3.1.7).
2.3.3 Northern dot blot analysis of human Y5 distribution
A DNA probe encompassing part of the human Y5 open reading frame (obtained by PCR as 
described in section 2.3.2.2) was radioactively labelled as described in section 2.3.3.2 and 
used to analyse a human master RNA blot (Clontech) in order to determine the distribution of 
the human Y5 receptor,
A human RNA master blot containing 50 high quality human Poly A+ RNA samples 
(Clontech) from various brain regions and peripheral tissues was prehybridised for at least 3 
hours at 42“C in 50mls ExpressHyb hybridisation solution (Clontech). After addition of 
labelled probe, hybridisation was allowed to proceed overnight at 42“C with constant agitation. 
Following overnight hybridisation the master blot was washed to remove any non specific 
binding of radiolabelled probe. The blot was washed twice in a solution of 2XSSC/0.1% SDS 
at room temperature for 20 minutes and then washed a further two times for 20 minutes in 
0.2X SSC/01%SDS at 50°C. Once satisfied that sufficient removal of any non specific 
radioactivity had been achieved, the blot was wrapped in cling film to prevent dehydration. 
The poly A+ samples on the master blot had been normalised (prior to purchase) to the mRNA 
expression levels of eight housekeeping genes in order to ensure accurate assessment of 
mRNA abundance in different tissues. A human ubiquitin control cDNA probe (one of the 
housekeeping genes used in the normalisation process) was supplied as a positive control 
cDNA probe and used to confirm consistent hybridisation for all samples on the master blot 
(data not shown).
2.3.3.1 Signal detection
The blot was exposed to phosphorimager screens with cassettes and the resulting images 
captured from the screen to a database using a bio-imaging analyser (Fujix BAS 100 MacBAS, 
Fuji Photo Film Co Ltd).
The blot was then exposed to film (Kodak X-OMAT-AR) with an intensifying screen, and 
allowed to expose at -70°C, before developing film using conventional photographic 
technology.
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23.3.2 Rat Y5 probe preparation
The paitial human Y5 PCR encompassing a 800 base pair fragment of the human Y5 open 
reading frame obtained by PCR on human genomic DNA as described in section 2.3.2.2 was 
radiolabelled as described;
32-P labelled fragments used for blot hybridisation were prepaied by random-primed DNA 
synthesis by the method of Feinberg (Feinberg and Vogelstein, 1983) using a kit (High Prime, 
Boehringer Mannheim ). In a typical reaction, approximately 50-100ng DNA was strand 
separated by incubating at 94°C for 10 minutes in a final volume of 1 Ipl. The DNA was then 
snap-cooled on ice and 4pl of 5 x High Prime solution (supplied), containing 4 units Klenow 
polymerase, 0.125mM dATP, dTTP, dGTP in a stabilisation buffer and 50% glycerol were 
added to the tube. 50jLiCi [a^^P] dCTP (3000Ci/mmol, Amersham) were added and the 
reaction incubated for 45 minutes at 37°C. The reaction was teiminated by incubating at 65°C 
for 10 minutes and unincorporated nucleotide removed using Chromaspin TE 10 columns 
(Clontech). The reaction contents were applied to Chromaspin spin columns, and centrifuged 
at room temperature for 5 minutes at 3,000 X g. The unincorporated radionucleotide remained 
attached to the column matiix after elution of the incorporated labelled DNA from the column 
upon centrifugation. Labelled DNA was eluted from the Chromaspin columns in 50pl TE and 
liquid scintillation specti'ophotometiy used to determine label incorporation and DNA specific 
activity. DNA was routinely labelled to a specific activity of approximately 1 x 10^ dpm/pg. 
The labelled DNA was strand separated by incubating at 94°C for 10 minutes immediately prior 
to use in hybridisation of Northern, Southern or dot blots.
2.4 Results and Discussion
2.4.1 Sequence alignments of the Yl, Y2 and Y4 receptors
When this project started, the sequence of thiee human NPY receptors had been defined using 
molecular cloning. To assist the design of degenerate primers to use in the identification of 
novel NPY receptors, the sequences of the human receptors were aligned in order to identify 
regions of homology. Alignments of the human Yl and Y4 receptors is shown in figure 2.5, 
and alignment of all thi'ee receptors is shown in figure 2.6.
In figure 2.5 showing the sequence alignments of the human Yl and Y4 receptors, the amino 
acids shared between the two receptors are denoted by an asterisk.
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Figure 2,5. Alignment of Yl and Y4 sequences.
HuNPY 1 = Human Y1 receptor 
HuNPY4 = Human Y4 receptor
Asterisks C") represent amino acids conserved between receptor sequences and, dashes 
mark gaps introduced to optimise alignments.
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HuNPY1 MNSTLFSQVENHSVHS-NFSEKNAQLLAFENDDCHLPLAMIFTLALAYGAVIILGVSGN HUNPY4 MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVMVFIVTSYSIETWGVLGN
*  *  -k -k -k k k k  k k k
HuNPYl LALIIIILKQKEMRNVTNILIVNLSFSDLLVAIMCLPFTFVYTLMDHWVFGEAMCKLNPF HuNPY4 LCLMCVTVRQKEKANVTNLLIANLAFSDFLMCLLCQPLTSVYTIMDYWIFGETLCKMSAF
*  *  "k -k 'k ' k ' k k ' k ' k i f ' k - k ' k ' k - k ' k  *  *  *  * * *  * *  *  * * *  *  *  *
HuNPYl VQCVSITVSIFSLVLIAVERHQLIINPRGWRPNNRHAYVGIAVIWVLAVASSLPFLIYQV HuNPY4 IQCMSVTVSILSLVLVALERHQLIINPTGWKPSISQAYLGIVLIWVIACVLSLPFLANSI
•k -k -k -k k  k  k  k  k  k  k  k  k k k k k k k k k  k k  k  k  k  k k  k  k  k k  k k  k  k k
HuNPYl MTDEPFQN-VTLDAYKDKYVCFDQFPSDSHRLSYTTLLLVLQYFGPLCFIFICYFKIYI HuNPY4 LENVFHKNHSKALEFLADKWCTESWPLAHHRTIYTTFLLLFQYCLPLGFILVCYARIYR* * * * * * * * ***** * * * * * * * * * *
HuNPYl RLKRRNNMMDKMRDNKYRSSETKRINIMLLSIWAFAVCWLPLTIFNTVFDWNHQIIATC HuNP Y4 RLQRQGRVFHKG - - YS LRAGHMKQVNWLWMWAFAVLWL PLHVFNS LEDWHHEAI PIC
*  *  *  *  *  *  *  *  * * * * * * * * * *  *  *  *  *  *  *  *
HuNPYl NHNLLFLLCHLTAMISTCVNPIFYGFLNKNFQRDLQFFFNFCDFRSRDDDYETIAMSTMH HuNPY4 HGNLIFLVCHLLAMASTCVNPFIYGFLNTNFKKEIKALVLTCQQSAPLEESEHLPLSTVH
* *  * *  * * * * * *  k  k k  k  k  k k  k  k k k  k
HuNPYl TDVSKTSLKQASPVAFKKINNNDDNEKI HuNPY4 TEVSKGSLRLS G--RSNP-------
k  k k  k  k k k
Alignments of the Y1 and Y4 receptors revealed that 42% sequence homology was exlribited 
between these receptors at the amino acid level, with transmembrane regions displaying 57% . 
In figure 2.6 showing the sequence alignments of the human Yl, Y4 and Y2 receptors, the 
amino acids shaied between all three receptors are denoted by an asterisk. The Y1 
and Y2 receptors, surprisingly share only 31% overall sequence identity, with 40% in 
transmembrane regions. This level of homology for receptors that recognise the same ligand is 
surprisingly low, indeed it is the lowest percentage reported for receptors that bind the same 
ligand (Larhammar, 1996b). Of the three receptors, the Y2 receptor, as outlined in figure 2.6 
exhibits low sequence identity to both Yl and Y4 receptors. The lack of apparent sequence 
homology between the Y2 and Yl or Y4 receptors has been attributed, in certain reports, to 
evolutionary divergence, which has resulted in stmctural diversity of the NPY receptor gene 
family. However, both the Yl and Y2 subtypes display conservation across species, having 
94% identity between human and rat, thus the evolutionary rate for Yl and Y2 receptors 
appears to be in the slower range for G-protein coupled receptors as each displays 94% 
homology between man and rat (Larhammar, 1996b).
A slow rate of evolution in combination with great sequence divergence between the Y 1 and Y2 
receptors would suggest that the gene duplication that generated Yl and Y2 from a common 
ancestral gene took place long ago, presumably before the origin of vertebrates (Larhammar, 
1996b). Another possibility to explain the structural difference between Yl and Y2 would be 
functional convergence of stmcturally veiy different receptors i.e., Yl and Y2 have evolved 
NPY/PYY binding separately. This possibility chelates support from the seemingly veiy 
different modes of interaction of Yl and Y2 with the ligand. As discussed in Chapter 1 section 
1.6, the Yl receptor binds to both the N-and C-terminus of NPY and related PP family 
members, whereas the Y2 receptor exhibits almost exclusive binding to the C-terminus 
(Wahlestedt, 1986). Sequence comparisons have revealed that the positions identified to 
interact with ligands differ between the Yl and Y2 receptors, and subsequent mutagenesis 
studies confirmed these findings (Walker, 1994). The greater percentage identity observed 
between Yl and Y4 receptors also supports this theory as both these receptors bind to, and 
require both termini of their ligands for receptor activation.
Vaiying degrees of conservation across species aie also observed within this receptor family. 
The Y4 receptor exhibits only modest sequence identity between human and rat; one of the 
lowest percentages reported for orthologous G-protein coupled receptors between different 
orders of mammals. The low Y4 conservation contrasts with the reported high identities for 
Y1 and Y2 receptors, suggesting a rapid evolutionary rate for the Y4 receptor, which like its 
ligand, PP is also rather divergent between man and
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Figure 2.6. Alignment of Yl, Y2 and Y4 sequences.
HuNPYl = Human Yl receptor 
HuNPY2 = Human Y2 receptor 
HuNPY4 = Human Y 4 receptor
Asterisks denote amino acids conserved between receptor sequences and, dahses 
mark gaps introduced to optimise alignments.
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HuNPYl ---- MNSTLFSQVENHSVHS--NFSEKNAQLLAFEN---DDCHLPLAMIFTLALAYGAVHuNP Y4 ---- MNTSHLLALLL PKS PQGENRS KPLGTPYNFS----EHCQDS VDVMVFIVTS YSIEHuNPY2 MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQWLILAYCSI
HuNPYl IILGVSGNLALIIIILKQKEMRNVTNILIVNLSFSDLLVAIMCLPFTFVYTLMDHWVFGE HuNPY4 TWGVLGNLCLMCVTVRQKEKANVTNLLIANLAFSDFLMCLLCQPLTSVYTÏMDYWIFGE HuNPY2 ILLGVIGNSLVIHWIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLTYTLMGEWKMGP * * * * * * * * * * * * *  * * *  * * *  * *
HuNPYl AMCKLNPFVQCVSITVSIF SLVLIAVERHQLIINPRGWRPNNRHAYVGIAVIWVLAVAS S 
HuNPY4 TLCKMSAFIQCMSVTVSILSLVLVALERHQLIINPTGWKPSISQAYLGIVLIWVIACVLS HuNPY2 VLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLA
•k -k *  *  *  *  *  *  *  *  *
HuNPYl LPFLIYQVMTDEPFQN--VTLDAYKDKYVCFDQFPSDS HRLSYTTLLLVLQYFGPLCHUNPY4 LPFLANSILENVFHKNHSKALEFLADKWCTESWPLAH HRTIYTTFLLLFQYCLPLGHUNPY2 SPLAIFREYSLIEIIP------- DFEIVACTEKWPGEEKSIYGTVYSLSSLLILYVLPLG* . * . *  * * * * *
HuNPYl FIFICYFKIYIRLKRRNNMMDKMRDNKYRSSETKRINIMLLSIWAFAVCWLPLTIPNTV HuNPY4 FILVCYARIYRRLQRQGRVFHKG-TYSLRAGHMKQVNWLWMWAFAVLWLPLHVFNSLHuNPY2 IISFSYTRIWSKLK NHVSPGAANDHYHQRRQKTTKMLVCWWFAVSWLPLHAFQLA* * * * ** *** **** *
HuNPYl FDWNHQIIATCNHNLLFLLCHLTAMISTCVNPIFYGFLNKNFQRDLQFFFNFCDFRSRDD HUNPY4 EDWHHEAIPICHGNLIFLVCHLLAMASTCVNPFIYGFLNTNFKKEIKALVLTCQQSAPLE HuNPY2 VDIDSQVLDLKEYKLIFTVFHIIAMCSTFANPLLYGWMNSNYRAFLSAFRCEQRLDAIHS 
* * * * * * * * * * * * * *
HuNPYl DYETIAMSTMHTDVSKTSLKQASPVAFKKINNNDDNEKIHUNPY4 ESEHLPLSTVHTEVSKGSLRLS G— RSNP-------HuNPY2 EVSVTFKAKKNLEVRKNSGPND SFTEATNV------
*  *  *
rat, with 8 replacements in 36 positions and suggests that PP and its receptor have co-evolved 
at a rapid pace. The great sequence vai’iability between species for the Y4 receptor is mirrored 
in pharaiacology and tissue distribution as diseussed in Chapter 1 section 1.6. In man the Y4 
receptor appears to bind human PP with a similai" affinity to PYY and NPY, implying that all 
three peptides may serve as ligands at physiologieal concentrations, whereas the rat and mouse 
Y4 receptors seem to be more selective for PP (Larhammar’, 1996b). Thus within the same 
family there ar'e highly conserved receptors and peptide ligands as well as one rapidly evolving 
receptor and ligand.
2.4.2 Human foetal brain PCR
Figure 2.3 illustrates the regions of Y l, Y4 and Y2 receptor sequence which exhibited 
adequate amino acid conservation for oligonucleotide primer design.
After performing the PCR reaetion described in section 2.3.1.2, using the primers described in
2.3.1.1, following the cycling parameters outlined and running an aliquot on a 1% agarose 
gel, a product of the predicted molecular weight (800 base pairs) was obtained as illustrated in 
figure 2.7a. This PCR product was subcloned into the p-TAG vector as described in sections
2.3.1.2, 2.3.1.3 and 2.3.1.4. DNA was isolated as described in section 2.3.1.5 and 
restriction digest with the enzymes Eco R I and Xho I  revealed that the PCR product had been 
successfully cloned into the p-TAG vector (see figure 2.7b). DNA was prepared for 
sequencing as detailed in section 2.3.1.8, however subsequent sequence analysis failed to find 
any homology between the DNA obtained by PCR and any of the cloned NPY receptor 
subtypes. Upon further investigation, the sequence appeared to correspond to vector 
containing the Lac Z gene, and also shared homology with regions of sequence from the large 
T antigen. From these results it would appear’ that the degenerate oligonucleotide primers 
annealed to the expression vector which the foetal brain library was constructed in (CDM 8), as 
opposed to regions of the cDNA corresponding to Yl, Y2 or Y4 receptors.
2.4.3 Sequence alignments of the Yl, Y2, Y4 and Y5 receptors
During the course of this thesis, an additional NPY receptor Y5 was reported. This new 
sequence was then compared to the previous alignments. Figure 2.8 shows alignments of the 
protein sequences of the Yl, Y2, Y4 and Y5 receptors, with identical amino acids denoted by 
an asterisk.
From these sequence alignments, the Y5 receptor appeared to be another divergent form being 
as different to both the Y1 and Y2 receptors as the latter are to one another, even though the Y5 
receptor gene is located on the same chromosome as the Y1 receptor. Despite the low sequence
66
Figure 2.7 Results of the degenerate PCR carried out on human foetal brain eDNA.
A: Paired degenerate oligonucleotide primers (see figure 2.3 and Appendix II) 
designed to consei-ved regions of the human NPY Yl, Y2 and Y4 receptors were used 
to amplify cDNA with sequence homology from a human foetal brain cDNA library. 
An aliquot of lOpl of lOOgl total volume was electrophoresed on an agarose gel as 
outlined in section 2.3.1.7. DNA was visualised under ultraviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
Lane 1 : PCR product obtained from PCR reaction carried out with human foetal brain 
cDNA and degenerate oligonucleotide primers. Product size = 800bp (*' '^'').
Lane 2; Negative control PCR reaction. No product obtained as expected.
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. Hind UHEcoR I-digested X DNA.
B: The 800bp PCR product obtained as shown in figure 2.7A lane I was subeloned 
into the p-TAG vector.
Following isolation of miniprep DNA, the recombinant plasmid was digested with 
restriction enzymes EcoRI and Xho I in order to confirm the generation of recombinant 
plasmid DNA.
Lanes 2 and 9 contain PCR insert of 800bp (*=^ *).
Restriction digested DNA mar-kers (M) were electrophoresed alongside reaction 
products. Hind UHEcoR I-digested IDNA.
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Figure 2.8. Alignment of NPY-family receptor sequences.
HuNP Y 1 = Human Y1 receptor 
HuNPY2 = Human Y2 receptor 
HuNPY4 = Human Y4 receptor 
HuNPY5 = Human Y5 receptor
Asterisks (*) denote amino acids conserved between receptor sequences, and dashes 
mark gaps introduced to optimise alignments.
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HuNPYl ---------- MNSTLFSQVENHSVHSNFSEKNAQLLAFENDDCHLPLAMIFTLALAYGAVHuNPY4 --------- MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVMVFIVTSYSIEHuNPY2 MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQWLILAYCSI HuNPYS --------- MDLELDEYYNKTLATENNTAATRNSDFPVWDDYKSSVDDLQYFLIGLYTFV
HuNPYl IILGVSGNLALIIIILKQKEMRNVTNILIVNLSFSDLLVAIMCLPFTFVYTLMDHWVFGE HuNPY4 TWGVLGNLCLMCVTVRQKEKANVTNLLIANLAFSDFLMCLLCQPLTSVYTIMDYWIFGE HuNPY2 ILLGVIGNS LVIHWIKFKSMRTVTNFFIANLAVADLLVNTLC L PFTLTYTLMGEWKMGP HuNPYS SLLGFMGNLLILMALMKKRNQKTTVNFLIGNLAFSDILWLFCSPFTLTSVLLDQWMFGK * * * * * * * * * * * * * *
HuNPYl AMCKLNPFVQCVSI TVS IFSLVLIAVERHQLIINPRGWRPNNRHAYVGIAVIWVLAVAS SHuNPY4 TLCKMSAFIQCMSVTVSILSLVLVALERHQLIINPTGWKPSISQAYLGIVLIWVIACVLSHUNPY2 VLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLAHuNPYS VMCHIMPFLQCVSVLVSTLILISIAIVRYHMIKHPISNNLTANHGYFLIQYILPLVCLTV * * * * * * * *
HuNPYl LPFLIYQVMTDEPFQN— VTLDA--------------------------------------YKHuNP Y 4 LPFLANSILENVFHKNHSPCALEF" " — — — — —-----—---------------—------- LAHUNPY2 SPLAIFREYSLIEIIP--------------------------------------------- DEHuNPYS SHTSVCRSISCGLSNKENRLEENEMINLTLHPSKKSGPQVKLSGSHWSYSFIKKHRRRYS
HuNPYl DKYVCFDQFPSDS HRLSYTTLLLVLQYFGPLCFIFICYFKIYIRLKRR-NNMMDKMHuNPY4 DKWCTESWPLAH HRTIYTTFLLLFQYCLPLGFILVCYARIYRRLQRQ-GRVFHKGHUNPY2 EIVACTEKWPGEEK-SIYGTVYSLSSLLILYVLPLGIISFSYTRIWSKLK NHVSPGHuNPYS KKTACVLPAPERPSQENHSRILPENFGSVRSQLSSSSKFIPGVPTCFEIKPEENSDVHEL
HuNPYl RDNKYRSSETKR INIMLLSIWAFAVCWLPLTIFNTVFDWNHQIIATCNHNLLFLLCHUNPY4 TYS-LRAGHMKQ VNWLWMWAFAVLWLPLHVFNSLEDWHHEAIPICHGNLIFLVCHuNPY2 AANDHYHQRRQK TTKMLVCWWFAVSWLPLHAFQLAVDIDSQVLDLKEYKLIFTVFHuNPYS RVKRSVTRIKKRSRSVFYRLTILILVFAVSWMPLHLFHWTDFNDNLISNRHFKLVYCIC
*  * * * * * * *  *  *
HuNPYl HLTAMISTCVNPIFYGFLNKNFQRDLQFFFNFCDFRSRDDDYETIAMSTMHTDVSKTSLK HuNPY4 HLLAMASTCVNPFIYGFLNTNFKKEIKALVLTCQQSAPLEESEHLPLSTVHTEVSKGSLR HUNPY2 HIIAMCSTFANPLLYGWMNSNYRAFLSAFRCEQRLDAIHSEVSVTFKAKKNLEVRKNSGP HuNPYS HLLGMMSCCLNPILYGFLNNGIKADLVSLIHCLHM--------------------------
"k *  *  *  *  k  "k k
HuNPYl
HUNPY4HUNPY2HuNPYS
QAS PVAFKKINNNDDNEKI
LSGRSNP------------NDSFTEATNV---------
homology, there appears to be a clustering of amino acid sequence similarity between the Yl 
and Y4 receptors, while the Y2 and Y5 receptors clearly define another family. The receptors 
Y2 and Y5 are equally distantly related to one another as to the Y1/Y4 group, and it is 
interesting to note that the Y1/Y4 group and the Y2/Y5 group aie more distantly related to one 
another than any other G-protein coupled receptors that bind to the same endogenous ligand 
(Larhammar, 1996b). Possible explanations for this phenomenon aie that the Yl, Y2 and Y5 
receptors have evolved rapidly and hence accumulated differences in a short period of time. 
However, the similarity between speeies for any one receptor suggests that this is unlikely. 
For instance, the Y1 receptor is highly conserved between Xenopus laevis and mammals. The 
Y5 receptor, like the Yl and Y2 receptors exhibits great homology across species, displaying 
87% overall amino acid identity between man and rat, with 99% identity observed in 
transmembrane regions. Therefore the evolutionaiy rate for the Y5 receptor also appeal's to be 
in the slower range for G-protein coupled receptors. Another possibility is that the four genes 
arose long ago and have diverged from one another over a substantial period of time.
In 1996, a fifth member of the NPY receptor family was described, initially in mouse, and 
subsequently in primates and humans. This receptor was designated y6, after considerable 
debate regarding the nomenclature of this NPY receptor subtype (Weinberg, 1996; Gregor, 
1996 and Matsumoto, 1996). The y6 receptor is a functional receptor in mice, but represents a 
pseudogene in man and primates due to a premature stop codon which results in the formation 
of a tmncated receptor protein lacking the characteristic seven transmembrane domains, and 
fails to bind PP-fold peptides due to an inability to express the receptor protein. Mutagenesis 
studies of the pseudogene to restore the frame results in a protein with the predicted seven 
transmembrane domain topology but still fails to bind members of the PP-fold family of 
peptides. Therefore in humans this receptor does not represent a functional NPY receptor 
subtype, and as a result protein alignments with this subtype were not carried out. When the 
amino acid sequence of the y6 receptor has been aligned with the other cloned NPY receptor 
subtypes in other species, the y6 receptor appears to exhibit sequence similarity with the Yl 
and Y4 receptors, representing a clustering of amino acid sequence between these three 
receptors while the Y2 and Y5 receptors clearly define another family (Gehlert, 1998).
The dendrogram illustrated in figure 2.9 demonstrates the apparent divergence of the receptors 
that bind the NPY-family of peptides.
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Figure 2.9. Distance tree for NPY family peptide receptors.
Branch lengths coiTespond to sequence divergence calculated from the alignment in 
figure 2.8 using the CLUSTAL programme for GCG (Wisconsin Package Version 9.1, 
Genetics Computer Group (GCG) software, Madison, Wise),
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Figure 2.10 Identification of the rat NPY Y5 receptor in rat brain cDNA.
A: Paired oligonucleotide primers (see figure 2.4A and Appendix II) designed to the rat 
Y5 open reading frame were used to amplify corresponding cDNA fragments from rat 
brain cDNA.
Aliquots of lOpl of lOOpl total volume were electrophoresed on an agarose gel as 
outlined in section 2.3.1.7. DNA was visualised under ultraviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
Lanes 1 and 3: PCR product obtained from rat brain cDNA using rat Y5 homologous 
oligonucleotide primers. Product size = ~800bp (***).
Lane 2; Negative control PCR reaction containing no DNA template. No product 
obtained as expected.
Lane 4: Positive control PCR product obtained from rat brain cDNA using G3PDH 
primers. Product size =500bp.
Restriction digested DNA mai’kers were electrophoresed alongside reaction products.
Ikb DNA ladder (Life Technologies) (M).
B: The 800bp PCR products amplified from the rat brain cDNA using rat Y5 
homologous oligonucleotide primers were subloned into the pCR 2.1 vector.
Following isolation of miniprep DNA, the recombinant plasmid was digested with the 
restriction enzyme EcoRl in order to confirm the generation of recombinant plasmid 
DNA.
Lanes 5, 7, 9 and 10 contain the PCR insert of 800bpC^**).
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. IKb DNA ladder (Life Technologies).
71
M I 2 3 4 5 6 7 8 9  10 1t
MMM
2.4.4 Human and rat Y5 receptor PCR
Figure 2.4 illustrates the regions of the human and rat Y5 receptor sequence where 
oligonucleotide primers were designed.
PCR reactions were carried out as described in section 2.3.2.2, using combinations of primers 
designed to yield either full length or partial Y5 cDNA products. A partial rat Y5 product was 
obtained using rat brain cDNA (Clontech) as a template (Figure 2.10a). Subsequent 
subcloning into the vector pCR2.1 was confiimed by restriction digest analysis using EcoR I 
to excise the 800 base pair PCR product from mini-prep DNA prepaied from the transformed 
plasmid (Figure 2.10b). Sequence analysis of those minipreps containing the tai'get sequence 
revealed that the PCR product obtained was homologous to a region of the rat Y5 open reading 
frame. However, despite the use of multiple alternative 5' oligonucleotides, a full length rat Y5 
product was unobtainable (see figure 2.4 for schematic of rat Y5 primer design and Appendix 
II for sequence of primers).
A longer length human Y5 PCR product of 1200 base pairs was obtained using human 
hypothalamic cDNA (Clontech) as template (Figure 2.11a). However despite repeated efforts 
and employing different strategies, this PCR product proved impossible to subclone. The 
experience encountered here with both the rat and human PCR has been observed in other 
laboratories working in the field (Dan Larhamnw personal communication) and although the 
reasons for this aie unclear, it may reflect secondary stmcture at the 5’ end of this receptor. 
This secondary structure does not appeal' to be the result of a highly GC rich region of 
sequence, as the sequence fails to exhibit 5' GC abundance.
A partial human Y5 PCR product was obtained using human genomic DNA (Promega Corp) as 
template (Figure 2.1 lb). Subsequent subcloning of this 800 base pair product into the vector 
pCR2.1 was confirmed upon analysis of restriction digests with EcoK I (Figure 2.11c). 
Sequence analysis of those minipreps containing the tai'get sequence revealed that the PCR 
product obtained was homologous to a region of the human Y5 open reading frame.
Both the rat and human Y5 sequences appear to be correct and no mutants have been 
introduced during the PCR procedure. This is significant, as the use of Taq polymerase in the 
PCR reactions may have resulted in the introduction of mutants into the amplified DNA. As 
Taq DNA polymerase does not have 3' to 5' exonuclease activity, this polymerase does not 
possess proofreading properties like other thermostable polymerases such as Vent or Pfu 
polymerase which have the ability to excise incorrectly incoiporated nucleotides during the 
synthesis of DNA strands complementaiy to the template. Therefore, the fidelity of this
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Figure 2.11 Identification of the human Y5 receptor in human hypothalamic cDNA 
and human genomic DNA.
A: Paired oligonucleotide primers (see figure 2.4B and Appendix II) designed to the 
human Y5 open reading frame were used to amplify corresponding cDNA fragments 
from human hypothalamic cDNA. Primer annealing temperature for amplification of 
human Y5 PCR products was varied, as follows:
Lane 1 : Annealing temperature 50°C 
Lane 3: Annealing temperature 55“C 
Lane 5: Annealing temperature 58“C 
Lane 7: Annealing temperature 60°C 
Lane 9: Annealing temperature 62°C
Aliquots of lOpl of lOOgl total volume were electrophoresed on an agarose gel as 
outlined in section 2.3.1.7. DNA was visualised under ultraviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
PCR products of predicted size 1200bp (***) were obtained with each of the annealing 
temperatures described above using the human Y5 homologous primers. Lane 10 
represents the negative control reaction containing no product as expected. Positive 
control reactions were carried out as described (data not shown).
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. 1Kb DNA ladder (Life Technologies).
B: Paired oligonucleotide primers (see figure 2.4B and Appendix II) designed to the 
human Y5 open reading frame were used to amplify corresponding cDNA fragments 
from human genomic DNA.
Lanes 1 and 3 : PCR product obtained from human genomic DNA using human Y5 
primers. Product size 800bp 6»=^ '*).
Lane 2: Negative control 
All other lanes empty.
C: The 800bp PCR products amplified from the human genomic DNA using human Y5 
homologous primers were subcloned into the vector pCR2.1. Miniprep DNA was 
digested with the restriction enzyme EcoRl in order to confirm the generation of 
recombinant plasmid DNA.
All lanes with the exception of lanes 6, 8 and 11 contain the PCR insert of 800bp (***)
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polymerase is not as high as that exhibited by other DNA polymerases such as Vent or Pfu 
polymerase, which are between 5- to 15-fold greater than Taq polymerase. Although both 
Vent and Pfu polymerases have higher thermostabilty than Taq polymerase, making them 
more robust enzymes, the inability of these enzymes to generate 3' dA overhangs on their 
reaction products, leaving blunt-ended fragments, made the use of Taq polymerase more 
favourable in the experiments carried out, as the subcloning procedure employed relied upon 
the presence of 3'dA overhangs.
2.4.5 Human RNA master blot
Analysis of the signals detected after screening the human RNA master blot (Clontech) 
containing 50 different poly A+ selected RNA samples from human tissues, detected Y5 
receptor mRNA readily in kidney, and to a lesser extent in small intestine, liver and lung. No 
signal was detected in other tissues including the spleen (Figure 2.12). No signal was detected 
in the Poly A+ RNA from various brain regions. However, as hypothalamic Poly A+ RNA 
was not present on the master blot, this result is not entirely surprising as Y5 mRNA is 
believed to be concentrated predominantly in this brain region, with levels of expression 
extiemely low or absent in other aieas of the brain (Gerald, 1996). The finding of abundant 
Y5 receptor mRNA in the kidney was surprising as the initial report described a lack of the 
niRNA in peripheral tissues. To confiim this finding, PCR was carried out as described in 
section 2.3.2.2 using a human kidney cDNA library (Clontech) as a source of template and 
human Y5 primers. A product of correct molecular weight was obtained confirming the 
presence of Y5 mRNA signal detected by Northern blot analysis (Figure 2.13). The Y5 
receptor has been postulated to play a role in the renal effects of NPY where it is involved in 
mediating the enhancement of diuresis and natriuresis (Bischoff, 1997).
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Figure 2.12 Analysis of the distribution of the human NPY Y5 receptor by Northern 
blot analysis.
A human RNA master blot (Clontech) containing 50 different poly A+ selected RNA 
samples was screened with a ^^P-labelled cDNA probe encompassing a region of the 
human Y5 open reading frame cDNA.
Human Y5 mRNA was readily detected in kidney, and to a lesser extent in small 
intestine, liver and lung. No human Y5 mRNA was detected in other tissues including 
the spleen.
l=kidney
2=liver
3=small intestine 
4=lung
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Figure 2.13 Confirmation of the presence of the human Y5 receptor in the kidney by 
PCR analysis.
Paired oligonucleotide primers (see figure 2.4B and Appendix H) designed to the human 
Y5 open reading frame were used to amplify corresponding cDNA fragments from a 
human kidney cDNA library.
An aliquot of lOpl of lOOgl total volume were electrophoresed on an agarose gel as 
outlined in section 2.3.1.7. DNA was visualised under ulti'aviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
Lane 1 : Negative control PCR reaction containing no DNA template. No product was 
obtained as expected.
Lane 2: PCR product obtained from human kidney cDNA using human Y5 homologous 
primers. Product size 1200bp.
Restriction digested DNA markers (M) were electiophoresed alongside reaction 
products. Ikb DNA ladder (Life Technologies).
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2.5 Summary
1)Structural alignments of the sequences of the Y l, Y2, Y4 and Y5 receptors demonstrate that 
they are members of the lai’ge superfamily of G-protein coupled receptors, which are 
membrane spanning receptors and exhibit a chaiacteristic seven transmembrane domain 
structure.
2)The NPY family of receptors are extremely diverse. Despite recognising the same ligand(s), 
namely members of the PP-fold family of peptides including NPY, PYY and PP, the cloned 
receptors for NPY display a structural diversity exhibiting low percentage identities between 
family members even in transmembrane regions. The diversity observed may reflect different 
structural requirements of NPY, which ai'e essential in order to elicit activation of receptor 
subtypes.
3) There appear to be two families of NPY receptors, as even with the low sequence homology 
displayed between subtypes, there is a clustering of amino acid sequence between the Y l, Y4 
and y6 receptors, while the Y2 and Y5 receptors clearly define another family.
4) Members of the NPY receptor family appeal* to display significant homology between 
species, with interspecies variation minimal. This is demonstrated by the high percentage 
identities in receptor amino acid sequences observed between man and rat for the Y l, Y2 and 
Y5 receptors. The Y4 receptor does not exhibit species conservation of receptor sequence, a 
phenomenon which may reflect the vaiiability of the PP ligand across species, as Pancreatic 
polypeptide is believed to be a rapidly evolving ligand which displays considerable divergence 
between man and rat.
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Chapter 3
Isolation and characterisation of a rat Y5 genomic clone.
Chapter 3
3.1 Introduction
The role of neuropeptides, in paiticulai* NPY, in the physiology of feeding behaviour has 
gathered tremendous recognition as a result of findings which document alterations in 
endogenous levels of these neuropeptides following staivation and satiety. The potent 
stimulatory effects NPY elicits on ingestive behaviour ai*e well chaiacterised and of widespread 
interest. The phaimcological profile known to mimic NPY stimulated feeding could not be 
attributed to the previously described NPY receptors and the G-protein coupled receptor 
believed to mediate NPY induced eating was cloned from rat hypothalamus in 1996 (Gerald, 
1996). This new receptor (known as Y5) appealed to demonstrate an identical phannacology 
to that known to promote NPY feeding in satiated rats (Gerald, 1996 and Kalra, 1990).
The physiology of feeding is extremely complex, involving numerous interactions between 
neurotransmitters, neuropeptides and hormones known to play a role in the regulation of this 
fundamental behaviour. This complex circuitiy undoubtedly includes NPY, which together 
with other established mediators of feeding behaviour (see section 1.9) serves to maintain 
energy homeostasis and nutiient balance. Following the cloning of the Y5 receptor, the 
published cDNA sequence encoding the mRNA for this receptor provided a valuable tool for 
studying the regulation of this crucial gene. By gaining knowledge on the control of this gene, 
a major constituent in the network of feeding regulation may be further understood, in 
particular, as regaids interactions with the many other entities in the complex circuitry.
3.1.1 The role of the Y5 gene in the regulation of feeding
In order to establish further the role of NPY and the Y5 receptor in the regulation of feeding 
behaviour, an experimental strategy was employed which would enable the identification and 
chaiacterisation of the Y5 receptor gene. To deteimine the moleculai* organisation and 
regulation of the rat Y5 receptor gene, isolation and chaiacterisation of a Y5 genomic clone 
was necessary in order to identify exon and intron organisation. By determining the genomic 
organisation of the Y5 gene, the 5'UT region of this gene could be identified and putative 
regulatory sequence elements of the promoter region could be identified. These can then be 
exploited to cairy out promoter studies and determine the pattern of regulation for the Y5 gene. 
The cloning of the Y5 receptor cDNA (Gerald, 1996) enabled the design of oligonucleotide 
primers homologous to the Y5 receptor which could be radiolabelled and used in the screening 
of a rat genomic library to identify a Y5 genomic clone.
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However, the NPY Yl receptor has also been implicated in the control of feeding (Kanatani, 
1996, 1998). The stmcture of the gene encoding the Yl receptor has been previously 
determined, and is characterised by the presence of a single 97-bp intron in the coding region 
following transmembrane V (Herzog, 1993), and the existence of several alternative 5' exons 
that allow for the regulation of tissue-speeific expression of the receptor (Ball, 1995).
3.1.2 The use of lambda (X) bateriophage in genomic library screening.
The large cloning capacity of lambda (?i) bacteriophages allows the construction of highly 
redundant genomic libraries, whieh are an important tool in the identification and 
chaiacterisation of receptor genes. The subsequent chaiacterisation of phage recombinants 
identified upon libraiy screening, can prove to be a complex procedure: a) Purification of lai'ge 
amounts of phage DNA is time consuming when compared with the ease of working with high 
copy vectors, b) Restriction mapping can prove tedious because the insert of a 1 recombinant is 
smaller than the vector backbone, and c) Subcloning of insert fragments can present difficulties 
due to the lack of unique restriction sites flanking the insert and the low cloning efficiencies for 
large fragments. The novel IPS vector (Nehls, 1994) used to construct the rat genomic libraiy 
screened in the experiments described in this chapter, circumvents these problems as it features 
an automatic plasmid subcloning facility of insert fragments, and therefore combines the 
advantage of lai'ge insert genomic libraiies with the convenience of working with high copy 
plasmids. The IPS vector is a replacement vector of lambda phage origin which can 
accommodate inserts of up to 20Kb, thereby allowing the complete representation of complex 
genomes in a reasonable number of recombinants. The linear vector contains two loxP sites in 
direct orientation flanking a high copy plasmid backbone and the insert. Recombination 
between these two sites is mediated by Cre recombinase. The Cre-lox site specific 
recombination system is particulai’ly simple and well chai'acterised, and is accomplished with 
the use of Cre, a 48 KDa protein which is capable of catalysing the recombination between 
directly repeated sites on the same molecule to excise the intervening segment (figure 3 .1). 
This leads to the excision of the multi-copy plasmid from the phage genome, and is termed 
automatic subcloning as it obviates the need for tedious subcloning of the insert (Sauer, 1987 
and 1988). The use of Bluescript facilitates further manipulation of excised plasmid DNA, as 
demonstrated by the convenience of working with high copy plasmids .
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3.2 Experimental strategy
The experiments described in this chapter were caixied out with the aim of identifying and 
characterising the rat Y5 receptor gene, the rationale behind this strategy ultimately aimed at 
determining the pattern of regulation of expression for this gene which is strongly implicated in 
the control of food intake.
3.2.1 Identification of a positive clone
The published cDNA sequence encoding the rat Y5 open reading frame was exploited in order 
to design oligonucleotide primers bearing homology to the 5' region of the rat Y5 receptor. 
These were subsequently used to screen a rat genomic library. Hybridisation screening of the 
rat genomic library with radiolabelled oligonucleotide primers homologous to the Y5 receptor 
cDNA was carried out in order to identify a rat Y5 genomic clone (Benton, 1977). 
Identification of a positive clone following the initial primary screening of the library, 
permitted a secondary screening process and the subsequent identification of a positive clone. 
This was then used to isolate plasmid DNA bearing the NPY Y5 gene.
3.2.2 Isolation and analysis strategy
The Cre lox excision system was used to subclone the isolated DNA clone into Bluescript and 
restriction digest analysis was carried out on the plasmid DNA in order to assess insert size and 
to determine by diagnostic restriction digest whether the isolated genomic DNA contains rat Y5 
receptor sequence.
3.2.3 Southern blot analysis strategy
Southern blot analysis was carried out on the isolated DNA in order to identify any regions of 
homology between the isolated DNA and the rat Y5 receptor. A DNA probe encompassing a 
region of the rat Y5 open reading frame was used to detect regions of rat Y5 sequence within 
the isolated genomic DNA, and to identify the 5' region of the Y5 gene. Identification of 
sequence beai’ing homology to the rat Y5 receptor was confirmed using PCR technology and 
subsequent sequence analysis.
The experimental strategy employed in the experiments described in this chapter is summaiised 
in figure 3.2
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Figure 3.1. Schematic of the XPS vector structure, detailing the Cre recombinase 
automatic subcloning facility.
81
IPS SI-SII-N
Xba h 
C O SR'ssaB-(H-X-R-N-S) (S-N-R-X-H)-B-K
loxP> loxP>
Cre
recombinase
in E c o / / B N N 132
automatic
subcloning
pPS
loxP
pBluescript
SI-SII-N
3.3 Chapter specific methods.
3.3.1 Oligonucleotide design.
Oligonucleotide primers specific for regions of messenger RNA (mRNA) coding for the rat Y5 
receptor (Gerald, 1996) were used as radiolabelled probes in the rat genomic libraiy screening 
in order to isolate the rat Y5 genomic clone by hybridisation screening. A pictorial 
representation of the primers alongside the Y5 mRNA is given in figure 3.3 and the 
oligonucleotide sequences can be found in Appendix II. Care was taken in oligonucleotide 
design to avoid sequences which might contribute to secondary structure and to incorporate a 
relatively high proportion of G and/or C residues to achieve higher dissociation temperature 
(Td ) values. Oligonucleotides were synthesised commercially by Oswel DNA Service
(University of Southampton) and reconstituted in water. All oligonucleotides were checked for 
complementary hybridisation with the DNA data bank using the blast or fasta programmes for 
GCG (Wisconsin Package Version 9.1, Genetics Computer Group (GCG), Madison, Wise).
3.3.2 End labelling (5') of oligonucleotides.
T4 polynucleotide kinase (T4PNK) was used to phosphorylate the 5'-end of oligonucleotides 
with 32p to a specific activity of 2.5 X 10^ dpm/pg, as outlined (Maxam and Gilbert, 1980). 
In a typical reaction, Igg of oligonucleotide was labelled using a 5'-DNA terminus labelling 
system (Life Technologies) in a 25pl reaction volume, with lOpCi [y^^P] ATP (5000Ci/mmol, 
Amersham). One microlitre of labelled product was spotted onto DEAE ion exchange paper 
(DE-81, Whatman) and analysed using liquid scintillation spectrophotometry to determine
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Figure 3.2. Schematic depicting experimental strategy for rat Y5 genomic clone 
identification.
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Figure 3.3. Oligonucleotide primers schematic.
Schematic of rat Y5 cDNA sequence and the oligonucleotide primers used for genomic 
library screening purposes. Hatched regions on the cDNA correspond to translated 
sequences.
Oligonucleotide primers 1, 2 and 3 represent those used in genomic libraiy screening 
procedure.
Oligonucleotide primers 1,2,3 and 4 represent those used in Southern blot analysis.
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label incorporation and specific activity. Samples containing no enzyme were also analysed 
as negative controls to compare incorporation of radioactivity. All samples were washed in 
0.5M sodium phosphate to remove free nucleotides before counting. CHROMASPIN TE 10 
columns (Clontech) were used to purify the oligonucleotides before use.
3.3.3 Genomic library screening.
3.3.3.1 Preparation of plating bacteria (C600).
The bacterial strain C600 (Cre-) was prepared in order to prepare serial dilutions of the 
genomic libraiy for titie determination. A single colony of the bacterial strain was grown in 
50ml LB++ in a 250ml flask, with vigorous agitation at 37“C to saturation (usually overnight). 
The culture was then centrifuged at 2500 X g for 10 minutes to pellet the bacteria, which were 
subsequently resuspended in 25ml 20mM MgSOq.
3.3.3.2 Titre determination of rat genomic library.
The titre of the rat genomic libraiy was assessed in order to ensure that all clones within the 
library were represented in the library plating and subsequent screening. Serial dilutions of the 
library were prepared in SM solution (Appendix I). Three hundred microlitres of the C600 
plating bacteria were infected with Ipl of a 10"^, 10"^, 10""^ ’ 10"^’ 10~^  libraiy dilution and 
allowed to incubate for 30 minutes at 37°C. LB/MgS04 plates were prepared, as was LB/top
agar, which was cooled to 55°C before addition of the infected bacteria. The infected bacteria 
and LB /top agar mixture was poured onto prewarmed (37°C ) LB/MgSOq plates, allowed to
set, and incubated in an inverted position at 37°C overnight to allow plaque growth. Plaques 
were counted following overnight incubation and the exact title of the plaque forming units 
(pfus) of the libraiy stock was calculated, as the number of plaques obtained is equivalent to 
the number of phage present in Igl of the corresponding serial dilution. The titre of the library 
was calculated as 5.4 X 10^ phage/gl. As the suggested number of pfus to guarantee 
complete representation of the rat genome in one plating is 2 X 10^ pfus, the estimated titie 
value of 5.4 X 10^ pfus was therefore sufficient to ensure representation of the rat genome. 
The recommended number of pfus per plate was calculated at 20-50 X 10^ pfu's per 12cm X 
12cm plate, therefore a 1:1000 dilution of the libraiy was required. Three millilitres of C600 
plating bacteria were infected with lOpl of the libraiy dilution calculated to yield 50 X 10  ^
pfus, and incubated at 37“C for 30 minutes. Following incubation, 9mls of LB/top agai" were 
added to the infected bacteria and the sample poured onto prewaimed (37°C) LB/MgS04
plates. After cooling at room temperature, the plates were incubated at 37°C overnight in an 
inverted position. Plates were checked at regular intervals in order to assess plaque formation 
and growth, as plaque growth was optimal when individual plaques were readily observed,
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and no plaque diffusion was present. When optimal plaque growth had been obtained, plates 
were stored at 4°C until transfer to nylon membrane.
3.3.3.3 Transfer of plaques to nylon membrane.
In order to screen the rat genomic library with the Y5 specific radiolabelled oligonucleotide 
primers, transfer of the plaque DNA in the pfus to nylon membrane was necessary. Twenty 
plates containing 50 X 10  ^ pfus, and representing the entire rat genome were subjected to the 
following procedure in order to ensure efficient transfer of the plaque DNA to the nylon 
membrane. Nylon membrane (Hybond, Amersham) was carefully placed on top of the pfu 
containing agar, ensuring the entire surface of the plate was covered by the membrane. A 
syringe was used to form a series of holes at the edge of the membrane to facilitate orientation 
following the screening process. The membrane was positioned correctly on the plates and 
carefully removed after 2 minutes. Duplicate lifts were carried out as described, leaving the 
membrane on the plates for 4 minutes to ensure efficient transfer. After drying at room 
temperature for 10 minutes, the membranes were denatured by submerging in a solution 
containing 1.5M NaCl and 0.5M NaOH for 2 minutes, neutralised in a solution containing 
1.5M NaCl and 0.5M Tris-HCl (pHS.O) for 5 minutes. The membranes were then rinsed in 2 
X SSC solution for 2 minutes, air-dried between 2 sheets of filter paper and UV crosslinked at 
700,000gJ for approximately 30 seconds with an ultraviolet crosslinker (Amersham) to cross­
link nucleic acids to the membrane.
3.3.3.4 Filter hybridisation.
Filters were equilibrated in prehybridisation solution containing 5 X SSC, 5 X Denhardts, 
0.1% SDS, 20mM NaH2P04 and lOOmg/ml sheared and denatured salmon sperm DNA at
60°C with rotation for at least 3 hours (in a Techne hybridisation vessel). After addition of 
labelled oligonucleotide probe, hybridisation was allowed to proceed overnight at 60°C with 
constant agitation. Following overnight hybridisation, the hybridisation solution was removed 
and the filters were washed twice for 15 minutes at 60°C in a solution of 5 X SSC/0.1%SDS. 
Filters were then subjected to more stringent washing conditions, by washing twice for 15 
minutes at 60°C in a solution of 3 X SSC/0.1%SDS. Once satisfied that sufficient removal of 
any non specific radioactivity had been achieved the filters were wrapped in cling film to 
prevent dehydration. Membranes containing no DNA, but treated identically to the filters 
containing bacteriophage DNA, were used as negative controls in order to ensure hybridisation 
between the probe and DNA on the membrane was specific.
Detection of a positive signal was carried out as described in section 2.3.3.1, and positive 
plaques were picked from the corresponding agar plates following careful alignment of filter 
and plate, to ensure isolation of the correct plaque was achieved. Single plaques were picked
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using an inverted 1ml pipette tip, transferred to an eppendorf tube containing SOOgl SM/20gl 
chloroform, vortexed and stored at 4“C until further processing was carried out.
3.3.3.5 Isolation of plasmid DNA from bacteriophage.
The bacterial strain BNN132 (Cre+), which expresses Cre recombinase essential for the 
excision of the DNA from the X phage vector, was prepared as described in the manufacturers 
instractions (Mo Bi Tec). The BNN132 strain was sti'eaked on to LB agar plates containing 
25pg/ml kanamycin and grown overnight at 37°C. A single colony of the Cre+ recombinase 
containing strain was grown in 50ml LB++ in a 250ml flask, with vigorous agitation at 37“C 
to saturation (usually overnight). The culture was then centrifuged at 2500 X g for 10 minutes 
to pellet the bacteria, which were subsequently resuspended in 25ml 20mM MgSOq.
The bacteria were infected with the purified phage by adding 50gl purified phage to 200gl of 
Cre+ plating cells, and incubating at 37“C for 30 minutes, following gentle mixing. The 
bacteria and phage mixture were then plated on to LB agar plates containing 50 pg/ml 
ampicillin, inverted and incubated at 37°C overnight. Following overnight incubation, a single 
colony was picked and grown to saturation with vigorous agitation at 37°C in 5mls of 
LB/ampicillin( 1 OOpg/ml). Plasmid "miniprep" DNA was isolated as described in section 
2.3.2.4.
3.3.4 Plasmid "Maxipreparation"
Large-scale plasmid preparations were performed using a kit (Qiafilter maxi kit, Qiagen). The 
method used was as instructed in the manufacturers protocol. The plasmid containing strain 
of E.Coli was grown overnight in 100ml LB medium containing appropriate selective 
antibiotic, at 37°C with vigorous shaking. The bacterial cells were harvested by centrifiigation 
at 6000 X g for 15 minutes at 4°C, and the pellet resuspended in 10ml of buffer PI (supplied). 
To this, 10ml of lysis buffer P2 (supplied) was added, mixed carefully by inversion and 
incubated at room temperature for 5 minutes. Following incubation at room temperature, 10ml 
of chilled neutralisation buffer P3 (supplied) was added to the lysate, mixed immediately but 
gently by inversion and poured directly into the barrel of a QIA filter caitridge (supplied). The 
lysate was then incubated for 10 minutes at room temperature before pushing the liquid 
through the filter, removing insoluble complexes containing chromosomal DNA, salt, detergent 
and proteins which form during the neutralisation step. The cleared lysate was then loaded 
onto a previously equilibrated QIAGEN-tip 500 by gravity flow. The selectivity of the resin in 
the QIAGEN-tip ensures that only plasmid DNA binds, while degraded RNA, cellulai' 
proteins, and metabolites are not retained and appear* in the flow-through fraction. The 
QIAGEN-tip was then washed with 2 X 30ml buffer QC (supplied) to ensure removal of 
contaminants. The plasmid DNA was then eluted from the QIAGEN-tip with 15ml of high salt
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buffer QF (supplied) and precipitated by the addition of 10.5ml of isopropanol at room 
temperature, followed by centrifugation at 15,000 X g for 30 minutes at 4°C. The DNA pellet 
obtained following centrifugation was washed in 5ml room temperature 70% ethanol to remove 
residual salt and centrifuged at 15,000 X g for 10 minutes at room temperature. The pellet 
obtained was air-dried for 5-10 minutes and the DNA resuspended in 1ml of TE buffer pH 8.0.
3.3.5 Southern blot analysis
Following restriction digest of DNA as described in section 2.3.1.6, DNA was transferred 
from agarose gels to membrane by capillaiy action for subsequent hybridisation analysis as 
described (Southern, 1975); nylon chaige-modified membrane (Hybond, Amersham) was 
substituted for nitrocellulose and transfer was allowed to proceed overnight. After 
electrophoresis and photography, the gel was soaked for 45 minutes in 1.5M NaCl/0.5M 
NaOH at room temperature to denature the DNA. The gel was then neutralised by soaking in a 
solution containing 2M Tris pH 7.4/2M NaOH for 40 minutes at room temperature. The gel 
was then laid on several layers of filter paper (Whatmann 3MM) soaked in 10 X SSC; these 
layers were overlaid on a filter paper wick extending from a tray filled with 10 X SSC. A piece 
of nylon membrane, cut to the size of the gel and nicked in the corner for orientation purposes, 
was prewet in 5 X SSC and laid on top of the gel such that all bubbles were excluded between 
the gel and membrane. Three layers of solution saturated filter paper were placed on top of the 
membrane avoiding trapping of bubbles and then a 4-6 cm pile of dry absorbant paper was 
placed on top. A glass plate and a IKg weight added weight needed to ensure contact of dry 
paper with wet filter paper. The following day, the damp blot was exposed, 30 seconds each 
side to ultraviolet light at 254nm to cross-link nucleic acid to the membrane and to assess 
transfer efficiency. Blots were then air-dried and stored between sheets of filter paper.
3.3.6 Recombinant plasmid generation-1.4Kb Pst fragment
The 1.4kb DNA fragment generated by digestion of genomic DNA with the restriction 
endonuclease Psti was cloned into Bluescript (SK-) for plasmid DNA preparation and 
sequencing. One microgram of vector DNA was digested to completion with Pstl. 
Simultaneously, genomic DNA was digested to completion using Pstl and electrophoresed 
through low melting point agarose gel. The 1.4Kb fragment was excised using a scalpel blade 
and heated to 65°C to melt the agarose. The vector fragment was then subjected to 
dephosphorylation using Shrimp Alkaline Phosphatase (SAP) (Amersham). This enzyme 
removes the 5' phosphate from DNA ends thereby preventing religation of the vector. This 
enzyme was inactivated by incubating at 65°C for 15 minutes following dephosphorylation. 
The DNA fragment was ligated using T4 DNA ligase (Boehringer Mannheim) in IX low salt 
buffer (Boehringer Mannheim: Appendix I) and ImM ATP incubated at 15“C overnight. DNA 
was transformed as described in section 2.3.1.4 and plasmid DNA was isolated as described in 
section 2.3.2.4.
3.4 Results,
3.4.1 Genomic library screening.
A rat genomic DNA libraiy constructed in IPS phage vector (Mo Bi Tec) was screened with a 
series of ^^P end-labelled oligonucleotides homologous to 5' regions of the rat Y5 open 
reading frame (figure 3.3). Six positive clones were obtained from 2 X 10^ bacteriophage 
plaques following the primary screening procedure described in section 3.3.3. Hybridisation 
screening of duplicate filters confirmed the presence and location of these clones which were 
subsequently isolated, and prepared for a further cycle of screening. Thiee positive clones 
were obtained from 2.6 X 10^ bacteriophage, again following the procedure described in 
section 3.3.3. The positive clones were isolated for prepai'ation of plasmid DNA from the 
bacteriophage.
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3.4.2 Diagnostic restriction analysis.
Three colonies were obtained following excision of the plasmid DNA from the tai'geted 
bacteriophage plaques using the Cre+ recombinase system to facilitate subcloning of the DNA 
insert into Bluescript. Plasmid DNA was prepared as described in sections 2.3.2.4.and 
3.3.3.6.
Following isolation of the excised DNA from tai'geted bacteriophage preparations, restriction 
digest analysis was carried out on the DNA in order initially to determine whether the isolated 
genomic DNA contained any sequence with homology to the rat Y5 receptor. DNA was 
subjected to digestion with the restriction endonucleases Bgl II and Ncol, as the Bluescript 
vector lacks restriction sites for these enzymes, making them ineffective at digestion of the 
vector. These enzymes were used to digest the isolated genomic DNA as these enzymes would 
not generate vector fragments. The use of other restriction enzymes may generate vector 
fragments. The MAPSORT programme for GCG ( Wisconsin Package Version 9.1, Genetics 
Computer Group (GCG), Madison, Wise.) permitted a detailed analysis of the restriction 
enzyme sites present within the rat Y5 open reading frame (Gerald, 1996), and revealed that the 
rat Y5 cDNA contains restriction sites for both Bgl II and Ncol enzymes. Following digestion 
to completion of lOpg DNA with both restriction enzymes and gel electrophoresis analysis, the 
DNA fragments generated enabled diagnostic analysis to be carried out. The generation of 
DNA fragments corresponding to the moleculai* weight predicted by the rat Y5 map would 
suggest that the isolated DNA may contain regions of rat Y5 sequence.
The inserts generated from restriction digestion using Bgl II and Ncol yielded a fragment of the 
predicted molecular weight, as determined from the restriction map of the rat Y5 cDNA. The 
presence of the 600bp predicted fragment suggested that the isolated genomic DNA contains rat 
Y5 sequence. Fragments of different molecular weights were also obtained, as the large 
genomic DNA insert is likely to contain numerous restriction sites for the enzymes used. The 
other fragments generated upon resti'iction digestion with Bgl II and Ncol were as follows; 
200bp, 400bp, 700bp, 800bp, lOOObp, 1200bp, 1800bp, 2500bp and 4000bp.
Figure 3.4a illustrates the restriction digest analysis of the isolated genomic DNA following 
digestion and gel analysis as described in sections 2.3.1.6 and 2.3.1.7
3.4.3 Restriction digest determination of insert size
In order to determine the size of the genomic insert, resti'iction analysis was cai'ried out using 
endonucleases which aie known to possess restriction sites in the cloning region
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Figure 3.4. Restriction digest analysis of isolated genomic DNA.
A: Diagnostic isolated genomic DNA digest.
lOjig genomic DNA was digested to completion with Bgl II and Ncol and 
electrophoresed on an agaiose gel as oultined in section 2.3.1.7. DNA was visualised 
under ultraviolet irradiation; photograph exposure time 0.5-1.0 seconds.
Lanes land 2: The migration position of the 600bp genomic DNA fragment predicted 
by the rat Y5 cDNA restriction map is denoted by
Restriction digested DNA markers (M) were electrophoresed alongside digested 
genomic DNA. 1Kb ladder (Life Technologies).
B: Resti'iction digest analysis of insert size.
10jig genomic DNA was digested to completion with Kpnl and Notl and treated as 
described above.
Lane 1 : The migration position of the genomic DNA fragments generated and the 
Bluescript vector (*) are denoted in base pair values.
Restriction digested DNA markers (M) were electrophoresed alongside digested genomic 
DNA. 1Kb ladder (Life Technologies).
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of the vector. By performing restriction analysis with Kpnl and Notl, which have restriction 
sites 5' and 3’ of the insert, the insert size was readily determined from the DNA fragments 
generated. The size of the genomic DNA calculated as 10.5kb as shown in figure 3.4b.
3.4.4 Restriction analysis and cloning of a partial Y5 receptor gene.
The restriction enzymes BamHl, Hindlll, Ncol , Notl and Pstl were used to digest 10|lg 
genomic DNA, in order to establish the number of restriction sites present within the insert and 
to obtain smaller DNA fragments for Southern blot analysis. The results of restriction digest 
analysis of the genomic DNA following gel electrophoresis ai*e shown in figure 3.5a. As 
illustrated in figure 3.5a, the resti'iction endonucleases Hindlll and Pstl were shown to be 
effective at digestion of the isolated genomic DNA, as observed by the generation of multiple 
DNA fragments. The restriction endonucleases Bam HI, and Notl were ineffective and failed 
to fragment the DNA. Consistent with one internal site, Nco I lineaiised the isolated genomic 
DNA. The size of the fragments obtained upon digestion with Hijîdül and Pstl were as 
follows; Hindlll 3500bp and TOOObp, Pstl 1400bp, 2700bp and 6000bp.
Southern blot analysis of the restriction digests shown in figure 3.5a was cai'ried out (as 
described in section 3.3.3.7) using a region of the rat Y5 receptor cDNA as a probe (see figure 
2.4a) in order to identify restriction fragments which may harbour regions of the rat Y5 gene. 
This probe comprises base pairs 621-1410 of the rat NPY Y5 cDNA, which contain the open 
reading frame of this receptor from transmembrane domain 5 (TM5) to the cai'boxy-terminal 
region of the receptor protein. As illustrated in figure 3.5b, Southern analysis revealed regions 
of homology between the rat Y5 cDNA probe and the 2.7 Kb fragment generated by Pstl.
3.4.5 The open reading frame of the rat NPY Y5 receptor between TM5 and the C-terminal 
region of the protein contains no introns
In order to confirm the presence of a region of the rat Y5 receptor gene within the isolated 
genomic DNA, the restriction digest was repeated, using lOpg DNA and the restriction 
endonuclease Pstl. The DNA from the 2.7Kb Pstl generated fragment was excised from the 
gel and purified using a kit (Qiaquick gel extraction, Qiagen). Following purification, the DNA 
was used as a template in a PCR reaction with oligonucleotide primers homologous to the rat 
Y5 receptor. Figure 2.4a highlights the combination of primers used in the PCR reaction, 
which was carried out as described in section 2.3.2.2, subjected to 40 cycled temperature 
conditions and an annealing temperature of 60°C. Negative contiol reactions were cai'ried out 
as described previously in section 2.3.2.2.
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Figure 3.5, Southern blot analysis of isolated genomic DNA.
A: Restriction analysis of isolated genomic DNA
lOgg per lane of isolated genomic DNA was digested to completion with the following 
resti'iction enzymes:
Lane a iHind III, lane b: BamHl, lane c: Nco I, lane d: Not I, lane e: Pstl, lane f: Hind 
III, lane g: BamHl, lane h: Pstl, lane i: Not I and lane j: Nco I.
DNA was electrophoresed on an agarose gel as outlined in section 2.3.I.7.and 
visualised under ultraviolet irradiation; photograph exposure time 0.5-1.0 seconds.
Restriction digested DNA markers (M) were electrophoresed alongside digested 
genomic DNA. 1Kb ladder (Life Technologies).
B: Autoradiogram of a Southern blot of the gel in figure 3.5A hybridised to a ^2 p_ 
labelled rat NPY Y5 cDNA probe encompassing the rat Y5 open reading frame from 
TM5 to the C-terminus of the receptor protein.
Lanes e and h contain Pst I digested genomic DNA. A single band corresponding to 
the 2.7Kb Pstl fragment (**">=) hybridised to the radiolabelled probe.
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Figure 3.6. Identification of a partial rat NPY Y5 receptor gene within the isolated 
genoniie DNA.
Paired oligonucleotide primers (see figure 2.4A and Appendix II) designed to the rat Y5 
open reading frame were used to amplify corresponding DNA fragments from the 
isolated genomic DNA. The 2.7Kb fragment generated by Pstl digestion which 
hybridised to a radiolabelled probe encompassing a region of the rat Y5 open reading 
frame (figure 3.5B) was used in the PCR reaction described (section 3.4.5).
Lanes 1, 3, 5 and 7: No PCR products obtained using a rat Y5 cDNA 5' forward 
primer and reverse primer (figure 2.4A). Expected PCR product molecular weight 
= 1200bp.
Lanes 2,4, 6, and 8 : PCR products of expected molecular weight were obtained using 
a rat Y5 cDNA internal 5' primer and reverse primer (figure 2.4A). Expected PCR 
product molecular weight = 800bp (***).
Restriction digested DNA markers (M) were electrophoresed alongside digested 
genomic DNA. 1Kb ladder (Life Technologies).
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As demonstrated in figure 3.6, gel electrophoretic analysis of the PCR products revealed that 
products of the predicted molecular weight were obtained using only one of the primer 
combinations. The internal forward primer (IP) and reverse primer (RP) (figure 2.4 A) 
generated a PCR product of the moleculai’ weight of 800bp. This moleculai' weight product 
was identical to that predicted from the cDNA sequence. Subsequent sequence and 
bioinformatic analysis of the PCR products obtained confirmed that the DNA shared 100% 
sequence identity with rat Y5 cDNA over this region (Gerald, 1996). These results suggest 
that the region of the rat Y5 gene situated between the internal primer (TM5) and reverse primer 
(C-terminus) (figure 2.4A) does not contain an intron in the sequence, as identical PCR 
products were obtained from cDNA (figure 2.10a) and genomic DNA.
3.4.6 Identification of the 5' untranslated region of the rat Y5 gene by restriction digest 
analysis and Southern blotting.
In order to examine regulation of the Y5 gene, cloning and chaiacterisation of the 5' flanking 
region of the gene is necessary to enable promoter studies to be cai'ried out. In order to 
construct a map of the 5' region of the rat Y5 receptor gene. Southern analysis was cai'ried out 
on isolated genomic DNA digested to completion with restriction endonucleases HindHl and 
Pstl (figure 3.7A).
Following digestion of lOjLig DNA and gel electrophoretic analysis, DNA was transferred to 
nylon membrane and Southern blot analysis was carried out using ^^P end-labelled 
oligonucleotide primers homologous to the 5' end of the rat Y5 open reading frame (figure 
3.3). Four individual identical Southern blots were cai'ried out and each probed with a 
different radiolabelled oligonucleotide primer corresponding to different regions of the 5' 
region of the cDNA.
The results of the Southern hybridisations described above are shown in figure 3.7B. The 
regions of homology observed between the radiolabelled oligonucleotide probes and the 
digested genomic DNA are tabulated below in table 3.1.
Hindlll fragments X = 7000bp
Y = 3500bp 
Pstl fragments X = 6000bp
Y = 2700bp 
Z =1400bp
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Figure 3.7 Identification of the 5' untranslated region of the rat Y5 gene by 
restriction digest analysis and Southern blotting.
A: Restriction analysis of isolated genomic DNA
lOjrg per lane of isolated genomic DNA was digested to completion with the following 
restriction enzymes:
Lanes a: Hiizd HI 
Lanes b: Pstl
DNA was electrophoresed on an agarose gel as outlined in section 2.3.1.7. and 
visualised under ultraviolet irradiation; photograph exposure time 0.5-1.0 seconds.
Restriction digested DNA markers (M) were electrophoresed alongside digested 
genomic DNA. 1Kb ladder (Life Technologies).
B: Autoradiogram of the four individual identical Southern blots of the gel in figure 
3.8A hybridised to a 32 P-end labelled oligonucleotide primers homologous to different 
regions of the 5' end of the rat Y5 open reading frame see figure 3.3 and Appendix II).
The radiolabelled oligonucleotide primer used to probe each blot is denoted numerically 
as illustrated (numbers 1-4 ), and the pattern of hybridisation obtained is described in 
detail in table 3.1
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33B35BBBB e n
a b a b a b
Oligo 1 Oligo 2 Oligo 3 Oligo 4
Hindlll X — ++++ +++ +++
Hindm  Y — +++ — +++
Pstl X — — +++ +++
Pstl Y — +++ — —
Pstl Z — ++++ — —
Table 3.1 (+++ and ++++denote hybridisation of radiolabelled oligonucleotide to genomic 
DNA fragment.).
As the table above and figure 3.7B demonstrate, the radiolabelled oligonucleotide primer 2 
hybridises strongly to the smallest Pstl generated fragment of 1.4Kb, demonstrating that 
regions of homology exist between this oligonucleotide primer and the 1.4Kb fragment of 
genomic DNA. As this oligonucleotide is homologous to the region of the Y5 cDNA 
encompassing the functional translation codon, this Pstl generated fragment of DNA may 
contain sequence from the 5'-untranslated region of the Y5 gene. The 1.4Kb fragment of 
DNA was subcloned into the vector Bluescript (SK) as described in section 3.3.6, and DNA 
was prepared for sequencing (section 2.3.1.9) and further analysis.
3.4.7 Sequence analysis of the 1.4Kb Pstl fragment
Sequence analysis of this DNA has revealed difficulty in identifying regions of homology with 
the cDNA which may suggest that this fragment only contains a very small exon. The 2 
oligonucleotides (3 & 4) downstream of the second primer hybridised to the largest fragment of 
Pst I suggesting that an intron separates the sequences between oligonucleotide 2 and 
oligonucleotides 3 and 4.
3.5 Discussion.
3.5.1 Isolation of a genomic rat Y5 receptor gene clone from a rat genomic libraiy
Screening of an amplified rat genomic libraiy yielded 3 positive clones when hybridised to 
oligonucleotide primers homologous to the rat Y5 open reading frame. The number of 
bacteriophage plaques screened in the amplified rat genomic libraiy was 2 XIO^. As the 
amplified library was calculated to possess a redundancy of 10, the number of bacteriophage 
plaques screened represents 10 rat genomes. The rat genome is likely to contain a single Y5 
gene, as the other members of the NPY receptor family are encoded by single copy genes 
(Larhammer, 1992., Gerald, 1995., Lundell, 1995., and Gregor, 1996).
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3.5.2 Diagnostic restriction digest analysis
The restriction digest carried out with the endonucleases Bgl II and Ncol, which are ineffective 
at digestion of the vector DNA, and are known to possess restriction sites within the rat Y5 
cDNA, enabled a diagnostic strategy to be employed. The rat Y5 cDNA restiiction map 
predicted a fragment size of molecular' weight 600bp upon digestion with the aforementioned 
endonucleases. As the isolated genomic DNA yielded a fragment of this size when digested to 
completion with Bgl II and Ncol, this suggested that the genomic DNA obtained from the 
library screening may contain DNA sequence corresponding to the rat Y5 receptor gene. The 
results of this diagnostic digest enabled the investigation and characterisation of the isolated 
genomic DNA to progress further.
3.5.3 Identification of a partial rat Y5 receptor gene.
Southern blot analysis was carried out in order to obtain DNA fragments of a manipulative 
size, and to confirm the presence of rat Y5 receptor DNA within the isolated genomic DNA. 
Restriction enzymes known to be 6 base pair recognition site restriction enzymes were selected 
at random and used to fragment the genomic DNA. As illustr’ated in figure 3.6a, the 
endonucleases HindRl and Pstl generated multiple DNA fragments, confirming the presence of 
restriction sites for these enzymes within the genomic DNA. Restriction sites for the 
endonucleases BamHl and Natl do not appeal* to be present in the isolated genomic DNA, as 
these failed to fragment the DNA upon digestion to completion.
Southern analysis with a ^^P-labelled cDNA probe encompassing a region of the open reading 
frame of the rat Y5 cDNA revealed that the 2700bp Pstl fragment was positive by hybridisation 
suggesting homology exists between the genomic DNA and this region of the rat Y5 cDNA. 
Following isolation and purification of this genomic DNA fragment, a PCR strategy was 
employed using oligonucleotide primers homologous to the rat Y5 cDNA (figure 2.4a). 
Sequence analysis of the resultant PCR product obtained confirmed that this fragment of 
genomic DNA contains a region of the rat Y5 open reading frame. In addition, as the sequence 
obtained for the PCR of the genomic fragment was identical to the cDNA, this indicates that the 
region of the NPY Y5 gene between TM5 and the C-terminal region contains no introns.
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3.5.4 Identification of the rat Y5 5' untranslated region.
As the regulation of feeding behaviour undoubtedly involves interactions between numerous 
neurotransmitters, neuropeptides and hormones known to play a role in mediating this 
fundamental function, further knowledge regarding the regulation of a major component in this 
complex circuiti'y would provide invaluable insight into one of the critical pathways responsible 
for energy homeostasis. In order to investigate further the regulation of the Y5 gene, 
identification of the promoter region of the gene is essential. By identifying the promoter 
region, sequence motifs chaiacteristic of binding sites for transcription factors may be located 
and reporter gene constructs designed in order to examine regulation of this crucial gene.
Recent published work implies that the organisation of the 5' end of this gene is vei-y complex 
(Herzog, 1997). Indeed, this genomic structure has been extremely difficult to subclone and 
evaluate (H.Herzog, personal communication). This may explain the difficulty encountered in 
this project in defining the 5’ end of this genomic fragment. Thus, oligonucleotide 1 failed to 
hybridise to any of the genomic fragments, suggesting that this region of the DNA is absent in 
this clone. Primer 2 which encompasses the proposed translation initiation codon (ATG) 
hybridised strongly to the smallest Pst I fragment suggesting that at least one exon encoding the 
5' region of the gene is located in this fragment. However, following sequence analysis, it has 
proved difficult to identify regions of homology implying either that the hybridisation observed 
is false or that the exon is extiemely small. Oligonucleotides 3 and 4 hybridise to the laigest 
Pst I fragment whereas the region encoding the open reading frame (from transmembrane 
domain 5 to the C-terminal region of receptor protein) is present on the 2.7 Kb Pst I fragment. 
This implies that there is at least one intron between oligonucleotide 4 and the open reading 
frame oligonucleotide encompassing paid of transmembrane domain 5.
As a role for the NPY Y1 receptor subtype in the control of NPY induced feeding behaviour 
has been suggested (Kanatani, 1996, 1998), it is noteworthy that the NPY Y1 receptor gene 
and the Y5 receptor gene are transcribed in opposite directions from a common promoter region 
on clii'omosome 4q31-q32. (Herzog, 1997). One of the alternatively spliced 5'exons of the YI 
receptor (1C) is also an integral paid of the coding region of the Y5 receptor, as exon 1C of the 
Yl receptor gene, if translated from the opposite strand, encodes sequences corresponding to 
the third lai'ge intiacellular loop of the Y5 receptor (Herzog, 1997). The close proximity of 
these two NPY receptor genes suggests that they have evolved from a gene duplication event, 
the Y5 receptor gene probably evolving by a gene duplication event from the Yl receptor gene, 
which is now encoded in the opposite orientation 23Kb upstream of exon 2 of the Y 1 gene. Of 
particulai* interest is the fact that the small intron interrupting the coding sequence of the Yl 
gene is converted into a functional sequence within the Y5 gene. The transcription of both
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genes from opposite strands of the same DNA sequence suggests that tianscriptional activation 
of one will have an effect on the regulation of gene expression of the other. As both Yl and 
Y5 genes are implicated in the regulation of food intake, coordinate expression of their specific 
genes may be important in the modulation of NPY activity.
3.6 Summary
1)Both the NPY Yl and Y5 receptor genes which aie implicated in the regulation of NPY 
induced feeding, are situated in close proximity to each other on chromosome 4q31-q32. 
Indeed, the Y1 and Y5 receptor genes lie on alternate overlapping strands of the same region of 
the chromosome. They are likely to have evolved from a gene duplication event, with the Y5 
receptor gene probably evolving as a result of a gene duplication from the Y1 receptor gene.
2)Exon Ic of the Yl receptor gene is an integral paid of the coding region of the Y5 receptor, 
corresponding to the third large intracellulai' loop of the Y5 receptor (Herzog, 1997).
3) As both Yl and Y5 receptor genes ai*e believed to be involved in the modulation of NPY 
elicited eating, coordinate regulation of the expression of these genes may play an important 
role in mediating this chaiacteristic NPY activity.
4)Three positive clones were isolated from a rat genomic library following hybridisation 
screening with radiolabelled oligonucleotide primers homologous to the rat Y5 receptor cDNA.
5)Southern blot analysis revealed that a Pstl generated genomic DNA fragment contained 
regions of homology with the open reading frame of the rat Y5 cDNA. Subsequent PCR and 
sequence analysis confirmed that this genomic DNA fragment encoded a region of the rat Y5 
open reading frame and that this part of the rat Y5 gene is intronless.
6)Southern blot analysis with oligonucleotide primers homologous to the 5' region of the rat 
Y5 open reading frame revealed that an oligonucleotide primer encoding the functional 
translation initiation codon hybridised to a Pstl generated genomic DNA fragment, suggesting 
that this DNA fragment may contain 5'UT region.
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Chapter 4
Novel receptor cloning : GenetrapperT^.
Chapter 4
4,1 Introduction
The potent orexigenic effects of NPY were first identified in 1983 (Clark, 1983). Since the 
initial findings of NPY induced stimulation of feeding were described, the role of NPY as a 
physiological mediator of ingestive behaviour has become well established. The NPY receptor 
subtype involved in mediating the potent augmentation in eating behaviour elicited by this 
neuropeptide and has also attracted widespread interest, and the field of study surrounding the 
feeding receptor for NPY has emerged as a rapidly evolving and highly competitive ai'ea of 
study. As the pharmacology of the cloned NPY receptor subtypes failed to mimic the 
pharmacology known to elicit NPY induced feeding, the tremendous interest associated with 
this peptides role in feeding was fuelled further. In 1996 an expression cloning strategy was 
reported to have identified the feeding receptor for NPY (Gerald, 1996). The receptor was 
designated Y5, and the pharmacology of the receptor expressed from this cDNA was shown to 
mirror that required to promote NPY-elicited eating. However, the role of the Y5 receptor as 
the sole mediator involved in the stimulation of feeding mediated by NPY was to prove 
contentious, as reports describing NPY Yl receptor involvement in the feeding response to 
NPY (Kanatani, 1996, 1998) resulted in considerable controversy surrounding the receptor 
subtype responsible for NPY mediated stimulation of feeding. In addition, studies were 
reported implicating a novel, previously unidentified NPY receptor subtype as the receptor 
involved in mediating feeding behaviour. Thus, the precise nature of the receptor involved in 
mediating feeding behaviour remains unclear.
The wealth of interest intrinsic to this aiea of reseai'ch is generated by the potential therapeutic 
benefits associated with the development of an antagonist to the NPY feeding receptor, as the 
increasing prevalence of obesity creates an enormous market for developing an effective 
appetite suppressant.
The hypothalamus is the brain region believed to co-ordinate and regulate signals relating to the 
control of nutrient and energy homeostasis. This brain region is densely innervated with NPY 
containing nerve fibres (Allen, 1983), and local injection of NPY elicits the most potent effects 
on food intake (Stanley, 1985). Thus, the receptor subtype responsible for mediating NPY 
induced stimulation of ingestive behaviour is likely to be located within the hypothalamus.
In an attempt to isolate novel NPY receptor family members, a novel cloning technology was 
employed. The Genetrapper'^^ cDNA positive selection system (Life Technologies) facilitates 
the rapid isolation of cDNA clones from DNA prepared from a cDNA library. As the desired
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NPY receptor subtype is believed to be distributed within the hypothalamus, a human 
hypothalamic cDNA libraiy was constructed to use in conjunction with this technology.
4.2 Experimental Strategy
The experimental rationale behind the GenetrappeH’^  cDNA Positive Selection system (Life 
Technologies Inc) is summarised in figure 4.1. A series of oligonucleotides homologous to 
individual NPY receptor gene family members, and one degenerate oligonucleotide selected 
from a conserved region within two NPY receptor genes were designed in order to isolate 
novel NPY receptor family members using the Genetrapper'^'^ methodology described.
4.3 Chapter specific methods
Unless otherwise stated, the materials used in the experiments described below were supplied 
by the manufacturer (Life Technologies Inc).
4.3.1 Human hypothalamic cDNA library constraction.
The cDNA library used in the experiments described in this chapter was constructed from 
human hypothalamus in the plasmid based mammalian expression vector pSPORT 1 (Life 
Technologies Inc). Briefly, five micrograms of human hypothalamic Poly A+ RNA (Clontech) 
were used as template for cDNA synthesis using a kit (SUPERSCRIPT Plasmid System, Life 
Technologies Inc). Fragments were size selected over 1Kb and directionally cloned into 
SaWNotl sites of pSPORT 1. A detailed description of the cDNA libraiy construction is 
described in the following sections.
4.3.1.1 First strand synthesis.
5 micrograms of human hypothalamic PolyA+ RNA were added to Notl primer adaptor and 
denatured for 60 seconds at 94 °C before chilling rapidly on ice. To the mRNA and adaptor 
primer mix, 5 X first strand buffer (supplied), O.IM DTT (supplied) and lOmM dNTP mix 
(supplied) were added before incubating at 45°C for 2 minutes. Following incubation, 5pi 
(250 units) Superscript II Reverse Transcriptase were added to the mixture and the reverse 
transcriptase reaction allowed to proceed at 45°C for 1 hour.
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Figure 4.1. Schematic of experimental strategy depicting the Genetrapper^M 
technology.
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4.3.1.2 Second strand synthesis.
The following components were added on ice in the order shown to the first strand reaction; 
93pl DEPC treated water, 30pl 5 X second strand buffer (supplied), 3pl lOmM dNTP mix, 10 
units E.coli DNA ligase, 40 units E.co/z DNA polymerase I and 2 units RNAse H. The 
total reaction volume of 150pl was vortexed to mix and incubated at 16°C for 2 hours before 
adding 10 units T4 DNA polymerase and incubating at 16°C for a further 5 minutes. The 
cDNA was precipitated as described below in section 4.3.1.3.
4.3.1.3 cDNA precipitation.
To the reaction mixture prepared above in section 4.3.1.2, 10|ll 0.5M EDTA and 150|il 
phenol:chloroform:isoamyl alcohol (25:24:1) were added prior to vortexing and centrifuging at 
room temperature for 5 minutes at 14000 X g to sepaiate the phases.
The upper, aqueous layer was removed, transferred to a fresh eppendorf tube and the cDNA 
precipitated by adding 70p.l of 7.5M NHqOAc, 500jal absolute ethanol (-20“C), and
centrifuging at room temperature for 20 minutes at 14,000 X g.
Following careful removal of the supernatant the pellet was overlaid with 70% ethanol (-20°C) 
and subjected to centrifugation for 2 minutes at 14,000 X g. The cDNA was then dried at 37 
°C for 10 minutes to evaporate residual ethanol.
4.3.1.4 Sal I adaptor ligation.
The following reagents were added on ice, in the order shown to the cDNA prepared as 
described in sections 4.3.1.1-4.3.1.4 ; 25|il DEPC treated water, 5 X T4 DNA ligase buffer, 
20pg Sal I adaptors and 5 units T4 DNA ligase. The reagents were mixed gently and incubated 
at 16°C for a minimum of 16 hours (usually overnight). The cDNA was then extracted and 
precipitated as described in section 4.3.1.3.
4.3.1.5 Not I  digestion.
The following reagents were added on ice, in the order shown to the cDNA from the Sal I 
adaptor addition described in section 4.3.1.4; 41 pi DEPC treated water, 5pi REact 3 buffer and
4.8 units N o t l . The reaction was allowed to proceed at 37°C for 2 hours before adding 50pl 
of phenol:chloroform:isoamyl alcohol (25:24:1) and centrifuging at room temperature for 5 
minutes at 14,000 X g to sepai’ate the phases. The upper aqueous layer was removed and run 
through a CHROMOSPIN TE 1000 column (Clontech). The cDNA was then precipitated with
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7M NHqOAc, absolute ethanol and glycogen (20pg/pl). The resulting cDNA pellet was 
washed with 70% ethanol and dried at 37°C for 5 minutes before resuspending in lOpl water.
4.3.1.6 Size selection of the cDNA inserts.
In order to effectively constmct a cDNA libraiy containing an average insert size above Ikb, 
the human hypothalamic cDNA prepared as described in sections 4.3.1.1-4.3.1.5 was 
electrophoresed in an agarose gel containing ethidium bromide (lOmg/ml) at 100 Volts for 1 
hour. Human hypothalamic cDNA was visualised using ultiaviolet illumination at 300-360nm 
to minimise damage to the DNA (figure 4.2). The cDNA was then excised from the gel in a 
size selection procedure whereby only cDNA above 1Kb was selected. This procedure 
facilitates the cloning of lai’ge inserts. After weighing the agarose sample, lOOpl buffer 
saturated phenol was added per pg of agarose, the sample vortexed for 1 minute and then 
dropped into liquid nitrogen for approximately 1 minute before centrifuging at room 
temperature for 15 minutes at 14,000 X g. To the lower phenol phase, lOOpl distilled water 
was added, and the sample vortexed, dropped into liquid nitrogen and centrifuged as described 
above. Following centrifugation, the upper aqueous layer was removed, and pooled together 
with the upper aqueous layer obtained initially. An equal volume of phenol/chloroform was 
added to the sample, which was vortexed and centrifuged as described. Following removal of 
the upper aqueous layer, an equal volume of chloroform was added and the sample vortexed 
and centrifuged as detailed above. The upper aqueous layer containing the size selected cDNA 
was precipitated with absolute ethanol and 7.5M NHpOAc. The resulting pellet was washed in 
75% ethanol and resuspened in lOpl distilled water after drying.
4.3.1.7. Ligation of cDNA to the vector.
The following ligation reaction was carried out in order to clone the size selected cDNA 
fragments directionally into a SalVNoti site in the vector pSPORT 1 (Life Technologies Inc).
5 X DNA ligase buffer, 2.5pg/ml pSPORT 1, Not 1-Sal I  cut, lOng cDNA and DEPC treated 
water were mixed in a final reaction volume of 19pi. One microlitie of T4 DNA (50U/ml) 
ligase was added and the reaction incubated overnight at 16“C followed by a further incubation 
for 3 hours at room temperature .
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4.3.1.8 Introduction of Ligated cDNA into E.coli by transformation
The ligated cDNA was purified by adding 5pi of yeast tRNA and 12.5jil 7.5M NHpOAc to the 
ligation reaction described above in section 4.3.1.7. The ligated cDNA was then precipitated 
by adding absolute ethanol (-20°C), vortexing and centrifuging at room temperature for 20 
minutes at 14,000 X g. The resulting supernate was removed and the DNA pellet overlaid with 
70% ethanol before centrifuging for 2 minutes at room temperature and 14,000 X g. The 
ligated cDNA was then dried at 37“C for 10 minutes before resuspending in lOpl sterile water. 
DNA was introduced into electrotransformable cells by adding I pi of the purified ligated cDNA 
to 40pl of electroti'ansformable ELECTROMAX DHIOB cells (Life Technologies). The ligated 
cDNA was introduced into the cells with a Gene Puiser electroporator (Biorad) using a field 
strength of 1.8 k, 25|aF and a pulse length of approximately 4ms. 960pl of SOC medium was 
added to the electroporated cells which were then incubated at 37°C for 1 hour with vigorous 
agitation.
Serial dilutions of lOOpl of the transformed bacteria were prepaied in LB medium, and then 
plated on to 100mm LB agar plates containing lOOpg/ml ampicillin. The plates were then 
inverted and incubated overnight at 37“C. The resulting colonies from the serial dilutions were 
counted in order to assess the initial titre of the human hypothalamic cDNA libraiy- which was 
calculated as containing 2 X 10  ^clones. The titie of the libraiy was assessed by multiplying 
the average number of colonies by the volume of the library, and then dividing by the plating 
volume.
The remaining transformed cells in 1ml LB were preserved by storing in 1ml 80% (w/v) 
glycerol at -70°C. In order to assess the percentage of clones containing inserts, a selection of 
individual bacterial colonies were picked and grown overnight for isolation of plasmid DNA as 
described in section 2.3.2.4. Following isolation of miniprep DNA, restriction digest analysis 
was caiTied out as described in section 2.3.1.6 using the restriction endonucleases Notl and 
Sail, as these restriction sites aie present in the multiple cloning site of the pSPORT 1 vector 
and will therefore enable any insert to be generated upon digestion. Gel electrophoretic 
analysis was performed as described in section 2.3.1.7 and revealed drat 85% of the clones 
contained cDNA inserts.
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4.3.1.9 Semi-solid amplification of human hypothalamic cDNA libraiy.
The human hypothalamic cDNA library was amplified using a semi-solid amplification method 
which prevents biasing of insert size upon amplification, and ensures that lai'ge cDNA inserts 
aie amplified.
A solution of 2 X LB containing 0.3% Seaprep agarose (FMC Bioproducts) was prepai'ed and 
ampicillin added at a final concentration of 200pg/ml. This media was prewarmed to 37°C and 
at least 1.5-3 X 10  ^cfu (colony forming units) of cells from the library were added. Aliquots 
of 25ml were pipetted into 50ml tubes and placed in ice water for between 20-60 minutes or at 
4°C until the agai'ose set. The aliquoted media containing agai'ose and cDNA library was 
placed at room temperature for 60 minutes followed by incubation at 30°C for 48 hours. By 
incubating at 30°C lai'ge inserts were successfully amplified. After 48 hours, the mixture 
containing amplified colonies/agai'ose was centrifuged at 5,800 X g for 20 minutes at room 
temperature. Following centrifugation, the supernatant was discarded and the bacterial pellet 
resuspended in 100ml of 2 X LB containing 12.5% glycerol. A lOOpl aliquot was removed for 
analysis, the remaining amplified librai'y was aliquoted, quickly frozen on dry ice and stored at 
-70“C. Following semi-solid amplification the titre of the library was assessed as 7.8 X lO^ O.
4.3.2 Oligonucleotide design.
The Genetrapper'^^ cDNA Positive Selection system requires oligonucleotides complementaiy 
to a segment of the target cDNA to isolate effectively homologous cDNA clones from the 
appropriate cDNA library. As the experimental rationale behind the experiments described in 
this chapter was aimed at the cloning of novel NPY receptor family members, the cDNA 
sequences of the known NPY receptor family members were used to design oligonucleotides 
for GenetrapperT^. For efficient cDNA capture and repair, care was taken when designing 
oligonucleotides to ensure that the G 4- C content was between 50% to 60% and that the 
oligonucleotides were between 16 to 25 nucleotides in length, in order to obtain an optimal 
yield of desired cDNA clones, while minimising the number of background colonies. As the 
isolation of a full length cDNA clone is desired, oligonucleotides were designed from the 5 ' 
region of the cDNA sequences of the other NPY receptor family members. Oligonucleotides 
were synthesised commercially (Life Technologies Inc), reconstituted in I X TE buffer and 
checked for complementaiy hybridisation with the DNA databank using the blast or fasta 
programmes for GCG (Wisconsin Package Version 9.1, Genetics Computer Group (GCG), 
Madison, Wise).
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4.3.3 Genetrapper™ .
Figure 4.1 is a schematic which summarises the Genetrapper^^ methodology described in 
detail in the following section.
4.3.3.1 Biotinyiation of oligonucleotides
Following reconstitution of oligonucleotides in TE buffer at a final concentration of Ipg/pl, 
oligonucleotides were biotinylated at the 3' end using the enzyme Terminal Deoxynucleotidyl 
Transferase and Biotin-14-dCTP to enable efficient capture of oligonucleotide/cDNA hybrids 
using streptavidin coated paiamagnetic beads.
The oligonucleotides were biotinylated in a reaction in which the following components were 
added in the order described; 5|il 5 X Terminal Deoxynucleotidyl Transferase (TdT ) buffer, 3 
pg oligonucleotide, 5pi Biotin -14-dCTP, autoclaved distilled water sufficient to bring the 
volume to 23pl and 2pl Terminal Deoxynucleotide Transferase(TdT). The reaction components 
were mixed by pipetting, centrifuged at room temperature for 2 seconds at 14,000 x g and 
incubated at 30°C for 1 hour. The biotinylated oligonucleotides were precipitated by adding 
Ipl of (20pg /pi ) glycogen, 26pl IM Tris-HCl (pH 7.5) and 120pl ethanol, vortexing and 
storing on dry ice for 10 minutes before centrifuging at 4“C for 30 minutes at 14,000 X g.
The supernatant was cai'efully removed and 200pl of 70% ethanol layered over the pellets, 
before centrifuging at 4°C for 2 minutes at 14,000 x g. The ethanol wash was removed and 
repeated once before drying the pellets at room temperature for 10 minutes and dissolving in 
15pi TE buffer. 3pi of biotinylated oligonucleotide was removed for analysis of biotinyiation 
reaction products.
4.3.3.2 Preparation of double stranded DNA from a human hypothalamic cDNA library.
One hundred millilitres of LB containing lOOpg/ml ampicillin was inoculated with 1ml of 
human hypothalamic cDNA library containing 1 X 10  ^ cells. The bacteria were grown to 
saturation overnight at 30°C with vigorous agitation. The bacteria were pelleted by 
centrifuging at 4,800 X g for 15 minutes at 4°C, the supernatant was discarded and the pellet 
resuspended in lOmls of buffer I (Appendix I) containing RNAse. lOmls of buffer II 
(Appendix I) were added to the resuspended bacteria, mixed by inversion and incubated at 
room temperature for 5 minutes. To this mixture, lOmls of cold 7.5M NH4OAC were added, 
the solution mixed by inversion and the cell mixture placed on ice for 10 minutes. Following 
incubation on ice, the sample was centrifuged at 3,000 X g for 15 minutes at 4°C. The 
resulting supernatant was poured thiough cheesecloth into a fresh centrifuge tube, an equal
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volume of ice-cold isopropanol was added, the contents of the tube were mixed well and 
centrifuged at 3,000 X g for 15 minutes at 4“C. Following centrifugation, the supernatant was 
discarded and the pellet resuspended in 500pl of buffer 1 and transferred to a fresh 
microcentrifuge tube. The solution was clarified by centi’ifuging at 4°C for 1 minute at 14,000 
X g and transferring the supernatant to a fresh tube. The DNA containing supernatant was 
incubated at 37°C for 30 minutes, followed by incubation at 65°C for 5 minutes. The 
supernatant sample was divided into 2 equal parts and an equal volume of 
phenol : chloroformiisoamylalcohol (25:24:1) added to each before vortexing to mix and 
centrifuging at room temperature for 5 minutes at 14,000 X g. The upper aqueous layer was 
removed from each sample and the phenol extraction procedure was repeated at least 3 times or 
until the interface between the 2 phases appeared clear. An equal volume of cold isopropanol 
was added to each sample, followed by centiifugation at 4°C for 15 minutes at 14,000 X g. 
The supernatant was discarded and 70% ethanol added to each sample, before centrifuging as 
above. The supernatant was caiefully removed and the DNA pellets dried at room temperature 
and resuspended in 50pl TE buffer. The double stranded human hypothalamic cDNA was 
quantified (section 2.3.1.6) before subsequent procedures were carried out.
4.3.3.3 Generation of single stranded DNA with Gene II and Exo III.
As the Genetrapper'^^ rationale relies upon the fomiation of hybrids between biotinylated 
oligonucleotides and an appropriate cDNA librai'y, the generation of single stranded cDNA 
inserts is essential.
The following reaction was prepared in order to convert the double stranded (ds) phagemid 
DNA to single stranded (ss) DNA. The replication initiator protein Genell is a site specific 
endonuclease that binds to the fl ori in phagemid vectors and nicks the viral strand of the 
supercoiled DNA. For each oligonucleotide hybridisation, the following were added to a 
microcentrifuge tube at room temperature: 10 X Genell buffer, 5pg ds human hypothalamic 
cDNA, 12pl distilled water and Ipl Genell. The reaction mixture was vortexed and centrifuged 
at room temperature for 2 seconds at 14,000 X g to collect contents before incubating at 30°C 
for 25 minutes. The reaction was then incubated at 65“C for 5 minutes and immediately chilled 
on ice for 1 minute. Ipl of the mixture was transferred to a tube containing 9pl of TE buffer 
and 2pl of gel loading dye for gel analysis. After nicking by Gene II, Exo III was used to 
digest the nicked strand from the 3' end, leaving a ss covalently-closed DNA.
To the remaining 19pl, 2pl of Exo III were added before vortexing, centrifuging at room 
temperature for 2 seconds at 14,000 X g and incubating at 37“C for 60 minutes. Following 
incubation, an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added and 
the mixture vortexed thoroughly and centrifuged at room temperature for 5 minutes at 14,000 
X g to sepaiate the phases. The upper aqueous layer (18pl) was transferred to a fresh tube and
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stored at 4 °C, Ipl being transferred to a fresh tube containing 9pl TE buffer and 2pl gel 
loading dye for gel analysis. Before proceeding to the cDNA capture hybridisation, it was 
ensured that the nicked form of double stranded DNA generated by Gene II treatment was 
completely converted to single stranded DNA following Exo III digestion by examining the 
Gene JU Exo III digested cDNA on an agarose gel (see results figure 4.5).
4.3.3.4 cDNA Capture hybridisation.
Hybrid formation between the biotinylated oligonucleotides and the ss DNA was performed as 
follows:
The biotinylated oligonucleotides were diluted to lOng/jil in TE buffer before using in the 
capture reaction. Six microlitres of 4 X hybridisation buffer was incubated at 37°C for 2 
minutes before adding the Genell/ExoIII ti'eated DNA and mixing by pipetting. The DNA was 
denatured in a 95°C water bath for 1 minute and chilled immediately on ice for 1 minute before 
adding Ipl of diluted biotinylated oligonucleotide (lOng), mixing and incubating at 37°C for 1 
hour.
4.3.3.5 Streptavidin bead preparation.
The streptavidin-coated paiamagnetic beads used to capture the hybrids were gently mixed by 
pipetting to ensure complete resuspension. 45pl of the bead suspension was required for each 
reaction and these were washed prior to use. Tubes containing the 45pl aliquots of beads were 
inserted into a microcentrifuge magnet and left to stand for 2 minutes, after which the 
supernatant was removed whilst retaining the tubes in the magnet. 100|ll of TE buffer was 
added to the beads which were resuspended in the solution by tapping. The beads were again 
placed against the magnet for 2 minutes, the supernatant removed and the beads resuspended in 
30pl of TE buffer.
4.3.3.6 cDNA Capture.
The hybridisation mixture was removed from 37“C, centrifuged at room temperature for 2 
seconds at 14,000 X g, and the prepared paiamagnetic beads added. The suspension was 
incubated for 30 minutes at room temperature and mixed frequently (using a Vortex Genie 
[Fisher] on setting 3). The tubes were then inserted into the magnet for 2 minutes to capture 
the magnetic beads, before discarding the supernatant. lOOpl of wash buffer was added to 
resuspend the beads, which were placed again in the magnet for 2 minutes before removing 
and discarding the supernatant. This washing step was repeated again and lOOpl of wash 
buffer was added to the beads to resuspend before transferring to a clean tube. The tubes were
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then inserted into the magnet for 5 minutes, after which the supernatant was removed and 
discarded, and this wash step repeated again.
Elution buffer (IX) was prepared in TE buffer at pH 8.0, 20pl was added to the washed 
magnetic beads and mixed by pipetting. The beads were then incubated at room temperature 
for 5 minutes, vortexing gently at 10 second intervals, before inserting into magnet for a 5 
minute period. The supernatant containing the captured cDNA clones was removed and 
transferred to a fresh tube. Elution from the magnetic beads was repeated by resuspending 
them in 15pl of TE buffer and insertion into the magnet for a further 5 minutes, following 
which the supernatant was pooled with the first elution supernatant.
The tube containing the combined supernatants was then inserted into the magnet for 10 
minutes to remove any remaining paramagnetic beads. The supernatant (35pl) was transferred 
to a fresh tube and Igl of glycogen, 18pl of 7.5M NHqOAc and 135|xl of ice-cold ethanol were
added, before mixing well and storing at -20°C overnight to precipitate the captured cDNA.
The captured cDNA was precipitated by centrifuging at 4°C for 30 min at 14,000 X g, carefully 
removing the supernatant from the pellet and washing in lOOpl of 70% ethanol before 
centrifuging at room temperature for 2 minutes at 14,000 X g . The ethanol was carefully 
removed and the pellets dried at room temperature for 10 minutes, before dissolving in lOpl of 
TE buffer.
4.3.3.7 Repair of captured cDNA
Before beginning the repair reaction to enrich further the tai’geted cDNA clone, a thermocycler 
was programmed for one cycle with the following parameters: 90°C denaturing step for 1 
minute, 55°C annealing step for 30 seconds and 70°C extension step for 15 minutes.
DNA primer/repair mixture was prepaied for each capture reaction by adding the following to a 
fresh microcentrifuge tube: llg l autoclaved distilled water, 0.5pl lOmM dNTP mix, 0.5pl 
repair enzyme (supplied), 2|al 10 X repair buffer, 5gl captured DNA and 50ng oligonucleotide 
(not biotinylated). The mixture was mixed by pipetting and centrifuged at room temperature 
for 2 seconds at 14,000 X g. The repair mix was then placed in the pre-programmed 
thermocycler and the repair reaction allowed to proceed. Following the repair cycle, the 
mixture was centrifuged at room temperature for 2 seconds at 14,000 X g. Repaired captured 
DNA was precipitated by adding Ipl glycogen, 18jil 7.0M NHpOAc, 135pl ethanol and 15pl 
distilled water, mixing and incubating on dry ice for 30 minutes. The repair mix was then 
centrifuged at 4°C for 30 minutes at 14,000 X g. Following centrifugation, the supernatant 
was removed and lOOpl 70% ethanol added to wash the pellet, before centrifuging for a further 
15 minutes at 4°C and 14,000 X g. The pellet was air dried and dissolved in lOpl TE buffer.
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4.3.3.8 Electroporation of the captured DNA.
2jil of the captured DNA was added to dOjil of electrotransformable ELECTROMAX DHIOB 
cells (Life Technologies Inc). The captured DNA was introduced into the cells using a Gene 
Puiser (Biorad) using a field strength of 2.5 kV and a pulse length of approximately 4ms. 
Following electroporation, 960jxl of SOC medium was added to the electioporated cells which 
were subsequently incubated at 37°C for 1 hour with vigorous agitation.
The transformed electroporated captured DNA was plated onto 22cm x 22cm LB agai' bioassay 
plates containing lOOjig/ml ampicillin. The plates were incubated, in an inverted position, 
overnight at 37°C.
4.3.3.9 Transfer of selected library to filters.
The colonies produced following the electroporation of the DHIOB cells with the selected 
libraiy were picked using a robot (Biopicker, Biorobotics Ltd) and grown up in 96-well 
microtitre plates in medium suitable for storage at -80°C (freezing medium). A gridding robot 
(Biogridder, Biorobotics Ltd) was used to grid samples of the clones onto Hybond-N nylon 
membrane (Amersham) in a known array. After growing up overnight at 30“C on the 
membrane, the clones were alkaline denatured in a solution containing 0.5M NaOH/1.5M NaCl 
for 7 minutes, neutralised in a solution containing 1.5M NaCL/lM Tris pH 8.0 for 3 minutes 
and washed in 2 X SSC for 2 minutes. The DNA was then UV cross-linked to the filter (UV 
Stratalinker 2400).
4.3.4 Screening for novel NPY receptor family members.
Replica filters of the selected libraiy were screened for various members of the NPY receptor 
family in an attempt to isolate novel family members. Oligonucleotide probes were 
radiolabelled with -y-32p ATP as described in section 3.3.2.5 and DNA probes labelled with a- 
3^P-dCTP as described in section 2.3.3.2.
Hybridisation was carried out as described in section 3.3.3.4 at 50“C in ExprèssHyb 
prehybridisation/hybridisation solution (Clontech). Filters were then washed at low stringency 
(6 X SSC/0.1%SDS, 2 X 20 minutes, room temperature) followed by a high stringency wash 
(6 X SSC/0.1%SDS, 2 X 20 minutes, 50“C). Following autoradiography as described in 
section 2.3.3.1, positive clones were picked from the original 96 well microtitre plates, DNA 
isolated as described in section 2.3.2.4 and the sequence determined.
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4.4 Results
4.4.1 Oligonucleotide design.
In an attempt to isolate novel NPY receptor family members, in particular novel receptor 
subtypes involved in the feeding response to NPY, the nucleotide sequences encoding the 
cDNA's of the cloned NPY receptor genes were aligned to facilitate design of a degenerate 
oligonucleotide based upon the known sequence of these receptors. However, as discussed in 
Chapter 2, the members of the NPY receptor gene family are paificularly divergent 
(Larhammar, 1996) and low percentage sequence identity is exhibited between receptor 
subtypes. As a result a degenerate oligonucleotide could not be designed based upon the 
sequences of the cloned human NPY receptors (Yl, Y2, Y4, Y5 and y6), as no readily 
identifiable region with reasonable degeneracy (<1000) could be identified despite lengthy 
sequence analysis. The degeneracy value is of tremendous importance, as an oligonucleotide 
degeneracy greater than 1000 will result in a high background signal upon applying the 
Genetrapper'^’^  technology. As the receptor subtype involved in mediating the feeding response 
to NPY is believed to be encoded by a rarely expressed mRNA (section 1.7), the presence of 
numerous clones with sequence identity unrelated to NPY receptor subtypes, will significantly 
impinge upon the ability to detect any novel NPY receptor sequences.
Due to the diversity of the NPY receptor gene family, as detailed above and in chapter 2, only 
one degenerate oligonucleotide was designed and this was based on the nucleotide sequences 
of the human Yl and y6 receptors. Figure 4.2 is a diagrammatic representation of the 
degenerate oligonucleotide design.
The remaining oligonucleotides used in the Genetrapper'^^ procedure were a series of 
individual oligonucleotides homologous to the Y2, Y4 and Y5 NPY receptor subtypes
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Figure 4.2 Schematic of rational design of human Yl/y6 receptor degenerate 
oligonucleotide.
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COOH
Human NPY Yl Receptor 
Human NPY y6 Receptor
I
Degenerate Y1/y6 Receptor 
Oligonucleotide GT1
Degeneracy x2 x2 x2x2
Total degeneracy = 32
Figure 4.3 Schematic of Genetrapper^^ oligonucleotide design.
Chai'acters in bold denote the nucleotide sequence of each oligonucleotide primer.
GT2= human Y2 receptor homologous oligonucleotide
GT3= human Y4 receptor homologous oligonucleotide
GT4= human Y5 receptor homologous oligonucleotide
GT5= human Y5 receptor homologous oligonucleotide (internal)
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Human NPY Y5 receptor 
(internal)
GT2
GT3
GT4
ACTTTCTGATAGCTACTGTCTGQ\CAC GT5
" 7
/
/
/
/
/
/
COOH
ATTGGCCTACTGCTCCATCATCTTGCT
TGGACGTGATGGTCTTCATCGTCACTTC
AAAAGCAGTGTAGATGACTTACAGTATT
Human NPY Y2 receptor 
Human NPY Y4 receptor 
Human NPY Y5 receptor
as outlined in figure 4.3. The sequences of the oligonucleotides used in the Gentrapper’^ ^ 
experiments can be found in Appendix II. A number of laboratories have reported difficulty 
cloning the 5' end of the cDNA for the various NPY receptors. Therefore, a further primer 
GT5 was designed that lies internal to the open reading frame of the NPY Y5 receptor. This 
primer was intended to be used as a control for the Genetrapper™ approach.
4.4.2 Analysis of the oligonucleotide biotinyiation reaction products.
3gl of fonuamide stop buffer was added to the 3pi of biotinylated oligonucleotide prior to 
vortexing and centiifuging at room temperature for 2 seconds at 14,000 x g. Dilutions of 
unbiotinylated oligonucleotides were prepaied to run as standards in order to determine the 
concentration of biotinylated oligonucleotide. As each oligonucleotide was reconstituted at a 
concentration of Ipg/pl, a series of standard dilutions of non-biotinylated oligonucleotides were 
prepai'ed at concentrations of 500ng, 200ng and 50ng. 5pi of each oligonucleotide dilution 
was then mixed with 5pl of formaiTiide stop buffer, vortexed and centrifuged at room 
temperature for 2 seconds at 14,000 x g.
The biotinylated oligonucleotides and standai'd dilutions were loaded on to a 15% TBE/Urea 
gel (Novex) and gel electrophoresis was carried out for 1.5 hours at 180 volts in IxTBE 
buffer, before staining with ethidium bromide (lOmg/ml) to visualise the oligonucleotide DNA 
and photographing with ultraviolet illumination at 254nm.
Figure 4 .4 illustrates analysis of the oligonucleotide biotinyiation reaction following gel 
electrophoresis.
Following gel analysis, the concentration of the biotinylated oligonucleotides was detemiined 
as 16.5ng/pl for oligonucleotides GT3, GT4 and GT5, and 7ng/pl for GTl and GT2.
4.4.3 Analysis of Genell and ExoIII digestion products
To determine whether the dsDNA had been successfully converted to ss DNA gel 
electrophoretic analysis was carried out. The DNA digested with Gene II or Genell-Exo III 
was electrophoresed for 1.5 hours at 100 Volts in a 0.8% agarose gel prepared in Ix TBE. A 
sample of the original ds human hypothalamic DNA was electrophoresed alongside the Genell 
and ExoIII treated samples.
The Gene II and Genell-Exo III treated DNA samples were compai'ed to the undigested double 
stranded phagemid DNA ( figure 4.5).
From the gel analysis of the Genell and ExoIII digested DNA illustrated in figure 4.5, the 
double stranded human hypothalamic cDNA appears to have been converted to
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Figure 4.4 Gel analysis of Genetrapper^^ oligonucleotide biotinyiation reaction 
products.
Biotinylated oligonucleotides were electrophoresed on an acrylamide gel as described 
(section 4.4.2). DNA was visualised under ultraviolet irradiation and photograph 
exposure time was 0.5-1.0 seconds.
Lane 1 : Biotinylated oligonucleotide GT3
Lane 2: Biotinylated oligonucleotide GT4
Lane 3: 500ng non-biotinylated oligonucleotide GT4
Lane 4: 200ng non-biotinylated oligonucleotide GT4
Lane 5: Biotinylated oligonucleotide GT5
Lane 6: 50ng non-biotinylated oligonucleotide GT5
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Figure 4.5 Gel analysis of Genell and ExoIII digestion products.
After digestion with Genell or Genell-Exonuclease in, dsDNA was electrophoresed on 
an agarose gel as described (section 4.3.3). DNA was visualised under ultraviolet 
irradiation and photograph exposure time was 0.5-1.0 seconds.
Lanes 1-4: 500ng Genell-treated human hypothalamic cDNA library.
Lane 5: SOOng undigested human hypothalamic cDNA library.
Lanes 6-9: SOOng Gene II-Exonuclease U treated human hypothalamic cDNA library.
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. 1Kb ladder (Life Technologies).
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single stranded DNA. After digestion with Genell more than 50% of the supercoiled DNA has 
been nicked by the enzyme, and therefore migrates as open circle DNA, appearing as a slowly 
migrating band on the gel. Following digestion with ExoIII, the nicked DNA generated by 
Genell has been completely converted to single stranded DNA, which migrates more quickly 
than the supercoiled DNA of the undigested sample.
4.4.4 Screening of the selected libraiy for NPY family members.
The biotinylated oligonucleotides designed as described in section 4.1, were used in individual 
capture reactions as described in the Genetrapper^^ methodology sections 4.3.3.
Replica filters of the selected library were screened, with the corresponding oligonucleotides 
used in the selection process, for members of the NPY receptor family and potential novel 
family members as described in section 4.3.4.
The number of colonies obtained following the electroporation of each oligonucleotide selected 
library and the positive colonies detected following hybridisation ai’e shown in Table 4.1.
Oligonucleotide Number of colonies 
obtained/ screened
Number of positive 
clones detected
GTl (Yl/y6 degenerate) 1152 -
GT2 (Y2 homologous) 2106 -
GT3(Y4 homologous) 4608 7
GT4 (Y5 homologous) 2592 2
GT5 (Y5 homologous 
internal)
4896 2
The positive clones identified by hybridisation screening of the replica filters using the 
appropriate radiolabelled oligonucleotide were isolated from the corresponding 96 well 
microtitre plate, grown overnight in deep well 96 well microtitre plates containing agar, and 
plasmid DNA isolated (as described in section 2.3.2.4.) for sequence analysis.
4.4.5 Sequence analysis of positive clones.
The DNA prepared from the positive clones obtained following screening of the replica filters 
was sequenced using an ABI automated sequencer, Bioinformatic analysis was carried out 
using the blast programme of GCG to determine whether the clones obtained displayed 
sequence homology with the known NPY receptors. However, following extensive 
bioinformatic analysis, the sequences of the isolated positive clones failed to demonstrate
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homology with any of the NPY receptor subtypes. Further sequence analysis revealed that the 
positively selected clones were shown to contain a region with significant homology to the 
oligonucleotides used in the Genetrapper’^ ^ cDNA selection procedure suggesting that the 
selection procedure had been appropriate.
Further analysis of the sequence of the 11 positive clones revealed a pattern of sequence 
identity. The positive clone sequences appeared to correspond to either human FK506-binding 
protein (Maki, 1990), human P-glycoprotein (Chen, 1997) or the protein encoded by the clone 
with accession number g 1935053. Following blast and bestfit alignments of the 
oligonucleotide sequences against these sequences found to encode the positive clones, regions 
of homology were shown to exist between the oligonucleotides and sequences obtained from 
positive clones.
The table below shows the percentage sequence identity between oligonucleotides and positive 
clone sequences.
Geneti'apper'^^
oligonucleotide
% Identity observed 
with FK506 
binding protein
% Identity observed 
with P-glycoprotein
% Identity observed 
with clone 
gl935053
GT3 80 90 94
GT4 70 90 68
GT5 65 80 65
Table 4.2 depicts the percentage sequence identity observed between the Genetrapper^^^ 
oligonucleotides and sequences of the positive clones targeted using these oligonucleotides 
following B e a n a l y s i s  using the GCG package (Wisconsin Package Version 9.1, Genetics 
Computer Group (GCG), Madison, Wise).
No NPY receptors were identified upon executing the Genetrapper'^^ technique as described. A 
recent paper (Shepard, 1997) has suggested that, for very rare mRNAs, one round of selection 
is insufficient to select the cDNA but that further rounds of selection are required. As the NPY 
receptors are known to be very rare even within the hypothalamus, a decision was made to take 
an oligonucleotide forward for a further selection round. To avoid problems at the 5' end of 
the cDNA, the oligonucleotide GT5 captured libraiy was selected for further screening 
following the protocol as described in sections 4.3. Colonies were obtained upon
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electroporation of the enriched GT5 captured libraiy and subsequently picked and transferred 
to filters for screening as described in section 4.3.3.9. Following hybridisation screening with 
a human Y5 receptor 3' UT cDNA probe (figure 6.2), twenty positive colonies were detected. 
These twenty positive clones remain to be subjected to sequencing and bioinformatic analysis, 
in order to confirm whether sequence identity exists between these clones and the human Y5 
receptor. This work is currently ongoing.
4.5 Discussion
The failure to isolate human NPY receptor clones from a human hypothalamic cDNA library 
using one degenerate oligonucleotide designed from a conserved region of the 5' region of the 
NPY Y 1 and y6 receptors and a series of oligonucleotides homologous to the remaining cloned 
NPY receptors (Y2, Y4 and Y5) can be attributed either to the low levels of expression 
exhibited by the NPY Y5 receptor or to the known difficulties of the 5' end of these cDNAs. 
The raRNA encoding this receptor protein is a particularly raie message, and the expression of 
this receptor protein is not abundant. This is exemplified by the initial efforts employed to clone 
the Y5 receptor (Gerald, 1996). The Y5 receptor was eventually cloned using an expression 
cloning strategy to detect functional NPY receptors in a rat hypothalamic cDNA libraiy 
(Gerald, 1996). Following a laborious screening procedure of an entire rat hypothalamic 
cDNA library, a single Y5 receptor clone was identified. Thus, 3.4 X 10  ^ clones were 
screened in 453 pools of 7500 clones each. Only 3 positive clones were identified, and of 
these 2 were subsequently shown to encode the Y1 receptor, and only one was a novel 
sequence, Y5. This demonstrates the extremely low level of expression exhibited by this NPY 
receptor. As the feeding receptor for NPY is undoubtedly hypothalamic, it is probable, that 
like the Y5 receptor any novel NPY receptor involved in regulating the feeding response to 
NPY will be encoded by a rare mRNA, making expression levels of the receptor extremely 
low.
The Genetrapper'^^ technology was successful as the positive clones detected and isolated were 
found to possess sequence homology to the oligonucleotides used in the capture procedure. 
Therefore, this proves that the technique was effective, as it enabled sequences with homology 
to the oligonucleotides to be preferentially taigeted from the library. As discussed above, the 
feeding receptor for NPY is likely to comprise a very rai'e message in the hypothalamic pool of 
cDNA. Therefore, cDNAs that show some homology with the oligonucleotides but are more 
abundant within the cDNA pool are likely to demonstrate favourable hybridisation. As the 
expression levels of the clones targeted by the Genetrapper' '^^ oligonucleotides are likely to be 
more abundant than NPY receptor subtypes present within the hypothalamus, the isolation of 
these clones is therefore more favourable.
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As table 4.2 illustrates, the percentage identities observed between the sequence of the positive 
clones and the oligonucleotides used in the Geneti’apper™ selection procedure suggest that 
considerable homology exists between these clones and the capture oligonucleotides.
In an attempt to favour the detection of novel NPY receptors from the human hypothalamic 
library, an enriching process was cairied out following a publication in 1997 which described 
optimisation of identification of rai’e messages using a technique simiiai' to Genetrapper^’^  
technology (Shepard, 1997). Depending on the relative abundance of the desired cDNA clone 
in the library, two or more rounds of enrichment may be necessary. By transforming the entire 
first round captured DNA and preparing DNA for another round of capture hybridisation, the 
captured libraiy becomes enriched thereby increasing the relative abundance of the clone of 
interest. The oligonucleotide GT5 was used to examine this. The cDNAs captured with this 
oligonucleotide from the first round of selection against the whole hypothalamic library were 
used in this enriching process. The reason for this is that this oligonucleotide was designed 
with homology to the human Y5 receptor and was also located in a more 3' position in the 
cDNA. The Y5 receptor appeal's to have considerable secondary structure at the 5’ end of the 
cDNA, as demonstrated by the PCR studies described in chapter 2 and through personal 
communication (Dan Larhammar, University of Uppsala), and so it may be difficult to enrich 
thi'ough the Genetrapper^^ approach. The presence of secondary structure within the 5' region 
of the Y5 receptor mRNA likely results in inefficient first strand cDNA synthesis making the 
presence of a full length Y5 cDNA improbable. Use of an oligonucleotide homologous to a 
region of the cDNA outwith this region may increase the likelihood of hybrid formation 
between the oligonucleotide used and the desired cDNA clone.
As this enriching stage will undoubtedly increase the proportion of sequences with similarity to 
the capture oligonucleotide identified in the initial screening step, a cDNA probe encompassing 
a region of the human Y5 3’untranslated region was used to screen the enriched library as this 
would increase the specificity of the probe as regards the NPY receptors, and diminish the 
detection of false positive clones. As expected, the enrichment procedure resulted in the 
detection of a greater number of positive colonies following hybridisation screening, 
suggesting that this enriching stage has successfully increased the relative abundance of the 
desired clone. Sequence analysis is required in order to confirm whether the positive clones 
obtained bear homology to the NPY Y5 receptor.
The Genetrappei'TM technology is an effective novel receptor cloning system, as demonstrated 
by its success in the cloning of other novel members of receptor gene families (Mark Fidock 
personal communication). The use of a tai'get specific libraiy in this technique facilitates the 
identification of raie mRNA clones which can be taigeted in a tissue specific manner, in a 
homology screening approach using a degenerate oligonucleotide based on conserved sequence
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from existing gene family members. As the NPY receptor gene family exhibits an 
iinchai'acteristic lack of sequence identity between members within the same species 
(Larhammar, 1996), a homology screening strategy proved difficult due to the lack of a readily 
identifiable region of sequence containing reasonable degeneracy. Significantly greater 
sequence homology between NPY receptor gene family members may have enabled the 
hypothalamic receptor believed to mediate NPY elicited feeding to be isolated more readily, as 
the presence of a contiguous sequence of nucleotides characteristic of NPY gene family 
members would provide a highly selective tool.
The Genetrappei'T^ technology also optimises the cloning of full length receptor cDNAs. The 
size selection of the cDNA library above 1Kb prevents isolation of paitial clones and the design 
of oligonucleotides in the 5’ region of the gene also preferentially favours the isolation of full 
length clones, which aie essential for subsequent functional studies. Identification of a full 
length clone using this technique therefore negates the need for subsequent cloning steps 
necessary to obtain a full length clone.
As the Geneti’apper'T  ^ technique is a cloning technique based on the formation of hybrids 
between oligonucleotides and target cDNA sequence in solution, non-functional pseudogenes 
may be isolated using this technology. In contrast to expression cloning strategies, 
Genetrapper”^’^  does not confer any functional analysis, therefore, novel clones isolated using 
this approach may represent a gene which does not express a functional receptor protein either 
in vivo or when transfected into mammalian cells. Functional studies ai'e therefore essential 
following the cloning of a novel receptor subtype using this technique, in order to determine 
whether the isolated novel clone will contribute to the physiology of the relevant ligand.
Other factors which contribute to the success of the Genetrapper^'^ technique are the design of 
the oligonucleotides used in the capture hybridisation and the quality of the cDNA libraiy used. 
Construction of the appropriate cDNA libraiy is a cracial factor which may determine the 
success of the technique. Poor first strand cDNA synthesis from appropriate mRNA will result 
in low quality cDNA and the subsequent inability to readily detect the desired transcript. A 
degenerate oligonucleotide primer designed from a conserved region of sequence from receptor 
gene family members is an effective means of targeting novel family members. Therefore, 
receptor gene families which possess high percentage identities between members are more 
amenable for Genetrapper"^^ technology.
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4.6 Summary
î)Degenerate oligonucleotide design proved difficult, as the low sequence identity exhibited 
between members of the NPY receptor family within the same species prevented identification 
of a readily identifiable region of reasonable degeneracy.
2)The novel receptor cloning technique Genetrapper'^^ was employed in an attempt to isolate 
novel NPY receptors, in particular the feeding receptor, using a human hypothalamic cDNA 
library and a series of oligonucleotides homologous to human NPY receptor subtypes and one 
degenerate oligonucleotide.
3)Eleven positive clones were identified following hybridisation screening of the colonies 
obtained after executing the Genetrapper"^^ strategy.
4)Sequence analysis of the positive clones revealed no NPY receptor sequence. However, 
upon further analysis these clones were shown to contain significant regions of homology with 
the oligonucleotides used in the Genetrapper™ procedure, proving that the technique is 
effective.
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Chapter 5
Novel receptor cloning : COS cell expression.
Chapter 5
5.1 Introduction
The di'amatic effects elicited by NPY on feeding behaviour and bodyweight have generated 
tremendous interest regarding the receptor subtype involved in the regulation of this 
physiologically fundamental behaviour. To date the identity of the receptor subtype believed to 
mediate this chaiacteristic effect of NPY remains highly controversial. In 1996 a novel NPY 
receptor subtype was cloned from rat hypothalamus (Gerald, 1996) and attributed the role of 
the feeding receptor, as the pattern of distribution and pharmacology of this Y5 receptor 
matched the proposed profile and location of the feeding receptor. Subsequent findings have 
proved contentious, with the NPY Y1 receptor rapidly emerging as a candidate for the role of 
feeding receptor (Kanatani, 1996, 1998, Ishihara, 1998). A gene knockout approach whereby 
both NPY Y1 and Y5 receptors were tai'geted, furthered the existing controversy, suggesting 
that both receptor subtypes may play a pait in NPY induced feeding (Marsh, 1998 and 
Pedrazzini, 1998). The identity of this long sought after receptor remains controversial to date, 
and the possibility that a novel, previously unidentified NPY receptor subtype may be 
responsible for mediating NPY elicited eating remains to be determined (O'Shea, 1997).
As discussed in detail in chapter 2, the NPY receptor gene family, unlike many other G-protein 
coupled receptor families, is extremely diverse. The cloned receptors for NPY (Yl, Y2, Y4, 
Y5 and y6) display significant structural diversity, with low percentage identities observed 
between family members even in transmembrane regions (Larhammar, 1996b). The lack of 
homology between NPY family members makes this gene family difficult to exploit using 
homology screening approaches, as discussed in chapter 4. As the sequence alignments in 
figure 2.8, and the difficulty encountered upon attempting to design a degenerate 
oligonucleotide for Genetrapper'^^ demonstrate, the lack of sequence identity exhibited between 
the NPY family members makes homology screening approaches unieliable for isolating novel 
family members. Therefore, an alternative cloning rationale was employed in an attempt to 
isolate new members of the NPY gene family, in paiticular the feeding receptor for NPY.
The experimental strategy employed in the experiments discussed in this chapter is a functional 
cloning approach whereby expression of receptor protein in mammalian cells is detected in a 
ligand binding assay. The lack of sequence homology between NPY receptor subtypes is 
inconsequential in this functional cloning approach, as the rationale behind this technique is 
based on the affinity of the ligand (NPY) for the receptor. Therefore this type of cloning 
strategy circumvents the need for sequence homology, as a functional clone hearing poor 
homology to other gene family members will be readily detected, through its affinity for the 
relevant ligand. As the NPY family of receptors are characterised pharmacologically by their
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ability to bind members of the PP family of peptides, a functional cloning approach would 
enable novel NPY receptor subtypes to be identified, following NPY or PYY binding and 
subsequent screening.
The rare mRNA predicted for the hypothalamic NPY feeding receptor (Gerald, 1996) may also 
be overcome in a functional cloning approach, as the affinity of the ligand for the receptor will 
enable even raiely expressed receptor proteins to be detected. As the pharmacology of the 
NPY feeding receptor has been previously described (Kalra, 1991, Stanley, 1992 and 
McLaughlin, 1991), the ligand known to potently stimulate feeding behaviour can be used in 
the binding assay to enable the clone of interest to be readily detected.
It is also noteworthy that expression cloning strategies were successful in the cloning of other 
NPY receptor subtypes. Both the NPY Y2 receptor and the NPY Y5 receptor were cloned 
using a functional cloning assay to identify novel NPY receptor subtypes (Rose, 1995 and 
Gerald, 1996).
The experimental results of two different expression cloning strategies ai'e described in this 
chapter. Both cloning strategies involved overexpression of a cDNA libraiy or DNA prepared 
from a cDNA library in mammalian host cells, followed by detection of cells expressing the 
target cDNA and the isolation of cDNA's encoding novel proteins using a functional assay. 
The mammalian host cells used in the experiments described are COS cells, which are 
frequently used host cells derived from modified African green monkey kidney epithelial cells. 
COS cells constitutively express the simian virus 40 (SV40) lai'ge T nucleai' antigen, which 
permits these cells to replicate transfected plasmids containing the SV40 origin of replication to 
high copy number. This high replication level results in a large number of plasmids in the 
transfected cells which enables plasmid DNA to be effectively recovered from selected positive 
COS cells (Seed, 1987 and Aruffo, 1987).
126
5.2 Experimental strategy
The expression cloning techniques described in this chapter differ in their screening procedures 
following ligand binding. The rationale behind each strategy employed in this chapter is 
described below.
5.2.1. Panning.
The panning technique employed in an attempt to isolate novel NPY receptor gene family 
members, is an inmiunoselection procedure based on the expression of desired clones in COS 
cells, followed by the physical selection of expressing cells (Seed, 1987). Following ligand 
binding with biotinylated ligand, the cells expressing positive clones were selected using a 
mouse monoclonal antibody against biotin and captured with paiamagnetic beads coated with 
an anti-mouse antibody. Plasmid DNA was extracted from the captured cells by the Hirt 
procedure, and the cDNA obtained was transfoimed into bacteria or used in a PCR reaction. 
Diagnostic restriction analysis and PCR permitted further analysis of the selected cDNA to be 
caiTied out. The panning strategy employed in the experiments described in this chapter is 
summarised in figure 5.1.
5.2.1.1 Validation of the panning methodology.
Before employing this technique as a means of identifying novel NPY receptor subtypes, 
experiments were carried out in order to ensure the system was effective. A known receptor 
was diluted with a competing plasmid before transfecting into COS cells and carrying out the 
panning procedure. After applying this technique the receptor used was successfully re­
cloned, proving that the selection system works. The known receptor used in this procedure 
was the human high affinity receptor for the immunoglobulin IgG; namely the FcyRI receptor 
which is a Type I single membrane spanning glycoprotein (Allen and Seed, 1989). A 
prepai ation of recombinant mammalian expression plasmid CDM containing the FcyRI receptor 
was used to transfect COS cells before executing the panning protocol.
5.2.1.2 Validation of the panning system using a G-protein coupled receptor.
As the known receptor used to validate the system was a single membrane receptor, a known 
G-protein coupled receptor was applied to this technique in order to determine whether the 
panning system would enable a seven transmembrane domain G-protein coupled receptor to be 
successfully cloned.
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Figure 5.1 Schematic depicting experimental strategy for COS cell panning.
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The G-protein coupled receptor used in these experiments was the rat NPY Y1 receptor, as a 
preparation of this receptor cDNA in the mammalian expression plasmid CDM had previously 
been constructed in the lab (J.C Bournat), and enabled validation of the technique using a G- 
protein coupled receptor.
5.2.2 Radioligand binding expression cloning
An expression cloning method where ^^^I-labelled PYY^^^  ^ was used to screen transfected 
COS cells in a ligand binding assay was also employed in an attempt to isolate novel NPY 
receptor subtypes. The rationale behind this expression cloning strategy is deteimined by the 
proposed pharmacology for the NPY feeding receptor, whereby screening for the binding of a 
high affinity ligand at this receptor, namely l^^I-labelled PYY -^36  ^ would enable positive 
expressing cells to be detected. In this expression cloning approach, detection of a positive 
pool following initial screening, requires further subdivision and re-screening until an 
individual clone is identified. Figure 5.2 summarises the expression cloning strategy employed 
in the experiments described in this chapter.
5.3 Chapter specific methods
5.3.1 COS cell culture.
COS-7 cells were maintained on disposable polystyrene plates (Costar®) in Dulbeco's 
Modified Eagles Medium (DMEM, Imperial Laboratories Ltd) supplemented with 10% calf 
serum (Sigma, Appendix I). Cells were maintained in a Napco® Model 5410 tissue culture 
incubator set at 37“C and 6.5% carbon dioxide with 100% humidity. Cell manipulations were 
carried out under sterile conditions in Microflow Laminai' Flow Cabinets (MDH Ltd.). Cells 
were split onto fresh plates eveiy few days by aspirating, washing twice in 5ml IX Phosphate 
buffered saline (PBS) (Appendix I ) then adding 1ml of trypsin (Appendix I ) to lift the cells. 
Cells were incubated at 37°C for 5 minutes before neuti'alising the trypsin by addition of 
DMEM supplemented with 10% calf serum and the cell suspension divided onto fresh plates 
(typically one plate was split on to four to six plates of the same size).
5.3.1.2 COS cell transfection.
COS-7 cells were plated at a density of approximately 4 X 10  ^ cells per 100mm plate one day 
before transfection at a confluency of approximately 50%. NU medium (Appendix I) 
containing lOOpM chloroquine was prewaimed to 37°C. Meanwhile 5pg (unless otherwise 
stated) cDNA plasmid was cai'efully mixed with 250pl TE buffer and ISOgl lOmg/ml filter 
sterile DEAE-dextran in 1 X PBS. Caie was taken upon addition of DNA to ensure the DNA
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didn't precipitate, and in the event of this occurring, the mixture was heated to 70°C and 
vortexed to redissolve the DNA. Culture medium was aspirated from cells and replaced with 
5ml of NU medium (lOOjuM chloroquine prewaimed to 37°C) for each plate. The DNA was 
evenly added dropwise to the NU media and gently mixed. Plates were returned to the 
incubator for 2 to 4 hours. During this incubation large bright vacuoles appeal* and some cells 
detach and/or round up. At this time, the cells were subjected to a DMSO shock. For this the 
NU medium was replaced with 5ml 1 X PBS containing 10% DMSO for 2 minutes at room 
temperature. The cells were then washed twice in 5ml 1 X PBS and returned to their 
maintenance medium (DMEM supplemented with 10% calf serum). Cells were incubated 
overnight at 37°C/6.5% carbon dioxide. The following day the cells were subjected to trypsin 
(see 5.3.1), and all the cells were plated onto a fresh tissue culture dish. Experiments were 
carried out on one of the following two days when expression levels are maximal, i.e 48 to 72 
hours post-ti'ansfection (Allen, 1989). Mock transfections, where no plasmid DNA was 
transfected were carried out when appropriate.
Transfection efficiency was determined by transfecting COS cells with p galactosidase (pGal) 
cDNA cloned in the expression vector CDM. All steps were perfomied similaiiy and the COS 
cells expressing pGal were revealed by incubating the glutaraldehye fixed slides in 0.2% XGal, 
lOmM Na phosphate, 150mM NaCl, ImM MgCl2, 3.3mM KqFe(CN6) trihydrate, 3.3mM 
K3Fe(CN)6 for 30 minutes at 37°C. The XGal solution was removed and the plates containing 
the cells were dried before microscopic examination. Transfected cells appealed blue, and the 
transfection efficiency was routinely determined as 40-50%.
5.3.2 Panning immunoselection procedure.
Forty eight hours post transfection with either rat hypothalamic cDNA or plasmid DNA in a 
mammalian expression vector, the panning procedure was carried out as described with the aiiu 
of identifying novel NPY receptor subtypes or confirming the effectiveness of the technique.
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5.3.2.1 Panning protocol for COS cells transfected with rat hypothalamic cDNA libraiy or 
NPY Y 1 receptor plasmid DNA.
5.3.2.1.1 Binding assay.
The transfected COS cells were lifted from the 100mm plates with a solution of PBS/ImM 
EDTA. Following centrifugation for 5 minutes at 2,000 X g at 4“C, the cell culture media was 
removed by aspiration and the cells resuspended in lOmls of a solution containing ice-cold 
HEPES buffered RPMI (20mM HEPES, Imperial Laboratories Ltd) containing 1% BSA 
(Sigma). The cells were then subjected to a second centiifugation step as described above and 
resuspended in 1ml of ice-cold HEPES buffered RPMI containing 1% BSA.
To each 1ml aliquot of transfected cells lOpl of ImM biotinylated PYY (Cambridge Research 
Biochemicals) was added to give a final working concentiation of lOpM. The cells were then 
incubated with constant agitation at 4“C for 2 hours to ensure adequate contact between 
transfected COS cells and biotinylated peptide, thereby facilitating ligand binding.
5.3.2.1.2 Dynabead preparation.
During the incubation of biotinylated PYY to paiamagnetic Dynabeads® (Dynal®) coated with 
sheep anti-mouse IgGl (Fc) were prepaied for use in the capture of cells expressing relevant 
receptor. A 300|il aliquot of Dynabeads® containing 1.2 X 10  ^beads was resuspended in 1ml 
of PBS/0.1 % albumin and placed in a magnetic microcentrifuge holder to pellet the beads. The 
supernatant was removed and the beads resuspended in 1ml PBS/0.1% albumin before 
repeating the washing procedure. The beads were finally resuspended in 600pl of PBS/0.1% 
albumin.
The washed beads were then incubated with Ipl monoclonal anti-biotin (4.2pg, Sigma) in 
order to coat the sheep anti-mouse IgG 1 beads with the corresponding monoclonal anti-biotin 
antibody. The Dynabead® and antibody prepaiation was incubated at 4°C for 90 minutes to 
ensure adequate antibody binding occurred. When satisfied that the paiamagnetic beads were 
sufficiently coated in monoclonal antibody, the beads were washed twice in PBS/0.1% 
albumin.
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5.3.2.1.3 Capture of COS cells expressing desired receptor.
The isolation of COS cells expressing the desired receptor protein was achieved by incubating 
the cells bound to the biotinylated peptide with the antibody coated beads, in order to peiiuit the 
targeted COS cells to be captured via the anti-biotin antibody and corresponding sheep anti­
mouse IgGl coated paramagnetic beads.
Before the cells were incubated with the antibody coated beads, a washing step was cairied out 
to ensure unbound biotinylated peptide was removed from the cell preparation, as the presence 
of free biotinylated peptide would hinder the selection and capture of expressing cells. 
Following incubation with the biotinylated peptide, the cells were added to lOmls of ice-cold 
HEPES buffered RPMI containing 1% BSA and centrifuged at 4°C for 5 minutes at 3,000 
rpm. The supernatant was carefully removed and the cells resuspended in 10ml of ice-cold 
HEPES buffered RPMI containing 1% BSA before centrifuging again at 4°C for 5 minutes at 
2,000X g. The supernatant was again removed, and the cells were resuspended in 1ml of ice- 
cold HEPES buffered RPMI containing 1% BSA.
The cells expressing desired receptor protein were captured by adding lOOpl of coated beads to 
the cells bound to the biotinylated peptide and incubating with constant agitation, at 4°C for 1 
hour. Following incubation, the beads were repeatedly washed in ice-cold HEPES buffered 
RPMI containing 1% BSA, placing the mixture in a magnetic microcenti'ifuge holder to capture 
the beads, and removing the supernatant containing uncaptured cells not bound to beads 
through the antibody and peptide.
5.3.2.1.4 DNA extraction.
Episomal DNA was extracted using the Hirt procedure (Hirt, 1967). The captured cells were 
lysed by incubating in a solution of SDS (0.6%) and lOmM EDTA for 5 minutes at room 
temperature. The eppendorf tube was then placed in a magnetic microcentrifuge holder to 
capture beads, and the supernatant containing the tai'geted episomal DNA removed and 
transferred to a fresh tube. The extracted DNA was precipitated by adding 5M NaCl and 
incubating in an ice/water mixture at 4°C overnight.
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5.3.2.1.5 Precipitation of extracted DNA.
Following overnight incubation at 4°C, the extracted DNA was centrifuged for 15 minutes at 
14,000 X g and 4“C. The supernatant was removed and re-centrifuged for a further 15 
minutes at 14,000 X g and 4“C before removing the supernatant and repeating the 
centrifugation step as described.
The supernatant was removed, and an equal volume of phenol:chloroform was added before 
vortexing thoroughly and centrifuging at room temperature for 5 minutes at 14,000 X g. The 
upper aqueous layer containing the episomal DNA was removed, and the DNA precipitated by 
adding 3 volumes of absolute ethanol and 40pg glycogen and storing at -20°C overnight after 
mixing. Following overnight incubation the DNA was pelleted by centrifuging at 4”C for 15 
minutes at 14,000 X g, and the pellet washed in 70% ethanol and re-centrifuged as described. 
The DNA pellet was air-dried before resuspending in lOOpl TE buffer.
The DNA was then amplified by chemically transforming bacteria as described in section
2.3.1.4 or used in a PCR reaction as described in section 2.3.2.2.
5.3.2.2 Panning protocol for COS cells transfected with FcyR I receptor.
5.3.2.2.1 Binding assay.
The transfected cells were removed from the 100mm cell culture dishes and centrifuged as 
described in section 5.3.2.1.1 As the transfected receptor is a high affinity receptor for IgG, a 
binding assay was carried out using biotinylated human IgG. The transfected COS cells were 
resuspended in 1ml of ice-cold HEPES buffered RPMI containing 1% BSA and incubated with 
5pi biotinylated human IgG for 2 hours at 4°C with constant rotation to ensure binding of the 
biotinylated immunoglobulin and FcyR I took place.
5.3.2.2.2 Dynabead® preparation.
Paramagnetic Dynabeads® coated in streptavidin, which displays a high affinity for biotin, and 
therefore will enable COS cells expressing the desired receptor to be captured via the 
biotinylated immunoglobulin and magnetic beads. The beads were prepared as described in 
section 5.3.2.1.2 and resuspended in ice-cold HEPES buffered RPMI containing 1% BSA
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5.3.2.23 Capture of COS cells expressing desired receptor.
The isolation of COS cells expressing the desired receptor protein was achieved by incubating 
the cells bound to the biotinylated antibody with the streptavidin coated beads, in order to 
pei'mit the tai’geted COS cells to be captured via the biotinylated antibody and streptavidin 
coated magnetic beads.
Before the cells were incubated with streptavidin coated beads, a washing step was carried out 
to ensure unbound biotinylated antibody was removed from the cell preparation. Following 
incubation with the biotinylated human IgG, the cells were added to 10ml of ice-cold HEPES 
buffered RPMI containing 1% BSA and centrifuged at 4“C for 5 minutes at 2,000 X g. The 
supernatant was cai’efully removed and the cells resuspended in 10ml of ice-cold HEPES 
buffered RPMI containing 1% BSA before centrifuging again at 4°C for 5 minutes at 2,000 X 
g. The supernatant was again removed, and the cells were resuspended in 1ml of ice-cold 
HEPES buffered RPMI containing 1% BSA.
The cells expressing desired receptor protein were captured by adding lOOpl of streptavidin 
coated beads to the cells bound to the biotinylated antibody and incubating with constant 
agitation, at 4°C for 1 hour. Following incubation, the beads were repeatedly washed in ice- 
cold HEPES buffered RPMI containing 1% BSA, placing the mixture in a magnetic 
microcentrifuge holder to capture the beads, and removing the supernatant containing 
uncaptured cells not bound to beads via the biotinylated antibody.
5.3.2.2.4 DNA extraction.
Episomal DNA was exti’acted as described in section 5.3.2.1.4 and precipitated for further 
analysis as described (5.3.1.2.5 ).
5.3.3. Radioligand binding expression cloning.
A rat hypothalamic cDNA library, size selected above 1Kb and directionally cloned into the 
mammalian expression vector pSPORT-CMV (Life Technologies Inc) was kindly supplied by 
Mark Fidock (Pfizer Central Reseaich, UK.). The average insert size was calculated as 1.5Kb 
and the library was shown to contain 4 X 10<^  clones.
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5.3.3.1 DNA prepaiation from rat hypothalamic cDNA library.
The rat hypothalamic libraiy was plated on LB agai* plates containing lOOpg/ml ampicillin, in 
pools of 2.5 X 1Q4 independent clones. Following overnight incubation at 37°C the bacteria 
from each pool were scraped, resuspended in 1.5ml LB medium and processed for plasmid 
purification by the alkaline lysis method (section 2.3.1.5).
5.3.3.2 COS cell transfection.
DNA prepared from the rat hypothalamic cDNA was transfected, in pools of 25,000 
independent clones, into 50% confluent COS-7 cells by the DEAF dextran method described in 
section 5.3.1.2. Mock transfections where no DNA was tiansfected were carried out as 
negative controls. 48 hours post-transfection the cells were analysed in a l^^I-labelled PYY^" 
36 binding screening assay in an attempt to identify novel NPY receptor subtypes.
5.3.3.3 Binding assay.
48 hours post-transfection the cells were analysed in a l^3%_iabelled PYY336 binding screening 
assay as described below.
Following aspiration of the maintenance medium (DMEM supplemented with 10% calf serum), 
the transfected cells were washed twice in an ice-cold solution of IX PBS/1 %NFM (non fat 
milk, Marvel), and five times in an ice-cold solution of HEPES buffered RPMI containing 
1%BSA. Positive pools were identified by incubating the cells with 2nM porcine 125i_iabelled 
PYY3-36 (Amersham, specific activity 2000Ci/mmol) in binding buffer- HEPES buffered 
RPMI containing 1%BSA for 2 hours at 4°C to permit binding of the radiolabelled ligand to 
receptor proteins expressed on the surface of the transfected cells. Following incubation, the 
cells were washed three times in ice-cold binding buffer without ligand, and a further twice in 
a solution of 1 X PBS/1%NFM. The cells were then fixed in a solution of 4% formaldehyde 
for 15 minutes at room temperature, rinsed twice in 1ml of distilled water and allowed to dry 
overnight. The cells were then exposed to autoradiographic film (Kodak XO-Mat) for 14 days 
at room temperature before developing, with the intention of subdividing the corresponding 
DNA from any positive pools for cell transfection and re-screening.
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5.4 Results
5.4.1 Validation of the panning methodology using the FcyRI receptor.
Following COS-7 cell transfection with 2pg FcyRI receptor cDNA, the panning procedure was 
carried out in order to tai'get and capture transfected cells expressing the desired receptor 
(section 5.3.2.2). The plasmid DNA obtained following Hirt extraction was transformed into 
E.Coli (MC1061P3) as described in section 2.3.1.4 plated onto LB agar plates containing 
12.5pg/ml ampicillin and 7.5|xg/ml tetracycline and incubated at 37”C overnight. Colonies 
were obtained following transformation of panning DNA from the FcyRI transfected cells. No 
colonies were obtained from the mock transfected cells after applying the panning procedure. 
Plasmid DNA was isolated from selected colonies as described in section 2.3.1.5, and 
diagnostic restriction digest analysis was can'ied out in order to confirm that the DNA obtained 
corresponded to FcyRI. Miniprep DNA was digested with the restriction endonuclease Xba I 
to excise the FcyRI cDNA (as described in section 2.3.1.6). A plasmid maxiprep of FcyRI in 
the same mammalian expression vector CDM was digested under identical conditions in order 
to compaie the restriction analysis pattern obtained following miniprep digestion. A 1% 
agarose gel was prepared and gel electrophoretic analysis carried out (2.3.1.7) on all the 
digested samples.
Gel electrophoretic analysis revealed that the DNA obtained upon executing the panning 
protocol corresponded to the FcyRI receptor, as the DNA fragments obtained upon restriction 
digest were the correct molecular weight predicted for the FcyRI receptor. Figure 5.3 shows 
the gel electrophoretic analysis of the digested minipreps and plasmid FcyRI DNA. As the 
results of this restriction digest analysis reveal, the panning protocol described in section
5.3.2.2 successfully allowed the transfected FcyRI DNA to be targeted and captured via the 
antibody and magnetic beads. This demonstrates that the panning immunoselection technique 
is an effective expression cloning method.
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Figure 5.3 Validation of the panning methodology using the FcyR I receptor.
After performing the panning procedure described (section 5.3.2.2) plasmid DNA was 
isolated from selected colonies and diagnostic restriction digest analysis was carried out 
to confirm that the DNA obtained corresponded to the transfected FcyRI receptor.
A plasmid maxiprep of FcyRI in the same mammalian expression vector CDM was 
digested under identical conditions in order to compare the restriction analysis pattern 
obtained following miniprep digestion.
DNA was electrophoresed on an agarose gel as outlined in section 2.3.1.7 and 
visualised on an agaiose gel under ultraviolet irradiation; photograph exposure time 
0.5-1.0 seconds.
Lane 1 : Plasmid maxiprep FcyRI digested with the restriction endonuclease Xba I 
Lanes 2-9: Plasmid minipreps obtained from panning procedure digested with the 
restriction endonuclease Xba I
Moleculai' weight of FcyRI = 1321bp (***)
Molecular weight of CDM expression vector = 3500bp (**)
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products.
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The panning technique was repeated in an attempt to determine the sensitivity of the technique 
with regards to the optimal concenti'ation of transfected DNA required for effective recovery 
following panning. A series of dilutions of the FcyRI receptor cDNA were transfected into 
COS-7 cells as described (5.3.1.2). The dilutions were carried out by diluting Ipg FcyRI 
DNA with a competing plasmid (CDM). The following concentrations of DNA were 
transfected individually into 100mm plates of COS-7 cells : Ipg FcyRI DNA, 0.1 pg FcyRI 
DNA, O.Olpg FcyRI DNA, O.OOlpg FcyRI DNA.
The panning procedure was carried out 48 hours post-transfection as described in section 
5.3.2.2. The DNA obtained following Hirt extraction was transformed as described above.
The resulting colony numbers were assessed in order to determine the amount of transfected 
plasmid DNA required for successful amplification following panning. As expected, the 
colonies were most abundant following transformation with panning DNA obtained from the 
Ipg FcyRI DNA transfected cells. A proportional decrease in colony numbers was observed 
following transformation with panning DNA from cells transfected with 0.1 pg FcyRI DNA 
and 0.0Ipg FcyRI DNA. No colonies were obtained following transformation with panning 
DNA from cells transfected with 0.00Ipg FcyRI DNA. A selection of colonies were picked 
from the plates and plasmid DNA isolated as described (2.3.1.5). Restriction digest analysis 
was performed as described above, and gel electrophoretic analysis confirmed that the panning 
DNA corresponded to the FcyR I receptor.
From the colony numbers obtained following transformation, the optimal concentration of 
DNA required for effective pannning appears to be 0.0Ipg, as the presence of colonies 
following transformation of panning DNA from cells transfected with 0.0Ipg FcyRI DNA 
suggests that this technique is effective at targeting and capturing cells expressing low levels of 
receptor protein.
These results demonstrate that the panning immunoselection technique is an effective 
expression cloning method, which can be used effectively to re-clone cells expressing relatively 
low amounts of DNA.
5.4.2 Panning using COS cells transfected with rat hypothalamic cDNA library.
Cell were screened for expression of novel NPY receptor subtypes, using the panning 
technique described in section 5.3.2.1. COS-7 cells were transfected with Ipg of DNA 
prepared from a rat hypothalamic cDNA library and subjected to panning 48 hours post­
transfection. Biotinylated peptides NPY, PYY and galanin were incubated with the transfected
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ceils, and panning was carried out to target expressing cells bound to the biotinylated peptides 
using the Dynabeads® as described in sections 5.3.2.1.2-5.3.2.1.5. Episomal DNA was 
extracted from the targeted, captured cells using the Hirt procedure as described (section
5.3.2.1.4).
The episomal DNA was transformed into E.Coli (TGI) as described in section 2.3.1.4, plated 
on agai- plates containing lOOpg/ml ampicilHn and incubated overnight at 37°C. However 
following overnight incubation, no colonies were obtained. The transformation was repeated 
using a fresh stock of competent bacteria, however no colonies were obtained following 
overnight incubation. The entire experiment was repeated and panning DNA was transformed 
as described. However, colonies failed to be obtained following overnight incubation of 
transformed bacteria.
5.4.3 Panning using COS cells transfected with NPY Y1 receptor cDNA.
COS cells were transfected with 5pg NPY Y1 receptor cDNA in the mammalian expression 
vector CDM, and subjected to the panning protocol outlined in sections 5.3.2.1 48 hours 
following transfection.
The DNA extracted using the Hirt procedure as described (5.3.2.1.4), was used in a PCR 
reaction with oligonucleotide primers homologous to the rat NPY Y1 receptor cDNA (figure
5.4). As illustrated in figure 5.4, 2 sets of oligonucleotide primers were used, encompassing 
either the full length Y1 receptor cDNA, or a partial Y1 cDNA product encompassing the 3' 
region of the open reading frame. An identical PCR reaction was cairied out using a sample of 
the Y1 receptor cDNA in CDM as a positive control, to ensure reaction conditions were 
optimal, and as a means of evaluating the PCR products obtained from the panning DNA. The 
PCR reaction was carried out as described in section 2.3.2.2, with an annealing temperature of 
58°C and undergoing 40 cycles to ensure maximal amplification of the desired DNA.
The PCR products obtained were subjected to gel electrophoresis, and photographed under 
ultraviolet light to visualise the DNA. As figure 5.5 illustrates, the PCR products obtained 
using both sets of Y1 homologous primers on the Hirt extracted DNA, migrated to the 
moleculai' weight predicted for the Y1 receptor. The positive control PCR products obtained 
from the Y1 cDNA were identical to those obtained from the panning DNA, suggesting that the 
DNA recovered following the panning procedure corresponded to the transfected Y1 receptor 
cDNA. These results confirm that the panning procedure described is an effective expression 
cloning strategy for the isolation of G-protein coupled receptors.
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Figure 5.4 Oligonucleotide primers schematic.
Schematic of cDNA sequences and the relevant oligonucleotide primers designed for 
PCR purposes. Hatched regions on the cDNA correspond to translated sequence, with 
wide bars representing oligonucleotide primers used in the PCR reaction.
FP = Forward primer 
IP = Internal primer 
RP = Reverse primer
Rat Y 1 receptor: PCR fragments; FP & RP = ~1200bp
IP & RP = -850bp
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1 2 6 2 - 1 2 8 1
3' 1 3 8 1
72-91 4 2 7 - 4 4 6
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Figure 5.5 Validation of the panning system using the NPY Y1 receptor.
Paired oligonucleotide primers (see figure 5.4 and Appendix II) designed to the rat 
NPY Y1 receptor open reading frame were used to amplify corresponding cDNA 
fragments from the DNA extracted following the panning procedure. A plasmid 
maxiprep of the rat Y1 receptor was used as a positive control reaction, and as a means 
of evaluating the PCR products obtained with the panning DNA.
Aliquots of lOpl of lOOpl total volume were electrophoresed on an agarose gel as 
described in section 2.3.1.7. DNA was visualised under ultraviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
Lane 1 PCR product obtained from panning DNA using Y1 homologous primers FP 
and RP. Product size = 1200bp (***)
Lane 2: PCR product obtained from panning DNA using Y1 homologous primers IP 
and RP. Product size =800bp(**)
Lanes 3 and 4: Negative control PCR reaction containing no DNA template. No 
products obtained as expected.
Lane 5 : Control PCR product obtained with Y1 plasmid DNA and Y1 homologous 
primers FP and RP.
Lane 6: Control PCR product obtained with Y1 plasmid DNA and Y1 homologous 
primers IP and RP.
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. 1Kb ladder (Life Technologies).
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5.4.4 Radioligand binding expression cloning.
The radioligand binding expression cloning strategy was employed as described (sections 
5.3.3) in an attempt to isolate the novel, hypothalamic feeding receptor for NPY. Screeing of 
COS-7 cells transfected with rat hypothalamic cDNA with radiolabelled ligand (l^^I-labelled 
PYY3“36) failed to reveal any positive pools of cDNA upon developing autoradiographic film. 
Half a million clones were screened in 20 pools, each containing 25,000 individual clones. 
The number of clones screened represented approximately one eighth of the clones present 
within the rat hypothalamic cDNA libraiy. As the mRNA for this receptor is raiely expressed, 
levels of the mRNA encoding this receptor will not be abundant within the hypothalamic 
library, therefore screening of the entire libraiy is necessaiy in order to optimise detection of 
the receptor. However, before further screening was accomplished, a paper was published in 
Nature in July of 1996, describing the cloning of the feeding receptor for NPY using an 
identical expression cloning method (Gerald, 1996). In this paper, the authors used a similai" 
approach to isolate the Y5 NPY receptor. However, unlike the study described in this thesis, 
the authors screened 3.4 million clones using 453 pools of 7500 clones per pool. This is a 
highly labour intensive approach. Despite screening a large number of clones, only thiee 
"positive" clones were identified and subsequent sequence analysis revealed that two of these 
thi'ee positives were in fact the Y1 receptor. Only one clone of the 3.4 million screened was a 
novel receptor and is now known as the Y5 receptor. This indicates the extreme raiity of this 
cDNA in the hypothalamic tissue.
5.5 Discussion.
A functional cloning approach was employed in an alternative attempt to isolate a novel NPY 
receptor from the hypothalamus that may mediate feeding behaviour. The lack of sequence 
homology exhibited between NPY receptor gene family members renders homology screening 
potentially ineffective as an experimental rationale for novel receptor gene cloning. The 
predicted low abundance of the mRNA encoding the feeding receptor also makes a functional 
cloning approach more amenable, as a rarely expressed receptor protein can be detected 
following ligand binding and screening.
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The COS cell panning strategy described (section 5.3.2 and figure 5.1) is an expression 
cloning technology which enables transiently transfected cells expressing a desired receptor 
protein to be tai’geted following binding of an appropriate ligand, and captured by screening for 
the ligand used. This expression cloning method enables a lai’ge number of clones to be 
effectively screened in one step, therefore enabling rapid screening of cDNA libraiies 
constructed from tissues believed to possess a receptor of interest. The use of radiolabelled 
ligands is not necessary in this technique, as the panning strategy uses an immunoselection 
procedure to screen for positive cells expressing the desired receptor.
5.5.1 Validation of the panning technique using the FcyRI receptor.
Before applying the technique to screen a rat hypothalamic cDNA libraiy for novel NPY 
receptor subtypes, the effectiveness of the system was validated. As the results obtained 
following the panning immunoselection procedure carried out on transiently transfected COS-7 
cells expressing the FcyRI receptor demonstrate, the panning system is an effective means of 
isolating desired receptor clones from a population of cells. As the FcyRI receptor was 
originally cloned using a similar method (Allen, 1989), the use of this receptor enabled the 
steps involved in the panning system to be evaluated unequivocally.
5.5.2 Attempts to isolate novel NPY receptor subtypes using COS cell panning technology.
The hypothalamus is the brain region responsible for the regulation and co-ordination of energy 
and nutrient homeostasis, and is the site of action where NPY elicits powerful stimulatory 
effects on feeding behaviour (Stanley, 1985). The mRNA encoding this receptor is therefore 
likely to be found within the hypothalamus and as a result, a hypothalamic cDNA library was 
first constructed in an attempt to isolate the feeding receptor for NPY.
After screening COS-7 cells transfected with rat hypothalamic cDNA, and executing the 
panning procedure outlined in section 5.3.2, no colonies were obtained following 
transformation of the extracted panning DNA. This suggests that either the amount of DNA 
recovered following panning of cells transfected with rat hypothalamic cDNA library was 
minute and therefore not amplified by bacterial transformation or that no DNA was recovered 
after canying out the panning technique. The expression levels of the hypothalamic feeding 
receptor for NPY are believed to be extremely low (Gerald, 1996), as the mRNA encoding this 
receptor is rarely expressed. As a result, it is increasingly likely that the quantity of DNA 
recovered from the COS cell panning experiment would be present in equally small quantities. 
Unlike a homology screening approach, where cDNA sequences unrelated to the receptor of 
interest may be targeted, this expression cloning technique confers specificity as regards
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isolation of cells expressing the desired receptor, as the ligand used is selective for members of 
the NPY receptor gene family. Another factor which would prevent effective isolation of the 
desired cDNA clone, is the presence of secondary structure within the mRNA encoding this 
receptor. As demonstrated in Chapter 2, considerable difficulties were encountered when 
attempts were made to obtain full length Y5 receptor PCR products. The presence of 
secondary structure in the 5’ region of the Y5 mRNA, would result in incomplete first strand 
cDNA synthesis during libraiy construction and ultimately lead to the generation of a cDNA 
clone which would not be expressed following cell transfection. The presence of 5' secondary 
stmcture has been documented by other groups in the field (Dan Larhammai', personal 
communication) and can be attributed to the difficulties experienced in amplification of the 
cDNA by PCR technology.
5.5.3 Attempts to isolate novel NPY receptor subtypes using radioligand binding expression 
cloning.
As detailed above, the feeding receptor for NPY is believed to be located within the 
hypothalamus, and therefore a cDNA libraiy constructed from this tissue is likely to contain the 
cDNA which encodes the feeding receptor. This expression cloning shategy has successfully 
enabled other NPY gene family members to be identified (Gerald, 1995, 1996).
Upon screening half a million clones using the radioligand binding expression cloning 
procedure described (section 5.3.3), no positive pool of cells expressing the feeding receptor 
for NPY was identified. As discussed above, the mRNA encoding this receptor does not 
confer abundance, and as only a proportion of the clones within the library were screened, the 
failure to isolate this receptor following screening with hindsight was not entirely surprising. 
Further screening was not carried out, as a Nature publication in July 1996 described the 
cloning of the feeding receptor for NPY (Gerald, 1996). The receptor was designated Y5, and 
was cloned using an expression cloning technology identical to the radioligand binding 
expression cloning described in this chapter. The extremely low expression levels exhibited by 
this receptor were clearly evident from the results of the expression cloning strategy used to 
clone this receptor. A rat hypothalamic cDNA library containing 3.4 X 10  ^ individual clones 
was analysed in a 1 ^ ^I-PYY-binding screening assay. Following screening of the entire 
library, a single clone corresponding to the rat NPY Y5 receptor was isolated from a positive 
pool identified by microscopic autoradiography (Gerald, 1996). The presence of a single Y5 
clone within a library constmcted from hypothalamic tissue demonstrates the incredibly low 
level of abundance exhibited by this receptor.
In addition to the likely rai'e nature of the mRNA encoding the feeding receptor an alternative 
explanation for the difficulty in cloning this receptor from the hypothalamus may lie in the lack
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of an appropriate cofactor/accessory molecule to enhance surface expression. Recently, a 
family of proteins have been identified (RAMPS) which facilitate surface expression of the 
human calcitonin gene related peptide CGRP mRNA. RAMP is the acronym for receptor- 
activity-modifying-protein. These appear* to be essential to transport the CGRP receptor to the 
plasma membrane and also modify the nature of ligand binding of the expressed receptor 
(McLatchie et al Nature, 1998).
5.5.4 Expression cloning of G-protein coupled receptors using the panning system.
As the receptor used to validate the panning system initially was a Type I single membrane 
spanning glycoprotein, the effectiveness of the panning technique in the expression cloning of 
G-protein coupled receptors remained to be established.
Validation of the panning system for use in the expression cloning of G-protein coupled 
receptors was cairied out by transfecting COS-7 cells with NPY Y1 receptor cDNA, and 
carrying out the panning procedure as described (sections 5.3.2.1). The DNA exti'acted from 
the targeted cells was subjected to a PCR reaction, in order to maximise detection of the DNA 
obtained from the panning procedure. As the amount of DNA obtained from the panning 
experiments cairied out with the rat hypothalamic cDNA libraiy were extremely low, PCR 
technology was used in order to amplify the DNA obtained using oligonucleotide primers 
homologous to the Y1 receptor. As the results of the PCR reaction illustrated in figure 5.5 
demonstrate, the panning technique enabled the Y1 receptor to be successfully re-cloned. 
Therefore, this suggests that the panning technology described in this chapter is efficient to 
clone G-protein coupled receptors. This technique could therefore be employed as a means of 
cloning novel receptors from a cDNA library using oligonucleotide primers homologous to the 
vector to amplify the desired DNA sequence in a PCR reaction.
The panning technology described has been demonstrated, by the results generated in this 
chapter to be an effective expression cloning technique. The demonstrated success of this 
technique in the cloning of G-protein coupled receptors, suggests that with further development 
this technique may prove to be an effective alternative to expression cloning which uses 
radiolabelled ligands to screen transfected cells. However, there aie a number of reasons why 
panning may fail and these ai*e impossible to predict in advance. It is an essential feature for 
functional expression approaches that the entire open reading frame of the mRNA is contained 
in the library. If the open reading frame is encoded by a long mRNA or there is mai'ked 
secondary stmcture in the mRNA which prevents progression of the reverse transcriptase, only 
a pai'tial cDNA will be synthesised and even though this is expressed, it will fail to be 
trafficked appropriately to the plasma membrane. In addition, if the receptor forms pait of a 
complex which is required to be pre-formed within the Endoplasmic Reticulum, then again
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even if a full length cDNA is present in the library, it cannot be expressed on the cell surface 
and therefore identified by ligand. However, despite the potential problems with this 
approach, it has been used successfully to identify a lai'ge number of receptors and when it 
works is a highly efficient method of obtaining a full length clone.
This technique may also have a role in validating the function of novel receptor genes cloned 
using a homology screening approach such as Genetrapper^'^f The use of the panning 
technology as a functional assay, would therefore permit a rapid and efficient assessment of 
the function of a novel receptor gene clone.
5.6 Summary
1) A functional expression cloning approach was employed in an attempt to clone the feeding 
receptor for NPY, as the structural diversity and lack of sequence homology exhibited by the 
NPY receptor gene family, make homology screening difficult.
2) A COS cell panning expression cloning technique was validated using a known receptor, in 
order to evaluate unequivocally that the steps involved in the panning system were effective for 
the isolation of desired receptor clones from a population of cells.
3) Attempts to isolate novel NPY receptor subtypes from a rat hypothalamic cDNA libraiy 
using COS cell panning technology were unsuccessful. The rai'e mRNA encoding the 
hypothalamic feeding receptor for NPY, reflected in the extiemely low expression levels 
exhibited by the hypothalamic feeding receptor for NPY, may result in the inability to detect the 
cDNA encoding this receptor using this technique.
4) Validation of the COS cell panning system using the NPY Y1 receptor demonstrated that the 
panning technology is an effective expression cloning strategy for the isolation of G-protein 
coupled receptors.
5) Radioligand binding expression cloning failed to reveal any positive clones. The rare nature 
of the mRNA encoding the feeding receptor can be attributed to the inability to detect a positive 
clone, as reflected by the results described in the cloning of the Y5 receptor describe din 1996 
(Gerald, 1996) where the clone of interest was detected following the screening of 3.4 X 10  ^
individual clones.
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Chapter 6
Regulation of receptor expression; 
Analysis of NPY Y1 and Y5 receptor mRNA
Chapter 6
6.1 Introduction.
The regulation of nutrient balance and energy homeostasis is a complex procedure involving 
interactions between numerous neurotransmitters, neuropeptides and hormones known to elicit 
profound effects on feeding behaviour and energy expenditure. Neuropeptide Y plays an 
important role in the regulation of feeding behaviour, as demonstrated by the potent stimulatoiy 
effects on ingestive behaviour induced upon central administration of this peptide (Clark, 1984, 
Stanley, 1984). The past decade has witnessed a remarkable wealth of interest with regaid to 
the role of NPY as a physiological mediator of food intake (Stanley, 1896 and Kalra, 1988). 
The paiaventricular nucleus (PVN) of the hypothalamus has been attributed the site of action of 
this peptide (Stanley, 1985 and Li, 1994), and the receptor subtype responsible for mediating 
NPY elicited eating is believed to be hypothalamic (Leibowitz 1992). As discussed in chapter 
1 section 1.9, NPY paiticipates in numerous interactions with other neuropeptides, 
neurotransmitters, and hormones known to ehcit stimulatory or inhibitory actions on feeding 
behaviour. The interactions between NPY and these mediators of feeding constitute the 
complex circuitry known to regulate this fundamental behaviour. The mechanism of action by 
which these interactions function is of particular interest, as by delineating the pattern of 
regulation, the intricate network which maintains nutrient and energy homeostasis may be 
further understood.
The identity of the receptor subtype responsible for mediating NPY elicited eating remains 
controversial to date. A hypothalamic NPY receptor designated Y5, was cloned in 1996 
(Gerald, 1996), the pharmacology of which mimicked that known to stimulate NPY induced 
feeding. However, the role of the NPY Y5 receptor as the feeding receptor for NPY proved 
contentious, as increasing evidence emerged describing a role for the NPY Y1 receptor in the 
regulation of NPY induced feeding (Kanatani, 1996, 1998, and Ishihara, 1998). The identity 
of the feeding receptor for NPY remains controversial, with increasing evidence emerging in 
favour of both the Y1 and Y5 receptors in the control of feeding (Marsh, 1998, Pedrazzini, 
1998).
As a result of the controversy surrounding the identity of the feeding receptor for NPY, the 
regulation of both Y1 and Y5 receptor subtypes is of paiticulai* interest, with regard to the 
conti'ol of feeding and interactions between NPY and other known mediators of ingestive 
behaviour. By examining the regulation of both the Y1 and Y5 receptors, a pattern of 
differential receptor regulation may be determined, thereby possibly facilitating an 
understanding of the role of each receptor.
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The experiments described in this chapter were caixied out in an attempt to examine the factors 
that regulate receptor mRNA levels. In order to investigate the regulation of expression of 
these receptor genes, mammalian cells constitutively expressing these receptor subtypes were 
used to examine changes in the levels of the mRNA encoding each receptor, following 
treatment with phannacological agents believed to be involved in gene regulation.
Human neuroblastoma cells, such as the SK-N-MC cell line, have been found to selectively 
bind Y1-receptor ligands (Sheikh, 1989 and Wahlestedt, 1991) and have subsequently been 
regarded as a model system for studies on the Y1 receptor. As these cells constitutively 
express the NPY Y1 receptor subtype, the transcriptional machineiy of the Y1 receptor gene is 
present within the cell, and therefore changes in the levels of expression of this gene following 
treatment with potential regulators can be readily detected by examining the levels of the mRNA 
for the receptor. These cells therefore present an effective means of rapidly determining 
changes in receptor expression, and allow the regulation of the YI receptor to be investigated. 
To date, a cell line constitutively expressing the Y5 receptor has not been described. As the Y5 
receptor has been identified peripherally in the kidney (Bischoff, 1997) and by Northern blot 
analysis described in chapter 2 (figure 2.12) it was reasoned that these cells may constitutively 
express the Y5 receptor. It is noteworthy that these cells constitutively express the leptin 
receptor and the galanin R2 receptor subtype (Fathi, 1998) both of which aie known to be 
involved in regulating glucose homeostasis.
In order to investigate the regulation of Y1 and Y5 receptor expression, analysis of the mRNA 
encoding the receptor protein is necessary to enable transcriptional regulation and ultimately 
gene expression to be examined. As only between 1-5% of total cellular' RNA is mRNA, the 
nuclear' polyadenylation of mRNAs (whereby a homopolymer of 200-250 adenosine 
nucleotides known as the poly A tail are added to the RNA transcript) performed by eukaryotic 
cells provides a useful tool for the selective isolation of mRNA from total cellular' RNA. 
Following hybridisation screening using a radiolabelled DNA probe complementary to either 
the Y1 or Y5 receptor cDNA, the expression levels of both receptors can be effectively 
examined, and a pattern of regulation determined.
6.2 Experimental Strategy.
A schematic representation of the experimental rationale employed in this chapter is illustrated 
in figure 6.1.
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Figure 6.1 Schematic depicting regulation of receptor mRNA levels experimental 
rationale.
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6.2.1 Design of gene specific probes.
The 3'untranslated (3'UT) represents the most divergent region of the gene. Therefore the use 
of a 3'UT specific probe will enable Y1 and Y5 gene specific analysis of the isolated mRNA 
following cell treatment. Oligonucleotide primers were designed from the 3'UT region of the 
human Y1 and Y5 receptor genes in order to amplify by PCR technology, DNA fragments 
encoding a region of the 3'UT.
6.2.2 Northern analysis of SK-N-MC mRNA.
In order to confirm the presence of the human Y1 receptor mRNA in SK-N-MC cells, poly A"^  
mRNA was isolated from total cell RNA, fractionated by electrophoresis through a 1% 
denaturing agarose gel, blotted onto nylon membrane and probed for the presence of the Y1 
receptor using a Y1 specific 3'UT 32p labelled probe.
6.2.3 Dot blot prepai'ation of poly A+ mRNA.
Following confirmation by Northern analysis that, under the hybridisation conditions defined, 
the Y1 specific probe only detected the Y1 mRNA transcript in poly A+ mRNA extracted from 
SK-N-MC cells, further experiments were completed using dot blot analysis. Poly A+ mRNA 
was extracted from SK-N-MC cells and bound to membrane using a dot blot appai atus to spot 
mRNA directly onto nylon membrane. This procedure was selected as it enabled rapid 
hybridisation analysis of poly A+ mRNA following cell treatment.
6.2.4 Hybridisation analysis.
In order to examine changes in the level of expression of the Y1 and Y5 receptors, dot blots 
containing poly A+ mRNA from treated cells were subjected to hybridisation screening with 
32p labelled 3'UT probes, corresponding to either the human Y1 or Y5 receptors. Changes in 
the level of receptor expression were observed as a change in the intensity of binding to the 
treated cell mRNA compaied with contiol (untreated) cell mRNA.
6.3 Chapter specific methods.
General precautions and procedures (Blumberg, 1987) were followed to minimise RNase 
contamination in the laboratory. When working with solutions and equipment used for RNA 
analysis, gloves were worn at all times to prevent "finger nucleases" contamination. Sterile, 
disposable plasticware was used wherever possible and plastic disposable pipette tips and 
microcentrifuge tubes were autoclaved prior to use. All glassware and other bakeable
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equipment, such as steel tweezers and foil, were baked at 270“C for at least eight hours to 
inactivate nucleases. Where possible, separate stocks were designated for RNA use only. 
Solutions for RNA use (with the exception of Tris-containing solutions) were tieated with 
0.05% diethyl pyrocai’bonate (DEPC), a non-specific inhibitor of ribonuclease, and then 
autoclaved to destroy any remaining DEPC. Dilutions of stock chemicals were made with 
DEPC-treated water. Electrophoresis gel rigs, combs and bottles dedicated for RNA use were 
well-rinsed with DEPC-treated water, covered and stored away from other general laboratoiy 
equipment.
6.3.1. SK-N-MC cell culture.
SK-N-MC cells were maintained on disposable polystyrene plates (Costai®) in Eagles 
Minimum Essential Medium with Earles salts (MEM, Gibco BRL) supplemented with 10% 
foetal calf serum (Sigma) (Appendix I). Cells were maintained in a Napco® Model 5410 tissue 
culture incubator set at 37°C and 6.5% carbon dioxide with 100% humidity. Cell 
manipulations were cairied out under sterile conditions in Microflow Larainai' Flow cabinets 
(MDH Ltd). Cells were split onto fresh plates every few days as described in section 5.3.1.
6.3.1.2. SK-N-MC cell treatment.
SK-N-MC cells were treated with various agents for between 1-5 days before harvesting 
during initial experiments, and for 15 minutes, 30 minutes, 1, 2, 4 or 6 hours before 
harvesting in subsequent experiments. Treatments were added directly into cell medium 24 
hours after cells had been replated. Forskolin (7p- Acetoxy-la,6p, 9a-trihydroxy-8, 13- 
epoxy-labd-14-en-l 1-one, Calbiochem.), an activator of adenylyl cyclase (deSouza, 1983) was 
applied at a concentration of lOpM. Dexamethasone, (9a-Fluro-16a-methylprednisolone, 
Sigma), a synthetic glucocorticoid, was used to treat cells at a concentration of IpM.
6.3.1.3 Cell quantitation.
Total cell counts were determined using a haemocytometer (Sigma). With the coverslip in 
place, a drop of cells suspended in growth medium were transferred to the haemocytometer by 
carefully touching the edge of the coverslip with the pipette tip and allowing the interface 
between the coverslip and the gridded markings on the haemocytometer to fill by capillary 
action. Cells were counted in the middle and four corner squares. The average number of cells 
per millilitre was calculated to be the average count per squai'e multiplied by 10 .^
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6.3.1.4 HEK cell culture.
HEK cells were maintained on disposable polystyrene plates (Costar®) in RPMI (Imperial 
Laboratories) supplemented with 10% foetal calf serum (Sigma) (Appendix I). Cells were 
maintained in a Napco® Model 5410 tissue culture incubator set at 37“C and 6.5% carbon 
dioxide with 100% humidity. Cell manipulations were carried out under sterile conditions in 
Microflow Laminar Flow Cabinets (MDH, Ltd.). Cells were split onto fresh plates every few 
days as described in section 5.3.1.
6.3.1.5 HEK cell treatment.
HEK cells were treated for two or four hours with forskolin (7(3- Acetoxy-la,6|3, 9a- 
trihydroxy-8, 13-epoxy-labd-14-en-11-one, Sigma), an activator of adenylyl cyclase (deSouza, 
1983) at a concentration of lOgM.
6.3.2 Oligonucleotide design and synthesis.
Oligonucleotide primers were designed from the 3'untranslated (3'UT) regions of the human 
NPY Y1 and Y5 receptors, as illustrated in figure 6.2. Each primer comprised 20 bases and 
was between 50-60% GC rich. These oligonucleotides were synthesised commercially by 
Oswel DNA Service (University of Southampton) and were dissolved in sterile water. (See 
Appendix II for sequences of the Y1 and Y5 3'UT oligonucleotide primers). AK 
oligonucleotides were checked for complementary hybridisation with the DNA data bank using 
the blast or fasta for GCG (Wisconsin Package Version 9.1, Genetics Computer Group 
(GCG), Madison, Wise).
6.3.3 PCR amplification of human Y1 and Y5 3’UT fragments from human genomic DNA.
The human NPY Y1 and Y5 3'UT oligonucleotide primers described in section 6.3.2 were 
used in a PCR reaction with human genomic DNA (section 2.3.2.2). The PCR products 
obtained using the thermostable Taq DNA polymerase were cloned into the pCR2.1 cloning 
vector using the TA cloning kit (Invitrogen) as described (sections 2.3.2.4 and 2.3.2.5). 
Plasmid DNA was isolated (2.3.2.6), and restriction digest and gel electrophoretic analysis 
carried out to confirm generation of recombinant plasmid DNA (section 2.3.1.6 and 2.3.1.7).
6.3.4 Extraction of Total RNA from SK-N-MC and HEK cells
Total cellulai' RNA was extracted and isolated using an RNeasy Midi kit (Qiagen) following 
manufacturer instructions as described. Cells were lysed directly in the culture dish by adding
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1.9ml lysis buffer RLT (supplied) containing lOpl/ml 14.5M p-mercaptoethanol. Buffer RLT 
contains guanidium isothiocyanate which together with p-mercaptoethanol inactivate RNases, 
to ensure isolation of intact RNA. This lysis step is essential as the complete disruption of the 
cell walls and plasma membranes of the cells and organelles is an absolute requirement to 
release all the RNA contained in the sample. After 5 minutes incubation in lysis buffer, the 
lysed cells were collected with a mbber policeman (Costar®), and transferred to an RNase free 
polypropylene tube (Sarstetd). Cells were then homogenised using a Q ia s h re d d e r^ M  (Qiagen) 
by applying the cell lysate to a Qiashi’edder unit and centiifuging for 2 minutes at room 
temperature and 14,000 X g. Homogenisation of the lysed cells is necessaiy to reduce the 
viscosity of the cell lysates produced by disruption, and complete homogenisation is required 
for effieient binding of the cell lysate to the RNeasy column used in this procedure. Following 
homogenisation, 1.9ml of 70% ethanol was added to the homogenised lysate to provide 
appropriate binding conditions, and mixed by vortexing. The sample was then applied to a 
RNeasy midi spin column (supplied), and centrifuged for 5 minutes at room temperature and 
3,000 X g to facilitate binding of the RNA to the spin column. The flow-through obtained 
following centrifugation was discarded, 3.8ml wash buffer RWl (supplied) were added to the 
spin column and the tube was centi’ifuged for 5 minutes at room temperature and 3,000 X g. 
The flow-through generated was discaided, and the spin column washed in 2.5ml buffer RPE 
(supplied) and centrifuged for 2 minutes at room temperature and 3,000 X g. A second wash 
in buffer RPE was cairied out as described, and the spin column centrifuged for 5 minutes at 
room temperature and 3,000 X g. The washing steps carried out enable any contaminants to be 
effectively removed, while the total RNA remains bound to the RNeasy spin column. Total 
RNA was eluted, after transferring the RNeasy spin column to a fresh RNase free tube, adding 
150jLil RNase free water (supplied) directly onto the spin column and centrifuging for 3 minutes 
at room temperature and 3,000 X g, after standing for 1 minute prior to centrifugation. The 
elution step was repeated as described in a further 150|iil RNase free water. Total RNA was 
routinely stored at -70°C.
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Figure 6.2 Oligonucleotide primers schematic.
Schematic of cDNA sequences and the relevant oligonucleotide primers designed for 
PCR. Hatched regions on the cDNA correspond to translated sequences; wide bars 
represent oligonucleotide primers used for PCR.
FP = forward primer 
RP = reverse primer 
A: Human NPY Y1 receptor
3'UT PCR fragment; FP & RP = ~360bp
B: Human NPY Y5 receptor
3'UT PCR fragment; FP & RP = ~240bp
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A) Human Y1 receptor
5'
3'
FP
____ _ 2 5 4 1 - 2 5 6 0
2 1 9 4 - 2 2 1 3  -------
RP
B) Human Y5 receptor
3'
FP
1 5 6 9 - 1 5 8 8
1 7 9 1 - 1 8 1 0
RP
6.3.5 Purification of poly A+ mRNA from total RNA extracted from SK-N-MC and HEK 
cells.
The total RNA isolated from the cells as described above was quantified (6.3,6) and prepared 
for poly A+ mRNA isolation using a kit (Oligotex mRNA Midi kit, Qiagen). Total cellulai* 
RNA was mixed with 250pl DEPC ti*eated water (diethyl pyrocarbonate, supplied) in an RNase 
free microcentrifuge tube, SOOpl 2 X binding buffer (supplied) and 30pl prewaimed (37°C) 
Oligotex suspension (supplied) was then added. The contents of the tube were mixed by gentle 
flicking, and incubated at 65°C for 3 minutes to disrupt secondary structure in the RNA. 
Following incubation, the sample was incubated for 10 minutes at room temperature to allow 
hybridisation between the oligotex and the poly A tail of the mRNA. Oligotex consists of 
polystyrene latex particles covalently linked to dTgo oligonucleotides which foiin hydrogen 
bonds with the polyA tail of the mRNA, and in doing so selectively purify poly A+ mRNA 
from a preparation of total RNA. The samples were then subjected to centrifugation for 2 
minutes at room temperature and 14,000 X g in order to pellet the oligotex resin bound to the 
poly A+ mRNA. The resulting supernatant was removed by cai*eful aspiration and 
discarded.The oligotex pellet was resuspended in 400pl wash buffer QW2 (supplied) by 
vortexing. The resuspended pellet was then transferred to a spin column (supplied) and 
centrifuged for 30 seconds at room temperature and 14,000 X g, before discarding the flow 
through and washing in a further 400|al wash buffer QW2. The sample was subjected to 
further centrifugation at room temperature for 30 seconds at 14,000 X g, and the flow through 
discarded. To recover the poly A+ mRNA from the oligotex pai'ticles, the spin column was 
transferred to a fresh RNase free microcentrifuge tube, and poly A+ mRNA was eluted by 
adding 25pl preheated (70°C) elution buffer (supplied) to the spin column, resuspending the 
resin by pipeting several times and centrifuging as described above. The first eluate was 
pooled with a second elution to ensure maximal yield was obtained. The eluted poly A+ 
mRNA was routinely stored at -70°C.
6.3.6 Quantification of RNA.
RNA was quantitated by spectrophotometry (DU-640B or DU-62, Beckman) at 260nm. RNA 
quantity was calculated, by assuming that an absorbance of 1 at 260nm corresponds to 40jig 
RNA per ml.
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6.3.7 RNA formaldehyde gel electrophoresis.
Formaldehyde-denatured RNA was resolved on 1% agarose gels. RNA samples were 
denatured at 60“C for 20 minutes in IX RNA electrophoresis buffer (Appendix I), 10% 
deionised formamdde and 10% formaldehye and electrophoresed in gels containing 1 X RNA 
electrophoresis buffer, 25jLig/ml ethidium bromide, 1.5% formaldehyde and O.IM 
iodoacetamide. Equal amounts of denatured RNA were loaded (0.5-2pg poly A+ mRNA, 20- 
40pg total RNA) in each lane. Electrophoresis was carried out at a constant lOOV in 1 X RNA 
electrophoresis buffer, 25pg/ml ethidium bromide for 2-3 hours. After electrophoresis, RNA 
was visualised in the gel with ultraviolet light at 254nm to assess RNA integrity and loading 
precision.
6.3.8 RNA transfer to membrane.
Transfer of size separated, gel electi'ophoresed RNA to membrane was performed as outlined 
(Thomas, 1980). The blotting procedure was identical to that described for Southern transfer 
of DNA (section 3.3.5) except that the dénaturation step was omitted and RNA handling 
procedures were used.
6.3.9 Dot blot preparation.
Poly A+ mRNA was spotted directly onto nylon membrane (Hybond N, Amersham) after 
equilibrating the membrane and a sheet of Whatman 3MM paper in 4 X SSC solution 
(Appendix I) for a few minutes prior to blotter assembly. Typically Ipg poly A+ mRNA was 
blotted onto the membrane following dénaturation for 20 minutes at 60°C. Poly A+ mRNA 
was bound to the membrane by passing 30pl poly A+ mRNA (volume made up in 4 X SSC) 
through an RNA Dot Blot Manifold (BRL) connected to a vacuum pump. Cai'e was taken to 
ensure the array of blotted samples was noted. Controls such as 70ng denatured Y1 3'UT and 
Y5 3'UT miniprep DNA (section 6.3.10) were blotted on to the same filter in a known array. 
After binding, the membrane was air-diied before cross-linking the RNA to the membrane by 
exposing the blot to ultraviolet light at 254nm for 30 seconds either side.
6.3.10 Dénaturation of Y1 and Y5 receptor 3’ UT miniprep DNA.
Before blotting on to nylon membrane, Y1 and Y5 receptor 3'UT miniprep DNA was 
denatured to enable effective hybridisation between the DNA and the probe. One microgram of 
Y1 3'UT or Y5 3’UT miniprep DNA was denatured by adding 2pl of a solution containing 2M 
NaOH/2mM EDTA and incubating at room temperature for 5 minutes. The denatured DNA
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was neutralised by adding 2\i\ 2M ammonium acetate (pH4.5), and precipitated by adding 50pl 
ice-cold absolute ethanol and chilling to -70°C. Following centrifugation at 14,000 X g for 15 
minutes at 4°C, the resulting pellet was rinsed in lOOpl ice-cold 70% ethanol and centrifuged 
for a further 15 minutes at 4°C and 14,000 X g. The DNA pellet was air-dried before 
resuspending in 7 ]l i 1 water.
6.3.11 Radioactive labelling of Y1 and Y5 3'UT DNA.
The Y1 and Y5 3'UT PCR products generated as described in section 6.3.3 were radiolabelled 
with 32p as described in section 2.3.3.2, and used in the hybridisation screening of the 
Northern and dot blots.
6.3.12 Hybridisation of Northern and dot blots.
Membrane was subjected to prehybridisation and hybridisation as described in section 2.3.3, 
using the prehybridising and hybridising solution described in section 3.3.3.4. Signal 
detection was carried out as described in section 2.3.3.1.
6.3.13 Rehybridisation of dot blots.
Blots were stripped of radioactive probe for rehybridisation by incubating blots in a solution of 
boiling 0.5% SDS (sodium dodecyl sulphate) until the solution reached room temperature. 
Stripped blots, were then equilibrated in 5X SSC solution for 20 minutes at room temperature, 
before storing in cling-film at -20° C.
6.4 Results.
6.4.1 Generation of Y1 and Y5 3'UT PCR products.
Figure 6.2 illustrates the regions of the human Y1 and Y5 receptor sequence where 3'UT 
oligonucleotides were designed. PCR reactions were carried out as described in section 6.3.3 
using the primers designed to generate a 3'UT fragment of DNA. PCR products of the correct 
molecular* weight were obtained from human genomic DNA (Promega) as illustrated in figure 
6.3A and B. Subsequent subcloning into the vector pCR2.1 was confirmed by restriction 
digest analysis with the endonuclease EcoR I to excise the PCR product (data not shown). 
Sequence analysis of those minipreps containing the target sequence (section 2.3.1.9) revealed 
that the PCR products obtained were identical to the 3'UT of the human Y1 and Y5 receptors 
respectively.
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6.4.2 Confirmation of Y1 and Y5 3'UT probe specificity
In order to confirm that both 3'UT probes were gene specific, and no cross-reactivity was 
observed between the Y1 3'UT probe and the Y5 3'UT miniprep DNA, or the Y5 3'UT probe 
and Y1 3'UT miniprep DNA, Southern blot analysis was canied out as described in section 
3.3.5. Miniprep DNA prepared following transformation of Y1 and Y5 3'UT PCR products 
was digested with Eco RI before cariying out gel electrophoresis and preparing a Southern 
blot. Two identical Southern blots were prepared, and probed individually with either 
radiolabelled Y1 3'UT PCR product or radiolabelled Y5 3'UT PCR product. Following signal 
detection, the results were analysed, and it was concluded that each probe specifically 
hybridised to the digested miniprep DNA containing the 3'UT insert identical to the PCR 
product probe, i.e. the Y1 3'UT probe hybridised specifically to the digested miniprep DNA 
containing the Y1 3'UT insert, and the Y5 3'UT probe hybridised specifically to the digested 
miniprep DNA containing the Y5 3'UT insert. As figure 6.4 illustrates, no cross reactivity was 
observed, demonstrating that both probes are gene specific. These results ensured that 
subsequent hybridisation screening of Northern and mRNA dot blots would enable changes in 
the expression of the specific receptor mRNA to be detected in a receptor specific manner.
6.4.3 Detection of human NPY Y1 receptor mRNA in SK-N-MC cells.
In order to ensure that the human NPY Y1 receptor could be readily detected in poly A+ mRNA 
isolated from SK-N-MC cells. Northern blot analysis was canied out. Four micrograms of 
poly A+ mRNA isolated from SK-N-MC cells was run on a denaturing gel as described 
(section 6.3.7). Two micrograms of total RNA isolated from SK-N-MC cells was run 
alongside the poly A+ mRNA as a molecular* weight marker. The Northern blot constructed 
was probed with a ^^P labelled Y1 3'UT probe as described (section 2.3.3). As illustrated in 
figure 6.5, a discrete band corresponding to the molecular* weight of the human NPY Y1 
receptor* transcript was detected in the poly A+ mRNA isolated from SK-N-MC cells. The size 
of the single hybridising Y1 transcript in SK-N-MC cells was approximately 3.5 kb, in 
accordance with previous reports detecting the Y1 transcript in these cells by Northern analysis 
(Larhammar, 1992).
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Figure 6.3 Analysis of human NPY Y 1 and Y5 receptor 3'untranslated region PCR 
products.
A: Paired oligonucleotide primers (see figure 6.2A and Appendix II) designed to the 
human NPY Y1 receptor 3'UT were used to amplify corresponding cDNA fragments 
from human genomic DNA.
Aliquots of lOpl of lOOpl total volume were electrophoresed on an agarose gel as 
outlined in section 2.3.1.7. DNA was visualised under ultr aviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
Lanes 1 and 2: PCR products obtained from human genomic DNA using Y1 receptor 
3'UT primers. Product size = 360bp (***)
Lane 3: Negative control PCR reaction containing no template. No product obtained as 
expected.
Lane 4: Positive control PCR product obtained from human genomic DNA using 
G3PDH primers. Product size = 500bp.
All other lanes were empty.
B: Paired oligonucleotide primers (see figure 6.2B and Appendix II) designed to the 
human NPY Y5 receptor 3'UT were used to amplify corresponding cDNA fragments 
from human genomic DNA.
Aliquots of lOpl of lOOgl total volume were electrophoresed on an agarose gel as 
outlined in section 2.3.1.7. DNA was visualised under ultraviolet irradiation; 
photograph exposure time 0.5-1.0 seconds.
Lane 1 : Positive control PCR product obtained from human genomic DNA using 
G3PDH primers. Product size = 500bp.
Lanes 2 and 3: PCR products obtained from human genomic DNA using Y5 receptor 
3'UT primers. Product size = 240bp (***).
Lane 4: Negative control PCR reaction containing no template. No product obtained as 
expected.
All other lanes were empty.
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. 1Kb ladder (Life Technologies).
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Figure 6.4 Southern blot analysis demonstrating human Y1 and Y5 receptor 3'UT 
probe specificity,
A: Miniprep DNA prepared following transformation of Y1 and Y5 3'UT PCR 
products was digested with Eco RI to excise the Y1 or Y5 3'UT DNA insert. DNA 
was electrophoresed on an agarose gel as outlined in section 2.3.1.7 and visualised 
under ultraviolet iiTadiation; photograph exposure time 0.5-1.0 seconds. Two identical 
gels were prepared.
Lane 1; 2pg Eco RI digested human Y1 3'UT miniprep DNA. Insert size =360bp(**'‘')
Lane 2: 2pg Eco RI digested human Y5 3'UT miniprep DNA. Insert size = 240bp (**) 
All other lanes were empty.
Restriction digested DNA markers (M) were electrophoresed alongside reaction 
products. 1Kb ladder (Life Technologies).
B: Two identical Southern blots were generated from the gel described above, and 
probed separately with either radiolabelled Y1 3'UT PCR product or radiolabelled Y5 
3'UT PCR product.
Autoradiogram 1: Southern blot of gel in figure 6.4A hybridised to a 32p-iabelled 
human Y1 receptor 3'UT probe. *** denotes Y1 3'UT DNA insert.
Autoradiogram 2: Southern blot of gel in figure 6.4A hybridised to a 3^P-labelled 
human Y5 receptor 3'UT probe .** denotes Y5 3’UT DNA insert.
These results demonstrate that each probe specifically hybridised to the digested 
miniprep DNA containing the 3'UT insert identical to the PCR product probe.
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Figure 6.5 Detection of human NPY Y1 receptor mRNA in SK-N-MC cells.
A: 4 pg of poly A+ mRNA isolated from SK-N-MC cells were denatured, 
electrophoresed on an RNA agaiose gel and photographed under ultraviolet 
illumination, as described in section 6.3.7. 2pg of total RNA isolated from SK-N-MC 
cells was run alongside the poly A+ mRNA as a molecular weight marker.
Lane 1 : SK-N-MC cell total RNA.
Double and single asterisk denote the migration position of 28S and 18S rRNA 
respectively.
Lane 2; Poly A+ mRNA isolated from SK-N-MC cells
B: A Northern blot was generated from the gel described above and analysed for the 
human NPY Y1 receptor by hybridisation with a ^^P labelled Y1 3’UT probe.
The asterisks (*** ) maik the position of hybridisation signal for the human NPY Y1 
receptor.
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6.4.4 Detection of human NPY Y5 receptor mRNA in HEK cells.
In an attempt to determine whether the human NPY Y5 receptor could be detected in HEK 
cells, Northern blot analysis was carried out. Four micrograms of poly A+ mRNA isolated 
from HEK cells was run on a denaturing gel as described, alongside an RNA molecular* weight 
mai'ker (Promega). The Northern blot constmcted was probed with a 32p labelled PCR 
product encompassing a region of the rat Y5 receptor cDNA. The oligonucleotides used to 
generate this PCR product are the internal primer and reverse primer illustrated in figure 2.4, 
and the size of the PCR product obtained was approximately 800bp.
As illustrated in figure 6.6, a discrete band corresponding to the molecular weight of the Y5 
receptor transcript was detected in the poly A+ mRNA isolated from HEK cells. The size of 
the single hybridising Y5 transcript in HEK cells was approximately 2.7 Kb, the same size as 
the Y5 transcript detected in whole brain mRNA described in the original Y5 cloning paper 
(Gerald, 1996).
6.4.5 Effect of forskolin treatment on Y1 receptor mRNA expression.
In the experiments described in this chapter, poly A+ RNA dot blots were the selected method 
of transferring RNA to nylon membrane, as they present a rapid method for detecting changes 
in expression levels of Y1 and Y5 receptor mRNA following hybridisation screening.
The initial experimental approach employed to investigate regulation of Y1 receptor mRNA 
expression examined the effects of forskolin on Y1 receptor expression following treatment for 
1-5 days. Forskolin was chosen as the stimulus as previous work in this laboratoi*y has shown 
that the 5' flanking region of the gene contains two cyclic AMP responsive elements (CRE’s) 
and that the rate of gene transcription is altered by cAMP This time course was selected 
initially as the effect of cAMP on mRNA levels was unknown. Therefore, by examining 
changes in the levels of Y1 receptor mRNA over the 5 day time course described, the effect on 
Y 1 mRNA levels could be elucidated.
To ascertain the effect of cAMP (cyclic adenosine monophosphate) on Y1 receptor expression, 
SK-N-MC cells were treated with lOpM forskolin over a five day period. Forskolin is a 
diterpine which acts to activate constitutively adenylyl cyclase, resulting in the increased 
production of cAMP. As the human NPY Y1 receptor gene contains 2 cAMP responsive 
elements (CRB), application of forskolin to the cells will result in changes in the level of 
mRNA expression as a result of the action of cAMP on the cAMP responsive elements present 
on the Y1 receptor gene (Bournat, 1998).
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Total RNA was extracted (section 6.3.4) from SK-N-MC cells following treatment with 
forskolin for 24 hours, 48 hours, 72 hours, 96 hours and 120 hours. Total RNA was also 
isolated from untreated SK-N-MC cells, following the time course outlined for treated cells. 
Poly A+ mRNA was prepared (section 6.3.5) from the total RNA exti'acted from both treated 
and untreated cells and quantified (6.3.6) to ensure equal amounts were blotted onto nylon 
membrane. Following quantification, Ipg of poly A+ mRNA from each of the forskolin 
treated cell tinie-points and Ipg poly A+ mRNA from each of the untreated cell time-points 
were blotted in a known array onto nylon membrane (Hybond N, Amersham, section 6.3.9). 
Denatured Y1 and Y5 3'UT DNA were also blotted as control samples to act as positive and 
negative controls for hybridisation. The blot was then subjected to hybridisation screening 
using a ^2p labelled Y1 3'UT PCR product in order to examine the effects of forskolin 
treatment on Y1 receptor mRNA expression.
Figure 6.7 illustrates the results obtained following hybridisation screening of the SK-N-MC 
mRNA dot blot with a human NPY Y1 receptor 3'UT probe. The data obtained revealed that 
forskolin treatment surprisingly resulted in a decrease in the levels of Y1 mRNA over the time 
points 24-96 hours. Levels of Y1 receptor mRNA expression following 120 hours forskolin 
treatment were comparable to basal levels of Y1 receptor mRNA expression. To check for 
eveness of mRNA loading, blots were probed for the housekeeping enzyme G3PDH (data not 
shown).
6.4.6 Effect of forskolin treatment on Y5 receptor mRNA expression.
As the human Y1 and Y5 receptors aie located on overlapping but opposite strands of the same 
chromosome (Herzog, 1997), it was reasoned that SK-N-MC cells may also constitutively 
express the Y5 receptor. In an attempt to ascertain whether the Y5 receptor is expressed in SK- 
N-MC cells, the blot prepared following SK-N-MC cell treatment with forskolin (section 
6.4.5) was rehybridised following removal of radioactive probe (6.3.13), with a Y5 3'UT 
probe to determine whether the human Y5 receptor mRNA could be detected in SK-N-MC 
cells. Following hybridisation screening with the human NPY Y5 receptor 3'UT probe, no 
signal was detected in either the control or forskolin treated cells. The probe did however 
hybridise with its own control DNA. This data indicates that the Y5 3'UT probe failed to 
hybridise to the SK-N-MC cell mRNA. These results suggest that the Y5 receptor is not 
expressed in SK-N-MC cells, or that the level of expression is veiy low. The Y5 3'UT probe 
did hybridise to the Y5 3'UT DNA present on the blot, demonstrating that the hybridisation 
conditions were appropriate.
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6.4.7 Effect of forskolin or dexamethasone treatment on Y1 receptor mRNA expression.
As the 5 day time course employed in the initial experiment canied out to investigate changes in 
Y1 receptor mRNA expression (6.4.5) revealed that levels of Y1 receptor mRNA expression 
were altered within 24 hours, a second time course of treatment was employed in an attempt to 
monitor changes in Y1 receptor mRNA expression in the period immediatetly following 
forskolin application. SK-N-MC cells were treated with lOpM forskolin for 2, 4 and 6 hours 
in order to ascertain the earlier effects of cAMP on Y1 receptor expression.
Total RNA was extracted (section 6.3.4) from SK-N-MC cells following tieatment with 
forskolin for 2 hours, 4 hours and 6 hours. Total RNA was also isolated from untreated SK- 
N-MC cells, following the time course outlined for treated cells. Poly A+ mRNA was prepaied 
(section 6.3.5) from the total RNA extracted from both tieated and untieated cells and 
quantified (6.3.6) to ensure equal amounts were blotted onto nylon membrane. Following 
quantification, Ipg of poly A+ mRNA from each of the forskolin and dexamethasone tieatment 
time-points and Ipg poly A+ mRNA from control (untreated) cells were blotted in a known 
airay onto nylon membrane (Hybond N, Amersham, section 6.3.9). Denatured Y1 and Y5 
3'UT DNA were also blotted as control samples to act as controls for hybridisation . The blot 
was then subjected to hybridisation screening using a 32p labelled Y1 3'UT PCR product in 
order to examine the effects of forskolin on Y1 receptor mRNA expression.
In paiallel with these experiments with forskolin, SK-N-MC cells were heated with IpM 
dexamethasone over similar' time points. Dexamethasone is a synthetic glucocorticoid which 
mimics the actions of the steroid hormone hydrocortisone. As the human NPY Y1 receptor 
gene contains 4 glucocorticoid responsive elements (GRE) (J.C.Bournat, University of 
Glasgow, 1998), application of dexamethasone has been shown previously to alter NPY Y1 
receptor gene transcription. However, little is known on the response of the mRNA.
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Figure 6.6 Detection of human NPY Y5 receptor mRNA in HEK cells.
A: 4 pg of poly A+ mRNA isolated from HEK cells were denatured, electrophoresed 
on an RNA agaiose gel and photographed under ultraviolet illumination, as described in 
section 6.3.7. An RNA moleculai' weight marker (M) (Promega) was run alongside 
RNA samples.
Lanes 1 and 2: 4 pg HEK cell poly A+ mRNA
B: A Northern blot was generated from the gel described above and analysed for the 
human NPY Y5 receptor by hybridisation with a ^^P labelled Y5 receptor cDNA probe 
encompassing a region of the rat open reading frame from TM5 to the C-terminus of the 
receptor protein.
The asterisks (***) mark the position of hybridisation signal for the human NPY Y5 
receptor.
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Figure 6.7 Effect of forskolin treatment on Y1 receptor mRNA expression.
Ipg of poly A+ mRNA from untreated SK-N-MC cells grown for 1-5 days (row B, 
samples 1-5) and Ipg of poly A+ mRNA from cells treated with lOpM forskolin for 1-5 
days (row A, samples 1-5) were blotted onto nylon membrane in a known array. 
Denatured Y1 and Y5 3'UT cDNA were also blotted onto the membrane as positive 
control samples.
The blot was then analysed for human Y1 mRNA expression by hybridisation with a 
32p labelled Y1 3'UT cDNA probe.
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5 Y1 DNA
Figure 6.8 illustrates the results obtained following hybridisation screening of the SK-N-MC 
mRNA dot blot with a human NPY Y1 receptor 3'UT probe. The results obtained revealed 
that following treatment with forskolin for 2 and 4 hours, levels of Y1 receptor mRNA 
expression were elevated when compaied with the basal levels of Y1 receptor mRNA 
expression observed in control (untieated) cell mRNA. 6 hours after addition of forskolin 
levels of Y1 receptor mRNA expression were compaiable to basal levels of Y1 receptor 
expression as observed in control cell mRNA. Therefore, following forskolin treatinent for 2- 
4 hours, Y1 receptor mRNA expression was elevated, but this response was reversed by 
treatment with forskolin for 6 hours.
Following treatment with dexamethasone only the 2 hour time point revealed an elevation in the 
levels of Y1 receptor mRNA expression when compaied with basal levels of Y1 receptor 
mRNA in control cell mRNA. Treatment with dexamethasone for 4 or 6 hours decreased Y1 
mRNA levels. Additional experiments were undertaken to confirm this transient increase in 
NPY Y1 mRNA levels. The two hour time point was repeated and in addition, eaiiier time 
points were included. This data confirmed that at 2 hours the mRNA levels of the Y1 receptor 
were elevated above control and this increase was observed within 30 minutes of ti'eatment 
with forskolin (data not shown).
To check for eveness of mRNA loading, blots were probed for the housekeeping enzyme 
G3PDH (data not shown).
6.4.8 Detection of human NPY Y5 receptor mRNA in HEK cells by dot blot analysis.
The following preliminaiy experiment was carried out in order to determine whether the human 
NPY Y5 receptor could be detected in HEK 293 cells and was similarly conti'olled by cAMP 
levels.
HEK cells were treated with lOpM forskolin for 2 hours, and RNA extracted from treated cells 
and untreated control cells. One microgram of isolated poly A+ mRNA from treated and 
untreated cells was dot-blotted onto nylon membrane, with all steps performed similarly to 
those described in section 6.4.5. Denatured Y1 and Y5 3'UT DNA were also blotted as 
controls for hybridisation. The blot was then subjected to hybridisation screening using a ^^P 
labelled Y5 3'UT PCR product in order to deteimine whether HEK cells express the Y5 
receptor. However, no signal could be detected as the Y5 3'UT probe failed to hybridise to the 
HEK cell mRNA isolated from either forskolin treated or untreated cells. The Y5 3'UT probe 
hybridised stongly to the Y5 3'UT DNA conh'ol sample on the blot, confirming that 
hybridisation conditions were favourable. This data indicates that Ipg poly A+ mRNA
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Figure 6.8 Effect of forskolin and dexamethasone treatment on Y1 receptor mRNA 
expression.
Ipg of poly A+ mRNA from untreated SK-N-MC cells (C), Igg of poly A+ mRNA 
from cells treated with lOpM forskolin for 2, 4 and 6 hours (row F, samples 2, 4 and
6) and Igg of poly A+ mRNA from cells treated with IpM dexamethasone for 2, 4 and 
6 hours (row D, samples 2, 4 and 6) were blotted onto nylon membrane in a known 
array. Denatured human Y1 and Y5 3'UT cDNA were also blotted onto the membrane 
as positive control samples.
The blot was then analysed for human Y1 mRNA expression by hybridisation with a 
32p labelled Y1 3'UT cDNA probe.
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Y1 DNA
contains insufficient Y5 mRNA to be detected by the dot blot method and is further evidence 
for the rarity of the mRNA.
6.5 Discussion.
In this chapter the levels of expression of the mRNAs for the NPY Y1 and Y5 receptors have 
been determined using Northern blot analysis of poly A+ selected RNA and subsequent dot 
blot analysis. To examine dynamic changes in the mRNA levels, dot blots provide a veiy rapid 
and convenient approach. However, it is essential to validate the hybridisation signal prior to 
interpreting data derived from the dot blot as the RNA is not fractionated in this procedure. A 
non specific signal in dot blots may arise from hybridisation of the probe to related mRNA 
species or to "bulk" effects of ribosomal RNA (28S and 18S). To avoid these issues, two 
decisions were made before embarking on these studies. First, Y1 and Y5 selective regions of 
the 3'UT region were obtained by PCR to use as probes for the study. The reason for this was 
to target the region displaying maximum diversity between these two genes. Because the 3'UT 
is not evolutionarily constrained by the need to conserve sequence to encode a protein, this 
region of the gene within families is recognised to be the most diverse. Thus, use of probes 
designed to this region of the mRNA, is likely to provide a higher level of specificity than use 
of probes within the open reading frame. The absolute specificity of the probes was 
determined by probing against the corresponding DNA of the Y1 and Y5 receptors. Thus, the 
Y1 probe only recognised Y1 DNA and the Y5 probe only recognised Y5 DNA.
The second factor employed to avoid non-specific signals in the dot blot experiments was use 
of poly A+ selected RNA. Three RNA species aie extracted and represented in the total RNA. 
These are the ribosomal RNAs (rRNA), transfer RNA (tRNA) and messenger RNA (mRNA). 
The vast bulk of the RNA is rRNA and this frequently binds to probe to give a non-specific 
signal. Messenger RNA can be selected away from the other RNA species by exploiting the 
fact that mRNAs ai*e polyadenylated, thus oligodT will hybridise to mRNA. The selection 
procedure used here appears to be very effective as no ribosomal RNA could be detected in the 
poly A+ selected lane by Northern analysis (figure 6.5).
Having made these two decisions, the specificity of the signal was validated by Northern 
analysis. Here unlike in dot blots, the mRNA is fractionated in a denaturing agarose gel and 
molecular weight of the positive signal can be estimated. These results demonstrated that the 
Y1 probe readily detected a signal in SK-N-MC mRNA (4pg) and that the band corresponded 
to a molecular weight of 3.5Kb consistent with previous reports (Larhammar, 1992). No other 
bands were observed. The mRNA for the Y5 receptor was more difficult to validate. Four 
micrograms of mRNA derived from HEK cells were fractionated and a weak band was
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observed with an estimated moleculai* weight of 2.7Kb consistent with previous reports 
(Gerald, 1996).
The relative ability to detect mRNAs for the Y1 and Y5 receptor highlight a feature throughout 
this thesis that the Y5 receptor appears to be expressed at vei*y low levels. Thus, the signal 
achieved by Northern analysis for the Y1 receptor meant that it was relatively simple to proceed 
to evaluate changes in expression using dot blot analysis, whereas the low signal observed in 
the Northern for the Y5 receptor predicted difficulties in detection by dot blot analysis.
Dot blots provide a convenient method of measuring changes in relative mRNA levels for a 
larger number of samples than can be handled by Northern analysis. Unlike Northerns where 
the number of wells (in our apparatus 8) restricts the number of samples that can be evaluated, 
dot blot manifolds allow the evaluation of a much lai'ger number of samples. The major 
disadvantages of dot blots can be controlled. These are specificity of the signal as discussed 
above and the absolute requirement for an accurate measurement of mRNA loaded. This later 
problem can be controlled by probing for a housekeeping gene such as G3PDH a gene which 
is unlikely to change expression. Dot blots were used to evaluate factors which would change 
NPY Y1 receptor mRNAs, however the rarity of the Y5 receptor mRNA resulted in a failure to 
detect a hybridisation signal for the Y5 receptor in either SK-N-MC or HEK cell mRNAs. 
Thus this approach could not be used to measure the factors that alter the Y5 receptor mRNA. 
For rai'e mRNA species such as the Y5 receptor, it may be necessary to find alternative 
methods of measuring changes in mRNA levels. The most sensitive method conveniently 
available is to use quantitative RT-PCR. However, the need for an internal standard to provide 
an accurate level of quantitation means that this approach is not trivial, controversial and time 
consuming. In the time constraints of this thesis, it was not possible to consider using this 
approach.
6.5.1 Detection of human NPY Y1 receptor mRNA in SK-N-MC cells.
Northern analysis cairied out on poly A+ mRNA isolated from SK-N-MC cells and screened 
with a human NPY Y1 3'UT probe, revealed that the Y1 receptor transcript could be readily 
detected in these cells using the probe designed (figure 6.3). A discrete band corresponding to 
the predicted moleculai* weight of the human Y1 transcript was readily detected in the poly A+ 
mRNA isolated from SK-N-MC cells. This confirmed that the Y1 3'UT probe effectively 
hybridised to the Y1 receptor mRNA, and that the Y1 transcript could be readily identified in 
SK-N-MC cells by this method. This result enabled subsequent experiments to be cai*ried out 
whereby poly A*^  mRNA isolated from SK-N-MC cells was dot-blotted onto nylon membrane 
and probed with the Y1 3'UT probe to detect changes in Y1 receptor mRNA expression, as it
171
had been established that the Y1 receptor 3'UT probe only hybridised to the Y1 mRNA under 
these hybridisation conditions.
6.5.2 Regulation of expression of the mRNA encoding the Y1 receptor in SK-N-MC cells.
The studies undertaken in this chapter have examined the levels of mRNA for the Y1 receptor 
in SK-N-MC cells following pharmacological manipulations. SK-N-MC cells aie derived 
from a human neuroblastoma and have previously been shown to express the Y1 receptor 
(Sheikh, 1989 and Wahlestedt, 1991). The studies undertaken here used this cell line as a 
model system to determine the response of the Y1 receptor mRNA to agents known to 
influence gene expression including activation of protein kinase A (PKA) following forskolin 
treatment, activation of protein kinase C (PKC) by phorbol esters and activation of the 
glucocorticoid receptor (GR) by dexamethasone. The 5' region of the Y1 gene contains 
consensus sequences able to respond to elevated cyclic AMP (CRE) activation of protein kinase 
C (API) and activation of the glucocorticoid receptor (GRE) and previous work in this 
laboratory has shown that these sequences are functional (Bournat, 1997). However the 
response of mRNA is not known.
6.5.2.1 Response to forskolin.
The promoter region of the human NPY Y1 receptor gene contains two CRE sites (Ball, 1995). 
The sequences encoding both CRE sites are located at positions -113 (conserved in human and 
rat Y1 receptor gene) and -493 (conseiwed in human, mouse and rat Y1 receptor gene). 
Forskolin is an activator of adenylyl cyclase, and by increasing the activity of this enzyme, 
augments the levels of intracellular cAMP. Elevation of intracellular' cAMP levels can result in 
increased transcriptional activity of a gene harbouring CRE sites. The rat Y1 receptor gene is 
highly responsive to intracellular cAMP, as observed by stimulation of rat Y1 receptor 
transcriptional activity in PC 12 cells following forskolin application (Bournat, 1997). In an 
attempt to investigate the effects of forskolin treatment on regulation of the human Y1 receptor 
gene in SK-N-MC cells, mRNA was isolated from SK-N-MC cells following treatment of cells 
with forskolin.
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In view of the fact that the 5' flanking region of the gene contains functional CREs, the initial 
experiments measuring mRNA levels in response to forskolin revealed an unexpected finding. 
The mRNA for the Y1 receptor was easily detectable in poly A+ RNA extracted from resting 
ceils. However at all time points after forskolin treatment (24, 48, 72, 96 and 120 hours) the 
level of the Y1 receptor mRNA was reduced or undetectable compared to control cells. These 
results led to an examination of mRNA levels at earlier time points. Consistent with the 
presence of CREs in the 5' flanking region of the gene, forskolin resulted in an increase in the 
NPY Y1 receptor mRNA levels but their increase was very transient. It was observed at the 
earliest time point studied (2hours) and was maintained 4 hours after treatment but levels were 
suppressed 6 hours after forskolin treatment.
The results of these experiments highlight the potential differences between measuring gene 
transcription using a reporter function and mRNA levels expressed from the endogenous gene. 
Transcription studies use heterologous expression of a fusion gene where a reporter function is 
placed under the control of the 5' flanking region of the gene of interest. Reporter functions 
such as chloramphenicol acetyl transferase (CAT), firefly luciferase or alkaline phosphatase, 
aie chosen on the basis of ease of assay. A function in this selection is that the mRNA and 
protein of the reporter function are relatively stable and so, after gene activation, the product of 
the fusion gene can accumulate in the cell and be measured. Reporter functions have been 
widely used to provide valuable information on factors that regulate gene transcription. 
However, reporter function can only give a read out of transcriptional activity. Levels of the 
mRNA for the endogenous gene and protein aie influenced by a large number of additional 
factors. These include for mRNA factors that regulate post-transcriptional processing and 
mRNA stability. For protein, translational control and post-translational processing play a 
role.
The results shown here demonstrate that forskolin results in a transient increase in mRNA 
followed by an apparent sustained suppression of the mRNA species.
6.5.2.2 Response to dexamethasone.
The NPY Y1 receptor gene contains four tandem GREs and dexamethasone treatment increases 
NPY Y1 receptor gene transcription. The data shown here demonstrates that the mRNA for the 
Y I receptor is increased after dexamethasone treatment but again this response is very transient 
in nature.
6.5.2.3 Y1 receptor mRNA regulation.
Taken together, this data indicates the Y1 receptor mRNA can be measured in SK-N-MC cells 
but that factors known to influence gene transcription have a very transient effect on the Y1
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receptor mRNA. This data implies that the mRNA encoding the receptor is very tightly 
regulated and that the mRNA is relatively unstable and short lived.
The manipulations used to investigate mRNA levels were pharmacological and avoided the 
need for cell surface receptor coupled mechanisms. Clearly it will be valuable to extend these 
studies to examine the effects of factors known to influence feeding behaviour on levels of the 
Y1 receptor mRNA. These studies may help resolve the controversy surrounding the role of 
receptor subtypes in mediating NPY induced feeding behaviour, as changes consistent with 
physiological effectors of feeding would re-inforce the potential role of the Y1 receptor in the 
control of feeding behaviour.
6.5.3 Failure to detect the Y5 mRNA in SK-N-MC cells.
No Y5 mRNA could be detected in poly A+RNA from SK-N-MC cells. This either means that 
the Y5 gene is not expressed in these cells or that the Y5 mRNA was below the detection limit 
of the procedure used in these studies. The Y1 and Y5 receptors aie encoded on opposite 
strands of the same region of the gene (Herzog, 1997). The structure of these two genes 
indicates a complex pattern of alternative splicing of the first exon for the gene, and potentially 
could lead to overlapping RNA transcripts. As duplex RNA species are rapidly eliminated 
from cells, it seems possible that such stmctural organisation may prevent the appeaiance of the 
two RNA species within the same cell. However, it remains a possibility that the mRNA 
species is very rare and this is suggested by the results obtained for the HEK cells.
6.6 Summary.
1) SK-N-MC cells express the Y1 receptor subtype as demonstrated by the presence of a band 
of the correct molecular weight in poly A+ RNA extracted from these cells.
2) Forskolin elicits a very ti'ansient increase in Y1 mRNA levels and this is followed by 
sustained suppression of the mRNA levels.
3) No hybridisation signal could be detected for the Y5 mRNA in SK-N-MC cells indicating 
either that this mRNA species is very raie and below the detection limit of the procedure or that 
the gene is not expressed in these cells.
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Chapter 7
General Discussion
The pancreatic polypeptide (PP-fold) family of peptides comprises the endocrine peptides, 
pancreatic polypeptide (PP) and peptide Y (PYY), and the neuronally derived peptide, 
neuropeptide Y (NPY). These three peptides constitute a family of regulatory peptides, 
characterised by a common distinct tertiary stmctural feature, the PP-fold (Glover, 1985). 
Since PP, the first member of the family, was identified in 1968 (Kimmel, 1968), the PP-fold 
family of peptides have emerged as a physiologically active family of peptides, with 
widespread functions in both the central and peripheral nervous system. The work carried out 
in this thesis was aimed at identifying a receptor subtype involved in mediating a chaiacteristic 
response to the neuronally derived family member NPY. Neuropeptide Y was discovered in 
1982 (Tatemoto, 1982), and has since emerged as a neuropeptide with widespread distribution 
and numerous functions. The physiological activity of NPY is not confined to the CNS, where 
NPY mediates numerous behavioural functions, but is also evident in the periphery, where 
NPY elicits numerous effects, including a role as a potent vasoconstrictor (Wahlestedt, 1990a). 
The diverse effects of the PP-fold family of peptides ai'e mediated by G-protein coupled 
receptors, which bind the members of the PP-fold family of peptides with differing affinities, 
depending on the receptor subtype.
NPY has a diverse functional role within the central nervous system, where it is involved in the 
regulation of blood pressure, circadian rhythm, anxiety and depression, endocrine function and 
metabolism, memoiy retention and feeding and obesity (Gehlert, 1998), The chai'acteristic 
effects of NPY are each mediated by specific subtypes of G-protein coupled receptors. The 
initial aim of the experimental reseai'ch undertaken in this thesis was directed at cloning the 
NPY receptor subtype involved in mediating NPY induced feeding.
As the pharmacology of the cloned NPY receptor subtypes, failed to mimic the pharmacology 
known to stimulate NPY-induced feeding, the receptor subtype responsible for mediating the 
feeding response to NPY was believed to be a novel, previously unidentified receptor subtype. 
(Kalra, 199land Stanley, 1992). When the experimental work described in this thesis began, 
four receptor subtypes had been described for the PP-fold family of peptides. Each receptor 
subtype has a distinct pharmacology, and exhibits a specific pattern of tissue distribution (see 
figure 1.8). The first NPY receptor subtype to be described was the Y1 receptor, which was 
cloned in 1991 (Eva, 1991), and is the best characterised receptor for NPY. This receptor was 
identified pharmacologically by its requirement for the whole NPY or PYY molecule, as 
demonstrated by studies where caihoxyl teiminal fragments of the peptide were shown to be 
ineffective at activation of this receptor subtype (Wahlestedt, 1986). The substituted analogue
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of NPY, Pro^^NPY is a selective agonist at the NPY Y1 receptor (Fuhlendorf, 1990). 
Receptor heterogeneity in the PP-fold family was suggested in 1986, following 
pharmacological identification of a second NPY receptor subtype (Wahlestedt, 1986). The 
NPY Y2 receptor was cloned in 1995 (Rose, 1995), and is distinguished pharmacologically 
from the Y1 receptor, by its ability to bind carboxy terminal fragments of NPY such as NPY^^' 
36 with similar affinity to NPY or PYY (Wahlestedt, 1986). The Y3 receptor is distinguished 
from other PP-fold family receptor subtypes by its high affinity for NPY, and relatively low 
affinity for PYY (Grundemai', 1991a & b). This receptor has yet to be cloned, and remains a 
phaimacologically distinct receptor subtype. The Y4 receptor was cloned in 1995 (Lundell,
1995) and is characterised by an unusual pharmacology, in that this receptor possesses 
extremely high affinity for PP with somewhat lower affinity for NPY and PYY (Gehlert,
1996).
The receptors responsible for mediating the actions of the PP-fold peptides exhibit significant 
structural differences. The stmctural diversity described for the NPY receptor gene family 
(Larhammar, 1996b) is exemplified in the alignments described in chapter 2 (figures 2.5 and 
2.6). Initial attempts to design a degenerate oligonucleotide primer from conserved regions of 
the Y l, Y2 and Y4 receptor sequence were hindered by the lack of homology exhibited 
between these members of the NPY receptor family. Unlike most G-protein coupled receptor 
families, molecular cloning of the Yl, Y2 and Y4 receptors revealed an extremely low 
sequence identity between the Y2 receptor and both the Yl and Y4 receptors, and between the 
Yl and Y4 receptor (Larhammar 1996b). The sequence alignments illustrated in figures 2.5 
and 2.6 mirror previous findings, in that they exhibit clearly the low percentage identities 
displayed between receptors even in transmembrane regions, normally highly conserved within 
receptor gene families (Larhammar, 1996b). As discussed above, the receptor subtypes for 
NPY are readily identified by the maikedly different pharmacology exhibited by each subtype. 
The stmctural differences displayed by the Yl, Y2 and Y4 receptor subtypes may therefore 
result in differing modes of interaction of the receptors with their ligands.
The cloning of the NPY Y5 and y6 receptors in 1996 (Gerald, 1996., Weinberg, 1996) 
perpetuated further the heterogeneity exhibited by this receptor family. As the sequence 
alignments in figure 2.8 illustrate, there is a clustering of sequence similarity between the Y l, 
Y4 and y6 receptors, while the Y2 and Y5 receptors, clearly define another family (Gehlert, 
1998). The stixictural diversity of this gene family is illustrated further in Chapter 4, where 
attempts to design a degenerate oligonucleotide primer for the Genetrapper^i^ cloning 
experimental strategy proved unsuccessful due to the lack of homology exhibited between the 
NPY gene family members. The clustering of amino acid sequence between the Yl and y6 
receptors is also evident, as the only oligonucleotide primer designed with reasonable
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degeneracy was constructed from conserved regions of the Yl and y6 receptor sequence 
(figure 4.2). The lack of sequence homology exhibited between the PP-fold receptor subtypes 
constitutes the principal difficulty encountered in attempts to clone novel family members using 
a homology screening approach. As the alignments in figures 2.8 and 4.2 illustrate, design of 
an oligonucleotide primer with reasonably low degeneracy, based on conserved regions of 
NPY receptor family sequence is extremely difficult, and as a result render homology screening 
ineffective as a cloning strategy for identifying novel PP-fold family members.
One of the many interesting aspects of this peptide family is the varying degrees of genetic 
conservation exhibited. The evolution of the PP-fold family of peptides has been studied 
extensively (Larhammar, 1996a), and as a result has enabled a detailed analysis of the 
evolutionary events that have led to the present PP-fold family of peptides, and the receptor 
subtypes responsible for mediating the physiological effects of this peptide family. NPY 
displays a remarkable degree of sequence conservation, and is considered to be one of the most 
conserved peptide sequences known (Larhammar, 1993). This peptide exhibits very few 
differences in sequence across a wide variety of species, with twenty-two positions identical in 
all NPY sequences known (Larhammar, 1996a). PYY is more variable, exhibiting more 
divergent amino acids within the peptide sequence across species. The peptides NPY and PYY 
appear to have evolved from a gene duplication event, with a common ancestral NPY/PYY 
sequence diverging to give rise to the respective peptides (Larhammar, 1996a). Several lines 
of evidence suggest that the third member of the PP-fold family, PP, arose as a copy of the 
PYY gene relatively late in evolution (Larhammar, 1996a). This peptide exhibits striking 
sequence differences between species, with only seven amino acids conserved across a vaiiety 
of species (Larhammai*, 1996a). The evolutionary rate for these peptides is reflected in the 
degree of conservation between species exhibited by each individual receptor subtype. 
Between man and rat the Yl receptor displays 94% identity. A similar degree of conservation 
is shown by the Y2 receptor in man and rat where 94% of the amino acids are identical. This 
suggests that the evolutionary rate for these receptors is in the slower range for G-protein 
coupled receptors, and that the gene duplication which generated the Y1 and Y2 receptors from 
a common ancestral gene took place long ago, in correlation with the evolutionary rate of the 
receptor ligands NPY and PYY, which both exhibit a high degree of species conservation 
(Larhammar, 1996b). The great variability between species for the pancreatic polypeptide 
receptor (Y4) is evident in the modest 75% sequence identity exhibited between man and rat, 
which is one of the lowest percentages reported for G-protein coupled receptors (Larhammar, 
1996b). The low Y4 receptor conservation and rapid evolutionary rate of the Y4 receptor 
correlate with that of its ligand PP, which is also divergent between rat and man, suggesting 
that the receptor and its ligand have co-evolved at a rapid pace (Larhammar, 1996b).
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The past decade has witnessed the characterisation and cloning of receptors for the PP-fold 
family of peptides. The availability of new pharmacological tools and the advent of molecular 
biology enabled new receptors to be identified and their physiological role established. The 
structural diversity of this receptor gene family, suggests that further advances in molecular 
biology and development of pharmacological tools may result in the cloning and 
characterisation of previously unidentified PP-fold receptors with new physiological roles. At 
this stage it is difficult to estimate how many receptor subtypes constitute this family, and as 
this gene family is not amenable to a homology screening approach, as illustrated by the 
Genetrapper™ cloning strategy employed in chapter 4, the diversity of sequences observed 
with the present members would suggest a plethora of as yet "uncloned" subtypes which are 
more closely related.
The fascinating complexity intrinsic to this receptor family is tempered with the apparent loss of 
functionality observed with the y6 receptor in humans and primates (Gregor, 1996). The y6 
cDNA encodes a functional receptor in mice and rabbits but not in primates. The presence of a 
functional y6 receptor in mice and rabbits, suggests that the y6 receptor emerged as a non­
functional pseudogene in humans during evolution (Rose, 1997). The loss of function of this 
PP-fold receptor subtype furthers the speculation regarding unidentified PP-fold receptor 
subtypes, as the receptor(s) responsible for the physiological role played by the y6 receptor in 
mice and rabbits may be as yet undiscovered. The y6 receptor phenomenon poses numerous 
questions regarding the role of this receptor in mice, as the functionality of this receptor 
subtype appears to be species dependent. The physiological reason for the functional role of 
the y6 receptor subtype in mice remains unclear, and whether a functional equivalent exists in 
humans and primates remains to be determined. However, as exemplified by the y6 receptor, 
it may be that many potential members of this receptor gene family have been lost during 
evolution, and the seaich for additional human subtypes will prove futile.
As the PP-fold peptides NPY and PP, both have receptor subtypes which display a favourable 
affinity for the respective PP-fold peptide, the existence of a PYY-preferring receptor subtype, 
distinguished by a preference for PYY over NPY and PP represents another potential 
unidentified PP-fold receptor, with a role in mediating selectively the physiological functions of 
PYY.
Evidence in support of a PYY-preferring receptor has been suggested from reports outlining a 
preferential PYY response in several systems such as rat small intestine, where PYY has a 5-10 
fold higher affinity over NPY (Lai'burthe, 1986), adipocytes (Castan, 1993), and in a kidney 
proximal tubule cell line ( Voisin, 1993). The cloning and characterisation of such a receptor is 
essential in order to establish the physiological role attributed to this novel PYY-prefemng 
receptor subtype. As discussed above, the structural divergence exhibited by this receptor gene
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family render a homology screening approach to novel receptor cloning ineffective, and the 
identification of pharmacologically distinct novel receptor subtypes such as the PYY preferring- 
receptor, or the human functional equivalent of the mouse y6 receptor would be more 
favourably achieved using a functional expression cloning technology. As discussed in chapter 
5, the lack of sequence homology intrinsic to this gene family is inconsequential when a 
functional cloning strategy is employed, as the affinity of the receptor subtype for the PP-fold 
ligand enables effective identification and isolation. By exploiting the demonstrated 
pharmacology of a potential novel PP-fold receptor subtype in a functional cloning assay, 
additional members of this peptide gene family, bearing relatively low percentage identities to 
the cloned PP-fold receptors, may be identified. The panning immunoselection procedure 
described in chapter 5, is demonstrably an effective functional cloning technique for the 
isolation of G-protein coupled receptors, and is arguably a valuable technique for the isolation 
and identification of novel PP-fold receptors. Further experiments employing the panning 
technique with tissue specific cDNA libraries believed to harbour novel receptor clones, and 
ligand binding with a specific PP-fold peptide, should enable the effectiveness of this technique 
to be demonstrated further, while simultaneously identifying novel receptor clones.
The structural similarity exhibited by the PP-fold peptides (Glover, 1985) lends support to the 
existence of a receptor subtype which is capable of binding the currently identified PP-fold 
peptides; NPY, PYY and PP. In contrast to the receptor subtypes implicated in mediating the 
effects of an individual PP-fold family member, a receptor subtype believed to mediate the 
functions of all thice peptides has been described in the rat, and named the PP-fold receptor as 
a result of the ability of this receptor to bind NPY, PYY and PP with equal affinity (Nata, 
1990).
Further evidence in support of as yet unidentified PP-fold receptor subtypes has come from the 
cloning and identification of multiple NPY receptors in the zebrafish (Danio rerio) (Lundell, 
1997 and Ringvall, 1997). The zebrafish is a widely used model organism for the study of 
vertebrate development (Eisen, 1996), and the cloning of PP-fold receptor subtypes from the 
zebrafish has enabled the evolutionary events that have generated the various PP-fold receptor 
subtypes to be studied. The cloned zebrafish subtypes appear to be distinct from known 
mammahan subtypes with regard to primary sequence data, which suggests that the low 
percentage identity exhibited between the zebrafish receptors and the cloned mammalian PP- 
fold receptors is lower than expected for zebrafish orthologues of the mammalian receptors. 
Detailed studies on the sequence divergence exhibited between the cloned zebrafish receptor 
subtypes (Ringvall, 1997) suggest that at least two of the zebrafish receptors arose prior to the 
divergence of ray-finned fishes and the mammalian lineage, implying that mammals may 
possess orthologues of the zebrafish receptors (Ringvall, 1997). Therefore, it remains to be
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determined whether mammalian homologues exist, and further studies will be requhed before a 
role for these receptors in the large family of PP-fold receptors is established.
Neuropeptide Y, peptide YY and pancreatic polypeptide are firmly established as important 
mammahan peptides, but it is also likely that, like the receptor subtypes for these peptides, 
evolution may have provided additional members of this peptide family. The evidence in 
support of additional PP-fold receptor subtypes would suggest that there are more receptor 
subtypes in the PP-fold family than there are ligands. Therefore, the complete elucidation of 
this peptide family constitutes another important area of research, with the potential for 
interesting findings in the next decade^ regarding the identity and physiological role of new PP- 
fold family members. The presence in selected species of fish of a peptide, PY (Larhammar 
1996a), which appears to have been derived from a gene duplication of the PYY gene, which 
has not been found in any mammalian species to date, and whose functional role has not been 
described, suggests that several gene duplications of the PP-fold peptide sequences may have 
occurred during evolution.
Another copy of the PYY gene has been described in cows (Herzog, 1995). This gene, which 
exhibits greater than 95% nucleic acid sequence identity to the PYY gene (Larhammar, 1996a), 
encodes a protein which was originally found in bull semen and given the name 
seminalplasmin. However, the amino acid sequence has diverged considerably and lacks many 
of the PYY features such as the characteristic PP-fold structure (Larhammar, 1996a). The 
functional role of this protein is unknown, and whether seminalplasmin binds to a receptor 
with similarity to the PP-fold family members is unknown. The expansion of the CRF-like 
peptide family with the recent discovery of urocortin (Vaughan, 1995), the mammalian 
orthologue of the fish peptide urotensin I, suggests new peptides can even be identified in 
relatively well-established peptide families. Therefore, it is possible that additional members of 
the PP-fold family exist and remain to be discovered.
Further speculation regarding the presence of unidentified members of the PP-fold family has 
evolved from closer examination of PP binding within the brain. As the PP-fold peptide family 
member PP is a pancreatic peptide involved in the regulation of gastrointestinal and pancreatic 
function, and is not distributed in the brain, the presence of the PP binding sites within the 
brain (Gehlert, 1997) suggest that a novel undiscovered PP-like molecule may be present 
within the brain. As intracerebroventricular injection of PP has been shown to elicit an increase 
in feeding behaviour (Clark, 1984), it is possible that central administration of PP may result in 
the occupation of receptor sites normally occupied by a PP-like molecule distributed within the 
brain. Recent reports detailing the presence of PP binding sites in two principal brain 
structures (Gehlert 1997) which fail to bind ligand with high affinity for Yl and Y4 receptors, 
imply PP receptor heterogeneity. This favours the existence of a PP-like molecule present
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within the brain, as the lack of Yl and Y4 binding may be the result of the presence of a 
receptor subtype selective for a PP-like molecule, which can readily bind PP but not NPY or 
PYY.
The role of any additional members of the PP-fold family remains to be resolved, and a 
comprehensive understanding of the physiological role of such peptides can only be 
accomplished when the relevant receptor subtypes are cloned and characterised, and selective 
agonists and antagonists are developed.
The wealth of controversy surrounding the identity of the feeding receptor for NPY is tempered 
further by the implications discussed above which favour the existence of novel PP-fold 
receptors and PP-fold family members. The completion of the Human Genome project 
(currently expected to be fully elucidated in 2003) should resolve this issue unequivocally. As 
the aim of this world-wide collaboration is to obtain the complete sequence of the enthe human 
genome, bioinformatic analysis will enable all open reading frames to be readily identified, 
therefore the full complement of PP-fold receptors and family members may be revealed.
The work presented in this thesis has been aimed at the identification of the feeding receptor for 
NPY, and concentrated initially on novel cloning techniques employed in an attempt to isolate 
such a receptor. As the current literature illustrates (chapter 1, section 1.8), the identity of the 
feeding receptor for NPY is a highly contentious issue, implicating both the Yl and Y5 
receptors, and with a strong emphasis on the role of a novel NPY receptor subtype in the 
regulation of NPY elicited eating. The evidence in favour of a role for both the Y1 and Y5 
receptors in the control of NPY induced feeding has arisen as a result of studies using selective 
Yl receptor antagonists and receptor gene knockouts. The inhibition of feeding behaviour 
observed following administration of Yl receptor selective antagonists (Kanatani, 1996, 
1998), generated considerable interest in this NPY receptor subtype, with regard to NPY 
mediated feeding behaviour. Prior to the findings implicating the Yl receptor subtype in the 
control of feeding behaviour, the cloning of the Y5 receptor from hypothalamic tissue, coupled 
with the pattern of distribution and pharmacology displayed by this receptor (Gerald, 1996) 
had resulted in the consensus that the Y5 receptor was the NPY receptor responsible for 
mediating NPY induced feeding behaviour. It is somewhat remarkable that the genes encoding 
both NPY receptors implicated in the control of ingestive behaviour reside on the same 
chromosome, and are transcribed in opposite orientations, with a degree of overlap exhibited 
between the Y5 receptor gene and a distant promoter of the Yl receptor gene (Herzog, 1997). 
The Yl and Y5 receptors display considerable structural diversity, exhibited by the lack of 
sequence homology between these NPY receptor subtypes. As illustrated in the sequence 
alignments in chapter 2, the clustering of amino acid sequence observed within the PP-fold 
receptor gene family, whereby two distinct subfamilies are defined, does not include the Yl
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and Y5 receptor subtypes, as these receptor subtypes appear to belong to different, diverse PP- 
fold receptor subfamilies. A role for both receptors in the regulation of feeding behaviour was 
substantiated further following the findings of a recent genetic knock out study. Both Yl and 
Y5 receptors were demonstrated to play a part in the regulation of feeding, with fasting induced 
feeding, but not NPY induced feeding impaired in Y1-deficient mice (Pedrazzini, 1998), and 
feeding induced by high doses of NPY impaired in Y5 deficient mice (Marsh, 1998). A co­
operative relationship between these receptors in the regulation of ingestive behaviour has been 
corroborated by studies with receptor specific antagonists, as administration of the Y1 selective 
antagonist 1229U91 was capable of inhibiting feeding in Y5 deficient rats (Marsh, 1998). The 
work presented in chapter 3 of this thesis was directed at the cloning and characterisation of a 
rat Y5 receptor genomic clone, with the ultimate aim of investigating the regulation of the Y5 
receptor gene. As feeding behaviour is undoubtedly complex, involving numerous interactions 
between neurotransmitters, neuropeptides and hormones, determining the pattern of Y5 
receptor gene regulation would enable pait of the intricate circuitry which modulates ingestive 
behaviour to be elucidated. By examining the regulation of both the Yl and Y5 receptor genes, 
the role of both receptors in the control of NPY elicited eating could be delineated. Future 
work carried out would be directed at elucidating further the role of the Yl and Y5 receptors in 
the regulation of NPY induced feeding behaviour. Characterising the promoter region of the 
rat Y5 receptor gene, and identifying transcription factor binding sites within this region, 
would enable promoter studies to be caiTied out using a reporter gene construct to detect 
changes in the level of expression of the Y5 gene following interactions with other known 
mediators of feeding. By comparing the regulation of the Yl and Y5 receptor genes, the role 
of each receptor in the modulation of feeding may be determined, and the role of the co­
ordinate regulation of both Yl and Y5 receptor genes in the control of NPY induced feeding 
may be established.
The work presented in chapter 6 of this thesis was carried out with the intention of 
investigating the regulation of both Yl and Y5 receptors, by examining changes in the levels of 
receptor mRNA expression. Cell lines constitutively expressing Yl and Y5 receptor subtypes 
were used as model systems for the analysis of transcriptional activity following cell treatment 
with pharmacological agents believed to be involved in gene regulation. Future work would 
enable the regulation of the Yl and Y5 receptor genes to be investigated by reporter gene 
promoter studies, and by examining changes in the levels of Yl and Y5 receptor mRNA 
expression.
The role of a novel, previously undiscovered NPY receptor in the regulation of NPY induced 
feeding remains speculative. As demonstrated by the work presented in this thesis, the lack of 
homology exhibited by this PP-fold receptor family renders this receptor gene family difficult 
to exploit in a homology screening approach to receptor cloning. Screening potential target
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tissues for additional PP-fold receptors is therefore difficult, as the stmctm'al diversity 
characteristic of this gene family, and the implications that another structurally diverse set of 
PP-fold receptor may exist, make identification of novel receptor subtypes increasingly 
challenging. As discussed above, and illustrated by the work presented in this thesis, a 
functional cloning approach is a more amenable strategy for isolating novel PP-fold receptors, 
as the affinity of the PP-fold ligand for the receptor subtype effectively overcomes the lack of 
homology between family members. However, the rarity of the mRNA encoding the feeding 
receptor for NPY (Gerald, 1996) makes the screening of target cDNA libraries laborious, and 
the success of the technique relies heavily on the quality of the cDNA library used in the 
technique. As demonstrated in chapter 2 of this thesis, the presence of secondary structure at 
the 5' end of the Y5 receptor open reading frame, make cloning by PGR technology difficult. 
The presence of secondary stmcture also has implications for a functional cloning approach, as 
secondary structure present in the receptor mRNA will result in inefficient cDNA synthesis, 
and the inability of the cDNA to be expressed when transfected into appropriate cells. 
Therefore, the presence of secondary structure within the mRNA of a novel feeding receptor 
for NPY, will make isolation of the clone from a cDNA library by a functional cloning 
approach difficult. The isolation of novel PP-fold receptor subtypes is therefore a challenging 
pursuit, the lack of homology displayed by this receptor gene family making homology 
screening an ineffective strategy, while a functional cloning approach may be hindered by 
mitigating factor such as cDNA quality. An ideal approach for the identification of additional 
members of this receptor gene family would utilise both cloning techniques, as the function of 
a clone identified by homology screening could be assessed using an expression cloning 
technique to ensure that any novel member isolated did not encode a pseudogene, and thereby 
represented a physiologically functional receptor. Therefore, the potential disadvantages of 
both cloning techniques may be overcome by combining two different, experimental strategies 
with essentially identical aims.
As discussed above, the entire number of PP-fold receptors that constitute the family remains 
to be fully identified, and it is possible that a previously unidentified PP-fold receptor subtype 
is responsible for the regulation of NPY elicited eating. As the role of PP in the modulation of 
feeding behaviour remains to be established, with regard to the potential existence of a PP-like 
peptide member of the PP-fold family, the identity of the feeding receptor may be more 
complicated. The increase in food intake elicited by PP appears to be mediated by the Y5 
receptor, as a Y5 selective antagonist has been demonstrated to attenuate PP induced feeding, 
with no effect on NPY induced feeding (Kanatani, 1997). The findings described following 
genetic knock out of the Y5 receptor in mice, also suggest a role for the Y5 receptor in the 
control of PP feeding, as PP feeding was completely abolished in Y5-deficient mice, while 
NPY feeding in these animals was unaffected (Marsh, 1998). Therefore it is possible that a 
novel NPY receptor mediates NPY induced feeding, while the Y5 receptor is responsible for
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regulating feeding elicited by an undiscovered PP-like molecule within the brain. The role of a 
novel receptor subtype with high affinity for a PP-like molecule in the regulation of feeding 
behaviour remains to be established. The role of a novel PP-like molecule present in the brain 
in the regulation of feeding behaviour also remains to be delineated. The potent stimulation of 
feeding observed following PP administration (Clark, 1984), and the clear cut role of this 
peptide in the regulation of feeding, as illustrated in knock out studies (Marsh, 1998) suggest 
that the stimulation of feeding elicited by NPY, may be the result of the combined actions of 
NPY with a novel, undiscovered PP-like molecule.
The cloning of the entire family of PP-fold receptors, and the complete elucidation of the PP- 
fold peptide family may provide the answers required to determine the receptor subtype 
involved in NPY induced feeding. Whether a novel PP-fold family member exists, and has a 
role to play in the regulation of ingestive behaviour also remains to be delineated. For the time 
being, the PP-fold family of peptides, and the receptor subtypes responsible for mediating their 
physiological actions, remain an intriguing and incredibly provocative area of research, which 
undoubtedly presents considerable "food for thought".
184
REFERENCES
Aakerlund, L., Gather, U., Fuhlendorff, J., Schwartz, T.W., and Thastmp, O., (1990). Yl 
receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition 
of adenylate cyclase. FEBS Letters 260(1): 73-78.
Ahima, R.S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., and 
Flier, J.S., (1996). Role of leptin in the neuroendocrine response to fasting. Nature 382: 
250-252.
Akabayashi, A., Wahlestedt, C., Alexander, J.T., and Leibowitz, S.F., (1994). Specific 
inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense 
oligonucleotides suppresses feeding behavior and insulin secretion. Molecular Brain Research 
21: 55-61.
Albers, H.E., and Ferris, C F., (1985). Neuropeptide Y: role in light dark cycle entrainment 
of hamster circadian rhythms. Neuroscience Letters 50: 163-168.
Allen, J., Novotny, J., Martin, J., and Heinrich, G., (1987). Molecular structure of 
mammalian neuropeptide Y: Analysis by molecular cloning and computer-aided comparison 
with crystal structure of avian homologue. Proceedings of the National Academy o f Sciences 
USA 84: 2532-2536.
Allen, J.M and Seed, B., (1989). Isolation and expression of functional high-affinity Fc 
receptor complementary DNAs. Science 243:378-381.
Allen, Y.S., Adrian, T.E., Allen, J.M., Tatemoto, K., Crow, T.J., Bloom, S.R., and Polak, 
J.M., (1983). Neuropeptide Y distribution in the rat brain. Science 221: 877-879.
Andrews, P.C., Hawke, D., Shively, I.E., and Dixon, I.E., (1985). A nonamidated peptide 
homologous to porcine peptide YY and neuropeptide YY. Endocrinology 116: 2677-2681.
Arase, K., York, D.A., Shimizu, H., Shargill, N., and Bray, G.A., (1988). Effects of 
corticotrophin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. 
American Journal of Physiology 255: E255-E259.
Aruffro, A. and See, B., (1987). Molecular cloning of a CD28cDNA by a high efficiency 
COS cell expression system. Proceedings of the National Academy o f Sciences of the United 
States o f America 84: 8573-8577.
185
Ball, H.J., Shine, J., and Herzog, H., (1995). Multiple promoters regulate tissue-specific 
expression of the human NPY-Yl receptor gene. The Journal o f Biological Chemistry 270: 
27272-27276.
Bard, J.A., Walker, M.W., Branchek, T.A., and Weinshank, R.L., (1995). Cloning and 
functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide 
Y, and peptide YY. The Journal o f Biological Chemistry 270(45): 26762-26765.
Benton, W.D., and Davis, R.W., (1977). Screening Igt recombinant clones by hybridisation 
to single plaques in situ. Science 196: 180-182.
Bernet, P., Maubert, E., Bernard, J., Montel, V., and Dupouy, J.P., (1994). In vitro 
steroidogenic effects of neuropeptide Y (NPYi-36), Yl and Y2 receptor agonists (Leu^l- 
Pro^4 NPY, NPY 18-36) and peptide YY (PYY) on rat adrenal capsule/zona glomerulosa. 
Regulatory Peptides 52i 187-193.
Billington, C.J., Briggs, J.E., Harker, S., Grace, M., and Levine, A.S., (1994). 
Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy 
metabolism. American Journal o f Physiology 266: R1675-R1770.
Billington, C.J., and Levine, A.S., (1996). Appetite regulation: Shedding new light on 
obesity. Current Biology 6(8): 920-923.
Bing, C., Hopkins, D., Wang, Q., Prankish, H., Buckingham, R., and Williams, G., (1998). 
Direct stimulation of BAT thermogenesis does not affect hypothalamic neuropeptide Y. 
Peptides 19(1): 167-170.
Bischoff, A., Avramadis, P., Erdbrugger, W,, Munter, K., and Michel, M.C., (1997). 
Receptor subtypes Yl and Y5 are involved in the renal effects of neuropeptide Y. Brit J Pharm 
120: 1335-1343.
Blomqvist, A.G.,Soderberg, C., Lundell, I., Milner, R.J., and Larhammar, D., (1992). 
String evolutionary conservation of Neuropeptide Y: Sequences of chicken, goldfish and 
Torpedo marmorata DNA clones. Proc. NatLSci.USA 89: 2350-2354.
Blomqvist, A.G., Roubos, E.W., Larhammar, D., and Martens, G.J.M., (1995). Cloning 
and sequence analysis of a neuropeptide Y/peptide YY receptor Yl cDNA from Xenopus 
laevis. Biochimica et Biophysica Acta 1261: 439-441.
186
Blumberg, D.D., (1987). General precautions for working in a molecular biology laboratory. 
Methods in Enzymology 152:
Blundell, T.L., Pitts, I.E., Tickle, I.J., Wood, S.P., and Wu, C.-W., (1981). X-ray analysis 
(1.4-A resolution) of avian pancreatic polypeptide: Small globular protein hormone. Proc. 
Natl. Acad. Set USA 78: 4175-4179.
Booth, D.A., (1980). Acquired behaviour controlling energy intake and output. In Obesity ed. 
A.S. Stunkard, pg. 101-143 (Philadelphia W.B.).
Bouali, S.M., Fournier, A., St-Pierre, S., and Jolicoeur, F.B., (1994). In vivo central actions 
of NPY(l-30), an N-terminal fragment of neuropeptide Y. Peptides 15(5): 799-802.
Bournat, J.C., (1997). Molecular studies on the control of the expression of the NPY-Yl 
receptor gene. PhD thesis, University of Glasgow.
Burkhoff, A.M., Linemeyer, D., and Salon, J., (1998). Distribution of a novel hypothalamic 
neuropeptide Y receptor gene and its absence in rat. Molecular Brain Research 53: 311-316.
Burlet, A., Grouzmann, E., Musse, N., Fernette, B., Nicolas, J.P., and Burlet, C., (1995). 
The immunological impairment of arcuate neuropeptide Y neurons by ricin A chain produces 
persistent decrease of food intake and body weight. Neuroscience 66(1): 151-159.
Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P., (1995). Recombinant 
mouse ob protein: evidence for a peripheral dsignal linking adiposity and central neural 
networks. Science 269: 546-549.
Castan, I ,  Valet, P., Larrouy, D., Voisin, T., Remaury, A., Daviaud, D., Laburthe, M., and 
Lafontan, M., (1993). Distribution of PYY receptors in human fat cells: An antilipolytic 
system alongside the alpha2-adrenergic system. American Journal o f Physiology 265: E74- 
E80.
Chen, G., Duran, G,E., Steger, K.A., Lacayo, N.J., Jaffrezou, J.P., Dumontet, C., and 
Sikic, B.I., (1997). Multidrug-resistant human sarcoma cells with a mutant P-Glycoprotein, 
altered phenotype, and resistance to cyclosporins. The Journal o f Biological Chemistry 272: 
5974-5982.
187
Cheng, X.P., Broberger, C., Tong, Y.G., Xue, Y.T., Gong, J., and Xhang, X., (1998). 
Regulation of expression of neuropeptide Y Yl and Y2 receptors in the arcuate nucleus of 
fasted rats. Brain Research 792(1): 89-96.
Clark, J.T., Kalra, P.S., Crowley, W.R., and Kalra, S.P., (1984). Neuropeptide Y and 
human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115(1): 427- 
429.
Clark, J.T., Kalra, P.S., and Kalra, S.P., (1985). Neuropeptide Y stimulates feeding but 
inhibits sexual behavior in rats. Endocrinology 117: 2435-2442.
Clark, J.M (1988). Novel non-templated nucleotide addition reactions catalysed by 
prokaryotic and eukaryotic DNA polymerases. Nucleic Acids Research 16: 9677-9686.
Coleman, D.L., (1973). Effects of parabiosis of obese mice with diabetes and normal mice. 
Diabetologia 9: 294-298.
Colmers, W.F., and Bleakman, D., (1989). Presynaptic inhibition by neuropeptide Y and 
baclofen in hippocampus: insensitivity to pertussis toxin treatment. Brain Research 498: 99- 
104,
Criscione, L., Schaffhauser, A.O., Whitebread, S., and Walker, M.W., (1997). Antisense 
oligonucleotides targeted against the NPY Y5 receptor and a selective Y5 receptor antagonist 
inhibit food intake in rodents. Abstract, Society for Neuroscience 23:
Daniels, A.J., Matthews, J.E., Slepetis, R.J., Jansen, M., Viveros, O.H., Tadepalli, A., 
Harrington, W., Heyer, D., Landavazo, A., Leban, J.J., and Spaltenstein, A., (1995). High- 
affinity neuropeptide Y receptor antagonists. Proc, Natl. Acad. Sci. USA 92: 9067-9071.
deSouza, N.J. , Dohadwalla, A.N., and Reden, J., (1983). Forskolin - a labdane diterpenoid 
with antihypertensive, positive inotropic, platelet-aggregation inhibitory, and adenylaye cyclase 
activating properties. Medical Research Reviews 3: 201-219.
Doods, H.N., Wieland, H.A., Engel, W., Eberlein, W., Willim, K.-D., Entzeroth, M., 
Wienen, W., and Rudolf, K., (1996). BIBP 3226, the first selective neuropeptide Yl receptor 
antagonist: A review of its pharmacological properties. Regulatory Peptides 65: 71-77.
Dourish, C.T., Rycroft, W., and Iversen, S.D., (1989). Postponement of satiety by blockade 
of cholecystotokinin (CCK-B) receptors. Science 245: 1509-1511.
188
Dryden, S., McCarthy, H.D., Malabu, U.H., Ware, M., and Williams, G., (1993). Increased 
neuropeptide Y concentrations in specific hypothalamic nuclei of the rat following treatment 
with methysergide: Evidence that NPY may mediate serotonin's effects on food intake. 
Peptides 14: 791-796.
Dryden, S., Wang, Q., Frankish, H.M., and Williams, G., (1996). Differential effects of the 
5-HT1B/2C receptor agonist mCPP and the 5-HTia  agonist flesinoxan on hypothalamic
neuropeptide Y in the rat: Evidence that NPY may mediate serotonin's effects on food intake. 
Peptides 17(6): 943-949.
Dryden, S., Pickavance, L., Tidd, D., and Williams, G., (1998). The lack of specificity of 
neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly 
in inhibiting food intake and NPY gene expression in the rat hypothalamus. Journal o f  
Endocrinology 157: 169-175.
Dumont, Y., Fournier, A., St-Pierre, S., and Quirion, R., (1993). Comparative
characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat 
brain. Journal o f Neuroscience 13(1): 73-86.
Dumont, Y., Cadieux, A., Pheng, L.H., Fournier, A., St-Pierre, S and Quirion, R., (1994). 
Peptide YY derivatives as selective neuropeptide Y'peptide YY Yl and Y2 agonists devoided 
of activity for the Y3 receptor subtype. Molecular Brain Research 26: 320-324.
Dumont, Y., Fournier, A., and Quirion, R., (1998). Expression and characterization of the 
neuropeptide Y Y5 receptor subtype in the rat brain. The Journal of Neuroscience 18(15): 
5565-5574.
Egawa, M., Yoshimatsu, H., and Bray, G.A., (1990). Effect of corticotropin releasing 
hormone and neuropeptide Y on electrophysiological activity of sympathetic nerves to 
interscapular brown adipose tissue. Neuroscience 34(3): 771-775.
Ekblad, E., Edvinsson, L., Wahlestedt, C., Uddman, R., Hakanson, R., and Sundler, F., 
(1984). Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve 
fibers. Regulatory Peptides 8: 225-235.
Erickson, J.C., Clegg, K.E., and Palmiter, R.D., (1996). Sensitivity to leptin and 
susceptibility to seizures of mice lacking neuropeptide Y. Nature 381: 415-418.
189
Erickson, J.C., Ahima, R.S., Hollopeter, G., Flier, J.S., and Palmiter, R.D., (1997). 
Endocrine function of neuropeptide Y knockout mice. Regulatory Peptides 70: 199-202.
Eva, C., Keinanen, K., Monyer, H., Seeburg, P., and Sprengel, R., (1990). Molecular 
cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor 
family. FEBS Letters 271: 81-84.
Eva, C., Oberto, A., Sprengel, R., and Genazzani, E., (1992). The murine NPY-Yl receptor 
gene: Structure and delineation of tissue-specific expression. FEBS Letters 314(3): 285-288.
Fathi, Z., Battaglino, P.M., Iben, E.G., Li, H., Baker, E., Zhang, D.L., McGovern, R., 
Mahle, C.D., Sutherland, G.R., lismaa, T.P., Dickinson, K.E.J., and Zimanyi, I.A., (1998). 
Molecular characterisation, pharmacological properties and chromosomal localisation of the 
human GALR2 galanin receptor. Molecular Brain Research 58: 156-169.
Feifel, D., and Vaccarino, F.J., (1994). Growth hormone-regulatory peptides (GHRH and 
somatostatin) and feeding: A model for the integration of cenbal and peripheral function. 
Neuroscience and Biobehavioral Reviews 18(3): 421-433.
Feinberg, A.P., and Vogelstein, B (1983). A technique for radiolabelling DNA restriction 
endonuclease fragments to high specific activity. Analytical Biochemistry 132: 6-13.
Flood, J.F., Baker, M L., Hernandez, E.N., and Morley, J.E., (1989). Modulation of 
memory processing by neuropeptide Y varies with brain injection site. Brain Research 503: 
73-82.
Flood, J.F., and Morley, J.E., (1991). Increased food intake by neuropeptide Y is due to an 
increased motivation to eat. Peptides 12(6): 1329-1332.
Foucart, S., and Majewski, H., (1989). Inhibition of noradrenaline release by neuropeptide Y 
in mouse ahia does not involve inhibition of adenylate cyclase or a pertussis toxin-susceptible 
G protein. Naunyn-Schmiedeberg's Archives o f Pharmacology 340: 658-665.
Frederich, R.C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B.B., and Flier, J.S., 
(1995). Leptin levels reflect body lipid-content in mice-Evidence for diet-induced resistance to 
leptin action. Nature Medicine 1: 1311-1314.
190
Fuhlendorff, J., Gether, U., Aakerlund, L., Langeland-Johansen, N., Thogersen, H., 
Melberg, S.G., Olsen, U.B., Thastrup, O., and Schwartz, T.W., (1990). [Leu^l, Pro34] 
Neuropeptide Y: A specific Yl receptor agonist. Proc. Natl. Acad. Sci. USA 87: 182-186.
Fuxe, K., Agnati, L.F., Harfstrand, A., Zini, I., Tatemoto, K., Pich, E.M., Hokfelt, T., 
Mutt, V., and Terenius, L., (1983). Central administration! of neuropeptide Y induces 
hypotension bradypnea and EEG synchronization in the rat. Acta. Physiol. Scand. 118: 189- 
192.
Gehlert, D., Gachemheimer, S.L., and Schober, D.A., (1992). [Leu31 Pro34] Neuropeptide 
Y identifies a subtype of 1251-labelled peptide YY binding sites in the rat brain. Neurochem. 
Int 21: 45-67.
Gehlert, D.R., Beavers, L.S., Johnson, D., Gackenheimer, S.L., Schober, D.A., and 
Gadski, R.A., (1996a). Expression cloning of a human brain neuropeptide Y Y2 receptor. 
Molecular Pharmacology 49: 224-228.
Gehlert, D.R., Schober, D.A., Beavers, L., Gadski, R., Hoffman, J.A., Smiley, D.L., 
Chance, R.E., Lundell, I., and Larhammar, D., (1996b). Characterization of the peptide 
binding requirements for the cloned human pancreatic polypeptide-preferring receptor. 
Molecular Pharmacology 50: 112-118.
Gehlert, D.R., Schober, D.A., Gackenheimer, S.L., Beavers, L., Gadski, R., Lundell, I., 
and Larhammar, D., (1997a). [125i] Leu^l, Pro^4_pYY is a high affinity radioligand for rat 
PP1/Y4 and Yl receptors: Evidence for heterogeneity in pancreatic polypeptide receptors. 
Peptides 18(3): 397-401.
Gehlert, D.R., and Gackenheimer, S.L., (1997). Differential distribution of neuropeptide Y 
Yl and Y2 receptors in rat and guinea-pig brains. Neuroscience 76(1): 215-224.
Gehlert, D.R., (1998). Multiple receptors for the pancreatic polypeptide (PP-fold) family : 
physiological implications. Proc Soc Exp Biol Med 218(l):7-22.
Gerald, C., Walker, M.W., Vaysse, P.J. J., He, C., Branchek, T.A., and Weinshank, R.L.,
(1995). Expression cloning and pharmacological characterization of a human hippocampal 
neuropeptide Y/peptide YY Y2 receptor subtype. The Journal o f Biological Chemistry 
270(45): 26758-26761.
191
Gerald, C., Walker, M.W., Criscione, L., Gustafson, E.L., Batzl-Hartmann, C., Smith, 
K.E., Vaysse, P., Durkin, M.M., Laz, T.M., Linemeyer, D.L., Schaffhauser, A.O., 
Whitebread, S., Hofbauer, K.G., Taber, R.L, Branchek, T.A., and Weinshank, R.L.,
(1996). A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382: 
168-171.
Gibbs, J., Young, R.C., and Smith G.P., (1973). Cholecystokinin decreases food intake in 
rats. Journal o f Comparative Physiology 84: 488-495.
Gibson, E.L., Kennedy, A.J., and Curzon, G., (1993). D-fenfluramine-induced and d- 
norfenfluramine-induced hypophagia - differential mechanisms and involvement of 
postsynaptic 5-HT receptors. European Journal o f Pharmacology 242(1): 83-90.
Glaum, S.R., Miller, R.J., Rhim, H., Maclean, D., Géorgie, L.M., MacKenzie, R.G., 
Grundemai', L., (1997). Characterization of Y3 receptor-mediated synaptic inhibition by 
chimeric neuropeptide Y-peptide YY peptides in the rat brainstem. British Journal o f  
Pharmacology 120: 481-487.
Glover, I.D., Barlow, D.J., Pitts, J.E., Wood, S.P., Tickle, I.J., Blundell, T.L., Tatemoto, 
K., Kimmel, J.R., Wollmer, A., Strassburger, W., and Zhang, Y.-S., (1985).
Conformational studies on the pancreatic polypeptide hormone family. European Journal o f  
Biochemistry 142: 379-385.
Gosnell, B.A., Morley, J.E.and Levine, A.S., (1986). Opioid-induced feeding; Localization 
of sensitive brain sites. Brain Research 369: 177-184.
Gregor, P., Millham, M.L., Feng, Y., DeCarr, L.B., McCaleb, M.L., Cornfield, L.J., 
(1996a). Cloning and characterization of a novel receptor to pancreatic polypeptide, a member 
of the neuropeptide Y receptor family. FEBS Letters 381: 58-62.
Gregor, P., Feng, Y., DeCarr, L.B., Cornfield, L.J., and McCaleb, M.L., (1996b). 
Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated 
human homologue. The Journal o f Biological Chemistry 271(44): 27776-27781.
Grignaschi, G., Sironi, F., and Samanin, R., (1995). The 5-HTig receptor mediates the 
effect of £/-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y. 
European Journal o f Pharmacology 274: 221-224.
192
Grossman, S.P., (1960). Eating and drinking elicited by direct adrenergic or cholinergic 
stimulation of hypothalamus. Science 132: 301-302.
Grouzmann, E., Buclin, T., Marthe, M., Cannizzaro, C., Dorner, B., Razaname, A., and 
Mutter, M., (1997). Characterization of a selective antagonist of neuropeptide Y at the Y2 
receptor; Synthesis and pharmacological evaluation of a Y2 antagonist. The Journal o f 
Biological Chemistry 272(12): 7699-7706.
Grundemar, L., Wahlestedt, C., and Reis, D.J., (1991). Neuropeptide Y acts at an atypical 
receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the 
brainstem. The Journal of Pharmacology and Experimental Therapeutics 258(2): 633-638.
Grundemar, L., Wahlestedt, C., and Reis, D.J., (1991). Long-lasting inhibition of the 
cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y 
injected into the nucleus tractus solitarius of the rat. Neuroscience Letters 122: 135-139.
Grundemar, L., and Hakanson, R., (1994). Neuropeptide Y effector systems: perspectives 
for drug development. Trends Pharmacological Science 15: 153-159.
Harris, R.B.S., (1990). Role of set-point theory in regulation of body weight. FASEB 
Journal^: 3310-3318.
Hazelwood, R.L., (1993). The pancreatic polypeptide (PP-fold) family: Gastrointestinal, 
vascular, and feeding behavioral implications. Proc Soc Exp Biol Med. 202: 44-63.
Herzog, H., Hort, Y.J., Ball, H.J., Hayes, G., Shine, J., and Selbie, L.A., (1992). Cloned 
human neuropeptide Y receptor couples to two different second messenger systems. Proc. 
Natl. Acad. Sci. USA 89; 5794-5798.
Herzog, H., Baumgartner, M., Vivero, C., Selbie, L.A., Auer, B., and Shine, J., (1993). 
Genomic organization, localization, and allelic differences in the gene for the human 
neuropeptide Y Yl receptor. The Journal of Biological Chemistry 268: 6703-6707.
Heilig, M., . Neuropeptide Y in relation to behaviour and psychiatric disorders; some animal 
and clinical observations. In Colmers and Wahlestedt, Ed. The biology of neuropeptide Y and 
related peptides. Totowa, NJ Humana, 1993, pp
193
Heilig, M., (1995). Antisense inhibition of neuropeptide Y (NPY) Yl receptor expression 
blocks the anxiolytic-like action of NPY in the amygdala and paradoxically increases feeding. 
Regulatory peptides 59(2): 201-205.
Herzog, H., Baumgartner, M., Vivero, C., Selbie, L.A., Auer, B., and Shine, J., (1993). 
Genomic organization, localisation and allelic differences in the gene for the human 
neuropeptide Y Yl receptor. The Journal of Biological Chemistry 268: 6703-6707.
Herzog, H., Hort, Y., Schneider, R., and Shine, J., (1995). Seminalplasmin: Recent 
evolution of another member of the neuropeptide Y gene family. Proc.NatlAcad.Sci USA 
92: 594-598.
Herzog, H., Darby, K., Ball, H., Hort, H., Beck-Sickinger, A., and Shine, J (1997). 
Overlapping gene structure of the human neuropeptide Y receptor subtypes Yl and Y5 
suggests coordinate transcriptional regulation. Genomics 41:1-5.
Hinson, J., Ranh, C., and Coupet, J., (1988). Neuropeptide Y stimulates inositol 
phospholipid hydrolysis in rat brain miniprisms. Brain Research 446: 379-382.
Hirabayashi, A., Nishiwaki, K., Shimada, Y., and Ishikawa, N., (1996). Role of 
neuropeptide Y and its receptor subtypes in neurogenic pulmonary edema. European Journal 
of Pharmacology 296: 297-305.
Hilt, B., (1967). Selective extraction of polyoma DNA from infected mouse cell cultures. 
Journal of Molecular Biology 26: 365-369.
Hofbauer, K.G., Schaffhauser, A.O., Batzl-Hartmann, C., Strieker-Kongrad, A., 
Whitebread, S., Cumin, P., Rigollier, P., Yamaguchi, Y., Chiesi, M., Levens, N.,Schilling, 
W., Walker, M.W., Gerald, C., Rueeger, H., and Criscione, L., (1997). Antisense 
oligonucleotides targeted against the NPY Y5 receptor and a selective Y5 receptor antagonist 
inhibit food intake in rodents. Regulatory Peptides 71:211.
Holliday, N.D., and Cox, H.M., (1997). Stably transfected neuropeptide Y Yl receptors 
exhibit a PYY-preferring phenotype when expressed in a human colonic epithelial cell line. 
British Journal of Pharmacology 120: P290.
Horvarth, T.L., Naftolin, P., Kalra, S.P., and Lenarth, C., (1992). Neuropeptide Y 
innervation of p-endorphin-containing cells in the rat mediobasal hypothalamus: a light and 
electronmicroscopic double-immunostaining analysis. Endocrinology 131: 2461-2467.
194
Howard, A.D., Tan, C., Shiao, L.L., Palyha, O.C., McKee, K.K., Weinberg, D.H., 
Feighner, S.D., Cascieri, M.A., Smith, R.G., and VanDerPioeg, L.H.T., (1997). Molecular 
cloning and characterisation of a new receptor for galanin. FEBS Letters 405: 285-290.
Hu, Y., Bloomquist, B.T., Cornfield, L.J., DeCarr, L.B., Flores-Riveros, J.R., Friedman, 
L., Jiang, P., Lewis-Higgins, L., Sadlowski, Y., Schaefer, J., Velazquez, N., and McCaleb, 
M.L., (1996). Identification of a novel hypothalamic neuropeptide Y receptor associated with 
feeding behavior. The Journal of Biological Chemistry 271(42): 26315-26319.
Hulsey, M.G., Pless, C.M., White, B.D., and Martin, R.J., (1995). ICV administration of 
anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content 
and peptide release. Regulatory Peptides 59: 207-214.
Ishihara, A., Tanaka, T., Kanatani, A., Fukami, T., Ihara, M., and Fukuroda, T (1997). A 
potent neuropeptide Y antagonist 1229U91, suppressed spontaneous food intake in Zucker 
fatty rats. American Journal o f Physiology 43(5): R1500-R1504.
Ivengar, S., Simmons, R.M.A., Li, D.L., Canhell, B., Lobb., K.L., Schober, D., Helton, 
D., Kallman, M.J., Bruns, R.F., Calligro, D.O., and Gehlert, D., (1997). Effect of new 
structurally novel, neuropeptide Y antagonists on NPY-induced feeding. Society for  
Neuroscience Abstract 23:pg 1766 690.2.
Jacques, D., Tong, Y., Dumont, Y., Shen, S.H., and Quirion, R., (1997). Localization of 
the neuropeptide Y Y5 receptor gene in the human brain; An in situ hybridisation study. 
Regulatory Peptides 71: 219.
Jhanwar-Uniyal, M., Beck, B., Jhanwar, Y.S., Burlet, C., and Leibowitz, S.F., (1993). 
Neuropeptide Y projection from arcuate nucleus to parvocellular division of paraventricular 
nucleus: specific relation to the ingestion of carbohydrate. Brain Research 631: 97-106.
Jolicoeur, F.B., Michaud, J.N., Menard, D., and Fournier, A., (1991). In vivo structure 
activity supports the existence of heterogenous neuropeptide Y receptors. Brain Research 
Bulletin 26: 309-311.
Kalra, S.P., Dube, M.G., and Kalra, P.S., (1988). Continuous intraventricular infusion of 
neuropeptide Y evokes episodic food intake in satiated female rats: Effects of adrenalectomy 
and cholecystokinin. Peptides 9: 723-728.
195
Kalra, S.P., Dube, M.G., Sahu, A., Phelps, C.P., and Kalra, P.S., (1991). Neuropeptide Y 
secretion increases in the paraventricular nucleus in association with increased appetite for 
food, Proc. Natl. Acad. Sci. USASS: 10931-10935.
Kalra, S.P., and Kalra, P.S., (1996). Is neuropeptide Y a naturally occurring appetite 
transducer? Current Opinion in Endocrinology and Diabetes 3: 157-163.
Kalra, P.S., Dube, M.G., Xu, B., and Kalra, S.P., (1997). Increased receptor sensitivity to 
neuropeptide Y in the hypothalamus may underlie transient hyperphagia and body weight gain. 
Regulatory Peptides 12: 121-130.
Kanatani, A., Ishihara, A., Asahi, S., Tanaka, T., Ozaki, S., and Ihara,M., (1996). Potent 
Neuropeptide YYl receptor antagonist, 1229U91: Blockade of Neuropeptide Y-induced and 
physiological food intake. Endocrinology 137(8): 3177-3182.
Kanatani, A., Fukami, T., Fukudora, H., Iwaasa, H., MacNeil, D., VanDerPioeg, L., and 
Ihara, M., (1997). Y5 receptors are not involved in physiologically relevant feeding in rodents 
Regulatory Peptides 71: 212.
Kanatani, A., Ito, J., Ishihara,A., Iwaasa, H., Fukuroda, T., Fukami, T., MacNeil, D.J., 
VanDerPioeg, L.H.T., and Iharas, M., (1998). NP Y-induced feeding involves the action of a 
Y1-like receptor in rodents. Regulatory Peptides 75-6: 409-415.
Kask, a., rgo, L., Korrovits, P., Wikberg., J.E.S., and Schioth, H.B., (1998). Evidence that 
orexigenic effects of melanocortin 4 receptor antagonist HS014 are mediated by neuropeptide 
Y. Biochem Biophys Res Commun 248(2): 245-249.
Kaye, W.H., Berrettini, W., Gwirtsman, H., and George, D.T., (1990). Altered 
cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia 
nervosa. Arch. Gen. Psychiatry 41: 548-556.
Kennedy, G.C., (1952). The role of depot fat in the hypothalamic control of food intake in the 
rat. Proceedings o f The Royal Society 140: 578-592.
Kerkerian, L., Guy, J., Lefevre, G., and Pelletier, G., (1985). Effects of Neuropeptide Y 
(NPY) on the release of anterior pituitary hormones in the rat. Peptides 6: 1201-1204.
Kimmel, J.R., Hayden, L.J., and Pollock, H.G., (1975). Isolation and characterization of a 
new pancreatic polypeptide hormone. The Journal of Biological Chemistry 250: 9369-9376.
196
Kotz, C.M., Briggs, J.E., Pomonis, J.D., Grace, M.K., Levine, A.S., and Billington, C J  
(1998). Neural site of leptin influence on neuropeptide Y signalling pathways altering feeding 
and uncoupling protein. American Journal of Physiology 275: R478-484.
Kristensen, P., Judge, M.E., Thim, L., Ribel, U., Christjansen, K.N., Wulff, B.S., 
Clausen, J.T., Jensen, P.B., Madsen, O.D., Vrang, N., Larsen, P.J., and Hastrup, S., 
(1998). Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72- 
76.
Kyrkouli, S.E., Stanley, B.G., Seirafi, R.D., and Leibowitz, S.F., (1990). Stimulation of 
feeding by galanin: Anatomical localization and behavioral specificity of this peptide's effects in 
the brain. Peptides 11: 995-1001.
Laburthe, M., Chenut, B., Rouyer-Fessard, C., Tatemoto, K., Couvineau, A., Servin, A., 
and Amiranoff, B., (1986). Interaction of peptide YY with rat intestinal epithelial plasma 
membranes: Binding of the radioiodinated peptide. Endocrinology 118: 1910-1917.
Lambert, P.D., Wilding, J.P.H.and Al-Dokhayel, A.A.M., (1993). A role for neuropeptide 
Y, dynorphin and noradrenaline in the central control of food intake after food deprivation. 
Endocrinology 133: 29-32.
Lambert, P.D., Wilding, J.P.H., Al-Dokhayel, A.A.M., Gilbey, S.G., Ghatei, M.A., and 
Bloom, S.R., (1994). Naloxone-induced anorexia increases neuropeptide Y concentrations in 
the dorsomedial hypothalamus: Evidence for neuropeptide Y-Opioid interactions in the control 
of food intake. Peptides 15(4): 657-660.
Lambert, P.D., Couceyro, P R., Megirr, K.M., Vechia, S.E., Smith Y., and Kuhar, M.J., 
(1998). CART peptides in the central control of feeding and interactions with neuropeptide Y. 
Synapse 29(4): 293-298.
Larhammar, D., Blomqvist, A.G., Yee, F., Jazin, E., Yoo, H., and Wahlestedt, C., (1992). 
Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Yl 
type. The Journal o f Biological Chemistry 267: 10935-10938.
Larhammar, D., Blomqvist, A.G., and Wahlestedt, C., (1993). The receptor revolution - 
multiplicity of G-protein-coupled receptors. Drug Design and Discovery 9: 179-188.
197
Larhammar, D., (1996a). Evolution of neuropeptide Y, peptide YY and pancreatic 
polypeptide. Regulatory Peptides 62: 1-11.
Larhammar, D., (1996b). Structural diversity of receptors for neuropeptide Y, peptide YY and 
pancreatic polypeptide. Regulatory Peptides 65:165-174.
Leibel, R.L., Rosenbaum, M., and Hirsch, J., (1995). Changes in energy expenditure 
resulting from altered body weight. New England Journal of Medicine 332: 621-628.
Leibowitz, S.F., (1986). Brain monoamines and peptides: role in the control of eating 
behavior. Federation Proceedings 45: 1396-1403.
Leibowitz, S.F., (1990). Hypothalamic Neuropeptide Y in relation to energy balance. Annals 
o f the New York Academy o f Sciences 611: 284-301.
Leibowitz, S.F., (1992). Neurochemical-neuroendocrine systems in the brain controlling 
macronutrient intake and metabolism. Trends in Neuroscience 15(12): 491-497.
Leibowitz, S.F., (1994). Specificity of hypothalamic peptides in the control of behavioral and 
physiological processes. Annals o f the New York Academy of Sciences 739: 12-35.
Levine, A.S., and Morley, J,E., (1984). Neuropeptide Y: A potent inducer of consummatoiy 
behavior in rats. Peptides 5(6): 1025-1029.
Levine, A.S., and Billington, C.J., (1989). Opioids: are they regulators of feeding? Physiol. 
Biochem Behav. 575: 209-219.
Lewis, D.E., Shellard, L., Koeslag, D.G., Boer, D.E., McCarthy, H.D., McKibbin, P.E., 
Russell, J.C., and Williams, G., (1993). Intense exercise and food restriction cause similar 
hypothalamic neuropeptide Y increases in rats. American Journal o f Physiology 264: E279- 
E284.
Li, B.-H., Xu, B., Rowland, N.E., and Kalra, S.P., (1994). c-fos expression in the rat 
brain following central administration of neuropeptide Y and effects of food consumption. 
Brain Research 665: 277-284.
Li, X.-J., Wu, Y.-N., North, R.A., and Forte, M., (1992). Cloning, functional expression, 
and developmental regulation of a neuropeptide Y receptor from Drosophila melanogaster. The 
Journal o f Biological Chemistry 267(1): 9-12.
198
Li, D.L., Simmons, R.M.A., Bruns, R.F., Gehlert, D., and Ivengar, S., (1997). Effect of 
the neuropeptide Y Yl antagonists BIBP3226 and 1229U91 on NPY induced feeding. Society 
fo r  Neuroscience abstract 23: pg 1766 690.3.
Limbird, L.E., (1988). Receptors linked to inhibition of adenylate cyclase; Additional 
signalling mechanisms. FASEB Journal 2: 2686-2695.
Lopezvalpuesta, F.J., Nyce, J.W., Griffinbiggs, T.A., Ice, J.C., and Myers, R.D., (1996). 
Antisense to NPY-Yl demonstrates that Yl receptors in the hypothalamus underlie NPY 
hypothermia and feeding in rats. Proceedings o f the Royal Society of London seriesB- 
Biological sciences 263(1372): 881-886.
Luiten, P.G.M., Ter Horst, G.J., and Steffens, A.B., (1987). The hypothalamus, inhinsic 
connections and outflow pathways to the endocrine system in relation to the control of feeding 
and metabolism. Progress in Neurobiology 28: 1-54.
Lundell, L, Blomqvist, A.G., Berglund, M.M., Schober, D.A., Johnson, D., Statnick, M.A., 
Gadski, R.A., Gehlert, D R., and Larhammar, D., (1995). Cloning of a human receptor of 
the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. The 
Journal o f Biological Chemistry 21^(49): 29123-29128,
Lundell, L, Statnick, M.A., Johnson, D., Schober, D.A., Starback, P., Gehlert, D R., and 
Larhammar', D., (1996). The cloned rat pancreatic polypeptide receptor exhibits profound 
differences to the orthologous human receptor. Proc. Natl. Acad. Sci. USA 93: 5111-5115.
Lundell, L, Berglund, M.M., Starback, P., Salaneck, E., Gehlert, D.R., and Larhammar, D., 
(1997). Cloning and characterisation of a novel neuropeptide Y receptor subtype in the 
zebrafish. DNA and cell biology \6{XX): 1357-1363.
Lynch, W.C., Hart, P., and Babcock, A.M., (1994). Neuropeptide Y attenuates satiety: 
Evidence from a detailed analysis of patterns ingestion. Brain Research 636: 28-34.
Maffei, M., Halaas, J., Ravussin, E., Pratley, R.E., Lee, G.H., Zhang, Y., Fei., H., 
Lallione, R., Rangathan, S., Kern, P.A., and Friedman, J.M., (1995). Leptin levels in 
human and rodent : Measurement of plasma leptin and ob RNA in obese and weight-reduced 
subjects. Nature Medicine X: 1155-1161.
199
Maki, N., Sekiguchi, F., Nishimaki, J., Miwa,K., Hayano, T., Takahashi, N., and Suzuki, 
M, (1990). Complementary DNA encoding the human T-cell FK506 binding protein, a 
peptidylprolyl cis-trans isomerase distinct from cyclophilin. Proc.Natl.Acad.Sci.USA 887: 
5440-5443.
Malabu, U.H., Kilpatrick, A., Ware, M., Vernon, R.G., and Williams, G., (1994). 
Increased neuropeptide Y concentrations in specific hypothalamic regions of lactating rats: 
Possible relationship to hyperphagia and adaptive changes in energy balance. Peptides 15(1): 
83-87.
Malmstrom, R.E., and Lundberg, J.M., (1995). Neuropeptide Y accounts for sympathetic 
vasoconstriction in guinea-pig vena cava; evidence using BIBP3226 and 3435. European 
Journal of Pharmacology 294: 661-668.
Maniatis, T., Fritsch, E.F., and Sambrook, L., (1982). Moleculai' Cloning. (A Laboratoiy 
Manual) (Cold Spring Harbor: Cold Spring Hai'bor Laboratoiy.)
Mann, P.E., Pasternak, G.W., Hahn, E,F., Curreri, G., Lubin, E.and Bodnar, R.J.,
(1988). Comparison of the effects of chronic administration of naloxone and naloxonazine 
upon food intake and maintenance of body weight in rats. Neuropharmacology 27: 349-355.
Mann, P.E., Pasternak, G.W., Hahn, E,F., Curreri, G., Lubin, E.and Bodnar, R.J.,
Marsh, D.J., Hollopeter, G., Kafer, K.E., and Palmiter, R.D., (1998). Role of the 
neuropeptide Y receptor in feeding and obesity. Nature Medicine 4(6): 718-721.
Matsumoto, M., Nomura, T., Momose, K., Ikeda, Y., Kondou, Y., Akiho, H., Togami, J., 
Kimura, Y., Okada, M., and Yamaguchi, T., (1996). Inactivation of a novel neuropeptide 
Y/Peptide YY receptor gene in primate species. The Journal o f Biological Chemistry 
271(44): 27217-27220.
Matthews, I.E., Chance, W.T., Grizzle, M.K., Heyer, D., and Daniels, A.I., (1997). Food 
intake inhibition and body weight loss in rats treated with G1 264879A, An NPY Y1 receptor 
antagonist. Society fo r  Neuroscience Abstract 23:
Maxam, A.M., and Gilbert, W., (1980). Sequencing end-labelled DNA with base-specific 
chemical cleavages. Methods in Enzymology 65: 499-503.
Mayer, J., (1955). Regualtion of energy intake and the body weight; the glucostatic theory and 
the lipostatic hypothesis. Ami NY Acad.ScL 63:15-24.
200
McDonald, J.K., (1990). Role of Neuropeptide Y in reproductive functions. Ann. NY Acad. 
Sci 211: 258-272.
McLatchie, L.M., Fraser, N.J., Main, M.J., Wise., A., Brown, J., Thompson, N., Solari, 
R., Lee, M.G., and Foord, S.M., (1998). RAMPS regulate the transport and ligand specificity 
of the calcitonin-receptor-like receptor. Nature 393: 333-339.
McLaughlin, C.L., Tou, J.S., Rogan, G.J., and Baile, C.A., (1991). Full amino acid 
sequence of centrally administered NPY required for maximal food intake response. 
Physiology and Behaviour 49: 521-526.
Menendez, J.A., McGregor, I.S., Healey, P.A., Atrens, D.M., and Leibowitz, S.F., (1990). 
Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the 
hypothalamus. Brain Research 51&. 8-14.
Menendez, J.A., Atrens, D.M., and Leibowitz, S.F., (1992). Metabohc effects of galanin 
injections into the paraventricular nucleus of the hypothalamus. Peptides 13: 323-327.
Menzaghi, F., Heinrichs, S.C., Pich, E.M., Tilders, F.J.H., and Koob, G.F., (1993). 
Functional impairment of hypothalamic corticoti'ophin-releasing factor neurons with 
immunotargeted taxins enhances food intake induced by neuropeptide Y. Brain Research 
618:78-83.
Mercer, J.G., Lawrence, C.B., and Atkinson, T.,(1996). Hypothalamic NPY and CRF gene 
expression in the food-deprived Syrian hamster. Physiology and Behaviour 60: 121-127.
Michel, M.C., Beck-Sickinger, A., Cox, H., Doods, H.N., Herzog, H., Larhammar, D., 
Quirion, R., Schwartz, T., and Westfall, T., (1997). XVI International Union of 
Phai'macology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY and 
Pancreatic polypeptide receptors. Pharmacological Reviews 50: 143-150.
Miner, J.L., Della-Fera, M.A., Paterson, J.A., and Baile, C.A., (1989). Lateral 
cerebroventricular injection of neuropeptide Y stimulates feeding in sheep. American Journal 
o f Physiology 251X R383-R387.
Morley, I.E., Hernandez, E.N., and Flood, J.F., (1987a). Neuropeptide Y increases food 
intake in mice. American Journal of Physiology 253: R516-R522.
201
Morley, J.E., Levine, A.S., Gosnell, B.A., Kneip, J., and Grace, M., (1987b). Effect of 
neuropeptide Y on ingestive behaviors in the rat. American Journal o f Physiology 252: R599- 
R609.
Myers, T.W., and Gelfand, D.H (1991). Reverse transcription and DNA amplification by a 
Thermus thermophilus DNA polymerase. Biochemistry (USA) 30: 7661-7666.
Naggert, J., Harris, T., and North, M., (1997). The genetics of obesity. Current Opinion in 
Genetics and Development 7: 398-404.
Nakamura, M., Sakanaka, C., Aoki, Y., Ogasawara, H., Tsuji, T., Kodama, H., Matsumoto, 
T., Shimizu, T., and Noma, M., (1995). Identification of two isoforms of mouse 
neuropeptide Y-Yl receptor generated by alternative splicing; Isolation, genomic structure, and 
functional expression of the receptors. The Journal o f Biological Chemistry 270: 30102- 
30110.
Nakamura, M; Yokoyama, M; Wantabe, H and Matsumoto, T; (1997). Moleculai' cloning, 
organization and localization of the gene for the mouse neuropeptide Y Y5 receptor. 
Biochimica et Biophysica Acta-Biomembranes 1328 (2):83-89.
Nata, K., Yonekura, H., Yamoto, H and Okamoto, H., (1990). Identification of a novel 65- 
kDa cell surface receptor common to pancreatic polypeptide, neuropeptide Y and peptide YY. 
Biophysical and Biophysical Research communications 171: 330-335.
Nehls, M., Messerle, M., Sirulnik, A., Smith, A. J. H., and Boehm, T., (1994). 2 large 
insert vectors, Lambda-PS and Lambda-KO, facilitate rapid mapping and targeted disruption of 
mammalian genes. Biotechniques 17 (4): 770-775.
Norenberg, W., Bek, M., Limberger, N., Takeda, K., and files, P., (1995). Inhibition of 
nicotinic acetylcholine receptor channels in bovine adrenal chromaffin cell by Y3-type 
neuropeptide Y receptors via the adenylate cyclase/protein kinase A system. Naunyn- 
Schmiedeberg's Arch.Pharmacol. 351:337-347.
O'Shea, D., Morgan, D.G.A., Meerans, K., Edwards, C.M.B., Turton, M.D., Choi, S.J., 
Heath, M.M., Gunn, L, Taylor, G.M., Howards, J.K., Bloom, C.I., Small, C.J., Haddo, 
O., Ma, J.J., Callanin, W., Smith, D.M., Ghatei, M.A., and Bloom, S.R., (1997). 
Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology 
138: 196-202.
202
Parrott, R.F., Heavens, R.P., and Baldwin, B.A., (1986). Stimulation of feeding in the 
satiated pig by intracerebroventriculai" injection of neuropeptide Y. Physiology and Behavior 
36: 523-525.
Pedrazzini, T., Seydoux, S., Kunster., P., Aubert, J.F., Grouzmann, E., Beermann, F and 
Brunner, H.R., (1998). Cardiovasculai' response, feeding behaviour and locomoter activity in 
mice lacking the NPY Y1 receptor. Nature Medicine 4(6): 722-726.
Pollock, J.D., and Rowland, N., (1981). Peripherally administered serotonin decreases food 
intake in rats. Pharmacology Biochemistry and Behavior 15: 179-183.
Potter, E.K., Fuhlendorff, J., and Schwartz, T.W., (1991). [Pro^^j neuropeptide Y 
selectively identifies postjunctional-mediated actions of neuropeptide Y in vivo in rats and 
dogs. European Journal o f Pharmacology 195: 15-19.
Qu, D., Ludwig, D.S., Gammeltoft, S., Piper, M., Pelleymounter, M.A., Cullen, M.J., 
Mathes, W.F., Przypek, J., Kanarek, R., and Maratos-Fiier, E., (1996). A role for melanin- 
concentrating hormone in the central regulation of feeding behavior. Nature 380: 243-247.
Rimland, J.M., Seward, E.P., Humbert, Y., Ratti, E., Trist, D.G., and North, R.A., (1996). 
Coexpression with potassium channel subunits used to clone the Y2 receptor for neuropeptide 
Y. Molecular Pharmacology 49: 387-390.
Ringvall, M., Berglund, M.M., and Lai'hammai', D., (1997). Multiplicity of neuropeptide Y 
receptors: Cloning of a third distinct type in the zebrafish. Biochemical and Biophysical 
Research communications 241: 749-755.
Rist, B., Zerbe, O., Ingenhoven, N., Scapozza, L., Peers, C., Vaughan, P.F.T., McDonald, 
R.L., Wieiand, H.A., and Beck-Sickinger, A.G., (1996). Modified, cyclic dodecapeptide 
analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor. FEBS Letters 
394: 169-173.
Rogers, P., McKibbin, P.E., and Williams, G., (1991). Acute fenfluramine administration 
reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat - possible 
implications for the anorectic effect of fenfluramine. Peptides 12(2): 251-255.
Rose, P.M., Fernandes, P., Lynch, J.S., Frazier, S.T., Fisher, S.M., Kodukula, K., 
Kienzle, B., and Seethala, R., (1995). Cloning and functional expression of a cDNA
203
encoding a human type 2 neuropeptide Y receptor. The Journal of Biological Chemistry 
270(39): 22661-22664.
Rose, P.M., Lynch, J.S., Frazier, S.T., Fisher, S.M., Chung, W., Battaglino, P., Faith, Z., 
Leibel, R., and Fernandes, P., (1997). Moleculai* genetic analysis of a human neuropeptide Y 
receptor: The human homolog of the murine "Y5" receptor may be a pseudogene. The Journal 
o f Biological Chemistry 272 (6) : 3622-3627.
Rowland, N.E., (1988). Peripheral and cenhal satiety factors in neuropeptide Y-induced 
feeding in rats. Peptides 9: 989-992.
Rowland, N.E., Morien, A., and Li, B.-H., (1996). The physiology and brain mechanisms 
of feeding. Nutrition 12: 626-639.
Rowland, N.E., and Kalra, S.P., (1997). Potential role of neuropeptide ligands in the 
treatment of overeating. CNS Drugs 7(6): 419-426.
Sahu, A., Kalra, P.S., and Kalra, S.P., (1988a). Food deprivation and ingestion induce 
reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 
9(1): 83-86.
Sahu, A., Kalra, S.P., Crowley, W.R., and Kalra, P.S., (1988b). Evidence that NPY- 
containing neurons in the brainstem project into selected hypothalamic nuclei: Implication in 
feeding behavior. Brain Research 457: 376-378.
Sahu, A., Sninsky, C.A., Phelps, C.P., Dube, M.G., Kalra, P.S., and Kalra, S.P., (1992). 
Neuropeptide Y release from the pai'aventricular nucleus increases in association with 
hyperphagia in streptozotocin-induced diabetic rats. Endocrinology 131: 2979-2985.
Sahu, A., (1998). Evidence suggesting that galanin (GAL), melanin-concentrating hormone 
(MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) aie 
targets of leptin signaling in the hypothalamus. Endocrinology 139(2): 795-798.
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, 
S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R.S., Buckingham, R.E., 
Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., Liu, W.-S., Terrett, J.A., 
Elshourbagy, N.A., Bergsma, D.J., and Yanagisawa, M., (1998). Orexins and orexin 
receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that 
regulate feeding behavior. Cell 92: 573-585.
204
Sanger, F.S., Nicklen, S., and Coulson, A.R., (1977). DNA sequencing with chain- 
termination inhibitors. Proceedings o f the National Academy o f Sciences 74:5463-
Sauer, B., (1987). Functional expression of the Cre-lox site specific recombination system in 
the yeast Saccharomyces cerevisiae. Molecular and Cellular Biology 7: 2087-2096.
Sauer, B., and Henderson, N., (1988). Site-specific DNA recombination in mammalian cells 
by the Cre recombinase of bacteriophage PI. Proc. Natl. Acad. Sci. USA 85: 5166-5170.
Sautel, M., Rudolf, K., Wittneben, H., Herzog, H., Martinez, R., Munoz, M., Eberlein, W., 
Engel, W., Walker, P., and Beck-Sickinger, A.G., (1996). Neuropeptide Y and the 
nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. 
Molecular Pharmacology 50: 285-292.
Sawchenko, P.E., and Pfeiffer, S.W., (1988). Ultrastmctural locahzation of neuropeptide Y 
and galanin immunoreactivity in the pai'aventricular nucleus of the hypothalamus in the rat. 
Brain Research 474: 231-245.
Schaffhauser, A.O., Strieker-Kongrad,A., Brunner, L., Cumin, F., Gerald, C., Whitebread, 
S., Criseione, L., and Hofbauer, K.G., (1997). Inhibition of food intake by neuropeptide Y 
Y5 receptor antisense oligonucleotides. Diabetes 46: 1792-1798.
Schober, D.A., VanAbbema, A.M., Smiley, D.L., Bruns, R.F., and Gehlert, D.R., (1998). 
The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic 
polypeptide-preffering (NPY Y-4) receptor. Peptides 19: 537-542.
Seed, B., and Aruffro, A., (1987). Molecular cloning of the CD2 antigen, the T-cell 
eiythrocyte receptor, by a rapid immunoselection procedure. Proc.Natl.Acad.Sci.USA  84: 
3365-3369.
Serradeil-Le Gal, C., Valette, G., Rouby, P. E., Pellet, A., Oury-Donat, F., Brossard, G., 
Lespy, L., Mai'ty, E., Neliat, G., de Cointet, P., Maffrand, J.-P., and Le Fur, G., (1995). 
SRI20819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS 
Letters 562: 192-196.
Serradeil-Le Gal, C., (1997). SR 120819A or the first generation of orally active Y1-receptor 
antagonists. In Neuropeptide Y and drug development, L.Grundemar and S.R Bloom, eds 
(London Academic Press), pp 157-174.
205
Shepard, A.R., and Rae, J.L., (1997). Magnetic bead capture of cDNAs from double­
stranded plasmid cDNA libraries. Nucleic Acids Research 25: 3183-3185.
Sheikh, S.P., O'Hare, M.T., Tortora, O., and Schwartz, T.W., (1989). Binding of 
monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cell lines 
The Journal o f Biological Chemistry 264: 6648-6654.
Shor-Posner, G., Grinker, J.A., Marinescu, C., Brown, O., and Leibowitz, S.F., (1986). 
Hypothalamic serotonin in the control of meal patterns and macronutrient selection. Brain 
Research Bulletin 17: 663-671.
Southern, E.M., (1975). Detection of specific sequences among DNA fragments separated by 
gel electrophoresis. Journal o f Molecular Biology 98: 503-517.
Spina, M., Meiiopich, E., Chan, RKW., Basso, A.M., Rivier, J., Vale, W., and Kob, G.F
(1996). Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 273: 
1561-1564.
Stanley, B.G., and Leibowitz, S.F., (1984). Neuropeptide Y: Stimulation of feeding and 
drinking by injection into the paraventricular nucleus. Life Sciences 35(26): 2635-2642.
Stanley, B.G., and Leibowitz, S.F., (1985a). Neuropeptide Y injected in the paraventricular 
hypothalamus: A powerful stimulant of feeding behavior. Proc. Natl. Acad. Sci. USA 82: 
3940-3943.
Stanley, B.G., Daniel, D R., Chin, A.S., and Leibowitz, S.F., (1985b). Paraventricular 
nucleus injections of peptide YY and neuropeptide Y preferentially enhance caibohydrate 
ingestion. Peptides 6(6): 1205-1211.
Stanley, B.G., Kyrkouli, S.F., Lamport, S., and Leibowitz, S.F., (1986). Neuropeptide Y 
chi'onically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia 
and obesity. Peptides 1(6): 1189-1192.
Stanley, B.G., Lanthier, D., and Leibowitz, S.F., (1988). Multiple brain sites sensitive to 
feeding stimulation by opioid agonists: A cannula-mapping study. Pharmacology 
Biochemistry and Behavior 31: 825-832.
206
Stanley, B.G., Lanthier, D., Chin., A.S., and Leibowitz, S.F., (1989). Suppression of 
neuropeptide Y-elicited eating by adrenalectomy or hypophysectomy : reversal with 
corticosterone. Brain Research 501: 32-36.
Stanley, B.G., Magdalin, W., Seirafi, A., Nguyen, M.M, and Leibowitz, S.F., (1992). 
Evidence for Neuropeptide Y mediation of feeding produced by food deprivation and for a 
variant of the Y1 receptor mediating this peptide's effects. Peptides 13: 581-587.
Stanley, B.G., Magdalin, W., Seirafi, A., Thomas, W.J., and Leibowitz, S.F., (1993). The 
perifornieal area: The major focus of (a) patchily distributed hypothalamic neuropeptide Y- 
sensitive feeding systems(s). Brain Research 604: 304-317.
Steffens, A.B., (1969). Rapid absorption of glucose in the intestinal tract of the rat after 
ingestion of a meal. Physiology and Behavior 4: 829-832.
Stephens, T.W., Basinski, M., Bristow, P.K., Bue-Valleskey, J.M., Burgett, S.G., Craft, 
L., Hale, J., Hoffmann, J., Hsiung, H.M., Kiiaueiunas, A., MacKellar, W., Rosteck Jr., 
P.R., Schoner, B., Smith, D., Tinsley, F.C., Zhang, X.-Y., and Heiman, M., (1995). The 
role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377: 530- 
532.
Tatemoto, K., (1982a). Isolation and chaiacterization of peptide YY (PYY), a candidate gut 
hormone that inhibits pancreatic exocrine secretion. Proc. Natl. Acad. Sci. USA 79: 2514- 
2518.
Tatemoto, K., Carlquist, M., and Mutt, V., (1982b). Neuropeptide Y - a novel brain peptide 
with structural similaiities to peptide YY and pancreatic polypeptide. Nature 296: 659-660.
Tatemoto, K., (1982c). Neuropeptide Y: Complete amino acid sequence of the brain peptide. 
Proc. Natl. Acad. Sci. USA 79: 5485-5489.
Tempel, D.L., and Leibowitz, S.F., (1989). PVN steroid implants: Effect on feeding patterns 
and macronutrient selection. Brain Research Bulletin 23: 553-560.
Tempel, D.L., Shor-Posner, G., Dwyer, D., and Leibowitz, S.F., (1989). Nocturnal patterns 
of macronutrient intake in freely feeding and food-deprived rats. American Journal o f  
Physiology 256: R541-R548.
207
Thomas, P.S., (1980). Hybridisation of denatured RNA and small DNA fragments 
transferred to nitrocellulose. Proceedings o f the National Academy o f Sciences, USA 
77:5201-5205.
Turton, M.D., O'Shea, D., Gunn, L, Beak, S.A., Edwards, C.M.B., Meeran, K., Choi, 
S.J., Taylor, G.M., Heath, M.M., Lambert, P.D., Wilding, J.P.H., Smith, D.M., Ghatei, 
M.A., Herbert, J., and Bloom, S.R., (1996). A role for glucagon-like peptide-1 in the central 
regulation of feeding. Nature 379: 69-72.
Vaughan, J., Donaldson, C., Bittencourt, J., Perrin, M.H., Lewis, K., Sutton, S., Chan, R., 
Turnbull, A.V., Lovejoy, D., Rivier, C., Rivier, J., Sawehenko, P.E., and Vale., W.,
(1995). Urocortin, a mammalian neuropeptide related to fish urotensin and to coiticotropin 
releasing factor. Nature 378: 287-292.
Verbalis, J.G., McCann, M.J., McHale, C M., and Strieker, E.M., (1986). Oxytocin 
secretion in response to cholecystokinin and food: Differentiation of nausea from satiety. 
Science 252: 1417-1419.
Voisin, T., Bens, M., Cluzeaud, F., Vandewalle, A., and Laburthe, M., (1993). Peptide YY 
receptors in the proximal tubule PKSV-PCT cell line derived from transgenic mice. The 
Journal of Biological Chemistry 268(27): 20547-20554.
Wahlestedt, C., Yanaihaia, N., and Hakanson, R., (1986). Evidence for different pre- and 
post-junctional receptors for neuropeptide Y and related peptides. Regulatory Peptides 13: 
307-318.
Wahlestedt, C., Skagerberg, G., Ekman, R., Heilig, M., Sundler, F., and Hakanson, R., 
(1987). Neuropeptide Y (NPY) in the area of the hypothalamic paraventriculai' nucleus 
activates the pituitary-adrenocortical axis in the rat. Brain Research 417: 33-38.
Wahlestedt, C., Hakanson, R., Vaz, C.A., and Zukowska-Grojec, Z., (1990a).
Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo. American Journal o f  
Physiology 258: R736-R742.
Wahlestedt, C., Grundemar, L., Hakanson, R., Heiling, M., Shen, G.H., Zukowskagrojec, 
Z., and Reiss, D.J (1990b). Neuropeptide Y receptor subtypes, Y1 and Y2. In cential and 
peripheral significance of neuropeptide Y and related peptides, J.M Allen and J.I Koening, eds 
(New York: New York Academy of Sciences)611: 7-26.
208
Wahlestedt, C., Regunathan, S., and Reis, D.J., (1992). Identification of cultured cells 
selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life 
Sciences 50(4): PL7-PL12.
Walker, P., Munoz, M., Maitinez, R and Peitsch, M.C., (1994). Acidic residues in 
extracellular loops of the human Y1 neuropeptide Y receptor are essential for ligand binding. 
Journal o f Biological Chemistry 269: 2863-2869.
Walker, M et al; 1997. A stmcture-activity analysis of the cloned rat and human Y4 receptors 
for pancreatic polypeptide. Peptides, 18 (4):609-612.
Wang, Q., Bing, C., Al-Baiazanji, K., Mossakowaska, D.E., Wang, X.-M., McBay, D.L., 
Neville, W.A., Taddayon, M., Pickavance, L., Dryden, S., Thomas, M.E.A., McHale, M.T., 
Gloyer, I.S., Wilson, S., Buckingham, R., Arch, J.R.S., Trayhurn, P., and Williams, G.,
(1997). Interactions between leptin and hypothalamic neuropeptide Y neurons in the eontrol of 
food intake and energy homeostasis in the rat. Diabetes 46: 335-341.
Wank, S.A., (1995). Cholecystokinin receptors. American Journal of Physiology 32: G628- 
646.
Weigle, D.S., and Kuijper, I.E., (1996). Obesity genes and the regulation of body fat 
content. Bioessays 18(11): 867-874.
Weinberg, D.H., Sirinathsinghji, D.J.S., Tan, C.P., Shiao, L.-L., Morin, N., Rigby, M.R., 
Heavens, R.H., Rapoport, D R., Bayne, M.L., Cascieri, M.A., Strader, C.D., Linemeyer, 
D.L., and MacNeil, D.J., (1996). Cloning and expression of a novel neuropeptide Y receptor. 
The Journal o f Biological Chemistry 271(28): 16435-16438.
Weiser, M., Frishman, W.H., Michaelson, M.D., and Abdeen, M.A., (1997). The 
pharmacologic approach to the tieatment of obesity. Journal o f Clinical Pharmacology 37 : 
453-473.
Weiss, B., Jacquemin-Sablon, A., Live, T.R., Fareed, G.C., and Richardson, C.C., (1986). 
Enzymatic breakage and joining of deoxyribonucleic acid. Further purification and properties 
of polynucleotide kinase from Escherichia coli infected with bacteriophageT4. Journal o f  
Biological Chemistry 243: 4543-4555.
209
Wharton, J., Gordon, L., Byrne, J., Herzog, H., Selbie, L.A., Moore, K., Sullivan, 
M.H.F., Elder, M.G., Moscoso, G., Taylor, K.M., Shine, J., and Polak, J.M., (1993). 
Expression of the human neuropeptide tyrosine Y1 receptor. Proc. N atl Acad. Sci. USA 90: 
687-691.
White, J.D., and Kershaw, M., (1990). Increased hypothalamic neuropeptide Y expression 
following food deprivation. Molecular and Cellular Neurosciences 1: 41-48.
Wieiand, H.A., Willim, K., and Doods, H.N., (1995). Receptor binding profiles of NPY 
analogues and fragments in different tissues and cell lines. Peptides 16(8): 1389-1394.
Wieiand, H.A., Engel, W., Eberlein, W., Rudolf, K., and Doods, H.N., (1998). Subtype 
selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its 
effect on feeding in rodents. British Journal o f Pharmacology 125: 549-555.
Wilding, J., Widdowson, P., and Williams, G., (1997). Neurobiology. British Medical 
Bulletin 53(2): 286-306.
Yan, H., Yang, J., Marasco, J., Yamaguchi, K., Brenner, S., Collins, F., and Karbon, W.,
(1996). Cloning and functional expression of cDNAs encoding human and rat pancreatic 
polypeptide receptors. Proc. Natl. Acad. Sci. USA 93: 4661-4665.
Zarrinmayeh, H., Nunes, A.M., Ornstein, P.L., Zimmeiman, D.D., Arnold, M.B., Schober, 
D.A, Gackenheimer, S.L., Bruns, R.F., Hipskind, P.A., Britton, T.C., Cantrell, B.E, and 
Gehlert, D.R., (1998). Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy) 
methyl] benzimidazoles as selective neuropeptide Y1 receptor antagonists. Journal o f  
Medicinal Chemistry 41: 2709-2719.
Zhang, Y., Proenca, R., Maffei, M., Baione, M., Leopold, L., and Friedman, J.M., (1994). 
Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-431.
210
APPENDIX
Appendix I
SOLUTIONS
Ampicillin
lOOmg/ml stock in distilled water, filter sterilised, stored at -20“C
10% foetal calf medium (COS cells)
Dulbeco's modified Eagles Medium (DMEM) (Imperial ) supplemented with : 
New born calf serum (Gibco BRL) 10%
Glutamine 2.0mM
Gentamicin 15 gg/ml
Penicillin (Gibco BRL) lOOIU/ml
Streptomycin (Gibco BRL) lOOgg/ml
10% foetal calf medium (SK-N-MC cells)
Minimum Essential Medium (MEM) (Gibco BRL) supplemented with
Foetal calf serum (Sigma) 
Non-essential amino acids (10 X) 
Sodium pyruvate (lOOmM) 
Glutamine
10% 
5ml 
5 ml 
2.0mM
10% foetal calf medium (HEK cells)
RPMI (Imperial) supplemented with :-
Foetal calf serum (Sigma) 10%
Glutamine 2.0mM
Penicillin (Gibco BRL) lOOIU/ml
Streptomycin (Gibco BRL) lOOpg/ml
5 X Denaturing solution
NaOH 40g
NaCl 146. Ig
Make up to 1 litre with distilled water, autoclave to sterilise.
50 X Denhartds reagent
Ficoll
Polyvinylpyrrolidone
5g
5g
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Bovine serum albumin
make up to 500ml with distilled water and filter sterilise.
5g
Dexamethasone
lOmM stock in dimethly sulfoxide, stored at -70“ C
Ethidium bromide stock
lOmg/ml in TE, stored away from light
Forskolln
lOmM stock in dimethyl sulfoxide, stored at -70“C 
Genetrapper solutions
Information on the components of the supplied reagents with the Genetrapper™ cDNA 
positive selection system aie not available.
Buffer I
Tris-HCl pHS.O 15mM
EDTA lOmM
RNase A lOOpg/ml
RNaseTl 1,200 units/ml
Buffer II
NaOH
SDS
0.2M
1%
GTE
Glucose 
Tris-HCl pH8.0 
EDTA
50mM
25mM
lOmM
Hybridisation/Prehybridisation buffer
Denhardts solution (5X)
SSC (5X)
20mM NaH2P04
10% SDS
Denatured salmon sperm DNA (lOmg/ml) 
Distilled water
10ml
25ml
0.7g
1ml
lOOpl
65ml
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lodoacetamide
0.5M dissolved in EtOH, stored at 4°C 
IPTG
O.IM stock in distilled water, filter sterilised, stored at "20°C.
LB agar plates (Lennox L agar)
SELECT Peptone 140 lO.Og
Yeast extract 5.0g
NaCl 5.5g
Agar 12.0g
premixed (Gibco BRL) ; make up to 1 litre with distilled water.
Lennox L broth base
SELECT Peptone 140 lO.Og
Yeast extract 5.0g
NaCl 5.5g
premixed (Gibco BRL) ; make up to 1 litre with distilled water
10 X Low salt buffer (Boehringer Mannheim)
Tris-HCl
MgCl2
Dithioerythritol (DTE), pH 7.5
lOmM
lOmM
ImM
NaCl
5M in distilled water, sterilised by autoclave 
4 X Neutralisation solution
Tris-HCl 264.4g
Tris-base 38.8g
NaCl 116.8g
make up to 1 litre with distilled water, autoclave to sterilise
NU medium
DMEM supplemented with :- 
NU serum (Colloborative Research) 10%
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Glutamine 2.0mM
Penicillin (Gibco BRL) lOOIU/ml
Streptomycin (GibcoBRL) lOOpg/ml
Chloroquine was added immediately prior to use at a final concentration of lOOpM
PBS (Phosphate buffered saline) (20 X stock)
NaCl 80g
KCl 2g
Na2HP0 4 .2H20 11.5g
KH2PO4 2g
Make up to 500ml with distilled water, sterilise by autoclaving;pH7.4
Potassium Acetate solution (minipreps)
5.0M KOAc 60ml
Glacial acetic acid 11.5ml
Distilled water 28.5ml
This solution is 3.0M with respect to potassium and 5.0M with respect to acetate (~pH 4.8)
10 X RNA electrophoresis buffer
MOPS 0.2M
EDTA lOmM
SOC medium
Distilled water 250ml
Bacto-tryptone 5 g
Bacto-yeast extract 1.25g
NaCl 0.125g
250mM KCl 2.5ml
Autoclave to sterilise; immediately prior to use add 1.25ml sterile 2.0M MgCl2 and 5.0M
sterile glucose 
20 X SSC
NaCl 3M
Citric acid 0.3M
pH to 7.0 with NaOH.
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SM buffer
NaCl 5.8g
MgS04.7H20 2.0g
Tris-HCl pH 7.5 (IM) 50ml
2% gelatin solution 5ml
Make up to 1 litre with distilled water, sterilise by autoclaving.
TAE (50 X stock)
Tris-base 
Glacial acetic acid 
0.5M EDTA
Make up to 1 litre with distilled water
242g
57.1ml
100ml
TE
Tris-HCl pH8.0 
EDTA
lOmM
ImM
Tetracyclin
Tetracyelin 
Ascorbic acid
30mg/ml
15mg/ml
Trypsin (10 X stock)
Trypsin (13,000-20,000 units per mg)
0.5M EDTA 
IX PBS
Diluted to working concentration in IX PBS
50mg
1ml
99ml
X-Gal
2% stock in N' N'-dimethyl formamide; stored at -20°C.
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Appendix II
SYNTHETIC OLIGONUCLEOTIDES
Human Y l, Y2 and Y4 receptor degenerate oligonucleotide primers
Sequence title: ECl forward
5 'T A  (C/T) A C N (A/C/T )T N A T G G A (C/T) (T/C) A (C/T) T G G  (A/G) T (A/G) T T (C/T) 3'=nts
435-464
sequence title: TM7 reverse
5' G G (G/A) T T N A A (G/A) C A N G T N G A N G C C A T N G C 3 ' = n t s  930-956
n= eq u a l m ix  o f  A/T/G/C.
Rat NPY Y5 receptor specific primer sequences
(Gerald, 1996)
Sequence title: rat Y5 forward
5 ' C G T G C G A T C G T T C T T C A A G C T G C T A 3 '  = nts 1-24 
Tm=75.8T
Sequence title: rat Y5 forward primer (-11)
5 ' A T G G A G T T T A A G C T T G A G G A G 3 ’ = nts 58-80 
Tm=66.9T
Sequence title: rat Y5 forwai'd primer (MP)
5 ' C G G A A T G C A G C C T T C C C T G C C 3 '  = nts 125-146 
Tm=76.7'C
Sequence title: rat Y5 internal
5 ' G G C T C A G C A C T G C T G A G T A G 3 '  = nts 621-640 
Tm=72.4“C
Sequence title: rat Y5 reverse
5 ' G T G C A C A G A G A G A A T C A T G A C A T G T 3 '  = nts 1385-1410 
Tm=72.5T
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Human NPY Y 5 receptor specific primer sequences
Sequence title: human Y5 forward
5 ' G C A G T G T A G A T G A C T T A C A G 3 ' n t s =  121-141 
Tm=66.2“C
Sequence title: human Y5 internal
5 ' C T G A T A G C T A C T G C T T G G A C 3 ’nts = 492-512 
Tni=68.3“C
Sequence title: human Y5 reverse
5 ' A G A C A A C A G G A C A T C A T G C C 3 ' n t s =  1255-1275 
Tm=68.3“C
Genetrapper™ primer sequences
Human Y l/y6 receptor degenerate primer 
Sequence title:GT1
5' T (C/T) A C C  A(A/G) C A T  (A/C) C T G  A T T G  (C/T) (G/C)3'
Human Y2 receptor homologous primer 
Sequence title: GT2
5 G C C T A C T G C T C C A T C A T C T T 3 '
Human Y4 receptor homologous primer 
Sequence title: GT3
5 C G T G A T G G T C T T C A T C G T C A 3 '
Human Y5 receptor homologous primer 
Sequence title: GT4
5 ' G C A G T G T A G A T G A C T T A C A G 3 '
Human Y5 receptor (internal) homologous primer 
Sequence title: GT5
5 ' C T G A T A G C T A C T G T C T G G A C 3 '
(Hu, 1996)
218
Rat NPY Y l receptor specific primer sequences
Sequence title: rat Yl forward primer
5’A T T C A A C T C T G T T C T C C A G G 3 ’ = nts 72-91 
Tm= 66.2“C
Sequence title: rat Y1 internal primer
5 ' G C T T A C A T A G G C A T T A C T G T 3 '  =nts 427-446 
Tm= 64.2“C
Sequence title: rat Yl reverse primer
5 ' A C C A T G T G A C A G G C  T G T G C T 3 ’ = nts 1262-1281 
Tm= 70.3“C
Human Y l receptor 3’ UT specific primer sequences
Sequence title: human Yl 3' UT forward primer
5 ' C A G A C T T G T T C A G T G T T T G T C 3 ’ =nts 2194-2213 
Tm= 66.2°C
Sequence title: human Yl 3' UT reverse primer
5 ' G A T T C T G A G G C T C A A T C A T G 3 ’ = nts 2541-2560 
Tm= 66.2“C
Human Y5 receptor 3' UT specific primer sequences
Sequence title: human Y5 3’ UT forward primer
5’G T G C A G T C A G T G T C A A T C C A 3 '  = nts 1569-1588 
Tm= 68.3T
Sequence title: human Y5 3' UT reverse primer
5 ' T A A G A A G C C T A T G G A G T A G A 3 '  = nts 1791-1810 
Tm= 64.2°C
(Eva, 1990)
(Ball, 1995)
(Herzog, 1997)
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